6	SAPHRIS.xml:S1:4:1	O
ADVERSE	SAPHRIS.xml:S1:6:7	O
REACTIONS	SAPHRIS.xml:S1:14:9	O

The	SAPHRIS.xml:S1:27:3	O
following	SAPHRIS.xml:S1:31:9	O
adverse	SAPHRIS.xml:S1:41:7	O
reactions	SAPHRIS.xml:S1:49:9	O
are	SAPHRIS.xml:S1:59:3	O
discussed	SAPHRIS.xml:S1:63:9	O
in	SAPHRIS.xml:S1:73:2	O
more	SAPHRIS.xml:S1:76:4	O
detail	SAPHRIS.xml:S1:81:6	O
in	SAPHRIS.xml:S1:88:2	O
other	SAPHRIS.xml:S1:91:5	O
sections	SAPHRIS.xml:S1:97:8	O
of	SAPHRIS.xml:S1:106:2	O
the	SAPHRIS.xml:S1:109:3	O
labeling	SAPHRIS.xml:S1:113:8	O
:	SAPHRIS.xml:S1:121:1	O

Use	SAPHRIS.xml:S1:130:3	O
in	SAPHRIS.xml:S1:134:2	O
Elderly	SAPHRIS.xml:S1:137:7	O
Patients	SAPHRIS.xml:S1:145:8	O
with	SAPHRIS.xml:S1:154:4	O
Dementia	SAPHRIS.xml:S1:159:8	O
-	SAPHRIS.xml:S1:167:1	O
Related	SAPHRIS.xml:S1:168:7	O
Psychosis	SAPHRIS.xml:S1:176:9	O
[	SAPHRIS.xml:S1:186:1	O
seeBoxed	SAPHRIS.xml:S1:187:8	O
Warningand	SAPHRIS.xml:S1:196:10	O
Warnings	SAPHRIS.xml:S1:207:8	O
and	SAPHRIS.xml:S1:216:3	O
Precautions	SAPHRIS.xml:S1:220:11	O
(	SAPHRIS.xml:S1:232:1	O
5.1	SAPHRIS.xml:S1:233:3	O
and5	SAPHRIS.xml:S1:236:4	O
.	SAPHRIS.xml:S1:240:1	O
2	SAPHRIS.xml:S1:241:1	O
)]	SAPHRIS.xml:S1:242:2	O

Neuroleptic	SAPHRIS.xml:S1:251:11	B-AdverseReaction
Malignant	SAPHRIS.xml:S1:263:9	I-AdverseReaction
Syndrome	SAPHRIS.xml:S1:273:8	I-AdverseReaction
[	SAPHRIS.xml:S1:282:1	O
see	SAPHRIS.xml:S1:283:3	O
Warnings	SAPHRIS.xml:S1:287:8	O
and	SAPHRIS.xml:S1:296:3	O
Precautions	SAPHRIS.xml:S1:300:11	O
(	SAPHRIS.xml:S1:312:1	O
5.3	SAPHRIS.xml:S1:313:3	O
)]	SAPHRIS.xml:S1:316:2	O

Tardive	SAPHRIS.xml:S1:325:7	B-AdverseReaction
Dyskinesia	SAPHRIS.xml:S1:333:10	I-AdverseReaction
[	SAPHRIS.xml:S1:344:1	O
see	SAPHRIS.xml:S1:345:3	O
Warnings	SAPHRIS.xml:S1:349:8	O
and	SAPHRIS.xml:S1:358:3	O
Precautions	SAPHRIS.xml:S1:362:11	O
(	SAPHRIS.xml:S1:374:1	O
5.4	SAPHRIS.xml:S1:375:3	O
)]	SAPHRIS.xml:S1:378:2	O

Metabolic	SAPHRIS.xml:S1:387:9	B-AdverseReaction
Changes	SAPHRIS.xml:S1:397:7	I-AdverseReaction
[	SAPHRIS.xml:S1:405:1	O
see	SAPHRIS.xml:S1:406:3	O
Warnings	SAPHRIS.xml:S1:410:8	O
and	SAPHRIS.xml:S1:419:3	O
Precautions	SAPHRIS.xml:S1:423:11	O
(	SAPHRIS.xml:S1:435:1	O
5.5	SAPHRIS.xml:S1:436:3	O
)]	SAPHRIS.xml:S1:439:2	O

Hypersensitivity	SAPHRIS.xml:S1:448:16	B-AdverseReaction
Reactions	SAPHRIS.xml:S1:465:9	I-AdverseReaction
[	SAPHRIS.xml:S1:475:1	O
see	SAPHRIS.xml:S1:476:3	O
Contraindications	SAPHRIS.xml:S1:480:17	O
,	SAPHRIS.xml:S1:497:1	O
Warnings	SAPHRIS.xml:S1:499:8	O
and	SAPHRIS.xml:S1:508:3	O
Precautions	SAPHRIS.xml:S1:512:11	O
(	SAPHRIS.xml:S1:524:1	O
5.6	SAPHRIS.xml:S1:525:3	O
)	SAPHRIS.xml:S1:528:1	O
and	SAPHRIS.xml:S1:530:3	O
Patient	SAPHRIS.xml:S1:534:7	O
Counseling	SAPHRIS.xml:S1:542:10	O
Information	SAPHRIS.xml:S1:553:11	O
(	SAPHRIS.xml:S1:565:1	O
17	SAPHRIS.xml:S1:566:2	O
)]	SAPHRIS.xml:S1:568:2	O

Application	SAPHRIS.xml:S1:577:11	B-AdverseReaction
site	SAPHRIS.xml:S1:589:4	I-AdverseReaction
reactions	SAPHRIS.xml:S1:594:9	I-AdverseReaction
including	SAPHRIS.xml:S1:604:9	O
oral	SAPHRIS.xml:S1:614:4	I-AdverseReaction
ulcers	SAPHRIS.xml:S1:619:6	I-AdverseReaction
,	SAPHRIS.xml:S1:625:1	O
blisters	SAPHRIS.xml:S1:627:8	I-AdverseReaction
,	SAPHRIS.xml:S1:635:1	O
peeling	SAPHRIS.xml:S1:637:7	I-AdverseReaction
sloughing	SAPHRIS.xml:S1:645:9	I-AdverseReaction
and	SAPHRIS.xml:S1:655:3	O
inflammation	SAPHRIS.xml:S1:659:12	I-AdverseReaction
[	SAPHRIS.xml:S1:672:1	O
see	SAPHRIS.xml:S1:673:3	O
Adverse	SAPHRIS.xml:S1:677:7	O
Reactions	SAPHRIS.xml:S1:685:9	O
(	SAPHRIS.xml:S1:695:1	O
6.2	SAPHRIS.xml:S1:696:3	O
)]	SAPHRIS.xml:S1:699:2	O

Orthostatic	SAPHRIS.xml:S1:708:11	B-AdverseReaction
Hypotension	SAPHRIS.xml:S1:720:11	I-AdverseReaction
,	SAPHRIS.xml:S1:731:1	O
Syncope	SAPHRIS.xml:S1:733:7	B-AdverseReaction
,	SAPHRIS.xml:S1:740:1	O
and	SAPHRIS.xml:S1:742:3	O
other	SAPHRIS.xml:S1:746:5	O
Hemodynamic	SAPHRIS.xml:S1:752:11	B-AdverseReaction
Effects	SAPHRIS.xml:S1:764:7	I-AdverseReaction
[	SAPHRIS.xml:S1:772:1	O
see	SAPHRIS.xml:S1:773:3	O
Warnings	SAPHRIS.xml:S1:777:8	O
and	SAPHRIS.xml:S1:786:3	O
Precautions	SAPHRIS.xml:S1:790:11	O
(	SAPHRIS.xml:S1:802:1	O
5.7	SAPHRIS.xml:S1:803:3	O
)]	SAPHRIS.xml:S1:806:2	O

Leukopenia	SAPHRIS.xml:S1:815:10	B-AdverseReaction
,	SAPHRIS.xml:S1:825:1	O
Neutropenia	SAPHRIS.xml:S1:827:11	B-AdverseReaction
,	SAPHRIS.xml:S1:838:1	O
and	SAPHRIS.xml:S1:840:3	O
Agranulocytosis	SAPHRIS.xml:S1:844:15	B-AdverseReaction
[	SAPHRIS.xml:S1:860:1	O
see	SAPHRIS.xml:S1:861:3	O
Warnings	SAPHRIS.xml:S1:865:8	O
and	SAPHRIS.xml:S1:874:3	O
Precautions	SAPHRIS.xml:S1:878:11	O
(	SAPHRIS.xml:S1:890:1	O
5.8	SAPHRIS.xml:S1:891:3	O
)]	SAPHRIS.xml:S1:894:2	O

QT	SAPHRIS.xml:S1:903:2	B-AdverseReaction
Interval	SAPHRIS.xml:S1:906:8	I-AdverseReaction
Prolongation	SAPHRIS.xml:S1:915:12	I-AdverseReaction
[	SAPHRIS.xml:S1:928:1	O
see	SAPHRIS.xml:S1:929:3	O
Warnings	SAPHRIS.xml:S1:933:8	O
and	SAPHRIS.xml:S1:942:3	O
Precautions	SAPHRIS.xml:S1:946:11	O
(	SAPHRIS.xml:S1:958:1	O
5.9	SAPHRIS.xml:S1:959:3	O
)]	SAPHRIS.xml:S1:962:2	O

Hyperprolactinemia	SAPHRIS.xml:S1:971:18	B-AdverseReaction
[	SAPHRIS.xml:S1:990:1	O
see	SAPHRIS.xml:S1:991:3	O
Warnings	SAPHRIS.xml:S1:995:8	O
and	SAPHRIS.xml:S1:1004:3	O
Precautions	SAPHRIS.xml:S1:1008:11	O
(	SAPHRIS.xml:S1:1020:1	O
5.10	SAPHRIS.xml:S1:1021:4	O
)]	SAPHRIS.xml:S1:1025:2	O

Seizures	SAPHRIS.xml:S1:1034:8	B-AdverseReaction
[	SAPHRIS.xml:S1:1043:1	O
see	SAPHRIS.xml:S1:1044:3	O
Warnings	SAPHRIS.xml:S1:1048:8	O
and	SAPHRIS.xml:S1:1057:3	O
Precautions	SAPHRIS.xml:S1:1061:11	O
(	SAPHRIS.xml:S1:1073:1	O
5.11	SAPHRIS.xml:S1:1074:4	O
)]	SAPHRIS.xml:S1:1078:2	O

Potential	SAPHRIS.xml:S1:1087:9	B-Factor
for	SAPHRIS.xml:S1:1097:3	O
Cognitive	SAPHRIS.xml:S1:1101:9	B-AdverseReaction
and	SAPHRIS.xml:S1:1111:3	O
Motor	SAPHRIS.xml:S1:1115:5	B-AdverseReaction
Impairment	SAPHRIS.xml:S1:1121:10	I-AdverseReaction
[	SAPHRIS.xml:S1:1132:1	O
see	SAPHRIS.xml:S1:1133:3	O
Warnings	SAPHRIS.xml:S1:1137:8	O
and	SAPHRIS.xml:S1:1146:3	O
Precautions	SAPHRIS.xml:S1:1150:11	O
(	SAPHRIS.xml:S1:1162:1	O
5.12	SAPHRIS.xml:S1:1163:4	O
)]	SAPHRIS.xml:S1:1167:2	O

Body	SAPHRIS.xml:S1:1176:4	O
Temperature	SAPHRIS.xml:S1:1181:11	O
Regulation	SAPHRIS.xml:S1:1193:10	O
[	SAPHRIS.xml:S1:1204:1	O
see	SAPHRIS.xml:S1:1205:3	O
Warnings	SAPHRIS.xml:S1:1209:8	O
and	SAPHRIS.xml:S1:1218:3	O
Precautions	SAPHRIS.xml:S1:1222:11	O
(	SAPHRIS.xml:S1:1234:1	O
5.13	SAPHRIS.xml:S1:1235:4	O
)]	SAPHRIS.xml:S1:1239:2	O

Suicide	SAPHRIS.xml:S1:1248:7	B-AdverseReaction
[	SAPHRIS.xml:S1:1256:1	O
see	SAPHRIS.xml:S1:1257:3	O
Warnings	SAPHRIS.xml:S1:1261:8	O
and	SAPHRIS.xml:S1:1270:3	O
Precautions	SAPHRIS.xml:S1:1274:11	O
(	SAPHRIS.xml:S1:1286:1	O
5.14	SAPHRIS.xml:S1:1287:4	O
)]	SAPHRIS.xml:S1:1291:2	O

Dysphagia	SAPHRIS.xml:S1:1300:9	B-AdverseReaction
[	SAPHRIS.xml:S1:1310:1	O
see	SAPHRIS.xml:S1:1311:3	O
Warnings	SAPHRIS.xml:S1:1315:8	O
and	SAPHRIS.xml:S1:1324:3	O
Precautions	SAPHRIS.xml:S1:1328:11	O
(	SAPHRIS.xml:S1:1340:1	O
5.15	SAPHRIS.xml:S1:1341:4	O
)]	SAPHRIS.xml:S1:1345:2	O

Use	SAPHRIS.xml:S1:1354:3	O
in	SAPHRIS.xml:S1:1358:2	O
Patients	SAPHRIS.xml:S1:1361:8	O
with	SAPHRIS.xml:S1:1370:4	O
Concomitant	SAPHRIS.xml:S1:1375:11	O
Illness	SAPHRIS.xml:S1:1387:7	O
[	SAPHRIS.xml:S1:1395:1	O
see	SAPHRIS.xml:S1:1396:3	O
Warnings	SAPHRIS.xml:S1:1400:8	O
and	SAPHRIS.xml:S1:1409:3	O
Precautions	SAPHRIS.xml:S1:1413:11	O
(	SAPHRIS.xml:S1:1425:1	O
5.16	SAPHRIS.xml:S1:1426:4	O
)]	SAPHRIS.xml:S1:1430:2	O

The	SAPHRIS.xml:S1:1439:3	O
most	SAPHRIS.xml:S1:1443:4	O
common	SAPHRIS.xml:S1:1448:6	O
adverse	SAPHRIS.xml:S1:1455:7	O
reactions	SAPHRIS.xml:S1:1463:9	O
(	SAPHRIS.xml:S1:1473:1	O
5%	SAPHRIS.xml:S1:1476:2	O
and	SAPHRIS.xml:S1:1479:3	O
at	SAPHRIS.xml:S1:1483:2	O
least	SAPHRIS.xml:S1:1486:5	O
twice	SAPHRIS.xml:S1:1492:5	O
the	SAPHRIS.xml:S1:1498:3	O
rate	SAPHRIS.xml:S1:1502:4	O
of	SAPHRIS.xml:S1:1507:2	O
placebo	SAPHRIS.xml:S1:1510:7	O
)	SAPHRIS.xml:S1:1517:1	O
reported	SAPHRIS.xml:S1:1519:8	O
with	SAPHRIS.xml:S1:1528:4	O
acute	SAPHRIS.xml:S1:1533:5	O
treatment	SAPHRIS.xml:S1:1539:9	O
in	SAPHRIS.xml:S1:1549:2	O
adults	SAPHRIS.xml:S1:1552:6	O
with	SAPHRIS.xml:S1:1559:4	O
schizophrenia	SAPHRIS.xml:S1:1564:13	O
were	SAPHRIS.xml:S1:1578:4	O
akathisia	SAPHRIS.xml:S1:1583:9	B-AdverseReaction
,	SAPHRIS.xml:S1:1592:1	O
oral	SAPHRIS.xml:S1:1594:4	B-AdverseReaction
hypoesthesia	SAPHRIS.xml:S1:1599:12	I-AdverseReaction
,	SAPHRIS.xml:S1:1611:1	O
and	SAPHRIS.xml:S1:1613:3	O
somnolence	SAPHRIS.xml:S1:1617:10	B-AdverseReaction
.	SAPHRIS.xml:S1:1627:1	O

The	SAPHRIS.xml:S1:1629:3	O
safety	SAPHRIS.xml:S1:1633:6	O
profile	SAPHRIS.xml:S1:1640:7	O
of	SAPHRIS.xml:S1:1648:2	O
SAPHRIS	SAPHRIS.xml:S1:1651:7	O
in	SAPHRIS.xml:S1:1659:2	O
the	SAPHRIS.xml:S1:1662:3	O
maintenance	SAPHRIS.xml:S1:1666:11	O
treatment	SAPHRIS.xml:S1:1678:9	O
of	SAPHRIS.xml:S1:1688:2	O
schizophrenia	SAPHRIS.xml:S1:1691:13	O
in	SAPHRIS.xml:S1:1705:2	O
adults	SAPHRIS.xml:S1:1708:6	O
was	SAPHRIS.xml:S1:1715:3	O
similar	SAPHRIS.xml:S1:1719:7	O
to	SAPHRIS.xml:S1:1727:2	O
that	SAPHRIS.xml:S1:1730:4	O
seen	SAPHRIS.xml:S1:1735:4	O
with	SAPHRIS.xml:S1:1740:4	O
acute	SAPHRIS.xml:S1:1745:5	O
treatment	SAPHRIS.xml:S1:1751:9	O
.	SAPHRIS.xml:S1:1760:1	O

The	SAPHRIS.xml:S1:1766:3	O

most	SAPHRIS.xml:S1:1770:4	O
common	SAPHRIS.xml:S1:1775:6	O
adverse	SAPHRIS.xml:S1:1782:7	O
reactions	SAPHRIS.xml:S1:1790:9	O
(	SAPHRIS.xml:S1:1800:1	O
5%	SAPHRIS.xml:S1:1803:2	O
and	SAPHRIS.xml:S1:1806:3	O
at	SAPHRIS.xml:S1:1810:2	O
least	SAPHRIS.xml:S1:1813:5	O
twice	SAPHRIS.xml:S1:1819:5	O
the	SAPHRIS.xml:S1:1825:3	O
rate	SAPHRIS.xml:S1:1829:4	O
of	SAPHRIS.xml:S1:1834:2	O
placebo	SAPHRIS.xml:S1:1837:7	O
)	SAPHRIS.xml:S1:1844:1	O
reported	SAPHRIS.xml:S1:1846:8	O
with	SAPHRIS.xml:S1:1855:4	O
acute	SAPHRIS.xml:S1:1860:5	O
monotherapy	SAPHRIS.xml:S1:1866:11	O
treatment	SAPHRIS.xml:S1:1878:9	O
of	SAPHRIS.xml:S1:1888:2	O
manic	SAPHRIS.xml:S1:1891:5	O
or	SAPHRIS.xml:S1:1897:2	O
mixed	SAPHRIS.xml:S1:1900:5	O
episodes	SAPHRIS.xml:S1:1906:8	O
associated	SAPHRIS.xml:S1:1915:10	O
with	SAPHRIS.xml:S1:1926:4	O
bipolar	SAPHRIS.xml:S1:1931:7	O
I	SAPHRIS.xml:S1:1939:1	O
disorder	SAPHRIS.xml:S1:1941:8	O
in	SAPHRIS.xml:S1:1950:2	O
adults	SAPHRIS.xml:S1:1953:6	O
were	SAPHRIS.xml:S1:1960:4	O
somnolence	SAPHRIS.xml:S1:1965:10	B-AdverseReaction
,	SAPHRIS.xml:S1:1975:1	O
dizziness	SAPHRIS.xml:S1:1977:9	B-AdverseReaction
,	SAPHRIS.xml:S1:1986:1	O
extrapyramidal	SAPHRIS.xml:S1:1988:14	B-AdverseReaction
symptoms	SAPHRIS.xml:S1:2003:8	I-AdverseReaction
other	SAPHRIS.xml:S1:2012:5	B-Factor
than	SAPHRIS.xml:S1:2018:4	I-Factor
akathisia	SAPHRIS.xml:S1:2023:9	B-AdverseReaction
,	SAPHRIS.xml:S1:2032:1	O
and	SAPHRIS.xml:S1:2034:3	O
increased	SAPHRIS.xml:S1:2038:9	B-AdverseReaction
weight	SAPHRIS.xml:S1:2048:6	I-AdverseReaction
and	SAPHRIS.xml:S1:2055:3	O
during	SAPHRIS.xml:S1:2059:6	O
the	SAPHRIS.xml:S1:2066:3	O
adjunctive	SAPHRIS.xml:S1:2070:10	O
therapy	SAPHRIS.xml:S1:2081:7	O
trial	SAPHRIS.xml:S1:2089:5	O
in	SAPHRIS.xml:S1:2095:2	O
bipolar	SAPHRIS.xml:S1:2098:7	O
I	SAPHRIS.xml:S1:2106:1	O
disorder	SAPHRIS.xml:S1:2108:8	O
in	SAPHRIS.xml:S1:2117:2	O
adults	SAPHRIS.xml:S1:2120:6	O
were	SAPHRIS.xml:S1:2127:4	O
somnolence	SAPHRIS.xml:S1:2132:10	B-AdverseReaction
and	SAPHRIS.xml:S1:2143:3	O
oral	SAPHRIS.xml:S1:2147:4	B-AdverseReaction
hypoesthesia	SAPHRIS.xml:S1:2152:12	I-AdverseReaction
.	SAPHRIS.xml:S1:2164:1	O

The	SAPHRIS.xml:S1:2170:3	O
adult	SAPHRIS.xml:S1:2174:5	O
information	SAPHRIS.xml:S1:2180:11	O
below	SAPHRIS.xml:S1:2192:5	O
is	SAPHRIS.xml:S1:2198:2	O
derived	SAPHRIS.xml:S1:2201:7	O
from	SAPHRIS.xml:S1:2209:4	O
a	SAPHRIS.xml:S1:2214:1	O
clinical	SAPHRIS.xml:S1:2216:8	O
trial	SAPHRIS.xml:S1:2225:5	O
database	SAPHRIS.xml:S1:2231:8	O
for	SAPHRIS.xml:S1:2240:3	O
SAPHRIS	SAPHRIS.xml:S1:2244:7	O
consisting	SAPHRIS.xml:S1:2252:10	O
of	SAPHRIS.xml:S1:2263:2	O
over	SAPHRIS.xml:S1:2266:4	O
4565	SAPHRIS.xml:S1:2271:4	O
patients	SAPHRIS.xml:S1:2276:8	O
and	SAPHRIS.xml:S1:2285:3	O
or	SAPHRIS.xml:S1:2289:2	O
healthy	SAPHRIS.xml:S1:2292:7	O
subjects	SAPHRIS.xml:S1:2300:8	O
exposed	SAPHRIS.xml:S1:2309:7	O
to	SAPHRIS.xml:S1:2317:2	O
one	SAPHRIS.xml:S1:2320:3	O
or	SAPHRIS.xml:S1:2324:2	O
more	SAPHRIS.xml:S1:2327:4	O
sublingual	SAPHRIS.xml:S1:2332:10	O
doses	SAPHRIS.xml:S1:2343:5	O
of	SAPHRIS.xml:S1:2349:2	O
SAPHRIS	SAPHRIS.xml:S1:2352:7	O
.	SAPHRIS.xml:S1:2359:1	O

A	SAPHRIS.xml:S1:2361:1	O
total	SAPHRIS.xml:S1:2363:5	O
of	SAPHRIS.xml:S1:2369:2	O
1314	SAPHRIS.xml:S1:2372:4	O
SAPHRIS	SAPHRIS.xml:S1:2377:7	O
-	SAPHRIS.xml:S1:2384:1	O
treated	SAPHRIS.xml:S1:2385:7	O
patients	SAPHRIS.xml:S1:2393:8	O
were	SAPHRIS.xml:S1:2402:4	O
treated	SAPHRIS.xml:S1:2407:7	O
for	SAPHRIS.xml:S1:2415:3	O
at	SAPHRIS.xml:S1:2419:2	O
least	SAPHRIS.xml:S1:2422:5	O
24	SAPHRIS.xml:S1:2428:2	O
weeks	SAPHRIS.xml:S1:2431:5	O
and	SAPHRIS.xml:S1:2437:3	O
785	SAPHRIS.xml:S1:2441:3	O
SAPHRIS	SAPHRIS.xml:S1:2445:7	O
-	SAPHRIS.xml:S1:2452:1	O
treated	SAPHRIS.xml:S1:2453:7	O
patients	SAPHRIS.xml:S1:2461:8	O
had	SAPHRIS.xml:S1:2470:3	O
at	SAPHRIS.xml:S1:2474:2	O
least	SAPHRIS.xml:S1:2477:5	O
52	SAPHRIS.xml:S1:2483:2	O
weeks	SAPHRIS.xml:S1:2486:5	O
of	SAPHRIS.xml:S1:2492:2	O
exposure	SAPHRIS.xml:S1:2495:8	O
at	SAPHRIS.xml:S1:2504:2	O
therapeutic	SAPHRIS.xml:S1:2507:11	O
doses	SAPHRIS.xml:S1:2519:5	O
.	SAPHRIS.xml:S1:2524:1	O

In	SAPHRIS.xml:S1:2530:2	O
a	SAPHRIS.xml:S1:2533:1	O
3	SAPHRIS.xml:S1:2535:1	O
-	SAPHRIS.xml:S1:2536:1	O
week	SAPHRIS.xml:S1:2537:4	O
monotherapy	SAPHRIS.xml:S1:2542:11	O
trial	SAPHRIS.xml:S1:2554:5	O
,	SAPHRIS.xml:S1:2559:1	O
the	SAPHRIS.xml:S1:2561:3	O
most	SAPHRIS.xml:S1:2565:4	O
common	SAPHRIS.xml:S1:2570:6	O
adverse	SAPHRIS.xml:S1:2577:7	O
reactions	SAPHRIS.xml:S1:2585:9	O
(	SAPHRIS.xml:S1:2595:1	O
5%	SAPHRIS.xml:S1:2598:2	O
and	SAPHRIS.xml:S1:2601:3	O
at	SAPHRIS.xml:S1:2605:2	O
least	SAPHRIS.xml:S1:2608:5	O
twice	SAPHRIS.xml:S1:2614:5	O
the	SAPHRIS.xml:S1:2620:3	O
rate	SAPHRIS.xml:S1:2624:4	O
of	SAPHRIS.xml:S1:2629:2	O
placebo	SAPHRIS.xml:S1:2632:7	O
)	SAPHRIS.xml:S1:2639:1	O
reported	SAPHRIS.xml:S1:2641:8	O
in	SAPHRIS.xml:S1:2650:2	O
pediatric	SAPHRIS.xml:S1:2653:9	O
patients	SAPHRIS.xml:S1:2663:8	O
with	SAPHRIS.xml:S1:2672:4	O
bipolar	SAPHRIS.xml:S1:2677:7	O
I	SAPHRIS.xml:S1:2685:1	O
disorder	SAPHRIS.xml:S1:2687:8	O
treated	SAPHRIS.xml:S1:2696:7	O
with	SAPHRIS.xml:S1:2704:4	O
SAPHRIS	SAPHRIS.xml:S1:2709:7	O
were	SAPHRIS.xml:S1:2717:4	O
somnolence	SAPHRIS.xml:S1:2722:10	B-AdverseReaction
,	SAPHRIS.xml:S1:2732:1	O
dizziness	SAPHRIS.xml:S1:2734:9	B-AdverseReaction
,	SAPHRIS.xml:S1:2743:1	O
dysgeusia	SAPHRIS.xml:S1:2745:9	B-AdverseReaction
,	SAPHRIS.xml:S1:2754:1	O
oral	SAPHRIS.xml:S1:2756:4	B-AdverseReaction
paresthesia	SAPHRIS.xml:S1:2761:11	I-AdverseReaction
,	SAPHRIS.xml:S1:2772:1	O
nausea	SAPHRIS.xml:S1:2774:6	B-AdverseReaction
,	SAPHRIS.xml:S1:2780:1	O
increased	SAPHRIS.xml:S1:2782:9	B-AdverseReaction
appetite	SAPHRIS.xml:S1:2792:8	I-AdverseReaction
,	SAPHRIS.xml:S1:2800:1	O
fatigue	SAPHRIS.xml:S1:2802:7	B-AdverseReaction
,	SAPHRIS.xml:S1:2809:1	O
and	SAPHRIS.xml:S1:2811:3	O
increased	SAPHRIS.xml:S1:2815:9	B-AdverseReaction
weight	SAPHRIS.xml:S1:2825:6	I-AdverseReaction
.	SAPHRIS.xml:S1:2831:1	O

No	SAPHRIS.xml:S1:2833:2	O
new	SAPHRIS.xml:S1:2836:3	O
major	SAPHRIS.xml:S1:2840:5	O
safety	SAPHRIS.xml:S1:2846:6	O
findings	SAPHRIS.xml:S1:2853:8	O
were	SAPHRIS.xml:S1:2862:4	O
reported	SAPHRIS.xml:S1:2867:8	O
from	SAPHRIS.xml:S1:2876:4	O
a	SAPHRIS.xml:S1:2881:1	O
50	SAPHRIS.xml:S1:2883:2	O
-	SAPHRIS.xml:S1:2885:1	O
week	SAPHRIS.xml:S1:2886:4	O
,	SAPHRIS.xml:S1:2890:1	O
open	SAPHRIS.xml:S1:2892:4	O
-	SAPHRIS.xml:S1:2896:1	O
label	SAPHRIS.xml:S1:2897:5	O
,	SAPHRIS.xml:S1:2902:1	O
uncontrolled	SAPHRIS.xml:S1:2904:12	O
safety	SAPHRIS.xml:S1:2917:6	O
trial	SAPHRIS.xml:S1:2924:5	O
.	SAPHRIS.xml:S1:2929:1	O

A	SAPHRIS.xml:S1:2935:1	O
total	SAPHRIS.xml:S1:2937:5	O
of	SAPHRIS.xml:S1:2943:2	O
651	SAPHRIS.xml:S1:2946:3	O
pediatric	SAPHRIS.xml:S1:2950:9	O
patients	SAPHRIS.xml:S1:2960:8	O
were	SAPHRIS.xml:S1:2969:4	O
treated	SAPHRIS.xml:S1:2974:7	O
with	SAPHRIS.xml:S1:2982:4	O
SAPHRIS	SAPHRIS.xml:S1:2987:7	O
.	SAPHRIS.xml:S1:2994:1	O

Of	SAPHRIS.xml:S1:2996:2	O
these	SAPHRIS.xml:S1:2999:5	O
patients	SAPHRIS.xml:S1:3005:8	O
,	SAPHRIS.xml:S1:3013:1	O
352	SAPHRIS.xml:S1:3015:3	O
pediatric	SAPHRIS.xml:S1:3019:9	O
patients	SAPHRIS.xml:S1:3029:8	O
were	SAPHRIS.xml:S1:3038:4	O
treated	SAPHRIS.xml:S1:3043:7	O
with	SAPHRIS.xml:S1:3051:4	O
SAPHRIS	SAPHRIS.xml:S1:3056:7	O
for	SAPHRIS.xml:S1:3064:3	O
at	SAPHRIS.xml:S1:3068:2	O
least	SAPHRIS.xml:S1:3071:5	O
180	SAPHRIS.xml:S1:3077:3	O
days	SAPHRIS.xml:S1:3081:4	O
and	SAPHRIS.xml:S1:3086:3	O
58	SAPHRIS.xml:S1:3090:2	O
pediatric	SAPHRIS.xml:S1:3093:9	O
patients	SAPHRIS.xml:S1:3103:8	O
treated	SAPHRIS.xml:S1:3112:7	O
with	SAPHRIS.xml:S1:3120:4	O
SAPHRIS	SAPHRIS.xml:S1:3125:7	O
had	SAPHRIS.xml:S1:3133:3	O
at	SAPHRIS.xml:S1:3137:2	O
least	SAPHRIS.xml:S1:3140:5	O
1	SAPHRIS.xml:S1:3146:1	O
year	SAPHRIS.xml:S1:3148:4	O
of	SAPHRIS.xml:S1:3153:2	O
exposure	SAPHRIS.xml:S1:3156:8	O
.	SAPHRIS.xml:S1:3164:1	O

The	SAPHRIS.xml:S1:3166:3	O
safety	SAPHRIS.xml:S1:3170:6	O
of	SAPHRIS.xml:S1:3177:2	O
SAPHRIS	SAPHRIS.xml:S1:3180:7	O
was	SAPHRIS.xml:S1:3188:3	O
evaluated	SAPHRIS.xml:S1:3192:9	O
in	SAPHRIS.xml:S1:3202:2	O
403	SAPHRIS.xml:S1:3205:3	O
pediatric	SAPHRIS.xml:S1:3209:9	O
patients	SAPHRIS.xml:S1:3219:8	O
with	SAPHRIS.xml:S1:3228:4	O
bipolar	SAPHRIS.xml:S1:3233:7	O
I	SAPHRIS.xml:S1:3241:1	O
disorder	SAPHRIS.xml:S1:3243:8	O
who	SAPHRIS.xml:S1:3252:3	O
participated	SAPHRIS.xml:S1:3256:12	O
in	SAPHRIS.xml:S1:3269:2	O
a	SAPHRIS.xml:S1:3272:1	O
3	SAPHRIS.xml:S1:3274:1	O
-	SAPHRIS.xml:S1:3275:1	O
week	SAPHRIS.xml:S1:3276:4	O
,	SAPHRIS.xml:S1:3280:1	O
placebo	SAPHRIS.xml:S1:3282:7	O
-	SAPHRIS.xml:S1:3289:1	O
controlled	SAPHRIS.xml:S1:3290:10	O
,	SAPHRIS.xml:S1:3300:1	O
double	SAPHRIS.xml:S1:3302:6	O
-	SAPHRIS.xml:S1:3308:1	O
blind	SAPHRIS.xml:S1:3309:5	O
trial	SAPHRIS.xml:S1:3315:5	O
,	SAPHRIS.xml:S1:3320:1	O
of	SAPHRIS.xml:S1:3322:2	O
whom	SAPHRIS.xml:S1:3325:4	O
302	SAPHRIS.xml:S1:3330:3	O
patients	SAPHRIS.xml:S1:3334:8	O
received	SAPHRIS.xml:S1:3343:8	O
SAPHRIS	SAPHRIS.xml:S1:3352:7	O
at	SAPHRIS.xml:S1:3360:2	O
fixed	SAPHRIS.xml:S1:3363:5	O
doses	SAPHRIS.xml:S1:3369:5	O
ranging	SAPHRIS.xml:S1:3375:7	O
from	SAPHRIS.xml:S1:3383:4	O
2.5	SAPHRIS.xml:S1:3388:3	O
mg	SAPHRIS.xml:S1:3392:2	O
to	SAPHRIS.xml:S1:3395:2	O
10	SAPHRIS.xml:S1:3398:2	O
mg	SAPHRIS.xml:S1:3401:2	O
twice	SAPHRIS.xml:S1:3404:5	O
daily	SAPHRIS.xml:S1:3410:5	O
.	SAPHRIS.xml:S1:3415:1	O

The	SAPHRIS.xml:S1:3421:3	O
stated	SAPHRIS.xml:S1:3425:6	O
frequencies	SAPHRIS.xml:S1:3432:11	O
of	SAPHRIS.xml:S1:3444:2	O
adverse	SAPHRIS.xml:S1:3447:7	O
reactions	SAPHRIS.xml:S1:3455:9	O
represent	SAPHRIS.xml:S1:3465:9	O
the	SAPHRIS.xml:S1:3475:3	O
proportion	SAPHRIS.xml:S1:3479:10	O
of	SAPHRIS.xml:S1:3490:2	O
individuals	SAPHRIS.xml:S1:3493:11	O
who	SAPHRIS.xml:S1:3505:3	O
experienced	SAPHRIS.xml:S1:3509:11	O
a	SAPHRIS.xml:S1:3521:1	O
treatment	SAPHRIS.xml:S1:3523:9	O
-	SAPHRIS.xml:S1:3532:1	O
emergent	SAPHRIS.xml:S1:3533:8	O
adverse	SAPHRIS.xml:S1:3542:7	O
event	SAPHRIS.xml:S1:3550:5	O
of	SAPHRIS.xml:S1:3556:2	O
the	SAPHRIS.xml:S1:3559:3	O
type	SAPHRIS.xml:S1:3563:4	O
listed	SAPHRIS.xml:S1:3568:6	O
.	SAPHRIS.xml:S1:3574:1	O

A	SAPHRIS.xml:S1:3576:1	O
reaction	SAPHRIS.xml:S1:3578:8	O
was	SAPHRIS.xml:S1:3587:3	O
considered	SAPHRIS.xml:S1:3591:10	O
treatment	SAPHRIS.xml:S1:3602:9	O
emergent	SAPHRIS.xml:S1:3612:8	O
if	SAPHRIS.xml:S1:3621:2	O
it	SAPHRIS.xml:S1:3624:2	O
occurred	SAPHRIS.xml:S1:3627:8	O
for	SAPHRIS.xml:S1:3636:3	O
the	SAPHRIS.xml:S1:3640:3	O
first	SAPHRIS.xml:S1:3644:5	O
time	SAPHRIS.xml:S1:3650:4	O
or	SAPHRIS.xml:S1:3655:2	O
worsened	SAPHRIS.xml:S1:3658:8	O
while	SAPHRIS.xml:S1:3667:5	O
receiving	SAPHRIS.xml:S1:3673:9	O
therapy	SAPHRIS.xml:S1:3683:7	O
following	SAPHRIS.xml:S1:3691:9	O
baseline	SAPHRIS.xml:S1:3701:8	O
evaluation	SAPHRIS.xml:S1:3710:10	O
.	SAPHRIS.xml:S1:3720:1	O

EXCERPT	SAPHRIS.xml:S1:3728:7	O
:	SAPHRIS.xml:S1:3735:1	O
Commonly	SAPHRIS.xml:S1:3739:8	O
observed	SAPHRIS.xml:S1:3748:8	O
adverse	SAPHRIS.xml:S1:3757:7	O
reactions	SAPHRIS.xml:S1:3765:9	O
(	SAPHRIS.xml:S1:3775:1	O
incidence	SAPHRIS.xml:S1:3776:9	O
5%	SAPHRIS.xml:S1:3788:2	O
and	SAPHRIS.xml:S1:3791:3	O
at	SAPHRIS.xml:S1:3795:2	O
least	SAPHRIS.xml:S1:3798:5	O
twice	SAPHRIS.xml:S1:3804:5	O
that	SAPHRIS.xml:S1:3810:4	O
for	SAPHRIS.xml:S1:3815:3	O
placebo	SAPHRIS.xml:S1:3819:7	O
)	SAPHRIS.xml:S1:3826:1	O
were	SAPHRIS.xml:S1:3828:4	O
(	SAPHRIS.xml:S1:3833:1	O
6.1	SAPHRIS.xml:S1:3834:3	O
)	SAPHRIS.xml:S1:3837:1	O
:	SAPHRIS.xml:S1:3838:1	O

Schizophrenia	SAPHRIS.xml:S1:3848:13	O
Adults	SAPHRIS.xml:S1:3862:6	O
:	SAPHRIS.xml:S1:3868:1	O
akathisia	SAPHRIS.xml:S1:3870:9	B-AdverseReaction
,	SAPHRIS.xml:S1:3879:1	O
oral	SAPHRIS.xml:S1:3881:4	B-AdverseReaction
hypoesthesia	SAPHRIS.xml:S1:3886:12	I-AdverseReaction
,	SAPHRIS.xml:S1:3898:1	O
somnolence	SAPHRIS.xml:S1:3900:10	B-AdverseReaction
.	SAPHRIS.xml:S1:3910:1	O

Bipolar	SAPHRIS.xml:S1:3918:7	O
Disorder	SAPHRIS.xml:S1:3926:8	O
Adults	SAPHRIS.xml:S1:3935:6	O
(	SAPHRIS.xml:S1:3942:1	O
Monotherapy	SAPHRIS.xml:S1:3943:11	O
)	SAPHRIS.xml:S1:3954:1	O
:	SAPHRIS.xml:S1:3955:1	O
somnolence	SAPHRIS.xml:S1:3957:10	B-AdverseReaction
,	SAPHRIS.xml:S1:3967:1	O
dizziness	SAPHRIS.xml:S1:3969:9	B-AdverseReaction
,	SAPHRIS.xml:S1:3978:1	O
extrapyramidal	SAPHRIS.xml:S1:3980:14	B-AdverseReaction
symptoms	SAPHRIS.xml:S1:3995:8	I-AdverseReaction
other	SAPHRIS.xml:S1:4004:5	B-Factor
than	SAPHRIS.xml:S1:4010:4	I-Factor
akathisia	SAPHRIS.xml:S1:4015:9	B-AdverseReaction
,	SAPHRIS.xml:S1:4024:1	O
increased	SAPHRIS.xml:S1:4026:9	B-AdverseReaction
weight	SAPHRIS.xml:S1:4036:6	I-AdverseReaction
.	SAPHRIS.xml:S1:4042:1	O

Bipolar	SAPHRIS.xml:S1:4050:7	O
Disorder	SAPHRIS.xml:S1:4058:8	O
Pediatric	SAPHRIS.xml:S1:4067:9	O
Patients	SAPHRIS.xml:S1:4077:8	O
(	SAPHRIS.xml:S1:4086:1	O
Monotherapy	SAPHRIS.xml:S1:4087:11	O
)	SAPHRIS.xml:S1:4098:1	O
:	SAPHRIS.xml:S1:4099:1	O
somnolence	SAPHRIS.xml:S1:4101:10	B-AdverseReaction
,	SAPHRIS.xml:S1:4111:1	O
dizziness	SAPHRIS.xml:S1:4113:9	B-AdverseReaction
,	SAPHRIS.xml:S1:4122:1	O
dysgeusia	SAPHRIS.xml:S1:4124:9	B-AdverseReaction
,	SAPHRIS.xml:S1:4133:1	O
oral	SAPHRIS.xml:S1:4135:4	B-AdverseReaction
paresthesia	SAPHRIS.xml:S1:4140:11	I-AdverseReaction
,	SAPHRIS.xml:S1:4151:1	O
nausea	SAPHRIS.xml:S1:4153:6	B-AdverseReaction
,	SAPHRIS.xml:S1:4159:1	O
increased	SAPHRIS.xml:S1:4161:9	B-AdverseReaction
appetite	SAPHRIS.xml:S1:4171:8	I-AdverseReaction
,	SAPHRIS.xml:S1:4179:1	O
fatigue	SAPHRIS.xml:S1:4181:7	B-AdverseReaction
,	SAPHRIS.xml:S1:4188:1	O
increased	SAPHRIS.xml:S1:4190:9	B-AdverseReaction
weight	SAPHRIS.xml:S1:4200:6	I-AdverseReaction
.	SAPHRIS.xml:S1:4206:1	O

Bipolar	SAPHRIS.xml:S1:4214:7	O
Disorder	SAPHRIS.xml:S1:4222:8	O
Adults	SAPHRIS.xml:S1:4231:6	O
(	SAPHRIS.xml:S1:4238:1	O
Adjunctive	SAPHRIS.xml:S1:4239:10	O
)	SAPHRIS.xml:S1:4249:1	O
:	SAPHRIS.xml:S1:4250:1	O
somnolence	SAPHRIS.xml:S1:4252:10	B-AdverseReaction
,	SAPHRIS.xml:S1:4262:1	O
oral	SAPHRIS.xml:S1:4264:4	B-AdverseReaction
hypoesthesia	SAPHRIS.xml:S1:4269:12	I-AdverseReaction
.	SAPHRIS.xml:S1:4281:1	O

To	SAPHRIS.xml:S1:4290:2	O
report	SAPHRIS.xml:S1:4293:6	O
SUSPECTED	SAPHRIS.xml:S1:4300:9	O
ADVERSE	SAPHRIS.xml:S1:4310:7	O
REACTIONS	SAPHRIS.xml:S1:4318:9	O
,	SAPHRIS.xml:S1:4327:1	O
contact	SAPHRIS.xml:S1:4329:7	O
Forest	SAPHRIS.xml:S1:4337:6	O
Laboratories	SAPHRIS.xml:S1:4344:12	O
,	SAPHRIS.xml:S1:4356:1	O
LLC	SAPHRIS.xml:S1:4358:3	O
.	SAPHRIS.xml:S1:4361:1	O

at	SAPHRIS.xml:S1:4363:2	O
1	SAPHRIS.xml:S1:4366:1	O
-	SAPHRIS.xml:S1:4367:1	O
800	SAPHRIS.xml:S1:4368:3	O
-	SAPHRIS.xml:S1:4371:1	O
678	SAPHRIS.xml:S1:4372:3	O
-	SAPHRIS.xml:S1:4375:1	O
1605	SAPHRIS.xml:S1:4376:4	O
or	SAPHRIS.xml:S1:4381:2	O
FDA	SAPHRIS.xml:S1:4384:3	O
at	SAPHRIS.xml:S1:4388:2	O
1	SAPHRIS.xml:S1:4391:1	O
-	SAPHRIS.xml:S1:4392:1	O
800	SAPHRIS.xml:S1:4393:3	O
-	SAPHRIS.xml:S1:4396:1	O
FDA	SAPHRIS.xml:S1:4397:3	O
-	SAPHRIS.xml:S1:4400:1	O
1088	SAPHRIS.xml:S1:4401:4	O
or	SAPHRIS.xml:S1:4406:2	O
www	SAPHRIS.xml:S1:4409:3	O
.	SAPHRIS.xml:S1:4412:1	O
fda	SAPHRIS.xml:S1:4413:3	O
.	SAPHRIS.xml:S1:4416:1	O
gov	SAPHRIS.xml:S1:4417:3	O
medwatch	SAPHRIS.xml:S1:4421:8	O
.	SAPHRIS.xml:S1:4429:1	O

6.1	SAPHRIS.xml:S1:4441:3	O

Clinical	SAPHRIS.xml:S1:4445:8	O

Trials	SAPHRIS.xml:S1:4454:6	O
Experience	SAPHRIS.xml:S1:4461:10	O

Because	SAPHRIS.xml:S1:4475:7	O
clinical	SAPHRIS.xml:S1:4483:8	O
trials	SAPHRIS.xml:S1:4492:6	O
are	SAPHRIS.xml:S1:4499:3	O
conducted	SAPHRIS.xml:S1:4503:9	O
under	SAPHRIS.xml:S1:4513:5	O
widely	SAPHRIS.xml:S1:4519:6	O
varying	SAPHRIS.xml:S1:4526:7	O
conditions	SAPHRIS.xml:S1:4534:10	O
,	SAPHRIS.xml:S1:4544:1	O
adverse	SAPHRIS.xml:S1:4546:7	O
reaction	SAPHRIS.xml:S1:4554:8	O
rates	SAPHRIS.xml:S1:4563:5	O
observed	SAPHRIS.xml:S1:4569:8	O
in	SAPHRIS.xml:S1:4578:2	O
the	SAPHRIS.xml:S1:4581:3	O
clinical	SAPHRIS.xml:S1:4585:8	O
trials	SAPHRIS.xml:S1:4594:6	O
of	SAPHRIS.xml:S1:4601:2	O
a	SAPHRIS.xml:S1:4604:1	O
drug	SAPHRIS.xml:S1:4606:4	O
cannot	SAPHRIS.xml:S1:4611:6	O
be	SAPHRIS.xml:S1:4618:2	O
directly	SAPHRIS.xml:S1:4621:8	O
compared	SAPHRIS.xml:S1:4630:8	O
to	SAPHRIS.xml:S1:4639:2	O
rates	SAPHRIS.xml:S1:4642:5	O
in	SAPHRIS.xml:S1:4648:2	O
the	SAPHRIS.xml:S1:4651:3	O
clinical	SAPHRIS.xml:S1:4655:8	O
trials	SAPHRIS.xml:S1:4664:6	O
of	SAPHRIS.xml:S1:4671:2	O
another	SAPHRIS.xml:S1:4674:7	O
drug	SAPHRIS.xml:S1:4682:4	O
and	SAPHRIS.xml:S1:4687:3	O
may	SAPHRIS.xml:S1:4691:3	O
not	SAPHRIS.xml:S1:4695:3	O
reflect	SAPHRIS.xml:S1:4699:7	O
the	SAPHRIS.xml:S1:4707:3	O
rates	SAPHRIS.xml:S1:4711:5	O
observed	SAPHRIS.xml:S1:4717:8	O
in	SAPHRIS.xml:S1:4726:2	O
practice	SAPHRIS.xml:S1:4729:8	O
.	SAPHRIS.xml:S1:4737:1	O

Adult	SAPHRIS.xml:S1:4747:5	O
Patients	SAPHRIS.xml:S1:4753:8	O
with	SAPHRIS.xml:S1:4762:4	O
Schizophrenia	SAPHRIS.xml:S1:4767:13	O
:	SAPHRIS.xml:S1:4780:1	O
The	SAPHRIS.xml:S1:4783:3	O
following	SAPHRIS.xml:S1:4787:9	O
findings	SAPHRIS.xml:S1:4797:8	O
are	SAPHRIS.xml:S1:4806:3	O
based	SAPHRIS.xml:S1:4810:5	O
on	SAPHRIS.xml:S1:4816:2	O
the	SAPHRIS.xml:S1:4819:3	O
short	SAPHRIS.xml:S1:4823:5	O
-	SAPHRIS.xml:S1:4828:1	O
term	SAPHRIS.xml:S1:4829:4	O
placebo	SAPHRIS.xml:S1:4834:7	O
-	SAPHRIS.xml:S1:4841:1	O
controlled	SAPHRIS.xml:S1:4842:10	O
pre	SAPHRIS.xml:S1:4853:3	O
-	SAPHRIS.xml:S1:4856:1	O
marketing	SAPHRIS.xml:S1:4857:9	O
trials	SAPHRIS.xml:S1:4867:6	O
for	SAPHRIS.xml:S1:4874:3	O
schizophrenia	SAPHRIS.xml:S1:4878:13	O
(	SAPHRIS.xml:S1:4892:1	O
a	SAPHRIS.xml:S1:4893:1	O
pool	SAPHRIS.xml:S1:4895:4	O
of	SAPHRIS.xml:S1:4900:2	O
three	SAPHRIS.xml:S1:4903:5	O
6	SAPHRIS.xml:S1:4909:1	O
-	SAPHRIS.xml:S1:4910:1	O
week	SAPHRIS.xml:S1:4911:4	O
fixed	SAPHRIS.xml:S1:4916:5	O
-	SAPHRIS.xml:S1:4921:1	O
dose	SAPHRIS.xml:S1:4922:4	O
trials	SAPHRIS.xml:S1:4927:6	O
and	SAPHRIS.xml:S1:4934:3	O
one	SAPHRIS.xml:S1:4938:3	O
6	SAPHRIS.xml:S1:4942:1	O
-	SAPHRIS.xml:S1:4943:1	O
week	SAPHRIS.xml:S1:4944:4	O
flexible	SAPHRIS.xml:S1:4949:8	O
-	SAPHRIS.xml:S1:4957:1	O
dose	SAPHRIS.xml:S1:4958:4	O
trial	SAPHRIS.xml:S1:4963:5	O
)	SAPHRIS.xml:S1:4968:1	O
in	SAPHRIS.xml:S1:4970:2	O
which	SAPHRIS.xml:S1:4973:5	O
sublingual	SAPHRIS.xml:S1:4979:10	O
SAPHRIS	SAPHRIS.xml:S1:4990:7	O
was	SAPHRIS.xml:S1:4998:3	O
administered	SAPHRIS.xml:S1:5002:12	O
in	SAPHRIS.xml:S1:5015:2	O
doses	SAPHRIS.xml:S1:5018:5	O
ranging	SAPHRIS.xml:S1:5024:7	O
from	SAPHRIS.xml:S1:5032:4	O
5	SAPHRIS.xml:S1:5037:1	O
to	SAPHRIS.xml:S1:5039:2	O
10	SAPHRIS.xml:S1:5042:2	O
mg	SAPHRIS.xml:S1:5045:2	O
twice	SAPHRIS.xml:S1:5048:5	O
daily	SAPHRIS.xml:S1:5054:5	O
.	SAPHRIS.xml:S1:5059:1	O

Adverse	SAPHRIS.xml:S1:5069:7	O
Reactions	SAPHRIS.xml:S1:5077:9	O
Associated	SAPHRIS.xml:S1:5087:10	O
with	SAPHRIS.xml:S1:5098:4	O
Discontinuation	SAPHRIS.xml:S1:5103:15	O
of	SAPHRIS.xml:S1:5119:2	O
Treatment	SAPHRIS.xml:S1:5122:9	O
:	SAPHRIS.xml:S1:5131:1	O
A	SAPHRIS.xml:S1:5134:1	O
total	SAPHRIS.xml:S1:5136:5	O
of	SAPHRIS.xml:S1:5142:2	O
9%	SAPHRIS.xml:S1:5145:2	O
of	SAPHRIS.xml:S1:5148:2	O
SAPHRIS	SAPHRIS.xml:S1:5151:7	O
-	SAPHRIS.xml:S1:5158:1	O
treated	SAPHRIS.xml:S1:5159:7	O
patients	SAPHRIS.xml:S1:5167:8	O
and	SAPHRIS.xml:S1:5176:3	O
10%	SAPHRIS.xml:S1:5180:3	O
of	SAPHRIS.xml:S1:5184:2	O
placebo	SAPHRIS.xml:S1:5187:7	O
-	SAPHRIS.xml:S1:5194:1	O
treated	SAPHRIS.xml:S1:5195:7	O
patients	SAPHRIS.xml:S1:5203:8	O
discontinued	SAPHRIS.xml:S1:5212:12	O
due	SAPHRIS.xml:S1:5225:3	O
to	SAPHRIS.xml:S1:5229:2	O
adverse	SAPHRIS.xml:S1:5232:7	O
reactions	SAPHRIS.xml:S1:5240:9	O
.	SAPHRIS.xml:S1:5249:1	O

There	SAPHRIS.xml:S1:5251:5	O
were	SAPHRIS.xml:S1:5257:4	O
no	SAPHRIS.xml:S1:5262:2	O
drug	SAPHRIS.xml:S1:5265:4	O
-	SAPHRIS.xml:S1:5269:1	O
related	SAPHRIS.xml:S1:5270:7	O
adverse	SAPHRIS.xml:S1:5278:7	O
reactions	SAPHRIS.xml:S1:5286:9	O
associated	SAPHRIS.xml:S1:5296:10	O
with	SAPHRIS.xml:S1:5307:4	O
discontinuation	SAPHRIS.xml:S1:5312:15	O
in	SAPHRIS.xml:S1:5328:2	O
patients	SAPHRIS.xml:S1:5331:8	O
treated	SAPHRIS.xml:S1:5340:7	O
with	SAPHRIS.xml:S1:5348:4	O
SAPHRIS	SAPHRIS.xml:S1:5353:7	O
at	SAPHRIS.xml:S1:5361:2	O
the	SAPHRIS.xml:S1:5364:3	O
rate	SAPHRIS.xml:S1:5368:4	O
of	SAPHRIS.xml:S1:5373:2	O
at	SAPHRIS.xml:S1:5376:2	O
least	SAPHRIS.xml:S1:5379:5	O
1%	SAPHRIS.xml:S1:5385:2	O
and	SAPHRIS.xml:S1:5388:3	O
at	SAPHRIS.xml:S1:5392:2	O
least	SAPHRIS.xml:S1:5395:5	O
twice	SAPHRIS.xml:S1:5401:5	O
the	SAPHRIS.xml:S1:5407:3	O
placebo	SAPHRIS.xml:S1:5411:7	O
rate	SAPHRIS.xml:S1:5419:4	O
.	SAPHRIS.xml:S1:5423:1	O

Adverse	SAPHRIS.xml:S1:5433:7	O
Reactions	SAPHRIS.xml:S1:5441:9	O
Occurring	SAPHRIS.xml:S1:5451:9	O
at	SAPHRIS.xml:S1:5461:2	O
an	SAPHRIS.xml:S1:5464:2	O
Incidence	SAPHRIS.xml:S1:5467:9	O
of	SAPHRIS.xml:S1:5477:2	O
2%	SAPHRIS.xml:S1:5480:2	O
or	SAPHRIS.xml:S1:5483:2	O
More	SAPHRIS.xml:S1:5486:4	O
in	SAPHRIS.xml:S1:5491:2	O
SAPHRIS	SAPHRIS.xml:S1:5494:7	O
-	SAPHRIS.xml:S1:5501:1	O
Treated	SAPHRIS.xml:S1:5502:7	O
Patients	SAPHRIS.xml:S1:5510:8	O
with	SAPHRIS.xml:S1:5519:4	O
Schizophrenia	SAPHRIS.xml:S1:5524:13	O
:	SAPHRIS.xml:S1:5537:1	O
Adverse	SAPHRIS.xml:S1:5540:7	O
reactions	SAPHRIS.xml:S1:5548:9	O
associated	SAPHRIS.xml:S1:5558:10	O
with	SAPHRIS.xml:S1:5569:4	O
the	SAPHRIS.xml:S1:5574:3	O
use	SAPHRIS.xml:S1:5578:3	O
of	SAPHRIS.xml:S1:5582:2	O
SAPHRIS	SAPHRIS.xml:S1:5585:7	O
(	SAPHRIS.xml:S1:5593:1	O
incidence	SAPHRIS.xml:S1:5594:9	O
of	SAPHRIS.xml:S1:5604:2	O
2%	SAPHRIS.xml:S1:5607:2	O
or	SAPHRIS.xml:S1:5610:2	O
greater	SAPHRIS.xml:S1:5613:7	O
,	SAPHRIS.xml:S1:5620:1	O
rounded	SAPHRIS.xml:S1:5622:7	O
to	SAPHRIS.xml:S1:5630:2	O
the	SAPHRIS.xml:S1:5633:3	O
nearest	SAPHRIS.xml:S1:5637:7	O
percent	SAPHRIS.xml:S1:5645:7	O
,	SAPHRIS.xml:S1:5652:1	O
and	SAPHRIS.xml:S1:5654:3	O
SAPHRIS	SAPHRIS.xml:S1:5658:7	O
incidence	SAPHRIS.xml:S1:5666:9	O
greater	SAPHRIS.xml:S1:5676:7	O
than	SAPHRIS.xml:S1:5684:4	O
placebo	SAPHRIS.xml:S1:5689:7	O
)	SAPHRIS.xml:S1:5696:1	O
that	SAPHRIS.xml:S1:5698:4	O
occurred	SAPHRIS.xml:S1:5703:8	O
during	SAPHRIS.xml:S1:5712:6	O
acute	SAPHRIS.xml:S1:5719:5	O
therapy	SAPHRIS.xml:S1:5725:7	O
(	SAPHRIS.xml:S1:5733:1	O
up	SAPHRIS.xml:S1:5734:2	O
to	SAPHRIS.xml:S1:5737:2	O
6	SAPHRIS.xml:S1:5740:1	O
-	SAPHRIS.xml:S1:5741:1	O
weeks	SAPHRIS.xml:S1:5742:5	O
in	SAPHRIS.xml:S1:5748:2	O
patients	SAPHRIS.xml:S1:5751:8	O
with	SAPHRIS.xml:S1:5760:4	O
schizophrenia	SAPHRIS.xml:S1:5765:13	O
)	SAPHRIS.xml:S1:5778:1	O
are	SAPHRIS.xml:S1:5780:3	O
shown	SAPHRIS.xml:S1:5784:5	O
in	SAPHRIS.xml:S1:5790:2	O
Table	SAPHRIS.xml:S1:5794:5	O
8	SAPHRIS.xml:S1:5800:1	O
.	SAPHRIS.xml:S1:5803:1	O

Table	SAPHRIS.xml:S1:5809:5	O
8	SAPHRIS.xml:S1:5815:1	O
:	SAPHRIS.xml:S1:5816:1	O
Adverse	SAPHRIS.xml:S1:5818:7	O
Reactions	SAPHRIS.xml:S1:5826:9	O
Reported	SAPHRIS.xml:S1:5836:8	O
in	SAPHRIS.xml:S1:5845:2	O
2%	SAPHRIS.xml:S1:5848:2	O
or	SAPHRIS.xml:S1:5851:2	O
More	SAPHRIS.xml:S1:5854:4	O
of	SAPHRIS.xml:S1:5859:2	O
Adult	SAPHRIS.xml:S1:5862:5	O
Patients	SAPHRIS.xml:S1:5868:8	O
in	SAPHRIS.xml:S1:5877:2	O
Any	SAPHRIS.xml:S1:5880:3	O
SAPHRIS	SAPHRIS.xml:S1:5884:7	O
Dose	SAPHRIS.xml:S1:5892:4	O
Group	SAPHRIS.xml:S1:5897:5	O
and	SAPHRIS.xml:S1:5903:3	O
Which	SAPHRIS.xml:S1:5907:5	O
Occurred	SAPHRIS.xml:S1:5913:8	O
at	SAPHRIS.xml:S1:5922:2	O
Greater	SAPHRIS.xml:S1:5925:7	O
Incidence	SAPHRIS.xml:S1:5933:9	O
Than	SAPHRIS.xml:S1:5943:4	O
in	SAPHRIS.xml:S1:5948:2	O
the	SAPHRIS.xml:S1:5951:3	O
Placebo	SAPHRIS.xml:S1:5955:7	O
Group	SAPHRIS.xml:S1:5963:5	O
in	SAPHRIS.xml:S1:5969:2	O
6	SAPHRIS.xml:S1:5972:1	O
-	SAPHRIS.xml:S1:5973:1	O
Week	SAPHRIS.xml:S1:5974:4	O
Schizophrenia	SAPHRIS.xml:S1:5979:13	O
Trials	SAPHRIS.xml:S1:5993:6	O

Akathisia	SAPHRIS.xml:S1:6005:9	B-AdverseReaction
includes	SAPHRIS.xml:S1:6015:8	O
:	SAPHRIS.xml:S1:6023:1	O
akathisia	SAPHRIS.xml:S1:6025:9	B-AdverseReaction
and	SAPHRIS.xml:S1:6035:3	O
hyperkinesia	SAPHRIS.xml:S1:6039:12	B-AdverseReaction
.	SAPHRIS.xml:S1:6051:1	O

Extrapyramidal	SAPHRIS.xml:S1:6060:14	B-AdverseReaction
symptoms	SAPHRIS.xml:S1:6075:8	I-AdverseReaction
included	SAPHRIS.xml:S1:6084:8	O
dystonia	SAPHRIS.xml:S1:6093:8	B-AdverseReaction
,	SAPHRIS.xml:S1:6101:1	O
oculogyration	SAPHRIS.xml:S1:6103:13	B-AdverseReaction
,	SAPHRIS.xml:S1:6116:1	O
dyskinesia	SAPHRIS.xml:S1:6118:10	B-AdverseReaction
,	SAPHRIS.xml:S1:6128:1	O
tardive	SAPHRIS.xml:S1:6130:7	B-AdverseReaction
dyskinesia	SAPHRIS.xml:S1:6138:10	I-AdverseReaction
,	SAPHRIS.xml:S1:6148:1	O
muscle	SAPHRIS.xml:S1:6150:6	B-AdverseReaction
rigidity	SAPHRIS.xml:S1:6157:8	I-AdverseReaction
,	SAPHRIS.xml:S1:6165:1	O
parkinsonism	SAPHRIS.xml:S1:6167:12	B-AdverseReaction
,	SAPHRIS.xml:S1:6179:1	O
tremor	SAPHRIS.xml:S1:6181:6	B-AdverseReaction
,	SAPHRIS.xml:S1:6187:1	O
and	SAPHRIS.xml:S1:6189:3	O
extrapyramidal	SAPHRIS.xml:S1:6193:14	B-AdverseReaction
disorder	SAPHRIS.xml:S1:6208:8	I-AdverseReaction
(	SAPHRIS.xml:S1:6217:1	O
excluding	SAPHRIS.xml:S1:6218:9	B-Negation
akathisia	SAPHRIS.xml:S1:6228:9	B-AdverseReaction
)	SAPHRIS.xml:S1:6237:1	O
.	SAPHRIS.xml:S1:6238:1	O

?	SAPHRIS.xml:S1:6246:1	O

Somnolence	SAPHRIS.xml:S1:6248:10	B-AdverseReaction
includes	SAPHRIS.xml:S1:6259:8	O
the	SAPHRIS.xml:S1:6268:3	O
following	SAPHRIS.xml:S1:6272:9	O
events	SAPHRIS.xml:S1:6282:6	O
:	SAPHRIS.xml:S1:6288:1	O
somnolence	SAPHRIS.xml:S1:6290:10	B-AdverseReaction
,	SAPHRIS.xml:S1:6300:1	O
sedation	SAPHRIS.xml:S1:6302:8	B-AdverseReaction
,	SAPHRIS.xml:S1:6310:1	O
and	SAPHRIS.xml:S1:6312:3	O
hypersomnia	SAPHRIS.xml:S1:6316:11	B-AdverseReaction
.	SAPHRIS.xml:S1:6327:1	O

S	SAPHRIS.xml:S1:6335:1	O
Also	SAPHRIS.xml:S1:6337:4	O
includes	SAPHRIS.xml:S1:6342:8	O
the	SAPHRIS.xml:S1:6351:3	O
Flexible	SAPHRIS.xml:S1:6355:8	O
-	SAPHRIS.xml:S1:6363:1	O
dose	SAPHRIS.xml:S1:6364:4	O
trial	SAPHRIS.xml:S1:6369:5	O
(	SAPHRIS.xml:S1:6375:1	O
N	SAPHRIS.xml:S1:6376:1	O
90	SAPHRIS.xml:S1:6378:2	O
)	SAPHRIS.xml:S1:6380:1	O
.	SAPHRIS.xml:S1:6381:1	O

System	SAPHRIS.xml:S1:6393:6	O

Organ	SAPHRIS.xml:S1:6400:5	O
Class	SAPHRIS.xml:S1:6406:5	O
Preferred	SAPHRIS.xml:S1:6413:9	O
Term	SAPHRIS.xml:S1:6423:4	O
Placebo	SAPHRIS.xml:S1:6433:7	O
N	SAPHRIS.xml:S1:6444:1	O
378	SAPHRIS.xml:S1:6446:3	O
SAPHRIS	SAPHRIS.xml:S1:6460:7	O
5	SAPHRIS.xml:S1:6468:1	O
mg	SAPHRIS.xml:S1:6470:2	O
twice	SAPHRIS.xml:S1:6473:5	O
daily	SAPHRIS.xml:S1:6479:5	O
N	SAPHRIS.xml:S1:6488:1	O
274	SAPHRIS.xml:S1:6490:3	O
SAPHRIS	SAPHRIS.xml:S1:6504:7	O
10	SAPHRIS.xml:S1:6512:2	O
mg	SAPHRIS.xml:S1:6515:2	O
twice	SAPHRIS.xml:S1:6518:5	O
daily	SAPHRIS.xml:S1:6524:5	O
N	SAPHRIS.xml:S1:6533:1	O
208	SAPHRIS.xml:S1:6535:3	O
All	SAPHRIS.xml:S1:6549:3	O
SAPHRIS	SAPHRIS.xml:S1:6553:7	O
S	SAPHRIS.xml:S1:6564:1	O
5	SAPHRIS.xml:S1:6569:1	O
mg	SAPHRIS.xml:S1:6571:2	O
or	SAPHRIS.xml:S1:6574:2	O
10	SAPHRIS.xml:S1:6580:2	O
mg	SAPHRIS.xml:S1:6583:2	O
twice	SAPHRIS.xml:S1:6586:5	O
daily	SAPHRIS.xml:S1:6592:5	O
N	SAPHRIS.xml:S1:6601:1	O
572	SAPHRIS.xml:S1:6603:3	O

Gastrointestinal	SAPHRIS.xml:S1:6620:16	O
disorders	SAPHRIS.xml:S1:6637:9	O

Constipation	SAPHRIS.xml:S1:6734:12	B-AdverseReaction
6	SAPHRIS.xml:S1:6769:1	O
7	SAPHRIS.xml:S1:6785:1	O
4	SAPHRIS.xml:S1:6800:1	O
5	SAPHRIS.xml:S1:6817:1	O

Dry	SAPHRIS.xml:S1:6845:3	B-AdverseReaction
mouth	SAPHRIS.xml:S1:6849:5	I-AdverseReaction
1	SAPHRIS.xml:S1:6880:1	O
3	SAPHRIS.xml:S1:6896:1	O
1	SAPHRIS.xml:S1:6911:1	O
2	SAPHRIS.xml:S1:6928:1	O

Oral	SAPHRIS.xml:S1:6956:4	B-AdverseReaction
hypoesthesia	SAPHRIS.xml:S1:6961:12	I-AdverseReaction
1	SAPHRIS.xml:S1:6991:1	O
6	SAPHRIS.xml:S1:7007:1	O
7	SAPHRIS.xml:S1:7022:1	O
5	SAPHRIS.xml:S1:7039:1	O

Salivary	SAPHRIS.xml:S1:7067:8	B-AdverseReaction
hypersecretion	SAPHRIS.xml:S1:7076:14	I-AdverseReaction
0	SAPHRIS.xml:S1:7102:1	O
1	SAPHRIS.xml:S1:7119:1	O
4	SAPHRIS.xml:S1:7133:1	O
2	SAPHRIS.xml:S1:7150:1	O

Stomach	SAPHRIS.xml:S1:7178:7	B-AdverseReaction
discomfort	SAPHRIS.xml:S1:7186:10	I-AdverseReaction
1	SAPHRIS.xml:S1:7213:1	O
1	SAPHRIS.xml:S1:7230:1	O
3	SAPHRIS.xml:S1:7244:1	O
2	SAPHRIS.xml:S1:7261:1	O

Vomiting	SAPHRIS.xml:S1:7289:8	B-AdverseReaction
5	SAPHRIS.xml:S1:7324:1	O
4	SAPHRIS.xml:S1:7340:1	O
7	SAPHRIS.xml:S1:7355:1	O
5	SAPHRIS.xml:S1:7372:1	O

General	SAPHRIS.xml:S1:7397:7	O
disorders	SAPHRIS.xml:S1:7405:9	O

Fatigue	SAPHRIS.xml:S1:7511:7	B-AdverseReaction
3	SAPHRIS.xml:S1:7546:1	O
4	SAPHRIS.xml:S1:7562:1	O
3	SAPHRIS.xml:S1:7577:1	O
3	SAPHRIS.xml:S1:7594:1	O

Irritability	SAPHRIS.xml:S1:7622:12	B-AdverseReaction
1	SAPHRIS.xml:S1:7658:1	O
2	SAPHRIS.xml:S1:7673:1	O
1	SAPHRIS.xml:S1:7688:1	O
2	SAPHRIS.xml:S1:7705:1	O

Investigations	SAPHRIS.xml:S1:7730:14	O

Increased	SAPHRIS.xml:S1:7844:9	B-AdverseReaction
weight	SAPHRIS.xml:S1:7854:6	I-AdverseReaction
1	SAPHRIS.xml:S1:7880:1	O
2	SAPHRIS.xml:S1:7895:1	O
2	SAPHRIS.xml:S1:7910:1	O
3	SAPHRIS.xml:S1:7927:1	O

Metabolism	SAPHRIS.xml:S1:7952:10	O
disorders	SAPHRIS.xml:S1:7963:9	O

Increased	SAPHRIS.xml:S1:8066:9	B-AdverseReaction
appetite	SAPHRIS.xml:S1:8076:8	I-AdverseReaction
1	SAPHRIS.xml:S1:8102:1	O
3	SAPHRIS.xml:S1:8117:1	O
0	SAPHRIS.xml:S1:8132:1	O
2	SAPHRIS.xml:S1:8149:1	O

Nervous	SAPHRIS.xml:S1:8174:7	O
system	SAPHRIS.xml:S1:8182:6	O
disorders	SAPHRIS.xml:S1:8189:9	O

Akathisia	SAPHRIS.xml:S1:8288:9	B-AdverseReaction
3	SAPHRIS.xml:S1:8323:1	O
4	SAPHRIS.xml:S1:8339:1	O
11	SAPHRIS.xml:S1:8354:2	O
6	SAPHRIS.xml:S1:8371:1	O

Dizziness	SAPHRIS.xml:S1:8399:9	B-AdverseReaction
4	SAPHRIS.xml:S1:8434:1	O
7	SAPHRIS.xml:S1:8450:1	O
3	SAPHRIS.xml:S1:8465:1	O
5	SAPHRIS.xml:S1:8482:1	O

Extrapyramidal	SAPHRIS.xml:S1:8510:14	B-AdverseReaction
symptoms	SAPHRIS.xml:S1:8525:8	I-AdverseReaction
(	SAPHRIS.xml:S1:8534:1	O
excluding	SAPHRIS.xml:S1:8535:9	B-Negation
akathisia	SAPHRIS.xml:S1:8545:9	B-AdverseReaction
)	SAPHRIS.xml:S1:8554:1	O
7	SAPHRIS.xml:S1:8561:1	O
9	SAPHRIS.xml:S1:8577:1	O
12	SAPHRIS.xml:S1:8592:2	O
10	SAPHRIS.xml:S1:8609:2	O

Somnolence	SAPHRIS.xml:S1:8637:10	B-AdverseReaction
?	SAPHRIS.xml:S1:8649:1	O

7	SAPHRIS.xml:S1:8672:1	O
15	SAPHRIS.xml:S1:8688:2	O
13	SAPHRIS.xml:S1:8703:2	O
13	SAPHRIS.xml:S1:8720:2	O

Psychiatric	SAPHRIS.xml:S1:8745:11	O
disorders	SAPHRIS.xml:S1:8757:9	O

Insomnia	SAPHRIS.xml:S1:8859:8	B-AdverseReaction
13	SAPHRIS.xml:S1:8894:2	O
16	SAPHRIS.xml:S1:8910:2	O
15	SAPHRIS.xml:S1:8925:2	O
15	SAPHRIS.xml:S1:8942:2	O

Vascular	SAPHRIS.xml:S1:8967:8	O
disorders	SAPHRIS.xml:S1:8976:9	O

Hypertension	SAPHRIS.xml:S1:9081:12	B-AdverseReaction
2	SAPHRIS.xml:S1:9116:1	O
2	SAPHRIS.xml:S1:9132:1	O
3	SAPHRIS.xml:S1:9147:1	O
2	SAPHRIS.xml:S1:9164:1	O

Dose	SAPHRIS.xml:S1:9201:4	O
-	SAPHRIS.xml:S1:9205:1	O
Related	SAPHRIS.xml:S1:9206:7	O
Adverse	SAPHRIS.xml:S1:9214:7	O
Reactions	SAPHRIS.xml:S1:9222:9	O
:	SAPHRIS.xml:S1:9231:1	O
In	SAPHRIS.xml:S1:9234:2	O
the	SAPHRIS.xml:S1:9237:3	O
short	SAPHRIS.xml:S1:9241:5	O
term	SAPHRIS.xml:S1:9247:4	O
schizophrenia	SAPHRIS.xml:S1:9252:13	O
trials	SAPHRIS.xml:S1:9266:6	O
the	SAPHRIS.xml:S1:9273:3	O
incidence	SAPHRIS.xml:S1:9277:9	O
of	SAPHRIS.xml:S1:9287:2	O
akathisia	SAPHRIS.xml:S1:9290:9	B-AdverseReaction
appeared	SAPHRIS.xml:S1:9300:8	O
to	SAPHRIS.xml:S1:9309:2	O
be	SAPHRIS.xml:S1:9312:2	O
dose	SAPHRIS.xml:S1:9315:4	O
-	SAPHRIS.xml:S1:9319:1	O
related	SAPHRIS.xml:S1:9320:7	O
(	SAPHRIS.xml:S1:9328:1	O
seeTable	SAPHRIS.xml:S1:9329:8	O
8	SAPHRIS.xml:S1:9338:1	O
)	SAPHRIS.xml:S1:9339:1	O
.	SAPHRIS.xml:S1:9340:1	O

Monotherapy	SAPHRIS.xml:S1:9350:11	O

in	SAPHRIS.xml:S1:9362:2	O
Adult	SAPHRIS.xml:S1:9365:5	O
Patients	SAPHRIS.xml:S1:9371:8	O
with	SAPHRIS.xml:S1:9380:4	O
Bipolar	SAPHRIS.xml:S1:9385:7	O
Mania	SAPHRIS.xml:S1:9393:5	O
:	SAPHRIS.xml:S1:9398:1	O
The	SAPHRIS.xml:S1:9401:3	O
following	SAPHRIS.xml:S1:9405:9	O
findings	SAPHRIS.xml:S1:9415:8	O
are	SAPHRIS.xml:S1:9424:3	O
based	SAPHRIS.xml:S1:9428:5	O
on	SAPHRIS.xml:S1:9434:2	O
the	SAPHRIS.xml:S1:9437:3	O
short	SAPHRIS.xml:S1:9441:5	O
-	SAPHRIS.xml:S1:9446:1	O
term	SAPHRIS.xml:S1:9447:4	O
placebo	SAPHRIS.xml:S1:9452:7	O
-	SAPHRIS.xml:S1:9459:1	O
controlled	SAPHRIS.xml:S1:9460:10	O
trials	SAPHRIS.xml:S1:9471:6	O
for	SAPHRIS.xml:S1:9478:3	O
bipolar	SAPHRIS.xml:S1:9482:7	O
mania	SAPHRIS.xml:S1:9490:5	O
(	SAPHRIS.xml:S1:9496:1	O
a	SAPHRIS.xml:S1:9497:1	O
pool	SAPHRIS.xml:S1:9499:4	O
of	SAPHRIS.xml:S1:9504:2	O
two	SAPHRIS.xml:S1:9507:3	O
3	SAPHRIS.xml:S1:9511:1	O
-	SAPHRIS.xml:S1:9512:1	O
week	SAPHRIS.xml:S1:9513:4	O
flexible	SAPHRIS.xml:S1:9518:8	O
-	SAPHRIS.xml:S1:9526:1	O
dose	SAPHRIS.xml:S1:9527:4	O
trials	SAPHRIS.xml:S1:9532:6	O
)	SAPHRIS.xml:S1:9538:1	O
in	SAPHRIS.xml:S1:9540:2	O
which	SAPHRIS.xml:S1:9543:5	O
sublingual	SAPHRIS.xml:S1:9549:10	O
SAPHRIS	SAPHRIS.xml:S1:9560:7	O
was	SAPHRIS.xml:S1:9568:3	O
administered	SAPHRIS.xml:S1:9572:12	O
in	SAPHRIS.xml:S1:9585:2	O
doses	SAPHRIS.xml:S1:9588:5	O
of	SAPHRIS.xml:S1:9594:2	O
5	SAPHRIS.xml:S1:9597:1	O
mg	SAPHRIS.xml:S1:9599:2	O
or	SAPHRIS.xml:S1:9602:2	O
10	SAPHRIS.xml:S1:9605:2	O
mg	SAPHRIS.xml:S1:9608:2	O
twice	SAPHRIS.xml:S1:9611:5	O
daily	SAPHRIS.xml:S1:9617:5	O
.	SAPHRIS.xml:S1:9622:1	O

Adverse	SAPHRIS.xml:S1:9632:7	O
Reactions	SAPHRIS.xml:S1:9640:9	O
Associated	SAPHRIS.xml:S1:9650:10	O
with	SAPHRIS.xml:S1:9661:4	O
Discontinuation	SAPHRIS.xml:S1:9666:15	O
of	SAPHRIS.xml:S1:9682:2	O
Treatment	SAPHRIS.xml:S1:9685:9	O
:	SAPHRIS.xml:S1:9694:1	O
Approximately	SAPHRIS.xml:S1:9697:13	O
10%	SAPHRIS.xml:S1:9711:3	O
(	SAPHRIS.xml:S1:9715:1	O
38	SAPHRIS.xml:S1:9716:2	O
379	SAPHRIS.xml:S1:9719:3	O
)	SAPHRIS.xml:S1:9722:1	O
of	SAPHRIS.xml:S1:9724:2	O
SAPHRIS	SAPHRIS.xml:S1:9727:7	O
-	SAPHRIS.xml:S1:9734:1	O
treated	SAPHRIS.xml:S1:9735:7	O
patients	SAPHRIS.xml:S1:9743:8	O
in	SAPHRIS.xml:S1:9752:2	O
short	SAPHRIS.xml:S1:9755:5	O
-	SAPHRIS.xml:S1:9760:1	O
term	SAPHRIS.xml:S1:9761:4	O
,	SAPHRIS.xml:S1:9765:1	O
placebo	SAPHRIS.xml:S1:9767:7	O
-	SAPHRIS.xml:S1:9774:1	O
controlled	SAPHRIS.xml:S1:9775:10	O
trials	SAPHRIS.xml:S1:9786:6	O
discontinued	SAPHRIS.xml:S1:9793:12	O
treatment	SAPHRIS.xml:S1:9806:9	O
due	SAPHRIS.xml:S1:9816:3	O
to	SAPHRIS.xml:S1:9820:2	O
an	SAPHRIS.xml:S1:9823:2	O
adverse	SAPHRIS.xml:S1:9826:7	O
reaction	SAPHRIS.xml:S1:9834:8	O
,	SAPHRIS.xml:S1:9842:1	O
compared	SAPHRIS.xml:S1:9844:8	O
with	SAPHRIS.xml:S1:9853:4	O
about	SAPHRIS.xml:S1:9858:5	O
6%	SAPHRIS.xml:S1:9864:2	O
(	SAPHRIS.xml:S1:9867:1	O
12	SAPHRIS.xml:S1:9868:2	O
203	SAPHRIS.xml:S1:9871:3	O
)	SAPHRIS.xml:S1:9874:1	O
on	SAPHRIS.xml:S1:9876:2	O
placebo	SAPHRIS.xml:S1:9879:7	O
.	SAPHRIS.xml:S1:9886:1	O

The	SAPHRIS.xml:S1:9888:3	O
most	SAPHRIS.xml:S1:9892:4	O
common	SAPHRIS.xml:S1:9897:6	O
adverse	SAPHRIS.xml:S1:9904:7	O
reactions	SAPHRIS.xml:S1:9912:9	O
associated	SAPHRIS.xml:S1:9922:10	O
with	SAPHRIS.xml:S1:9933:4	O
discontinuation	SAPHRIS.xml:S1:9938:15	O
in	SAPHRIS.xml:S1:9954:2	O
patients	SAPHRIS.xml:S1:9957:8	O
treated	SAPHRIS.xml:S1:9966:7	O
with	SAPHRIS.xml:S1:9974:4	O
SAPHRIS	SAPHRIS.xml:S1:9979:7	O
(	SAPHRIS.xml:S1:9987:1	O
rates	SAPHRIS.xml:S1:9988:5	O
at	SAPHRIS.xml:S1:9994:2	O
least	SAPHRIS.xml:S1:9997:5	O
1%	SAPHRIS.xml:S1:10003:2	O
and	SAPHRIS.xml:S1:10006:3	O
at	SAPHRIS.xml:S1:10010:2	O
least	SAPHRIS.xml:S1:10013:5	O
twice	SAPHRIS.xml:S1:10019:5	O
the	SAPHRIS.xml:S1:10025:3	O
placebo	SAPHRIS.xml:S1:10029:7	O
rate	SAPHRIS.xml:S1:10037:4	O
)	SAPHRIS.xml:S1:10041:1	O
were	SAPHRIS.xml:S1:10043:4	O
anxiety	SAPHRIS.xml:S1:10048:7	B-AdverseReaction
(	SAPHRIS.xml:S1:10056:1	O
1.1%	SAPHRIS.xml:S1:10057:4	O
)	SAPHRIS.xml:S1:10061:1	O
and	SAPHRIS.xml:S1:10063:3	O
oral	SAPHRIS.xml:S1:10067:4	B-AdverseReaction
hypoesthesia	SAPHRIS.xml:S1:10072:12	I-AdverseReaction
(	SAPHRIS.xml:S1:10085:1	O
1.1%	SAPHRIS.xml:S1:10086:4	O
)	SAPHRIS.xml:S1:10090:1	O
compared	SAPHRIS.xml:S1:10092:8	O
to	SAPHRIS.xml:S1:10101:2	O
placebo	SAPHRIS.xml:S1:10104:7	O
(	SAPHRIS.xml:S1:10112:1	O
0%	SAPHRIS.xml:S1:10113:2	O
)	SAPHRIS.xml:S1:10115:1	O
.	SAPHRIS.xml:S1:10116:1	O

Adverse	SAPHRIS.xml:S1:10126:7	O
Reactions	SAPHRIS.xml:S1:10134:9	O
Occurring	SAPHRIS.xml:S1:10144:9	O
at	SAPHRIS.xml:S1:10154:2	O
an	SAPHRIS.xml:S1:10157:2	O
Incidence	SAPHRIS.xml:S1:10160:9	O
of	SAPHRIS.xml:S1:10170:2	O
2%	SAPHRIS.xml:S1:10173:2	O
or	SAPHRIS.xml:S1:10176:2	O
More	SAPHRIS.xml:S1:10179:4	O
Among	SAPHRIS.xml:S1:10184:5	O
SAPHRIS	SAPHRIS.xml:S1:10190:7	O
-	SAPHRIS.xml:S1:10197:1	O
Treated	SAPHRIS.xml:S1:10198:7	O
(	SAPHRIS.xml:S1:10206:1	O
Monotherapy	SAPHRIS.xml:S1:10207:11	O
)	SAPHRIS.xml:S1:10218:1	O
patients	SAPHRIS.xml:S1:10220:8	O
with	SAPHRIS.xml:S1:10229:4	O
Bipolar	SAPHRIS.xml:S1:10234:7	O
I	SAPHRIS.xml:S1:10242:1	O
Disorder	SAPHRIS.xml:S1:10244:8	O
:	SAPHRIS.xml:S1:10252:1	O
Adverse	SAPHRIS.xml:S1:10255:7	O
reactions	SAPHRIS.xml:S1:10263:9	O
associated	SAPHRIS.xml:S1:10273:10	O
with	SAPHRIS.xml:S1:10284:4	O
the	SAPHRIS.xml:S1:10289:3	O
use	SAPHRIS.xml:S1:10293:3	O
of	SAPHRIS.xml:S1:10297:2	O
SAPHRIS	SAPHRIS.xml:S1:10300:7	O
(	SAPHRIS.xml:S1:10308:1	O
incidence	SAPHRIS.xml:S1:10309:9	O
of	SAPHRIS.xml:S1:10319:2	O
2%	SAPHRIS.xml:S1:10322:2	O
or	SAPHRIS.xml:S1:10325:2	O
greater	SAPHRIS.xml:S1:10328:7	O
,	SAPHRIS.xml:S1:10335:1	O
rounded	SAPHRIS.xml:S1:10337:7	O
to	SAPHRIS.xml:S1:10345:2	O
the	SAPHRIS.xml:S1:10348:3	O
nearest	SAPHRIS.xml:S1:10352:7	O
percent	SAPHRIS.xml:S1:10360:7	O
,	SAPHRIS.xml:S1:10367:1	O
and	SAPHRIS.xml:S1:10369:3	O
SAPHRIS	SAPHRIS.xml:S1:10373:7	O
incidence	SAPHRIS.xml:S1:10381:9	O
greater	SAPHRIS.xml:S1:10391:7	O
than	SAPHRIS.xml:S1:10399:4	O
placebo	SAPHRIS.xml:S1:10404:7	O
)	SAPHRIS.xml:S1:10411:1	O
that	SAPHRIS.xml:S1:10413:4	O
occurred	SAPHRIS.xml:S1:10418:8	O
during	SAPHRIS.xml:S1:10427:6	O
acute	SAPHRIS.xml:S1:10434:5	O
monotherapy	SAPHRIS.xml:S1:10440:11	O
(	SAPHRIS.xml:S1:10452:1	O
up	SAPHRIS.xml:S1:10453:2	O
to	SAPHRIS.xml:S1:10456:2	O
3	SAPHRIS.xml:S1:10459:1	O
-	SAPHRIS.xml:S1:10460:1	O
weeks	SAPHRIS.xml:S1:10461:5	O
in	SAPHRIS.xml:S1:10467:2	O
patients	SAPHRIS.xml:S1:10470:8	O
with	SAPHRIS.xml:S1:10479:4	O
bipolar	SAPHRIS.xml:S1:10484:7	O
mania	SAPHRIS.xml:S1:10492:5	O
)	SAPHRIS.xml:S1:10497:1	O
are	SAPHRIS.xml:S1:10499:3	O
shown	SAPHRIS.xml:S1:10503:5	O
in	SAPHRIS.xml:S1:10509:2	O
Table	SAPHRIS.xml:S1:10513:5	O
9	SAPHRIS.xml:S1:10519:1	O
.	SAPHRIS.xml:S1:10522:1	O

Table	SAPHRIS.xml:S1:10528:5	O
9	SAPHRIS.xml:S1:10534:1	O
:	SAPHRIS.xml:S1:10535:1	O
Adverse	SAPHRIS.xml:S1:10537:7	O
Reactions	SAPHRIS.xml:S1:10545:9	O
Reported	SAPHRIS.xml:S1:10555:8	O
in	SAPHRIS.xml:S1:10564:2	O
2%	SAPHRIS.xml:S1:10567:2	O
or	SAPHRIS.xml:S1:10570:2	O
More	SAPHRIS.xml:S1:10573:4	O
of	SAPHRIS.xml:S1:10578:2	O
Adult	SAPHRIS.xml:S1:10581:5	O
Patients	SAPHRIS.xml:S1:10587:8	O
in	SAPHRIS.xml:S1:10596:2	O
Any	SAPHRIS.xml:S1:10599:3	O
SAPHRIS	SAPHRIS.xml:S1:10603:7	O
Dose	SAPHRIS.xml:S1:10611:4	O
Group	SAPHRIS.xml:S1:10616:5	O
and	SAPHRIS.xml:S1:10622:3	O
Which	SAPHRIS.xml:S1:10626:5	O
Occurred	SAPHRIS.xml:S1:10632:8	O
at	SAPHRIS.xml:S1:10641:2	O
Greater	SAPHRIS.xml:S1:10644:7	O
Incidence	SAPHRIS.xml:S1:10652:9	O
Than	SAPHRIS.xml:S1:10662:4	O
in	SAPHRIS.xml:S1:10667:2	O
the	SAPHRIS.xml:S1:10670:3	O
Placebo	SAPHRIS.xml:S1:10674:7	O
Group	SAPHRIS.xml:S1:10682:5	O
in	SAPHRIS.xml:S1:10688:2	O
3	SAPHRIS.xml:S1:10691:1	O
-	SAPHRIS.xml:S1:10692:1	O
Week	SAPHRIS.xml:S1:10693:4	O
Bipolar	SAPHRIS.xml:S1:10698:7	O
Mania	SAPHRIS.xml:S1:10706:5	O
Trials	SAPHRIS.xml:S1:10712:6	O

SAPHRIS	SAPHRIS.xml:S1:10724:7	O
5	SAPHRIS.xml:S1:10732:1	O
mg	SAPHRIS.xml:S1:10734:2	O
to	SAPHRIS.xml:S1:10737:2	O
10	SAPHRIS.xml:S1:10740:2	O
mg	SAPHRIS.xml:S1:10743:2	O
twice	SAPHRIS.xml:S1:10746:5	O
daily	SAPHRIS.xml:S1:10752:5	O
with	SAPHRIS.xml:S1:10758:4	O
flexible	SAPHRIS.xml:S1:10763:8	O
dosing	SAPHRIS.xml:S1:10772:6	O
.	SAPHRIS.xml:S1:10778:1	O

Extrapyramidal	SAPHRIS.xml:S1:10787:14	B-AdverseReaction
symptoms	SAPHRIS.xml:S1:10802:8	I-AdverseReaction
included	SAPHRIS.xml:S1:10811:8	O
:	SAPHRIS.xml:S1:10819:1	O
dystonia	SAPHRIS.xml:S1:10821:8	B-AdverseReaction
,	SAPHRIS.xml:S1:10829:1	O
blepharospasm	SAPHRIS.xml:S1:10831:13	B-AdverseReaction
,	SAPHRIS.xml:S1:10844:1	O
torticollis	SAPHRIS.xml:S1:10846:11	B-AdverseReaction
,	SAPHRIS.xml:S1:10857:1	O
dyskinesia	SAPHRIS.xml:S1:10859:10	B-AdverseReaction
,	SAPHRIS.xml:S1:10869:1	O
tardive	SAPHRIS.xml:S1:10871:7	B-AdverseReaction
dyskinesia	SAPHRIS.xml:S1:10879:10	I-AdverseReaction
,	SAPHRIS.xml:S1:10889:1	O
muscle	SAPHRIS.xml:S1:10891:6	B-AdverseReaction
rigidity	SAPHRIS.xml:S1:10898:8	I-AdverseReaction
,	SAPHRIS.xml:S1:10906:1	O
parkinsonism	SAPHRIS.xml:S1:10908:12	B-AdverseReaction
,	SAPHRIS.xml:S1:10920:1	O
gait	SAPHRIS.xml:S1:10922:4	B-AdverseReaction
disturbance	SAPHRIS.xml:S1:10927:11	I-AdverseReaction
,	SAPHRIS.xml:S1:10938:1	O
masked	SAPHRIS.xml:S1:10940:6	B-AdverseReaction
facies	SAPHRIS.xml:S1:10947:6	I-AdverseReaction
,	SAPHRIS.xml:S1:10953:1	O
and	SAPHRIS.xml:S1:10955:3	O
tremor	SAPHRIS.xml:S1:10959:6	B-AdverseReaction
(	SAPHRIS.xml:S1:10966:1	O
excluding	SAPHRIS.xml:S1:10967:9	B-Negation
akathisia	SAPHRIS.xml:S1:10977:9	B-AdverseReaction
)	SAPHRIS.xml:S1:10986:1	O
.	SAPHRIS.xml:S1:10987:1	O

?	SAPHRIS.xml:S1:10995:1	O

Somnolence	SAPHRIS.xml:S1:10997:10	B-AdverseReaction
includes	SAPHRIS.xml:S1:11008:8	O
the	SAPHRIS.xml:S1:11017:3	O
following	SAPHRIS.xml:S1:11021:9	O
events	SAPHRIS.xml:S1:11031:6	O
:	SAPHRIS.xml:S1:11037:1	O
somnolence	SAPHRIS.xml:S1:11039:10	B-AdverseReaction
,	SAPHRIS.xml:S1:11049:1	O
sedation	SAPHRIS.xml:S1:11051:8	B-AdverseReaction
,	SAPHRIS.xml:S1:11059:1	O
and	SAPHRIS.xml:S1:11061:3	O
hypersomnia	SAPHRIS.xml:S1:11065:11	B-AdverseReaction
.	SAPHRIS.xml:S1:11076:1	O

System	SAPHRIS.xml:S1:11088:6	O

Organ	SAPHRIS.xml:S1:11095:5	O
Class	SAPHRIS.xml:S1:11101:5	O
Preferred	SAPHRIS.xml:S1:11107:9	O
Term	SAPHRIS.xml:S1:11117:4	O
Placebo	SAPHRIS.xml:S1:11137:7	O
N	SAPHRIS.xml:S1:11148:1	O
203	SAPHRIS.xml:S1:11150:3	O
SAPHRIS	SAPHRIS.xml:S1:11164:7	O
5	SAPHRIS.xml:S1:11175:1	O
mg	SAPHRIS.xml:S1:11177:2	O
or	SAPHRIS.xml:S1:11180:2	O
10	SAPHRIS.xml:S1:11183:2	O
mg	SAPHRIS.xml:S1:11186:2	O
twice	SAPHRIS.xml:S1:11189:5	O
daily	SAPHRIS.xml:S1:11195:5	O
N	SAPHRIS.xml:S1:11205:1	O
379	SAPHRIS.xml:S1:11207:3	O

Gastrointestinal	SAPHRIS.xml:S1:11224:16	O
disorders	SAPHRIS.xml:S1:11241:9	O

Dry	SAPHRIS.xml:S1:11279:3	B-AdverseReaction
mouth	SAPHRIS.xml:S1:11283:5	I-AdverseReaction
1	SAPHRIS.xml:S1:11323:1	O
3	SAPHRIS.xml:S1:11346:1	O

Dyspepsia	SAPHRIS.xml:S1:11386:9	B-AdverseReaction
2	SAPHRIS.xml:S1:11430:1	O
4	SAPHRIS.xml:S1:11453:1	O

Oral	SAPHRIS.xml:S1:11493:4	B-AdverseReaction
hypoesthesia	SAPHRIS.xml:S1:11498:12	I-AdverseReaction
1	SAPHRIS.xml:S1:11538:1	O
4	SAPHRIS.xml:S1:11560:1	O

Toothache	SAPHRIS.xml:S1:11600:9	B-AdverseReaction
2	SAPHRIS.xml:S1:11644:1	O
3	SAPHRIS.xml:S1:11667:1	O

General	SAPHRIS.xml:S1:11704:7	O
disorders	SAPHRIS.xml:S1:11712:9	O

Fatigue	SAPHRIS.xml:S1:11759:7	B-AdverseReaction
2	SAPHRIS.xml:S1:11803:1	O
4	SAPHRIS.xml:S1:11826:1	O

Investigations	SAPHRIS.xml:S1:11863:14	O

Increased	SAPHRIS.xml:S1:11918:9	B-AdverseReaction
weight	SAPHRIS.xml:S1:11928:6	I-AdverseReaction
1	SAPHRIS.xml:S1:11963:1	O
5	SAPHRIS.xml:S1:11985:1	O

Metabolism	SAPHRIS.xml:S1:12022:10	O
disorders	SAPHRIS.xml:S1:12033:9	O

Increased	SAPHRIS.xml:S1:12077:9	B-AdverseReaction
appetite	SAPHRIS.xml:S1:12087:8	I-AdverseReaction
1	SAPHRIS.xml:S1:12121:1	O
4	SAPHRIS.xml:S1:12144:1	O

Musculoskeletal	SAPHRIS.xml:S1:12181:15	O
and	SAPHRIS.xml:S1:12197:3	O
connective	SAPHRIS.xml:S1:12201:10	O
tissue	SAPHRIS.xml:S1:12212:6	O
disorders	SAPHRIS.xml:S1:12219:9	O

Arthralgia	SAPHRIS.xml:S1:12240:10	B-AdverseReaction
1	SAPHRIS.xml:S1:12284:1	O
3	SAPHRIS.xml:S1:12307:1	O

Pain	SAPHRIS.xml:S1:12347:4	B-AdverseReaction
in	SAPHRIS.xml:S1:12352:2	I-AdverseReaction
extremity	SAPHRIS.xml:S1:12355:9	I-AdverseReaction
1	SAPHRIS.xml:S1:12392:1	O
2	SAPHRIS.xml:S1:12414:1	O

Nervous	SAPHRIS.xml:S1:12451:7	O
system	SAPHRIS.xml:S1:12459:6	O
disorders	SAPHRIS.xml:S1:12466:9	O

Akathisia	SAPHRIS.xml:S1:12506:9	B-AdverseReaction
2	SAPHRIS.xml:S1:12550:1	O
4	SAPHRIS.xml:S1:12573:1	O

Dizziness	SAPHRIS.xml:S1:12613:9	B-AdverseReaction
3	SAPHRIS.xml:S1:12657:1	O
11	SAPHRIS.xml:S1:12680:2	O

Dysgeusia	SAPHRIS.xml:S1:12720:9	B-AdverseReaction
1	SAPHRIS.xml:S1:12765:1	O
3	SAPHRIS.xml:S1:12787:1	O

Headache	SAPHRIS.xml:S1:12827:8	B-AdverseReaction
11	SAPHRIS.xml:S1:12871:2	O
12	SAPHRIS.xml:S1:12894:2	O

Other	SAPHRIS.xml:S1:12934:5	O
extrapyramidal	SAPHRIS.xml:S1:12940:14	B-AdverseReaction
symptoms	SAPHRIS.xml:S1:12955:8	I-AdverseReaction
(	SAPHRIS.xml:S1:12964:1	O
excluding	SAPHRIS.xml:S1:12965:9	B-Negation
akathisia	SAPHRIS.xml:S1:12975:9	B-AdverseReaction
)	SAPHRIS.xml:S1:12984:1	O
2	SAPHRIS.xml:S1:12991:1	O
7	SAPHRIS.xml:S1:13014:1	O

Somnolence	SAPHRIS.xml:S1:13054:10	B-AdverseReaction
?	SAPHRIS.xml:S1:13066:1	O

6	SAPHRIS.xml:S1:13098:1	O
24	SAPHRIS.xml:S1:13121:2	O

Psychiatric	SAPHRIS.xml:S1:13158:11	O
disorders	SAPHRIS.xml:S1:13170:9	O

Anxiety	SAPHRIS.xml:S1:13213:7	B-AdverseReaction
2	SAPHRIS.xml:S1:13257:1	O
4	SAPHRIS.xml:S1:13280:1	O

Depression	SAPHRIS.xml:S1:13320:10	B-AdverseReaction
1	SAPHRIS.xml:S1:13364:1	O
2	SAPHRIS.xml:S1:13387:1	O

Insomnia	SAPHRIS.xml:S1:13427:8	B-AdverseReaction
5	SAPHRIS.xml:S1:13471:1	O
6	SAPHRIS.xml:S1:13494:1	O

Monotherapy	SAPHRIS.xml:S1:13541:11	O
in	SAPHRIS.xml:S1:13553:2	O
Pediatric	SAPHRIS.xml:S1:13556:9	O
Patients	SAPHRIS.xml:S1:13566:8	O
with	SAPHRIS.xml:S1:13575:4	O
Bipolar	SAPHRIS.xml:S1:13580:7	O
Mania	SAPHRIS.xml:S1:13588:5	O
:	SAPHRIS.xml:S1:13593:1	O
The	SAPHRIS.xml:S1:13596:3	O
following	SAPHRIS.xml:S1:13600:9	O
findings	SAPHRIS.xml:S1:13610:8	O
are	SAPHRIS.xml:S1:13619:3	O
based	SAPHRIS.xml:S1:13623:5	O
on	SAPHRIS.xml:S1:13629:2	O
a	SAPHRIS.xml:S1:13632:1	O
3	SAPHRIS.xml:S1:13634:1	O
-	SAPHRIS.xml:S1:13635:1	O
week	SAPHRIS.xml:S1:13636:4	O
,	SAPHRIS.xml:S1:13641:1	O
placebo	SAPHRIS.xml:S1:13643:7	O
-	SAPHRIS.xml:S1:13650:1	O
controlled	SAPHRIS.xml:S1:13651:10	O
trial	SAPHRIS.xml:S1:13662:5	O
for	SAPHRIS.xml:S1:13668:3	O
bipolar	SAPHRIS.xml:S1:13672:7	O
mania	SAPHRIS.xml:S1:13680:5	O
in	SAPHRIS.xml:S1:13686:2	O
which	SAPHRIS.xml:S1:13689:5	O
SAPHRIS	SAPHRIS.xml:S1:13695:7	O
was	SAPHRIS.xml:S1:13703:3	O
administered	SAPHRIS.xml:S1:13707:12	O
at	SAPHRIS.xml:S1:13720:2	O
doses	SAPHRIS.xml:S1:13723:5	O
of	SAPHRIS.xml:S1:13729:2	O
2.5	SAPHRIS.xml:S1:13732:3	O
mg	SAPHRIS.xml:S1:13736:2	O
,	SAPHRIS.xml:S1:13738:1	O
5	SAPHRIS.xml:S1:13740:1	O
mg	SAPHRIS.xml:S1:13742:2	O
,	SAPHRIS.xml:S1:13744:1	O
or	SAPHRIS.xml:S1:13746:2	O
10	SAPHRIS.xml:S1:13749:2	O
mg	SAPHRIS.xml:S1:13752:2	O
twice	SAPHRIS.xml:S1:13755:5	O
daily	SAPHRIS.xml:S1:13761:5	O
.	SAPHRIS.xml:S1:13766:1	O

Adverse	SAPHRIS.xml:S1:13776:7	O

Reactions	SAPHRIS.xml:S1:13784:9	O
Leading	SAPHRIS.xml:S1:13794:7	O
to	SAPHRIS.xml:S1:13802:2	O
Discontinuation	SAPHRIS.xml:S1:13805:15	O
of	SAPHRIS.xml:S1:13821:2	O
Treatment	SAPHRIS.xml:S1:13824:9	O
:	SAPHRIS.xml:S1:13833:1	O
A	SAPHRIS.xml:S1:13836:1	O
total	SAPHRIS.xml:S1:13838:5	O
of	SAPHRIS.xml:S1:13844:2	O
6.7%	SAPHRIS.xml:S1:13847:4	O
(	SAPHRIS.xml:S1:13852:1	O
7	SAPHRIS.xml:S1:13853:1	O
104	SAPHRIS.xml:S1:13855:3	O
)	SAPHRIS.xml:S1:13858:1	O
of	SAPHRIS.xml:S1:13860:2	O
patients	SAPHRIS.xml:S1:13863:8	O
treated	SAPHRIS.xml:S1:13872:7	O
with	SAPHRIS.xml:S1:13880:4	O
SAPHRIS	SAPHRIS.xml:S1:13885:7	O
2.5	SAPHRIS.xml:S1:13893:3	O
mg	SAPHRIS.xml:S1:13897:2	O
twice	SAPHRIS.xml:S1:13900:5	O
daily	SAPHRIS.xml:S1:13906:5	O
,	SAPHRIS.xml:S1:13911:1	O
5.1%	SAPHRIS.xml:S1:13913:4	O
(	SAPHRIS.xml:S1:13918:1	O
5	SAPHRIS.xml:S1:13919:1	O
99	SAPHRIS.xml:S1:13921:2	O
)	SAPHRIS.xml:S1:13923:1	O
of	SAPHRIS.xml:S1:13925:2	O
patients	SAPHRIS.xml:S1:13928:8	O
treated	SAPHRIS.xml:S1:13937:7	O
with	SAPHRIS.xml:S1:13945:4	O
SAPHRIS	SAPHRIS.xml:S1:13950:7	O
5	SAPHRIS.xml:S1:13958:1	O
mg	SAPHRIS.xml:S1:13960:2	O
twice	SAPHRIS.xml:S1:13963:5	O
daily	SAPHRIS.xml:S1:13969:5	O
,	SAPHRIS.xml:S1:13974:1	O
and	SAPHRIS.xml:S1:13976:3	O
5.1%	SAPHRIS.xml:S1:13980:4	O
(	SAPHRIS.xml:S1:13985:1	O
5	SAPHRIS.xml:S1:13986:1	O
99	SAPHRIS.xml:S1:13988:2	O
)	SAPHRIS.xml:S1:13990:1	O
of	SAPHRIS.xml:S1:13992:2	O
patients	SAPHRIS.xml:S1:13995:8	O
treated	SAPHRIS.xml:S1:14004:7	O
with	SAPHRIS.xml:S1:14012:4	O
SAPHRIS	SAPHRIS.xml:S1:14017:7	O
10	SAPHRIS.xml:S1:14025:2	O
mg	SAPHRIS.xml:S1:14028:2	O
twice	SAPHRIS.xml:S1:14031:5	O
daily	SAPHRIS.xml:S1:14037:5	O
discontinued	SAPHRIS.xml:S1:14043:12	O
treatment	SAPHRIS.xml:S1:14056:9	O
due	SAPHRIS.xml:S1:14066:3	O
to	SAPHRIS.xml:S1:14070:2	O
adverse	SAPHRIS.xml:S1:14073:7	O
reactions	SAPHRIS.xml:S1:14081:9	O
compared	SAPHRIS.xml:S1:14091:8	O
to	SAPHRIS.xml:S1:14100:2	O
4%	SAPHRIS.xml:S1:14103:2	O
(	SAPHRIS.xml:S1:14106:1	O
4	SAPHRIS.xml:S1:14107:1	O
101	SAPHRIS.xml:S1:14109:3	O
)	SAPHRIS.xml:S1:14112:1	O
on	SAPHRIS.xml:S1:14114:2	O
placebo	SAPHRIS.xml:S1:14117:7	O
.	SAPHRIS.xml:S1:14124:1	O

The	SAPHRIS.xml:S1:14126:3	O
most	SAPHRIS.xml:S1:14130:4	O
common	SAPHRIS.xml:S1:14135:6	O
adverse	SAPHRIS.xml:S1:14142:7	O
reactions	SAPHRIS.xml:S1:14150:9	O
that	SAPHRIS.xml:S1:14160:4	O
led	SAPHRIS.xml:S1:14165:3	O
to	SAPHRIS.xml:S1:14169:2	O
discontinuation	SAPHRIS.xml:S1:14172:15	O
in	SAPHRIS.xml:S1:14188:2	O
pediatric	SAPHRIS.xml:S1:14191:9	O
patients	SAPHRIS.xml:S1:14201:8	O
treated	SAPHRIS.xml:S1:14210:7	O
with	SAPHRIS.xml:S1:14218:4	O
SAPHRIS	SAPHRIS.xml:S1:14223:7	O
(	SAPHRIS.xml:S1:14231:1	O
rates	SAPHRIS.xml:S1:14232:5	O
at	SAPHRIS.xml:S1:14238:2	O
least	SAPHRIS.xml:S1:14241:5	O
2%	SAPHRIS.xml:S1:14247:2	O
in	SAPHRIS.xml:S1:14250:2	O
any	SAPHRIS.xml:S1:14253:3	O
SAPHRIS	SAPHRIS.xml:S1:14257:7	O
arm	SAPHRIS.xml:S1:14265:3	O
and	SAPHRIS.xml:S1:14269:3	O
at	SAPHRIS.xml:S1:14273:2	O
least	SAPHRIS.xml:S1:14276:5	O
twice	SAPHRIS.xml:S1:14282:5	O
the	SAPHRIS.xml:S1:14288:3	O
placebo	SAPHRIS.xml:S1:14292:7	O
rate	SAPHRIS.xml:S1:14300:4	O
)	SAPHRIS.xml:S1:14304:1	O
were	SAPHRIS.xml:S1:14306:4	O
somnolence	SAPHRIS.xml:S1:14311:10	B-AdverseReaction
(	SAPHRIS.xml:S1:14322:1	O
3%	SAPHRIS.xml:S1:14323:2	O
in	SAPHRIS.xml:S1:14326:2	O
the	SAPHRIS.xml:S1:14329:3	O
2.5	SAPHRIS.xml:S1:14333:3	O
mg	SAPHRIS.xml:S1:14336:2	O
twice	SAPHRIS.xml:S1:14339:5	O
daily	SAPHRIS.xml:S1:14345:5	O
group	SAPHRIS.xml:S1:14351:5	O
,	SAPHRIS.xml:S1:14356:1	O
1%	SAPHRIS.xml:S1:14358:2	O
in	SAPHRIS.xml:S1:14361:2	O
the	SAPHRIS.xml:S1:14364:3	O
5	SAPHRIS.xml:S1:14368:1	O
mg	SAPHRIS.xml:S1:14369:2	O
twice	SAPHRIS.xml:S1:14372:5	O
daily	SAPHRIS.xml:S1:14378:5	O
group	SAPHRIS.xml:S1:14384:5	O
,	SAPHRIS.xml:S1:14389:1	O
and	SAPHRIS.xml:S1:14391:3	O
2%	SAPHRIS.xml:S1:14395:2	O
in	SAPHRIS.xml:S1:14398:2	O
the	SAPHRIS.xml:S1:14401:3	O
10	SAPHRIS.xml:S1:14405:2	O
mg	SAPHRIS.xml:S1:14407:2	O
twice	SAPHRIS.xml:S1:14410:5	O
daily	SAPHRIS.xml:S1:14416:5	O
group	SAPHRIS.xml:S1:14422:5	O
)	SAPHRIS.xml:S1:14427:1	O
,	SAPHRIS.xml:S1:14428:1	O
abdominal	SAPHRIS.xml:S1:14430:9	B-AdverseReaction
pain	SAPHRIS.xml:S1:14440:4	I-AdverseReaction
(	SAPHRIS.xml:S1:14445:1	O
2%	SAPHRIS.xml:S1:14446:2	O
in	SAPHRIS.xml:S1:14449:2	O
the	SAPHRIS.xml:S1:14452:3	O
10	SAPHRIS.xml:S1:14456:2	O
mg	SAPHRIS.xml:S1:14458:2	O
twice	SAPHRIS.xml:S1:14461:5	O
daily	SAPHRIS.xml:S1:14467:5	O
group	SAPHRIS.xml:S1:14473:5	O
)	SAPHRIS.xml:S1:14478:1	O
,	SAPHRIS.xml:S1:14479:1	O
and	SAPHRIS.xml:S1:14481:3	O
nausea	SAPHRIS.xml:S1:14485:6	B-AdverseReaction
(	SAPHRIS.xml:S1:14492:1	O
2%	SAPHRIS.xml:S1:14493:2	O
in	SAPHRIS.xml:S1:14496:2	O
the	SAPHRIS.xml:S1:14499:3	O
10	SAPHRIS.xml:S1:14503:2	O
mg	SAPHRIS.xml:S1:14505:2	O
twice	SAPHRIS.xml:S1:14508:5	O
daily	SAPHRIS.xml:S1:14514:5	O
group	SAPHRIS.xml:S1:14520:5	O
)	SAPHRIS.xml:S1:14525:1	O
No	SAPHRIS.xml:S1:14527:2	O
placebo	SAPHRIS.xml:S1:14530:7	O
-	SAPHRIS.xml:S1:14537:1	O
treated	SAPHRIS.xml:S1:14538:7	O
patients	SAPHRIS.xml:S1:14546:8	O
dropped	SAPHRIS.xml:S1:14555:7	O
out	SAPHRIS.xml:S1:14563:3	O
for	SAPHRIS.xml:S1:14567:3	O
these	SAPHRIS.xml:S1:14571:5	O
events	SAPHRIS.xml:S1:14577:6	O
.	SAPHRIS.xml:S1:14583:1	O

Adverse	SAPHRIS.xml:S1:14593:7	O
Reactions	SAPHRIS.xml:S1:14601:9	O
Occurring	SAPHRIS.xml:S1:14611:9	O
with	SAPHRIS.xml:S1:14621:4	O
SAPHRIS	SAPHRIS.xml:S1:14626:7	O
at	SAPHRIS.xml:S1:14634:2	O
an	SAPHRIS.xml:S1:14637:2	O
Incidence	SAPHRIS.xml:S1:14640:9	O
of	SAPHRIS.xml:S1:14650:2	O
2%	SAPHRIS.xml:S1:14653:2	O
or	SAPHRIS.xml:S1:14656:2	O
More	SAPHRIS.xml:S1:14659:4	O
in	SAPHRIS.xml:S1:14664:2	O
SAPHRIS	SAPHRIS.xml:S1:14667:7	O
-	SAPHRIS.xml:S1:14674:1	O
treated	SAPHRIS.xml:S1:14675:7	O
Bipolar	SAPHRIS.xml:S1:14683:7	O
Patients	SAPHRIS.xml:S1:14691:8	O
:	SAPHRIS.xml:S1:14699:1	O
Adverse	SAPHRIS.xml:S1:14702:7	O
reactions	SAPHRIS.xml:S1:14710:9	O
associated	SAPHRIS.xml:S1:14720:10	O
with	SAPHRIS.xml:S1:14731:4	O
the	SAPHRIS.xml:S1:14736:3	O
use	SAPHRIS.xml:S1:14740:3	O
of	SAPHRIS.xml:S1:14744:2	O
SAPHRIS	SAPHRIS.xml:S1:14747:7	O
(	SAPHRIS.xml:S1:14755:1	O
incidence	SAPHRIS.xml:S1:14756:9	O
of	SAPHRIS.xml:S1:14766:2	O
2%	SAPHRIS.xml:S1:14771:2	O
in	SAPHRIS.xml:S1:14774:2	O
any	SAPHRIS.xml:S1:14777:3	O
SAPHRIS	SAPHRIS.xml:S1:14781:7	O
dose	SAPHRIS.xml:S1:14789:4	O
group	SAPHRIS.xml:S1:14794:5	O
and	SAPHRIS.xml:S1:14800:3	O
greater	SAPHRIS.xml:S1:14804:7	O
than	SAPHRIS.xml:S1:14812:4	O
placebo	SAPHRIS.xml:S1:14817:7	O
)	SAPHRIS.xml:S1:14824:1	O
that	SAPHRIS.xml:S1:14826:4	O
occurred	SAPHRIS.xml:S1:14831:8	O
during	SAPHRIS.xml:S1:14840:6	O
acute	SAPHRIS.xml:S1:14847:5	O
therapy	SAPHRIS.xml:S1:14853:7	O
are	SAPHRIS.xml:S1:14861:3	O
shown	SAPHRIS.xml:S1:14865:5	O
in	SAPHRIS.xml:S1:14871:2	O
Table	SAPHRIS.xml:S1:14875:5	O
10	SAPHRIS.xml:S1:14881:2	O
.	SAPHRIS.xml:S1:14885:1	O

Table	SAPHRIS.xml:S1:14891:5	O
10	SAPHRIS.xml:S1:14897:2	O
:	SAPHRIS.xml:S1:14899:1	O
Adverse	SAPHRIS.xml:S1:14901:7	O
Reactions	SAPHRIS.xml:S1:14909:9	O
Reported	SAPHRIS.xml:S1:14919:8	O
in	SAPHRIS.xml:S1:14928:2	O
2%	SAPHRIS.xml:S1:14931:2	O
or	SAPHRIS.xml:S1:14934:2	O
More	SAPHRIS.xml:S1:14937:4	O
of	SAPHRIS.xml:S1:14942:2	O
Pediatric	SAPHRIS.xml:S1:14945:9	O
Patients	SAPHRIS.xml:S1:14955:8	O
(	SAPHRIS.xml:S1:14964:1	O
Ages	SAPHRIS.xml:S1:14965:4	O
10	SAPHRIS.xml:S1:14970:2	O
to	SAPHRIS.xml:S1:14973:2	O
17	SAPHRIS.xml:S1:14976:2	O
Years	SAPHRIS.xml:S1:14979:5	O
)	SAPHRIS.xml:S1:14984:1	O
in	SAPHRIS.xml:S1:14986:2	O
Any	SAPHRIS.xml:S1:14989:3	O
SAPHRIS	SAPHRIS.xml:S1:14993:7	O
Dose	SAPHRIS.xml:S1:15001:4	O
Group	SAPHRIS.xml:S1:15006:5	O
and	SAPHRIS.xml:S1:15012:3	O
Which	SAPHRIS.xml:S1:15016:5	O
Occurred	SAPHRIS.xml:S1:15022:8	O
at	SAPHRIS.xml:S1:15031:2	O
Greater	SAPHRIS.xml:S1:15034:7	O
Incidence	SAPHRIS.xml:S1:15042:9	O
Than	SAPHRIS.xml:S1:15052:4	O
in	SAPHRIS.xml:S1:15057:2	O
the	SAPHRIS.xml:S1:15060:3	O
Placebo	SAPHRIS.xml:S1:15064:7	O
Group	SAPHRIS.xml:S1:15072:5	O
in	SAPHRIS.xml:S1:15078:2	O
a	SAPHRIS.xml:S1:15081:1	O
3	SAPHRIS.xml:S1:15083:1	O
-	SAPHRIS.xml:S1:15084:1	O
Week	SAPHRIS.xml:S1:15085:4	O
Bipolar	SAPHRIS.xml:S1:15090:7	O
Mania	SAPHRIS.xml:S1:15098:5	O
Trial	SAPHRIS.xml:S1:15104:5	O

1	SAPHRIS.xml:S1:15113:1	O
Includes	SAPHRIS.xml:S1:15114:8	O
the	SAPHRIS.xml:S1:15123:3	O
preferred	SAPHRIS.xml:S1:15127:9	O
terms	SAPHRIS.xml:S1:15137:5	O
tachycardia	SAPHRIS.xml:S1:15143:11	B-AdverseReaction
and	SAPHRIS.xml:S1:15155:3	O
heart	SAPHRIS.xml:S1:15159:5	B-AdverseReaction
rate	SAPHRIS.xml:S1:15165:4	I-AdverseReaction
increased	SAPHRIS.xml:S1:15170:9	I-AdverseReaction
.	SAPHRIS.xml:S1:15179:1	O

2	SAPHRIS.xml:S1:15187:1	O
Includes	SAPHRIS.xml:S1:15188:8	O
the	SAPHRIS.xml:S1:15197:3	O
preferred	SAPHRIS.xml:S1:15201:9	O
terms	SAPHRIS.xml:S1:15211:5	O
oral	SAPHRIS.xml:S1:15217:4	B-AdverseReaction
hypoesthesia	SAPHRIS.xml:S1:15222:12	I-AdverseReaction
,	SAPHRIS.xml:S1:15234:1	O
oral	SAPHRIS.xml:S1:15236:4	B-AdverseReaction
paresthesia	SAPHRIS.xml:S1:15241:11	I-AdverseReaction
,	SAPHRIS.xml:S1:15252:1	O
and	SAPHRIS.xml:S1:15254:3	O
oral	SAPHRIS.xml:S1:15258:4	B-AdverseReaction
dysesthesia	SAPHRIS.xml:S1:15263:11	I-AdverseReaction
.	SAPHRIS.xml:S1:15274:1	O

3	SAPHRIS.xml:S1:15282:1	O
Includes	SAPHRIS.xml:S1:15283:8	O
the	SAPHRIS.xml:S1:15292:3	O
preferred	SAPHRIS.xml:S1:15296:9	O
terms	SAPHRIS.xml:S1:15306:5	O
abdominal	SAPHRIS.xml:S1:15312:9	B-AdverseReaction
pain	SAPHRIS.xml:S1:15322:4	I-AdverseReaction
,	SAPHRIS.xml:S1:15326:1	O
abdominal	SAPHRIS.xml:S1:15328:9	B-AdverseReaction
pain	SAPHRIS.xml:S1:15338:4	I-AdverseReaction
upper	SAPHRIS.xml:S1:15343:5	I-AdverseReaction
,	SAPHRIS.xml:S1:15348:1	O
abdominal	SAPHRIS.xml:S1:15350:9	B-AdverseReaction
pain	SAPHRIS.xml:S1:15360:4	I-AdverseReaction
lower	SAPHRIS.xml:S1:15365:5	I-AdverseReaction
,	SAPHRIS.xml:S1:15370:1	O
and	SAPHRIS.xml:S1:15372:3	O
abdominal	SAPHRIS.xml:S1:15376:9	B-AdverseReaction
discomfort	SAPHRIS.xml:S1:15386:10	I-AdverseReaction
.	SAPHRIS.xml:S1:15396:1	O

4	SAPHRIS.xml:S1:15404:1	O
Includes	SAPHRIS.xml:S1:15405:8	O
the	SAPHRIS.xml:S1:15414:3	O
preferred	SAPHRIS.xml:S1:15418:9	O
terms	SAPHRIS.xml:S1:15428:5	O
fatigue	SAPHRIS.xml:S1:15434:7	B-AdverseReaction
and	SAPHRIS.xml:S1:15442:3	O
lethargy	SAPHRIS.xml:S1:15446:8	B-AdverseReaction
.	SAPHRIS.xml:S1:15454:1	O

5	SAPHRIS.xml:S1:15462:1	O
Includes	SAPHRIS.xml:S1:15463:8	O
the	SAPHRIS.xml:S1:15472:3	O
preferred	SAPHRIS.xml:S1:15476:9	O
terms	SAPHRIS.xml:S1:15486:5	O
hyperinsulinemia	SAPHRIS.xml:S1:15492:16	B-AdverseReaction
and	SAPHRIS.xml:S1:15509:3	O
blood	SAPHRIS.xml:S1:15513:5	B-AdverseReaction
insulin	SAPHRIS.xml:S1:15519:7	I-AdverseReaction
increased	SAPHRIS.xml:S1:15527:9	I-AdverseReaction
.	SAPHRIS.xml:S1:15536:1	O

6	SAPHRIS.xml:S1:15544:1	O
Includes	SAPHRIS.xml:S1:15545:8	O
the	SAPHRIS.xml:S1:15554:3	O
preferred	SAPHRIS.xml:S1:15558:9	O
terms	SAPHRIS.xml:S1:15568:5	O
somnolence	SAPHRIS.xml:S1:15574:10	B-AdverseReaction
,	SAPHRIS.xml:S1:15584:1	O
sedation	SAPHRIS.xml:S1:15586:8	B-AdverseReaction
,	SAPHRIS.xml:S1:15594:1	O
and	SAPHRIS.xml:S1:15596:3	O
hypersomnia	SAPHRIS.xml:S1:15600:11	B-AdverseReaction
.	SAPHRIS.xml:S1:15611:1	O

System	SAPHRIS.xml:S1:15623:6	O

Organ	SAPHRIS.xml:S1:15630:5	O
Class	SAPHRIS.xml:S1:15636:5	O
AE	SAPHRIS.xml:S1:15646:2	O
Preferred	SAPHRIS.xml:S1:15649:9	O
Term	SAPHRIS.xml:S1:15659:4	O
Placebo	SAPHRIS.xml:S1:15669:7	O
N	SAPHRIS.xml:S1:15680:1	O
101	SAPHRIS.xml:S1:15682:3	O
Placebo	SAPHRIS.xml:S1:15689:7	O
SAPHRIS	SAPHRIS.xml:S1:15702:7	O
2.5	SAPHRIS.xml:S1:15713:3	O
mg	SAPHRIS.xml:S1:15717:2	O
twice	SAPHRIS.xml:S1:15723:5	O
daily	SAPHRIS.xml:S1:15729:5	O
N	SAPHRIS.xml:S1:15738:1	O
104	SAPHRIS.xml:S1:15740:3	O
2.5	SAPHRIS.xml:S1:15747:3	O
mg	SAPHRIS.xml:S1:15750:2	O
SAPHRIS	SAPHRIS.xml:S1:15758:7	O
5	SAPHRIS.xml:S1:15769:1	O
mg	SAPHRIS.xml:S1:15771:2	O
twice	SAPHRIS.xml:S1:15777:5	O
daily	SAPHRIS.xml:S1:15783:5	O
N	SAPHRIS.xml:S1:15792:1	O
99	SAPHRIS.xml:S1:15794:2	O
5	SAPHRIS.xml:S1:15800:1	O
mg	SAPHRIS.xml:S1:15801:2	O
SAPHRIS	SAPHRIS.xml:S1:15809:7	O
10	SAPHRIS.xml:S1:15820:2	O
mg	SAPHRIS.xml:S1:15823:2	O
twice	SAPHRIS.xml:S1:15829:5	O
daily	SAPHRIS.xml:S1:15835:5	O
N	SAPHRIS.xml:S1:15844:1	O
99	SAPHRIS.xml:S1:15846:2	O
10	SAPHRIS.xml:S1:15852:2	O
mg	SAPHRIS.xml:S1:15854:2	O
All	SAPHRIS.xml:S1:15862:3	O
SAPHRIS	SAPHRIS.xml:S1:15866:7	O
2.5	SAPHRIS.xml:S1:15877:3	O
,	SAPHRIS.xml:S1:15880:1	O
5	SAPHRIS.xml:S1:15882:1	O
,	SAPHRIS.xml:S1:15883:1	O
and	SAPHRIS.xml:S1:15885:3	O
10	SAPHRIS.xml:S1:15889:2	O
mg	SAPHRIS.xml:S1:15892:2	O

N	SAPHRIS.xml:S1:15903:1	O
101	SAPHRIS.xml:S1:15905:3	O
N	SAPHRIS.xml:S1:15939:1	O
104	SAPHRIS.xml:S1:15941:3	O
N	SAPHRIS.xml:S1:15955:1	O
99	SAPHRIS.xml:S1:15957:2	O
N	SAPHRIS.xml:S1:15970:1	O
99	SAPHRIS.xml:S1:15972:2	O
N	SAPHRIS.xml:S1:15985:1	O
302	SAPHRIS.xml:S1:15987:3	O

Cardiac	SAPHRIS.xml:S1:16004:7	O
Disorders	SAPHRIS.xml:S1:16012:9	O

Tachycardia	SAPHRIS.xml:S1:16096:11	B-AdverseReaction
1	SAPHRIS.xml:S1:16109:1	O
0	SAPHRIS.xml:S1:16129:1	O
3	SAPHRIS.xml:S1:16140:1	O
0	SAPHRIS.xml:S1:16154:1	O
1	SAPHRIS.xml:S1:16168:1	O
1	SAPHRIS.xml:S1:16181:1	O

Gastrointestinal	SAPHRIS.xml:S1:16208:16	O
Disorders	SAPHRIS.xml:S1:16225:9	O

Oral	SAPHRIS.xml:S1:16300:4	B-AdverseReaction
paraesthesia	SAPHRIS.xml:S1:16305:12	I-AdverseReaction
2	SAPHRIS.xml:S1:16319:1	O
4	SAPHRIS.xml:S1:16333:1	O
25	SAPHRIS.xml:S1:16344:2	O
25	SAPHRIS.xml:S1:16358:2	O
30	SAPHRIS.xml:S1:16372:2	O
27	SAPHRIS.xml:S1:16385:2	O

Nausea	SAPHRIS.xml:S1:16413:6	B-AdverseReaction
3	SAPHRIS.xml:S1:16446:1	O
6	SAPHRIS.xml:S1:16457:1	O
6	SAPHRIS.xml:S1:16471:1	O
6	SAPHRIS.xml:S1:16485:1	O
6	SAPHRIS.xml:S1:16498:1	O

Vomiting	SAPHRIS.xml:S1:16526:8	B-AdverseReaction
3	SAPHRIS.xml:S1:16559:1	O
4	SAPHRIS.xml:S1:16570:1	O
4	SAPHRIS.xml:S1:16584:1	O
4	SAPHRIS.xml:S1:16598:1	O
4	SAPHRIS.xml:S1:16611:1	O

Abdominal	SAPHRIS.xml:S1:16639:9	B-AdverseReaction
pain	SAPHRIS.xml:S1:16649:4	I-AdverseReaction
3	SAPHRIS.xml:S1:16655:1	O
7	SAPHRIS.xml:S1:16672:1	O
9	SAPHRIS.xml:S1:16683:1	O
3	SAPHRIS.xml:S1:16697:1	O
5	SAPHRIS.xml:S1:16711:1	O
6	SAPHRIS.xml:S1:16724:1	O

Glossodynia	SAPHRIS.xml:S1:16752:11	B-AdverseReaction
0	SAPHRIS.xml:S1:16785:1	O
0	SAPHRIS.xml:S1:16796:1	O
2	SAPHRIS.xml:S1:16810:1	O
0	SAPHRIS.xml:S1:16824:1	O
1	SAPHRIS.xml:S1:16837:1	O

General	SAPHRIS.xml:S1:16864:7	O
Disorders	SAPHRIS.xml:S1:16872:9	O
and	SAPHRIS.xml:S1:16882:3	O
Administrative	SAPHRIS.xml:S1:16886:14	O
Site	SAPHRIS.xml:S1:16901:4	O
Disorders	SAPHRIS.xml:S1:16906:9	O

Fatigue	SAPHRIS.xml:S1:16977:7	B-AdverseReaction
4	SAPHRIS.xml:S1:16986:1	O
5	SAPHRIS.xml:S1:17010:1	O
4	SAPHRIS.xml:S1:17021:1	O
8	SAPHRIS.xml:S1:17035:1	O
14	SAPHRIS.xml:S1:17049:2	O
9	SAPHRIS.xml:S1:17062:1	O

Irritability	SAPHRIS.xml:S1:17090:12	B-AdverseReaction
1	SAPHRIS.xml:S1:17123:1	O
1	SAPHRIS.xml:S1:17134:1	O
1	SAPHRIS.xml:S1:17148:1	O
2	SAPHRIS.xml:S1:17162:1	O
1	SAPHRIS.xml:S1:17175:1	O

Injury	SAPHRIS.xml:S1:17202:6	O
,	SAPHRIS.xml:S1:17208:1	O
Poisoning	SAPHRIS.xml:S1:17210:9	O
,	SAPHRIS.xml:S1:17219:1	O
and	SAPHRIS.xml:S1:17221:3	O
Procedural	SAPHRIS.xml:S1:17225:10	O
Complications	SAPHRIS.xml:S1:17236:13	O

Muscle	SAPHRIS.xml:S1:17311:6	B-AdverseReaction
strain	SAPHRIS.xml:S1:17318:6	I-AdverseReaction
0	SAPHRIS.xml:S1:17344:1	O
0	SAPHRIS.xml:S1:17355:1	O
0	SAPHRIS.xml:S1:17369:1	O
2	SAPHRIS.xml:S1:17383:1	O
1	SAPHRIS.xml:S1:17396:1	O

Investigations	SAPHRIS.xml:S1:17423:14	O

Increased	SAPHRIS.xml:S1:17537:9	B-AdverseReaction
weight	SAPHRIS.xml:S1:17547:6	I-AdverseReaction
0	SAPHRIS.xml:S1:17570:1	O
6	SAPHRIS.xml:S1:17581:1	O
2	SAPHRIS.xml:S1:17595:1	O
2	SAPHRIS.xml:S1:17609:1	O
3	SAPHRIS.xml:S1:17622:1	O

Hyperinsulinemia	SAPHRIS.xml:S1:17650:16	B-AdverseReaction
5	SAPHRIS.xml:S1:17668:1	O
0	SAPHRIS.xml:S1:17683:1	O
1	SAPHRIS.xml:S1:17694:1	O
3	SAPHRIS.xml:S1:17708:1	O
1	SAPHRIS.xml:S1:17722:1	O
2	SAPHRIS.xml:S1:17735:1	O

ALT	SAPHRIS.xml:S1:17763:3	B-AdverseReaction
increased	SAPHRIS.xml:S1:17767:9	I-AdverseReaction
0	SAPHRIS.xml:S1:17796:1	O
0	SAPHRIS.xml:S1:17807:1	O
0	SAPHRIS.xml:S1:17821:1	O
2	SAPHRIS.xml:S1:17835:1	O
1	SAPHRIS.xml:S1:17848:1	O

AST	SAPHRIS.xml:S1:17876:3	B-AdverseReaction
increased	SAPHRIS.xml:S1:17880:9	I-AdverseReaction
0	SAPHRIS.xml:S1:17909:1	O
0	SAPHRIS.xml:S1:17920:1	O
0	SAPHRIS.xml:S1:17934:1	O
2	SAPHRIS.xml:S1:17948:1	O
1	SAPHRIS.xml:S1:17961:1	O

Metabolism	SAPHRIS.xml:S1:17988:10	O
and	SAPHRIS.xml:S1:17999:3	O
Nutrition	SAPHRIS.xml:S1:18003:9	O
Disorders	SAPHRIS.xml:S1:18013:9	O

Increased	SAPHRIS.xml:S1:18106:9	B-AdverseReaction
appetite	SAPHRIS.xml:S1:18116:8	I-AdverseReaction
2	SAPHRIS.xml:S1:18139:1	O
10	SAPHRIS.xml:S1:18150:2	O
9	SAPHRIS.xml:S1:18164:1	O
6	SAPHRIS.xml:S1:18178:1	O
8	SAPHRIS.xml:S1:18191:1	O

Dehydration	SAPHRIS.xml:S1:18219:11	B-AdverseReaction
1	SAPHRIS.xml:S1:18252:1	O
0	SAPHRIS.xml:S1:18263:1	O
2	SAPHRIS.xml:S1:18277:1	O
0	SAPHRIS.xml:S1:18291:1	O
1	SAPHRIS.xml:S1:18304:1	O

Musculoskeletal	SAPHRIS.xml:S1:18331:15	O
and	SAPHRIS.xml:S1:18347:3	O
Connective	SAPHRIS.xml:S1:18351:10	O
Tissue	SAPHRIS.xml:S1:18362:6	O
Disorders	SAPHRIS.xml:S1:18369:9	O

Myalgia	SAPHRIS.xml:S1:18440:7	B-AdverseReaction
0	SAPHRIS.xml:S1:18473:1	O
0	SAPHRIS.xml:S1:18484:1	O
2	SAPHRIS.xml:S1:18498:1	O
1	SAPHRIS.xml:S1:18512:1	O
1	SAPHRIS.xml:S1:18525:1	O

Nervous	SAPHRIS.xml:S1:18552:7	O
System	SAPHRIS.xml:S1:18560:6	O
Disorders	SAPHRIS.xml:S1:18567:9	O

Somnolence	SAPHRIS.xml:S1:18644:10	B-AdverseReaction
6	SAPHRIS.xml:S1:18656:1	O
12	SAPHRIS.xml:S1:18677:2	O
46	SAPHRIS.xml:S1:18688:2	O
53	SAPHRIS.xml:S1:18702:2	O
49	SAPHRIS.xml:S1:18716:2	O
49	SAPHRIS.xml:S1:18729:2	O

Headache	SAPHRIS.xml:S1:18757:8	B-AdverseReaction
6	SAPHRIS.xml:S1:18790:1	O
8	SAPHRIS.xml:S1:18801:1	O
11	SAPHRIS.xml:S1:18815:2	O
9	SAPHRIS.xml:S1:18829:1	O
9	SAPHRIS.xml:S1:18842:1	O

Dizziness	SAPHRIS.xml:S1:18870:9	B-AdverseReaction
3	SAPHRIS.xml:S1:18903:1	O
6	SAPHRIS.xml:S1:18914:1	O
10	SAPHRIS.xml:S1:18928:2	O
5	SAPHRIS.xml:S1:18942:1	O
7	SAPHRIS.xml:S1:18955:1	O

Dysgeusia	SAPHRIS.xml:S1:18983:9	B-AdverseReaction
2	SAPHRIS.xml:S1:19016:1	O
4	SAPHRIS.xml:S1:19027:1	O
5	SAPHRIS.xml:S1:19041:1	O
9	SAPHRIS.xml:S1:19055:1	O
6	SAPHRIS.xml:S1:19068:1	O

Akathisia	SAPHRIS.xml:S1:19096:9	B-AdverseReaction
0	SAPHRIS.xml:S1:19129:1	O
2	SAPHRIS.xml:S1:19140:1	O
2	SAPHRIS.xml:S1:19154:1	O
1	SAPHRIS.xml:S1:19168:1	O
2	SAPHRIS.xml:S1:19181:1	O

Parkinsonism	SAPHRIS.xml:S1:19209:12	B-AdverseReaction
0	SAPHRIS.xml:S1:19242:1	O
1	SAPHRIS.xml:S1:19253:1	O
0	SAPHRIS.xml:S1:19267:1	O
2	SAPHRIS.xml:S1:19281:1	O
1	SAPHRIS.xml:S1:19294:1	O

Psychiatric	SAPHRIS.xml:S1:19321:11	O
Disorders	SAPHRIS.xml:S1:19333:9	O

Insomnia	SAPHRIS.xml:S1:19413:8	B-AdverseReaction
3	SAPHRIS.xml:S1:19446:1	O
3	SAPHRIS.xml:S1:19457:1	O
4	SAPHRIS.xml:S1:19471:1	O
3	SAPHRIS.xml:S1:19485:1	O
3	SAPHRIS.xml:S1:19498:1	O

Suicidal	SAPHRIS.xml:S1:19526:8	B-AdverseReaction
ideation	SAPHRIS.xml:S1:19535:8	I-AdverseReaction
1	SAPHRIS.xml:S1:19559:1	O
4	SAPHRIS.xml:S1:19570:1	O
1	SAPHRIS.xml:S1:19584:1	O
3	SAPHRIS.xml:S1:19598:1	O
3	SAPHRIS.xml:S1:19611:1	O

Anger	SAPHRIS.xml:S1:19639:5	B-AdverseReaction
0	SAPHRIS.xml:S1:19672:1	O
0	SAPHRIS.xml:S1:19683:1	O
0	SAPHRIS.xml:S1:19697:1	O
2	SAPHRIS.xml:S1:19711:1	O
1	SAPHRIS.xml:S1:19724:1	O

Reproductive	SAPHRIS.xml:S1:19751:12	O
System	SAPHRIS.xml:S1:19764:6	O
and	SAPHRIS.xml:S1:19771:3	O
Breast	SAPHRIS.xml:S1:19775:6	O
Disorders	SAPHRIS.xml:S1:19782:9	O

Dysmenorrhea	SAPHRIS.xml:S1:19853:12	B-AdverseReaction
1	SAPHRIS.xml:S1:19886:1	O
0	SAPHRIS.xml:S1:19897:1	O
2	SAPHRIS.xml:S1:19911:1	O
0	SAPHRIS.xml:S1:19925:1	O
1	SAPHRIS.xml:S1:19938:1	O

Respiratory	SAPHRIS.xml:S1:19965:11	O
,	SAPHRIS.xml:S1:19976:1	O
Thoracic	SAPHRIS.xml:S1:19978:8	O
,	SAPHRIS.xml:S1:19986:1	O
and	SAPHRIS.xml:S1:19988:3	O
Mediastinal	SAPHRIS.xml:S1:19992:11	O
Disorders	SAPHRIS.xml:S1:20004:9	O

Oropharyngeal	SAPHRIS.xml:S1:20097:13	B-AdverseReaction
pain	SAPHRIS.xml:S1:20111:4	I-AdverseReaction
2	SAPHRIS.xml:S1:20130:1	O
0	SAPHRIS.xml:S1:20141:1	O
3	SAPHRIS.xml:S1:20155:1	O
1	SAPHRIS.xml:S1:20169:1	O
1	SAPHRIS.xml:S1:20182:1	O

Nasal	SAPHRIS.xml:S1:20210:5	B-AdverseReaction
congestion	SAPHRIS.xml:S1:20216:10	I-AdverseReaction
1	SAPHRIS.xml:S1:20243:1	O
0	SAPHRIS.xml:S1:20254:1	O
2	SAPHRIS.xml:S1:20268:1	O
0	SAPHRIS.xml:S1:20282:1	O
1	SAPHRIS.xml:S1:20295:1	O

Dyspnea	SAPHRIS.xml:S1:20323:7	B-AdverseReaction
0	SAPHRIS.xml:S1:20356:1	O
0	SAPHRIS.xml:S1:20367:1	O
2	SAPHRIS.xml:S1:20381:1	O
0	SAPHRIS.xml:S1:20395:1	O
1	SAPHRIS.xml:S1:20408:1	O

Skin	SAPHRIS.xml:S1:20435:4	O
and	SAPHRIS.xml:S1:20440:3	O
Subcutaneous	SAPHRIS.xml:S1:20444:12	O
Tissue	SAPHRIS.xml:S1:20457:6	O
Disorders	SAPHRIS.xml:S1:20464:9	O

Rash	SAPHRIS.xml:S1:20535:4	B-AdverseReaction
1	SAPHRIS.xml:S1:20568:1	O
0	SAPHRIS.xml:S1:20579:1	O
1	SAPHRIS.xml:S1:20593:1	O
2	SAPHRIS.xml:S1:20607:1	O
1	SAPHRIS.xml:S1:20620:1	O

Dose	SAPHRIS.xml:S1:20660:4	O
-	SAPHRIS.xml:S1:20664:1	O
Related	SAPHRIS.xml:S1:20665:7	O
Adverse	SAPHRIS.xml:S1:20673:7	O
Reactions	SAPHRIS.xml:S1:20681:9	O
:	SAPHRIS.xml:S1:20690:1	O
In	SAPHRIS.xml:S1:20693:2	O
the	SAPHRIS.xml:S1:20696:3	O
short	SAPHRIS.xml:S1:20700:5	O
term	SAPHRIS.xml:S1:20706:4	O
pediatric	SAPHRIS.xml:S1:20711:9	O
bipolar	SAPHRIS.xml:S1:20721:7	O
trials	SAPHRIS.xml:S1:20729:6	O
the	SAPHRIS.xml:S1:20736:3	O
incidence	SAPHRIS.xml:S1:20740:9	O
of	SAPHRIS.xml:S1:20750:2	O
fatigue	SAPHRIS.xml:S1:20753:7	B-AdverseReaction
appeared	SAPHRIS.xml:S1:20761:8	O
to	SAPHRIS.xml:S1:20770:2	O
be	SAPHRIS.xml:S1:20773:2	O
dose	SAPHRIS.xml:S1:20776:4	O
-	SAPHRIS.xml:S1:20780:1	O
related	SAPHRIS.xml:S1:20781:7	O
(	SAPHRIS.xml:S1:20789:1	O
see	SAPHRIS.xml:S1:20790:3	O
Table	SAPHRIS.xml:S1:20795:5	O
10	SAPHRIS.xml:S1:20801:2	O
)	SAPHRIS.xml:S1:20805:1	O

Adjunctive	SAPHRIS.xml:S1:20815:10	O

Therapy	SAPHRIS.xml:S1:20826:7	O
in	SAPHRIS.xml:S1:20834:2	O
Adult	SAPHRIS.xml:S1:20837:5	O
Patients	SAPHRIS.xml:S1:20843:8	O
with	SAPHRIS.xml:S1:20852:4	O
Bipolar	SAPHRIS.xml:S1:20857:7	O
Mania	SAPHRIS.xml:S1:20865:5	O
:	SAPHRIS.xml:S1:20870:1	O
The	SAPHRIS.xml:S1:20873:3	O
following	SAPHRIS.xml:S1:20877:9	O
findings	SAPHRIS.xml:S1:20887:8	O
are	SAPHRIS.xml:S1:20896:3	O
based	SAPHRIS.xml:S1:20900:5	O
on	SAPHRIS.xml:S1:20906:2	O
a	SAPHRIS.xml:S1:20909:1	O
12	SAPHRIS.xml:S1:20911:2	O
week	SAPHRIS.xml:S1:20914:4	O
placebo	SAPHRIS.xml:S1:20919:7	O
-	SAPHRIS.xml:S1:20926:1	O
controlled	SAPHRIS.xml:S1:20927:10	O
trial	SAPHRIS.xml:S1:20938:5	O
(	SAPHRIS.xml:S1:20944:1	O
with	SAPHRIS.xml:S1:20945:4	O
a	SAPHRIS.xml:S1:20950:1	O
3	SAPHRIS.xml:S1:20952:1	O
week	SAPHRIS.xml:S1:20954:4	O
efficacy	SAPHRIS.xml:S1:20959:8	O
endpoint	SAPHRIS.xml:S1:20968:8	O
)	SAPHRIS.xml:S1:20976:1	O
in	SAPHRIS.xml:S1:20978:2	O
adult	SAPHRIS.xml:S1:20981:5	O
patients	SAPHRIS.xml:S1:20987:8	O
with	SAPHRIS.xml:S1:20996:4	O
bipolar	SAPHRIS.xml:S1:21001:7	O
mania	SAPHRIS.xml:S1:21009:5	O
in	SAPHRIS.xml:S1:21015:2	O
which	SAPHRIS.xml:S1:21018:5	O
sublingual	SAPHRIS.xml:S1:21024:10	O
SAPHRIS	SAPHRIS.xml:S1:21035:7	O
was	SAPHRIS.xml:S1:21043:3	O
administered	SAPHRIS.xml:S1:21047:12	O
in	SAPHRIS.xml:S1:21060:2	O
doses	SAPHRIS.xml:S1:21063:5	O
of	SAPHRIS.xml:S1:21069:2	O
5	SAPHRIS.xml:S1:21072:1	O
mg	SAPHRIS.xml:S1:21074:2	O
or	SAPHRIS.xml:S1:21077:2	O
10	SAPHRIS.xml:S1:21080:2	O
mg	SAPHRIS.xml:S1:21083:2	O
twice	SAPHRIS.xml:S1:21086:5	O
daily	SAPHRIS.xml:S1:21092:5	O
as	SAPHRIS.xml:S1:21098:2	O
adjunctive	SAPHRIS.xml:S1:21101:10	O
therapy	SAPHRIS.xml:S1:21112:7	O
with	SAPHRIS.xml:S1:21120:4	O
lithium	SAPHRIS.xml:S1:21125:7	O
or	SAPHRIS.xml:S1:21133:2	O
valproate	SAPHRIS.xml:S1:21136:9	O
.	SAPHRIS.xml:S1:21145:1	O

Adverse	SAPHRIS.xml:S1:21155:7	O
Reactions	SAPHRIS.xml:S1:21163:9	O
Associated	SAPHRIS.xml:S1:21173:10	O
with	SAPHRIS.xml:S1:21184:4	O
Discontinuation	SAPHRIS.xml:S1:21189:15	O
of	SAPHRIS.xml:S1:21205:2	O
Treatment	SAPHRIS.xml:S1:21208:9	O
:	SAPHRIS.xml:S1:21217:1	O
Approximately	SAPHRIS.xml:S1:21220:13	O
16%	SAPHRIS.xml:S1:21234:3	O
(	SAPHRIS.xml:S1:21238:1	O
25	SAPHRIS.xml:S1:21239:2	O
158	SAPHRIS.xml:S1:21242:3	O
)	SAPHRIS.xml:S1:21245:1	O
of	SAPHRIS.xml:S1:21247:2	O
SAPHRIS	SAPHRIS.xml:S1:21250:7	O
-	SAPHRIS.xml:S1:21257:1	O
treated	SAPHRIS.xml:S1:21258:7	O
patients	SAPHRIS.xml:S1:21266:8	O
discontinued	SAPHRIS.xml:S1:21275:12	O
treatment	SAPHRIS.xml:S1:21288:9	O
due	SAPHRIS.xml:S1:21298:3	O
to	SAPHRIS.xml:S1:21302:2	O
an	SAPHRIS.xml:S1:21305:2	O
adverse	SAPHRIS.xml:S1:21308:7	O
reaction	SAPHRIS.xml:S1:21316:8	O
,	SAPHRIS.xml:S1:21324:1	O
compared	SAPHRIS.xml:S1:21326:8	O
with	SAPHRIS.xml:S1:21335:4	O
about	SAPHRIS.xml:S1:21340:5	O
11%	SAPHRIS.xml:S1:21346:3	O
(	SAPHRIS.xml:S1:21350:1	O
18	SAPHRIS.xml:S1:21351:2	O
166	SAPHRIS.xml:S1:21354:3	O
)	SAPHRIS.xml:S1:21357:1	O
on	SAPHRIS.xml:S1:21359:2	O
placebo	SAPHRIS.xml:S1:21362:7	O
.	SAPHRIS.xml:S1:21369:1	O

The	SAPHRIS.xml:S1:21371:3	O
most	SAPHRIS.xml:S1:21375:4	O
common	SAPHRIS.xml:S1:21380:6	O
adverse	SAPHRIS.xml:S1:21387:7	O
reactions	SAPHRIS.xml:S1:21395:9	O
associated	SAPHRIS.xml:S1:21405:10	O
with	SAPHRIS.xml:S1:21416:4	O
discontinuation	SAPHRIS.xml:S1:21421:15	O
in	SAPHRIS.xml:S1:21437:2	O
subjects	SAPHRIS.xml:S1:21440:8	O
treated	SAPHRIS.xml:S1:21449:7	O
with	SAPHRIS.xml:S1:21457:4	O
SAPHRIS	SAPHRIS.xml:S1:21462:7	O
(	SAPHRIS.xml:S1:21470:1	O
rates	SAPHRIS.xml:S1:21471:5	O
at	SAPHRIS.xml:S1:21477:2	O
least	SAPHRIS.xml:S1:21480:5	O
1%	SAPHRIS.xml:S1:21486:2	O
and	SAPHRIS.xml:S1:21489:3	O
at	SAPHRIS.xml:S1:21493:2	O
least	SAPHRIS.xml:S1:21496:5	O
twice	SAPHRIS.xml:S1:21502:5	O
the	SAPHRIS.xml:S1:21508:3	O
placebo	SAPHRIS.xml:S1:21512:7	O
rate	SAPHRIS.xml:S1:21520:4	O
)	SAPHRIS.xml:S1:21524:1	O
were	SAPHRIS.xml:S1:21526:4	O
depression	SAPHRIS.xml:S1:21531:10	B-AdverseReaction
(	SAPHRIS.xml:S1:21542:1	O
2.5%	SAPHRIS.xml:S1:21543:4	O
)	SAPHRIS.xml:S1:21547:1	O
,	SAPHRIS.xml:S1:21548:1	O
suicidal	SAPHRIS.xml:S1:21550:8	B-AdverseReaction
ideation	SAPHRIS.xml:S1:21559:8	I-AdverseReaction
(	SAPHRIS.xml:S1:21568:1	O
2.5%	SAPHRIS.xml:S1:21569:4	O
)	SAPHRIS.xml:S1:21573:1	O
,	SAPHRIS.xml:S1:21574:1	O
bipolar	SAPHRIS.xml:S1:21576:7	B-AdverseReaction
I	SAPHRIS.xml:S1:21584:1	I-AdverseReaction
disorder	SAPHRIS.xml:S1:21586:8	I-AdverseReaction
(	SAPHRIS.xml:S1:21595:1	O
1.9%	SAPHRIS.xml:S1:21596:4	O
)	SAPHRIS.xml:S1:21600:1	O
,	SAPHRIS.xml:S1:21601:1	O
insomnia	SAPHRIS.xml:S1:21603:8	B-AdverseReaction
(	SAPHRIS.xml:S1:21612:1	O
1.9%	SAPHRIS.xml:S1:21613:4	O
)	SAPHRIS.xml:S1:21617:1	O
and	SAPHRIS.xml:S1:21619:3	O
depressive	SAPHRIS.xml:S1:21623:10	B-AdverseReaction
symptoms	SAPHRIS.xml:S1:21634:8	I-AdverseReaction
(	SAPHRIS.xml:S1:21643:1	O
1.3%	SAPHRIS.xml:S1:21644:4	O
)	SAPHRIS.xml:S1:21648:1	O
.	SAPHRIS.xml:S1:21649:1	O

Adverse	SAPHRIS.xml:S1:21659:7	O
Reactions	SAPHRIS.xml:S1:21667:9	O
Occurring	SAPHRIS.xml:S1:21677:9	O
at	SAPHRIS.xml:S1:21687:2	O
an	SAPHRIS.xml:S1:21690:2	O
Incidence	SAPHRIS.xml:S1:21693:9	O
of	SAPHRIS.xml:S1:21703:2	O
2%	SAPHRIS.xml:S1:21706:2	O
or	SAPHRIS.xml:S1:21709:2	O
More	SAPHRIS.xml:S1:21712:4	O
Among	SAPHRIS.xml:S1:21717:5	O
SAPHRIS	SAPHRIS.xml:S1:21723:7	O
-	SAPHRIS.xml:S1:21730:1	O
Treated	SAPHRIS.xml:S1:21731:7	O
(	SAPHRIS.xml:S1:21739:1	O
Adjunctive	SAPHRIS.xml:S1:21740:10	O
)	SAPHRIS.xml:S1:21750:1	O
Bipolar	SAPHRIS.xml:S1:21752:7	O
Patients	SAPHRIS.xml:S1:21760:8	O
:	SAPHRIS.xml:S1:21768:1	O
Adverse	SAPHRIS.xml:S1:21771:7	O
reactions	SAPHRIS.xml:S1:21779:9	O
associated	SAPHRIS.xml:S1:21789:10	O
with	SAPHRIS.xml:S1:21800:4	O
the	SAPHRIS.xml:S1:21805:3	O
use	SAPHRIS.xml:S1:21809:3	O
of	SAPHRIS.xml:S1:21813:2	O
SAPHRIS	SAPHRIS.xml:S1:21816:7	O
(	SAPHRIS.xml:S1:21824:1	O
incidence	SAPHRIS.xml:S1:21825:9	O
of	SAPHRIS.xml:S1:21835:2	O
2%	SAPHRIS.xml:S1:21838:2	O
or	SAPHRIS.xml:S1:21841:2	O
greater	SAPHRIS.xml:S1:21844:7	O
,	SAPHRIS.xml:S1:21851:1	O
rounded	SAPHRIS.xml:S1:21853:7	O
to	SAPHRIS.xml:S1:21861:2	O
the	SAPHRIS.xml:S1:21864:3	O
nearest	SAPHRIS.xml:S1:21868:7	O
percent	SAPHRIS.xml:S1:21876:7	O
,	SAPHRIS.xml:S1:21883:1	O
and	SAPHRIS.xml:S1:21885:3	O
SAPHRIS	SAPHRIS.xml:S1:21889:7	O
incidence	SAPHRIS.xml:S1:21897:9	O
greater	SAPHRIS.xml:S1:21907:7	O
than	SAPHRIS.xml:S1:21915:4	O
placebo	SAPHRIS.xml:S1:21920:7	O
)	SAPHRIS.xml:S1:21927:1	O
that	SAPHRIS.xml:S1:21929:4	O
occurred	SAPHRIS.xml:S1:21934:8	O
during	SAPHRIS.xml:S1:21943:6	O
acute	SAPHRIS.xml:S1:21950:5	O
adjunctive	SAPHRIS.xml:S1:21956:10	O
therapy	SAPHRIS.xml:S1:21967:7	O
at	SAPHRIS.xml:S1:21975:2	O
3	SAPHRIS.xml:S1:21978:1	O
weeks	SAPHRIS.xml:S1:21980:5	O
,	SAPHRIS.xml:S1:21985:1	O
a	SAPHRIS.xml:S1:21987:1	O
time	SAPHRIS.xml:S1:21989:4	O
when	SAPHRIS.xml:S1:21994:4	O
most	SAPHRIS.xml:S1:21999:4	O
of	SAPHRIS.xml:S1:22004:2	O
the	SAPHRIS.xml:S1:22007:3	O
patients	SAPHRIS.xml:S1:22011:8	O
were	SAPHRIS.xml:S1:22020:4	O
still	SAPHRIS.xml:S1:22025:5	O
participating	SAPHRIS.xml:S1:22031:13	O
in	SAPHRIS.xml:S1:22045:2	O
the	SAPHRIS.xml:S1:22048:3	O
trial	SAPHRIS.xml:S1:22052:5	O
,	SAPHRIS.xml:S1:22057:1	O
are	SAPHRIS.xml:S1:22059:3	O
shown	SAPHRIS.xml:S1:22063:5	O
in	SAPHRIS.xml:S1:22069:2	O
Table	SAPHRIS.xml:S1:22073:5	O
11	SAPHRIS.xml:S1:22079:2	O
.	SAPHRIS.xml:S1:22083:1	O

Table	SAPHRIS.xml:S1:22089:5	O
11	SAPHRIS.xml:S1:22095:2	O
:	SAPHRIS.xml:S1:22097:1	O
Adverse	SAPHRIS.xml:S1:22099:7	O
Reactions	SAPHRIS.xml:S1:22107:9	O
Reported	SAPHRIS.xml:S1:22117:8	O
in	SAPHRIS.xml:S1:22126:2	O
2%	SAPHRIS.xml:S1:22129:2	O
or	SAPHRIS.xml:S1:22132:2	O
More	SAPHRIS.xml:S1:22135:4	O
of	SAPHRIS.xml:S1:22140:2	O
Adult	SAPHRIS.xml:S1:22143:5	O
Patients	SAPHRIS.xml:S1:22149:8	O
In	SAPHRIS.xml:S1:22158:2	O
Any	SAPHRIS.xml:S1:22161:3	O
SAPHRIS	SAPHRIS.xml:S1:22165:7	O
-	SAPHRIS.xml:S1:22172:1	O
Dose	SAPHRIS.xml:S1:22173:4	O
Group	SAPHRIS.xml:S1:22178:5	O
and	SAPHRIS.xml:S1:22184:3	O
Which	SAPHRIS.xml:S1:22188:5	O
Occurred	SAPHRIS.xml:S1:22194:8	O
at	SAPHRIS.xml:S1:22203:2	O
Greater	SAPHRIS.xml:S1:22206:7	O
Incidence	SAPHRIS.xml:S1:22214:9	O
Than	SAPHRIS.xml:S1:22224:4	O
in	SAPHRIS.xml:S1:22229:2	O
the	SAPHRIS.xml:S1:22232:3	O
Placebo	SAPHRIS.xml:S1:22236:7	O
Group	SAPHRIS.xml:S1:22244:5	O
at	SAPHRIS.xml:S1:22250:2	O
3	SAPHRIS.xml:S1:22253:1	O
Weeks	SAPHRIS.xml:S1:22255:5	O
in	SAPHRIS.xml:S1:22261:2	O
Adjunctive	SAPHRIS.xml:S1:22264:10	O
Bipolar	SAPHRIS.xml:S1:22275:7	O
Mania	SAPHRIS.xml:S1:22283:5	O
Trials	SAPHRIS.xml:S1:22289:6	O

SAPHRIS	SAPHRIS.xml:S1:22301:7	O
5	SAPHRIS.xml:S1:22309:1	O
mg	SAPHRIS.xml:S1:22311:2	O
to	SAPHRIS.xml:S1:22314:2	O
10	SAPHRIS.xml:S1:22317:2	O
mg	SAPHRIS.xml:S1:22320:2	O
twice	SAPHRIS.xml:S1:22323:5	O
daily	SAPHRIS.xml:S1:22329:5	O
with	SAPHRIS.xml:S1:22335:4	O
flexible	SAPHRIS.xml:S1:22340:8	O
dosing	SAPHRIS.xml:S1:22349:6	O
.	SAPHRIS.xml:S1:22355:1	O

Extrapyramidal	SAPHRIS.xml:S1:22364:14	B-AdverseReaction
symptoms	SAPHRIS.xml:S1:22379:8	I-AdverseReaction
included	SAPHRIS.xml:S1:22388:8	O
:	SAPHRIS.xml:S1:22396:1	O
dystonia	SAPHRIS.xml:S1:22398:8	B-AdverseReaction
,	SAPHRIS.xml:S1:22406:1	O
parkinsonism	SAPHRIS.xml:S1:22408:12	B-AdverseReaction
,	SAPHRIS.xml:S1:22420:1	O
oculogyration	SAPHRIS.xml:S1:22422:13	B-AdverseReaction
,	SAPHRIS.xml:S1:22435:1	O
and	SAPHRIS.xml:S1:22437:3	O
tremor	SAPHRIS.xml:S1:22441:6	B-AdverseReaction
(	SAPHRIS.xml:S1:22448:1	O
excluding	SAPHRIS.xml:S1:22449:9	B-Negation
akathisia	SAPHRIS.xml:S1:22459:9	B-AdverseReaction
)	SAPHRIS.xml:S1:22468:1	O
.	SAPHRIS.xml:S1:22469:1	O

?	SAPHRIS.xml:S1:22477:1	O

Somnolence	SAPHRIS.xml:S1:22479:10	B-AdverseReaction
includes	SAPHRIS.xml:S1:22490:8	O
the	SAPHRIS.xml:S1:22499:3	O
following	SAPHRIS.xml:S1:22503:9	O
events	SAPHRIS.xml:S1:22513:6	O
:	SAPHRIS.xml:S1:22519:1	O
somnolence	SAPHRIS.xml:S1:22521:10	B-AdverseReaction
and	SAPHRIS.xml:S1:22532:3	O
sedation	SAPHRIS.xml:S1:22536:8	B-AdverseReaction
.	SAPHRIS.xml:S1:22544:1	O

System	SAPHRIS.xml:S1:22556:6	O

Organ	SAPHRIS.xml:S1:22563:5	O
Class	SAPHRIS.xml:S1:22569:5	O
Preferred	SAPHRIS.xml:S1:22575:9	O
Term	SAPHRIS.xml:S1:22585:4	O
Placebo	SAPHRIS.xml:S1:22605:7	O
N	SAPHRIS.xml:S1:22616:1	O
166	SAPHRIS.xml:S1:22618:3	O
SAPHRIS	SAPHRIS.xml:S1:22632:7	O
5	SAPHRIS.xml:S1:22643:1	O
mg	SAPHRIS.xml:S1:22645:2	O
or	SAPHRIS.xml:S1:22648:2	O
10	SAPHRIS.xml:S1:22651:2	O
mg	SAPHRIS.xml:S1:22654:2	O
twice	SAPHRIS.xml:S1:22657:5	O
daily	SAPHRIS.xml:S1:22663:5	O
N	SAPHRIS.xml:S1:22673:1	O
158	SAPHRIS.xml:S1:22675:3	O

Gastrointestinal	SAPHRIS.xml:S1:22692:16	O
disorders	SAPHRIS.xml:S1:22709:9	O

Dyspepsia	SAPHRIS.xml:S1:22745:9	B-AdverseReaction
2	SAPHRIS.xml:S1:22791:1	O
3	SAPHRIS.xml:S1:22813:1	O

Oral	SAPHRIS.xml:S1:22853:4	B-AdverseReaction
hypoesthesia	SAPHRIS.xml:S1:22858:12	I-AdverseReaction
0	SAPHRIS.xml:S1:22899:1	O
5	SAPHRIS.xml:S1:22921:1	O

General	SAPHRIS.xml:S1:22960:7	O
disorders	SAPHRIS.xml:S1:22968:9	O

Fatigue	SAPHRIS.xml:S1:23013:7	B-AdverseReaction
2	SAPHRIS.xml:S1:23059:1	O
4	SAPHRIS.xml:S1:23081:1	O

Edema	SAPHRIS.xml:S1:23121:5	B-AdverseReaction
peripheral	SAPHRIS.xml:S1:23127:10	I-AdverseReaction
1	SAPHRIS.xml:S1:23168:1	O
3	SAPHRIS.xml:S1:23189:1	O

Investigations	SAPHRIS.xml:S1:23228:14	O

Increased	SAPHRIS.xml:S1:23281:9	B-AdverseReaction
weight	SAPHRIS.xml:S1:23291:6	I-AdverseReaction
0	SAPHRIS.xml:S1:23327:1	O
3	SAPHRIS.xml:S1:23349:1	O

Nervous	SAPHRIS.xml:S1:23388:7	O
system	SAPHRIS.xml:S1:23396:6	O
disorders	SAPHRIS.xml:S1:23403:9	O

Dizziness	SAPHRIS.xml:S1:23441:9	B-AdverseReaction
2	SAPHRIS.xml:S1:23487:1	O
4	SAPHRIS.xml:S1:23509:1	O

Other	SAPHRIS.xml:S1:23549:5	O
extrapyramidal	SAPHRIS.xml:S1:23555:14	B-AdverseReaction
symptoms	SAPHRIS.xml:S1:23570:8	I-AdverseReaction
(	SAPHRIS.xml:S1:23579:1	O
excluding	SAPHRIS.xml:S1:23580:9	B-Negation
akathisia	SAPHRIS.xml:S1:23590:9	B-AdverseReaction
)	SAPHRIS.xml:S1:23599:1	O
5	SAPHRIS.xml:S1:23606:1	O
6	SAPHRIS.xml:S1:23628:1	O

Somnolence	SAPHRIS.xml:S1:23668:10	B-AdverseReaction
?	SAPHRIS.xml:S1:23680:1	O

10	SAPHRIS.xml:S1:23714:2	O
22	SAPHRIS.xml:S1:23736:2	O

Psychiatric	SAPHRIS.xml:S1:23775:11	O
disorders	SAPHRIS.xml:S1:23787:9	O

Insomnia	SAPHRIS.xml:S1:23828:8	B-AdverseReaction
8	SAPHRIS.xml:S1:23874:1	O
10	SAPHRIS.xml:S1:23896:2	O

Vascular	SAPHRIS.xml:S1:23935:8	O
disorders	SAPHRIS.xml:S1:23944:9	O

Hypertension	SAPHRIS.xml:S1:23988:12	B-AdverseReaction
1	SAPHRIS.xml:S1:24035:1	O
3	SAPHRIS.xml:S1:24056:1	O

Dystonia	SAPHRIS.xml:S1:24105:8	O
:	SAPHRIS.xml:S1:24113:1	O
Symptoms	SAPHRIS.xml:S1:24116:8	O
of	SAPHRIS.xml:S1:24125:2	O
dystonia	SAPHRIS.xml:S1:24128:8	B-AdverseReaction
,	SAPHRIS.xml:S1:24136:1	O
prolonged	SAPHRIS.xml:S1:24138:9	B-AdverseReaction
abnormal	SAPHRIS.xml:S1:24148:8	I-AdverseReaction
contractions	SAPHRIS.xml:S1:24157:12	I-AdverseReaction
of	SAPHRIS.xml:S1:24170:2	I-AdverseReaction
muscle	SAPHRIS.xml:S1:24173:6	I-AdverseReaction
groups	SAPHRIS.xml:S1:24180:6	I-AdverseReaction
,	SAPHRIS.xml:S1:24186:1	O
may	SAPHRIS.xml:S1:24188:3	B-Factor
occur	SAPHRIS.xml:S1:24192:5	O
in	SAPHRIS.xml:S1:24198:2	O
susceptible	SAPHRIS.xml:S1:24201:11	O
individuals	SAPHRIS.xml:S1:24213:11	O
during	SAPHRIS.xml:S1:24225:6	O
the	SAPHRIS.xml:S1:24232:3	O
first	SAPHRIS.xml:S1:24236:5	O
few	SAPHRIS.xml:S1:24242:3	O
days	SAPHRIS.xml:S1:24246:4	O
of	SAPHRIS.xml:S1:24251:2	O
treatment	SAPHRIS.xml:S1:24254:9	O
.	SAPHRIS.xml:S1:24263:1	O

Dystonic	SAPHRIS.xml:S1:24265:8	B-AdverseReaction
symptoms	SAPHRIS.xml:S1:24274:8	I-AdverseReaction
include	SAPHRIS.xml:S1:24283:7	O
:	SAPHRIS.xml:S1:24290:1	O
spasm	SAPHRIS.xml:S1:24292:5	B-AdverseReaction
of	SAPHRIS.xml:S1:24298:2	I-AdverseReaction
the	SAPHRIS.xml:S1:24301:3	I-AdverseReaction
neck	SAPHRIS.xml:S1:24305:4	I-AdverseReaction
muscles	SAPHRIS.xml:S1:24310:7	I-AdverseReaction
,	SAPHRIS.xml:S1:24317:1	O
sometimes	SAPHRIS.xml:S1:24319:9	O
progressing	SAPHRIS.xml:S1:24329:11	O
to	SAPHRIS.xml:S1:24341:2	O
tightness	SAPHRIS.xml:S1:24344:9	B-AdverseReaction
of	SAPHRIS.xml:S1:24354:2	I-AdverseReaction
the	SAPHRIS.xml:S1:24357:3	I-AdverseReaction
throat	SAPHRIS.xml:S1:24361:6	I-AdverseReaction
,	SAPHRIS.xml:S1:24367:1	O
swallowing	SAPHRIS.xml:S1:24369:10	B-AdverseReaction
difficulty	SAPHRIS.xml:S1:24380:10	I-AdverseReaction
,	SAPHRIS.xml:S1:24390:1	O
difficulty	SAPHRIS.xml:S1:24392:10	B-AdverseReaction
breathing	SAPHRIS.xml:S1:24403:9	I-AdverseReaction
,	SAPHRIS.xml:S1:24412:1	O
and	SAPHRIS.xml:S1:24414:3	O
or	SAPHRIS.xml:S1:24418:2	O
protrusion	SAPHRIS.xml:S1:24421:10	B-AdverseReaction
of	SAPHRIS.xml:S1:24432:2	I-AdverseReaction
the	SAPHRIS.xml:S1:24435:3	I-AdverseReaction
tongue	SAPHRIS.xml:S1:24439:6	I-AdverseReaction
.	SAPHRIS.xml:S1:24445:1	O

While	SAPHRIS.xml:S1:24447:5	O
these	SAPHRIS.xml:S1:24453:5	O
symptoms	SAPHRIS.xml:S1:24459:8	O
can	SAPHRIS.xml:S1:24468:3	O
occur	SAPHRIS.xml:S1:24472:5	O
at	SAPHRIS.xml:S1:24478:2	O
low	SAPHRIS.xml:S1:24481:3	O
doses	SAPHRIS.xml:S1:24485:5	O
,	SAPHRIS.xml:S1:24490:1	O
they	SAPHRIS.xml:S1:24492:4	O
occur	SAPHRIS.xml:S1:24497:5	O
more	SAPHRIS.xml:S1:24503:4	O
frequently	SAPHRIS.xml:S1:24508:10	O
and	SAPHRIS.xml:S1:24519:3	O
with	SAPHRIS.xml:S1:24523:4	O
greater	SAPHRIS.xml:S1:24528:7	O
severity	SAPHRIS.xml:S1:24536:8	O
with	SAPHRIS.xml:S1:24545:4	O
high	SAPHRIS.xml:S1:24550:4	O
potency	SAPHRIS.xml:S1:24555:7	O
and	SAPHRIS.xml:S1:24563:3	O
at	SAPHRIS.xml:S1:24567:2	O
higher	SAPHRIS.xml:S1:24570:6	O
doses	SAPHRIS.xml:S1:24577:5	O
of	SAPHRIS.xml:S1:24583:2	O
first	SAPHRIS.xml:S1:24586:5	O
generation	SAPHRIS.xml:S1:24592:10	O
antipsychotic	SAPHRIS.xml:S1:24603:13	O
drugs	SAPHRIS.xml:S1:24617:5	O
.	SAPHRIS.xml:S1:24622:1	O

An	SAPHRIS.xml:S1:24624:2	O
elevated	SAPHRIS.xml:S1:24627:8	O
risk	SAPHRIS.xml:S1:24636:4	B-Factor
of	SAPHRIS.xml:S1:24641:2	O
acute	SAPHRIS.xml:S1:24644:5	B-AdverseReaction
dystonia	SAPHRIS.xml:S1:24650:8	I-AdverseReaction
is	SAPHRIS.xml:S1:24659:2	O
observed	SAPHRIS.xml:S1:24662:8	O
in	SAPHRIS.xml:S1:24671:2	O
males	SAPHRIS.xml:S1:24674:5	O
and	SAPHRIS.xml:S1:24680:3	O
younger	SAPHRIS.xml:S1:24684:7	O
age	SAPHRIS.xml:S1:24692:3	O
groups	SAPHRIS.xml:S1:24696:6	O
[	SAPHRIS.xml:S1:24704:1	O
see	SAPHRIS.xml:S1:24705:3	O
Dosage	SAPHRIS.xml:S1:24709:6	O
and	SAPHRIS.xml:S1:24716:3	O
Administration	SAPHRIS.xml:S1:24720:14	O
(	SAPHRIS.xml:S1:24735:1	O
2.3	SAPHRIS.xml:S1:24736:3	O
)	SAPHRIS.xml:S1:24739:1	O
,	SAPHRIS.xml:S1:24740:1	O
Use	SAPHRIS.xml:S1:24742:3	O
in	SAPHRIS.xml:S1:24746:2	O
Specific	SAPHRIS.xml:S1:24749:8	O
Populations	SAPHRIS.xml:S1:24758:11	O
(	SAPHRIS.xml:S1:24770:1	O
8.4	SAPHRIS.xml:S1:24771:3	O
)	SAPHRIS.xml:S1:24774:1	O
,	SAPHRIS.xml:S1:24775:1	O
and	SAPHRIS.xml:S1:24777:3	O
Clinical	SAPHRIS.xml:S1:24781:8	O
Pharmacology	SAPHRIS.xml:S1:24790:12	O
(	SAPHRIS.xml:S1:24803:1	O
12.3	SAPHRIS.xml:S1:24804:4	O
)]	SAPHRIS.xml:S1:24808:2	O
.	SAPHRIS.xml:S1:24812:1	O

Extrapyramidal	SAPHRIS.xml:S1:24822:14	O

Symptoms	SAPHRIS.xml:S1:24837:8	O
:	SAPHRIS.xml:S1:24845:1	O
In	SAPHRIS.xml:S1:24848:2	O
the	SAPHRIS.xml:S1:24851:3	O
short	SAPHRIS.xml:S1:24855:5	O
-	SAPHRIS.xml:S1:24860:1	O
term	SAPHRIS.xml:S1:24861:4	O
,	SAPHRIS.xml:S1:24865:1	O
placebo	SAPHRIS.xml:S1:24867:7	O
-	SAPHRIS.xml:S1:24874:1	O
controlled	SAPHRIS.xml:S1:24875:10	O
schizophrenia	SAPHRIS.xml:S1:24886:13	O
and	SAPHRIS.xml:S1:24900:3	O
bipolar	SAPHRIS.xml:S1:24904:7	O
mania	SAPHRIS.xml:S1:24912:5	O
adult	SAPHRIS.xml:S1:24918:5	O
trials	SAPHRIS.xml:S1:24924:6	O
,	SAPHRIS.xml:S1:24930:1	O
data	SAPHRIS.xml:S1:24932:4	O
was	SAPHRIS.xml:S1:24937:3	O
objectively	SAPHRIS.xml:S1:24941:11	O
collected	SAPHRIS.xml:S1:24953:9	O
on	SAPHRIS.xml:S1:24963:2	O
the	SAPHRIS.xml:S1:24966:3	O
Simpson	SAPHRIS.xml:S1:24970:7	O
Angus	SAPHRIS.xml:S1:24978:5	O
Rating	SAPHRIS.xml:S1:24984:6	O
Scale	SAPHRIS.xml:S1:24991:5	O
for	SAPHRIS.xml:S1:24997:3	O
extrapyramidal	SAPHRIS.xml:S1:25001:14	B-AdverseReaction
symptoms	SAPHRIS.xml:S1:25016:8	I-AdverseReaction
(	SAPHRIS.xml:S1:25025:1	O
EPS	SAPHRIS.xml:S1:25026:3	B-AdverseReaction
)	SAPHRIS.xml:S1:25029:1	O
,	SAPHRIS.xml:S1:25030:1	O
the	SAPHRIS.xml:S1:25032:3	O
Barnes	SAPHRIS.xml:S1:25036:6	O
Akathisia	SAPHRIS.xml:S1:25043:9	O
Scale	SAPHRIS.xml:S1:25053:5	O
(	SAPHRIS.xml:S1:25059:1	O
for	SAPHRIS.xml:S1:25060:3	O
akathisia	SAPHRIS.xml:S1:25064:9	B-AdverseReaction
)	SAPHRIS.xml:S1:25073:1	O
and	SAPHRIS.xml:S1:25075:3	O
the	SAPHRIS.xml:S1:25079:3	O
Assessments	SAPHRIS.xml:S1:25083:11	O
of	SAPHRIS.xml:S1:25095:2	O
Involuntary	SAPHRIS.xml:S1:25098:11	O
Movement	SAPHRIS.xml:S1:25110:8	O
Scales	SAPHRIS.xml:S1:25119:6	O
(	SAPHRIS.xml:S1:25126:1	O
for	SAPHRIS.xml:S1:25127:3	O
dyskinesias	SAPHRIS.xml:S1:25131:11	B-AdverseReaction
)	SAPHRIS.xml:S1:25142:1	O
.	SAPHRIS.xml:S1:25143:1	O

The	SAPHRIS.xml:S1:25145:3	O
mean	SAPHRIS.xml:S1:25149:4	O
change	SAPHRIS.xml:S1:25154:6	O
from	SAPHRIS.xml:S1:25161:4	O
baseline	SAPHRIS.xml:S1:25166:8	O
for	SAPHRIS.xml:S1:25175:3	O
the	SAPHRIS.xml:S1:25179:3	O
all	SAPHRIS.xml:S1:25183:3	O
-	SAPHRIS.xml:S1:25186:1	O
SAPHRIS	SAPHRIS.xml:S1:25187:7	O
5	SAPHRIS.xml:S1:25195:1	O
mg	SAPHRIS.xml:S1:25197:2	O
or	SAPHRIS.xml:S1:25200:2	O
10	SAPHRIS.xml:S1:25203:2	O
mg	SAPHRIS.xml:S1:25206:2	O
twice	SAPHRIS.xml:S1:25209:5	O
daily	SAPHRIS.xml:S1:25215:5	O
treated	SAPHRIS.xml:S1:25221:7	O
group	SAPHRIS.xml:S1:25229:5	O
was	SAPHRIS.xml:S1:25235:3	O
comparable	SAPHRIS.xml:S1:25239:10	O
to	SAPHRIS.xml:S1:25250:2	O
placebo	SAPHRIS.xml:S1:25253:7	O
in	SAPHRIS.xml:S1:25261:2	O
each	SAPHRIS.xml:S1:25264:4	O
of	SAPHRIS.xml:S1:25269:2	O
the	SAPHRIS.xml:S1:25272:3	O
rating	SAPHRIS.xml:S1:25276:6	O
scale	SAPHRIS.xml:S1:25283:5	O
scores	SAPHRIS.xml:S1:25289:6	O
.	SAPHRIS.xml:S1:25295:1	O

In	SAPHRIS.xml:S1:25301:2	O
the	SAPHRIS.xml:S1:25304:3	O
short	SAPHRIS.xml:S1:25308:5	O
-	SAPHRIS.xml:S1:25313:1	O
term	SAPHRIS.xml:S1:25314:4	O
,	SAPHRIS.xml:S1:25318:1	O
placebo	SAPHRIS.xml:S1:25320:7	O
-	SAPHRIS.xml:S1:25327:1	O
controlled	SAPHRIS.xml:S1:25328:10	O
schizophrenia	SAPHRIS.xml:S1:25339:13	O
adult	SAPHRIS.xml:S1:25353:5	O
trials	SAPHRIS.xml:S1:25359:6	O
,	SAPHRIS.xml:S1:25365:1	O
the	SAPHRIS.xml:S1:25367:3	O
incidence	SAPHRIS.xml:S1:25371:9	O
of	SAPHRIS.xml:S1:25381:2	O
reported	SAPHRIS.xml:S1:25384:8	O
EPS	SAPHRIS.xml:S1:25393:3	B-AdverseReaction
-	SAPHRIS.xml:S1:25396:1	I-AdverseReaction
related	SAPHRIS.xml:S1:25397:7	I-AdverseReaction
events	SAPHRIS.xml:S1:25405:6	I-AdverseReaction
,	SAPHRIS.xml:S1:25411:1	O
excluding	SAPHRIS.xml:S1:25413:9	B-Negation
events	SAPHRIS.xml:S1:25423:6	O
related	SAPHRIS.xml:S1:25430:7	O
to	SAPHRIS.xml:S1:25438:2	O
akathisia	SAPHRIS.xml:S1:25441:9	B-AdverseReaction
,	SAPHRIS.xml:S1:25450:1	O
for	SAPHRIS.xml:S1:25452:3	O
SAPHRIS	SAPHRIS.xml:S1:25456:7	O
-	SAPHRIS.xml:S1:25463:1	O
treated	SAPHRIS.xml:S1:25464:7	O
patients	SAPHRIS.xml:S1:25472:8	O
was	SAPHRIS.xml:S1:25481:3	O
10%	SAPHRIS.xml:S1:25485:3	O
versus	SAPHRIS.xml:S1:25489:6	O
7%	SAPHRIS.xml:S1:25496:2	O
for	SAPHRIS.xml:S1:25499:3	O
placebo	SAPHRIS.xml:S1:25503:7	O
;	SAPHRIS.xml:S1:25510:1	O
and	SAPHRIS.xml:S1:25512:3	O
the	SAPHRIS.xml:S1:25516:3	O
incidence	SAPHRIS.xml:S1:25520:9	O
of	SAPHRIS.xml:S1:25530:2	O
akathisia	SAPHRIS.xml:S1:25533:9	B-AdverseReaction
-	SAPHRIS.xml:S1:25542:1	O
related	SAPHRIS.xml:S1:25543:7	O
events	SAPHRIS.xml:S1:25551:6	O
for	SAPHRIS.xml:S1:25558:3	O
SAPHRIS	SAPHRIS.xml:S1:25562:7	O
-	SAPHRIS.xml:S1:25569:1	O
treated	SAPHRIS.xml:S1:25570:7	O
patients	SAPHRIS.xml:S1:25578:8	O
was	SAPHRIS.xml:S1:25587:3	O
6%	SAPHRIS.xml:S1:25591:2	O
versus	SAPHRIS.xml:S1:25594:6	O
3%	SAPHRIS.xml:S1:25601:2	O
for	SAPHRIS.xml:S1:25604:3	O
placebo	SAPHRIS.xml:S1:25608:7	O
.	SAPHRIS.xml:S1:25615:1	O

In	SAPHRIS.xml:S1:25617:2	O
short	SAPHRIS.xml:S1:25620:5	O
-	SAPHRIS.xml:S1:25625:1	O
term	SAPHRIS.xml:S1:25626:4	O
placebo	SAPHRIS.xml:S1:25631:7	O
-	SAPHRIS.xml:S1:25638:1	O
controlled	SAPHRIS.xml:S1:25639:10	O
bipolar	SAPHRIS.xml:S1:25650:7	O
mania	SAPHRIS.xml:S1:25658:5	O
adult	SAPHRIS.xml:S1:25664:5	O
trials	SAPHRIS.xml:S1:25670:6	O
,	SAPHRIS.xml:S1:25676:1	O
the	SAPHRIS.xml:S1:25678:3	O
incidence	SAPHRIS.xml:S1:25682:9	O
of	SAPHRIS.xml:S1:25692:2	O
EPS	SAPHRIS.xml:S1:25695:3	B-AdverseReaction
-	SAPHRIS.xml:S1:25698:1	I-AdverseReaction
related	SAPHRIS.xml:S1:25699:7	I-AdverseReaction
events	SAPHRIS.xml:S1:25707:6	I-AdverseReaction
,	SAPHRIS.xml:S1:25713:1	O
excluding	SAPHRIS.xml:S1:25715:9	B-Negation
events	SAPHRIS.xml:S1:25725:6	O
related	SAPHRIS.xml:S1:25732:7	O
to	SAPHRIS.xml:S1:25740:2	O
akathisia	SAPHRIS.xml:S1:25743:9	B-AdverseReaction
,	SAPHRIS.xml:S1:25752:1	O
for	SAPHRIS.xml:S1:25754:3	O
SAPHRIS	SAPHRIS.xml:S1:25758:7	O
-	SAPHRIS.xml:S1:25765:1	O
treated	SAPHRIS.xml:S1:25766:7	O
patients	SAPHRIS.xml:S1:25774:8	O
was	SAPHRIS.xml:S1:25783:3	O
7%	SAPHRIS.xml:S1:25787:2	O
versus	SAPHRIS.xml:S1:25790:6	O
2%	SAPHRIS.xml:S1:25797:2	O
for	SAPHRIS.xml:S1:25800:3	O
placebo	SAPHRIS.xml:S1:25804:7	O
;	SAPHRIS.xml:S1:25811:1	O
and	SAPHRIS.xml:S1:25813:3	O
the	SAPHRIS.xml:S1:25817:3	O
incidence	SAPHRIS.xml:S1:25821:9	O
of	SAPHRIS.xml:S1:25831:2	O
akathisia	SAPHRIS.xml:S1:25834:9	B-AdverseReaction
-	SAPHRIS.xml:S1:25843:1	O
related	SAPHRIS.xml:S1:25844:7	O
events	SAPHRIS.xml:S1:25852:6	O
for	SAPHRIS.xml:S1:25859:3	O
SAPHRIS	SAPHRIS.xml:S1:25863:7	O
-	SAPHRIS.xml:S1:25870:1	O
treated	SAPHRIS.xml:S1:25871:7	O
patients	SAPHRIS.xml:S1:25879:8	O
was	SAPHRIS.xml:S1:25888:3	O
4%	SAPHRIS.xml:S1:25892:2	O
versus	SAPHRIS.xml:S1:25895:6	O
2%	SAPHRIS.xml:S1:25902:2	O
for	SAPHRIS.xml:S1:25905:3	O
placebo	SAPHRIS.xml:S1:25909:7	O
.	SAPHRIS.xml:S1:25916:1	O

In	SAPHRIS.xml:S1:25922:2	O
a	SAPHRIS.xml:S1:25925:1	O
3	SAPHRIS.xml:S1:25927:1	O
-	SAPHRIS.xml:S1:25928:1	O
week	SAPHRIS.xml:S1:25929:4	O
,	SAPHRIS.xml:S1:25933:1	O
placebo	SAPHRIS.xml:S1:25935:7	O
-	SAPHRIS.xml:S1:25942:1	O
controlled	SAPHRIS.xml:S1:25943:10	O
pediatric	SAPHRIS.xml:S1:25954:9	O
trial	SAPHRIS.xml:S1:25964:5	O
with	SAPHRIS.xml:S1:25970:4	O
bipolar	SAPHRIS.xml:S1:25975:7	O
I	SAPHRIS.xml:S1:25983:1	O
disorder	SAPHRIS.xml:S1:25985:8	O
,	SAPHRIS.xml:S1:25993:1	O
the	SAPHRIS.xml:S1:25995:3	O
incidences	SAPHRIS.xml:S1:25999:10	O
of	SAPHRIS.xml:S1:26010:2	O
EPS	SAPHRIS.xml:S1:26013:3	B-AdverseReaction
-	SAPHRIS.xml:S1:26016:1	I-AdverseReaction
related	SAPHRIS.xml:S1:26017:7	I-AdverseReaction
events	SAPHRIS.xml:S1:26025:6	I-AdverseReaction
,	SAPHRIS.xml:S1:26031:1	O
excluding	SAPHRIS.xml:S1:26033:9	B-Negation
events	SAPHRIS.xml:S1:26043:6	O
related	SAPHRIS.xml:S1:26050:7	O
to	SAPHRIS.xml:S1:26058:2	O
akathisia	SAPHRIS.xml:S1:26061:9	B-AdverseReaction
,	SAPHRIS.xml:S1:26070:1	O
were	SAPHRIS.xml:S1:26072:4	O
4%	SAPHRIS.xml:S1:26077:2	O
,	SAPHRIS.xml:S1:26079:1	O
3%	SAPHRIS.xml:S1:26081:2	O
,	SAPHRIS.xml:S1:26083:1	O
and	SAPHRIS.xml:S1:26085:3	O
5%	SAPHRIS.xml:S1:26089:2	O
for	SAPHRIS.xml:S1:26092:3	O
patients	SAPHRIS.xml:S1:26096:8	O
treated	SAPHRIS.xml:S1:26105:7	O
with	SAPHRIS.xml:S1:26113:4	O
SAPHRIS	SAPHRIS.xml:S1:26118:7	O
2.5	SAPHRIS.xml:S1:26126:3	O
mg	SAPHRIS.xml:S1:26130:2	O
,	SAPHRIS.xml:S1:26132:1	O
5	SAPHRIS.xml:S1:26134:1	O
mg	SAPHRIS.xml:S1:26136:2	O
,	SAPHRIS.xml:S1:26138:1	O
and	SAPHRIS.xml:S1:26140:3	O
10	SAPHRIS.xml:S1:26144:2	O
mg	SAPHRIS.xml:S1:26147:2	O
twice	SAPHRIS.xml:S1:26150:5	O
daily	SAPHRIS.xml:S1:26156:5	O
,	SAPHRIS.xml:S1:26161:1	O
respectively	SAPHRIS.xml:S1:26163:12	O
,	SAPHRIS.xml:S1:26175:1	O
as	SAPHRIS.xml:S1:26177:2	O
compared	SAPHRIS.xml:S1:26180:8	O
to	SAPHRIS.xml:S1:26189:2	O
3%	SAPHRIS.xml:S1:26192:2	O
for	SAPHRIS.xml:S1:26195:3	O
placebo	SAPHRIS.xml:S1:26199:7	O
-	SAPHRIS.xml:S1:26206:1	O
treated	SAPHRIS.xml:S1:26207:7	O
patients	SAPHRIS.xml:S1:26215:8	O
.	SAPHRIS.xml:S1:26223:1	O

EPS	SAPHRIS.xml:S1:26225:3	B-AdverseReaction
-	SAPHRIS.xml:S1:26228:1	I-AdverseReaction
related	SAPHRIS.xml:S1:26229:7	I-AdverseReaction
events	SAPHRIS.xml:S1:26237:6	I-AdverseReaction
include	SAPHRIS.xml:S1:26244:7	O
:	SAPHRIS.xml:S1:26251:1	O
bradykinesia	SAPHRIS.xml:S1:26253:12	B-AdverseReaction
,	SAPHRIS.xml:S1:26265:1	O
dyskinesia	SAPHRIS.xml:S1:26267:10	B-AdverseReaction
,	SAPHRIS.xml:S1:26277:1	O
dystonia	SAPHRIS.xml:S1:26279:8	B-AdverseReaction
,	SAPHRIS.xml:S1:26287:1	O
oromandibular	SAPHRIS.xml:S1:26289:13	B-AdverseReaction
dystonia	SAPHRIS.xml:S1:26303:8	I-AdverseReaction
,	SAPHRIS.xml:S1:26311:1	O
muscle	SAPHRIS.xml:S1:26313:6	B-AdverseReaction
contractions	SAPHRIS.xml:S1:26320:12	I-AdverseReaction
involuntary	SAPHRIS.xml:S1:26333:11	I-AdverseReaction
,	SAPHRIS.xml:S1:26344:1	O
muscle	SAPHRIS.xml:S1:26346:6	B-AdverseReaction
twitching	SAPHRIS.xml:S1:26353:9	I-AdverseReaction
,	SAPHRIS.xml:S1:26362:1	O
musculoskeletal	SAPHRIS.xml:S1:26364:15	B-AdverseReaction
stiffness	SAPHRIS.xml:S1:26380:9	I-AdverseReaction
,	SAPHRIS.xml:S1:26389:1	O
parkinsonism	SAPHRIS.xml:S1:26391:12	B-AdverseReaction
,	SAPHRIS.xml:S1:26403:1	O
protrusion	SAPHRIS.xml:S1:26405:10	B-AdverseReaction
tongue	SAPHRIS.xml:S1:26416:6	I-AdverseReaction
,	SAPHRIS.xml:S1:26422:1	O
resting	SAPHRIS.xml:S1:26424:7	B-AdverseReaction
tremor	SAPHRIS.xml:S1:26432:6	I-AdverseReaction
,	SAPHRIS.xml:S1:26438:1	O
and	SAPHRIS.xml:S1:26440:3	O
tremor	SAPHRIS.xml:S1:26444:6	B-AdverseReaction
.	SAPHRIS.xml:S1:26450:1	O

For	SAPHRIS.xml:S1:26456:3	O
events	SAPHRIS.xml:S1:26460:6	O
of	SAPHRIS.xml:S1:26467:2	O
akathisia	SAPHRIS.xml:S1:26470:9	B-AdverseReaction
,	SAPHRIS.xml:S1:26479:1	O
incidences	SAPHRIS.xml:S1:26481:10	O
were	SAPHRIS.xml:S1:26492:4	O
2%	SAPHRIS.xml:S1:26497:2	O
,	SAPHRIS.xml:S1:26499:1	O
2%	SAPHRIS.xml:S1:26501:2	O
,	SAPHRIS.xml:S1:26503:1	O
and	SAPHRIS.xml:S1:26505:3	O
1%	SAPHRIS.xml:S1:26509:2	O
for	SAPHRIS.xml:S1:26512:3	O
patients	SAPHRIS.xml:S1:26516:8	O
treated	SAPHRIS.xml:S1:26525:7	O
with	SAPHRIS.xml:S1:26533:4	O
SAPHRIS	SAPHRIS.xml:S1:26538:7	O
2.5	SAPHRIS.xml:S1:26546:3	O
mg	SAPHRIS.xml:S1:26550:2	O
,	SAPHRIS.xml:S1:26552:1	O
5	SAPHRIS.xml:S1:26554:1	O
mg	SAPHRIS.xml:S1:26556:2	O
,	SAPHRIS.xml:S1:26558:1	O
and	SAPHRIS.xml:S1:26560:3	O
10	SAPHRIS.xml:S1:26564:2	O
mg	SAPHRIS.xml:S1:26567:2	O
twice	SAPHRIS.xml:S1:26570:5	O
daily	SAPHRIS.xml:S1:26576:5	O
,	SAPHRIS.xml:S1:26581:1	O
respectively	SAPHRIS.xml:S1:26583:12	O
,	SAPHRIS.xml:S1:26595:1	O
as	SAPHRIS.xml:S1:26597:2	O
compared	SAPHRIS.xml:S1:26600:8	O
to	SAPHRIS.xml:S1:26609:2	O
0%	SAPHRIS.xml:S1:26612:2	O
for	SAPHRIS.xml:S1:26615:3	O
placebo	SAPHRIS.xml:S1:26619:7	O
-	SAPHRIS.xml:S1:26626:1	O
treated	SAPHRIS.xml:S1:26627:7	O
patients	SAPHRIS.xml:S1:26635:8	O
.	SAPHRIS.xml:S1:26643:1	O

Other	SAPHRIS.xml:S1:26653:5	O
Findings	SAPHRIS.xml:S1:26659:8	O
:	SAPHRIS.xml:S1:26667:1	O
Oral	SAPHRIS.xml:S1:26670:4	B-AdverseReaction
hypoesthesia	SAPHRIS.xml:S1:26675:12	I-AdverseReaction
and	SAPHRIS.xml:S1:26688:3	O
or	SAPHRIS.xml:S1:26692:2	O
oral	SAPHRIS.xml:S1:26695:4	B-AdverseReaction
paresthesia	SAPHRIS.xml:S1:26700:11	I-AdverseReaction
may	SAPHRIS.xml:S1:26712:3	O
occur	SAPHRIS.xml:S1:26716:5	O
directly	SAPHRIS.xml:S1:26722:8	O
after	SAPHRIS.xml:S1:26731:5	O
administration	SAPHRIS.xml:S1:26737:14	O
of	SAPHRIS.xml:S1:26752:2	O
SAPHRIS	SAPHRIS.xml:S1:26755:7	O
and	SAPHRIS.xml:S1:26763:3	O
usually	SAPHRIS.xml:S1:26767:7	O
resolves	SAPHRIS.xml:S1:26775:8	O
within	SAPHRIS.xml:S1:26784:6	O
1	SAPHRIS.xml:S1:26791:1	O
hour	SAPHRIS.xml:S1:26793:4	O
.	SAPHRIS.xml:S1:26797:1	O

Laboratory	SAPHRIS.xml:S1:26807:10	O
Test	SAPHRIS.xml:S1:26818:4	O
Abnormalities	SAPHRIS.xml:S1:26823:13	O
:	SAPHRIS.xml:S1:26836:1	O

Transaminases	SAPHRIS.xml:S1:26848:13	O
:	SAPHRIS.xml:S1:26861:1	O
Transient	SAPHRIS.xml:S1:26864:9	O
elevations	SAPHRIS.xml:S1:26874:10	B-AdverseReaction
in	SAPHRIS.xml:S1:26885:2	I-AdverseReaction
serum	SAPHRIS.xml:S1:26888:5	I-AdverseReaction
transaminases	SAPHRIS.xml:S1:26894:13	I-AdverseReaction
(	SAPHRIS.xml:S1:26908:1	O
primarily	SAPHRIS.xml:S1:26909:9	O
ALT	SAPHRIS.xml:S1:26919:3	I-AdverseReaction
)	SAPHRIS.xml:S1:26922:1	O
in	SAPHRIS.xml:S1:26924:2	O
the	SAPHRIS.xml:S1:26927:3	O
short	SAPHRIS.xml:S1:26931:5	O
-	SAPHRIS.xml:S1:26936:1	O
term	SAPHRIS.xml:S1:26937:4	O
schizophrenia	SAPHRIS.xml:S1:26942:13	O
and	SAPHRIS.xml:S1:26956:3	O
bipolar	SAPHRIS.xml:S1:26960:7	O
mania	SAPHRIS.xml:S1:26968:5	O
adult	SAPHRIS.xml:S1:26974:5	O
trials	SAPHRIS.xml:S1:26980:6	O
were	SAPHRIS.xml:S1:26987:4	O
more	SAPHRIS.xml:S1:26992:4	O
common	SAPHRIS.xml:S1:26997:6	O
in	SAPHRIS.xml:S1:27004:2	O
treated	SAPHRIS.xml:S1:27007:7	O
patients	SAPHRIS.xml:S1:27015:8	O
.	SAPHRIS.xml:S1:27023:1	O

In	SAPHRIS.xml:S1:27025:2	O
short	SAPHRIS.xml:S1:27028:5	O
-	SAPHRIS.xml:S1:27033:1	O
term	SAPHRIS.xml:S1:27034:4	O
,	SAPHRIS.xml:S1:27038:1	O
placebo	SAPHRIS.xml:S1:27040:7	O
-	SAPHRIS.xml:S1:27047:1	O
controlled	SAPHRIS.xml:S1:27048:10	O
schizophrenia	SAPHRIS.xml:S1:27059:13	O
adult	SAPHRIS.xml:S1:27073:5	O
trials	SAPHRIS.xml:S1:27079:6	O
,	SAPHRIS.xml:S1:27085:1	O
the	SAPHRIS.xml:S1:27087:3	O
mean	SAPHRIS.xml:S1:27091:4	O
increase	SAPHRIS.xml:S1:27096:8	B-AdverseReaction
in	SAPHRIS.xml:S1:27105:2	I-AdverseReaction
transaminase	SAPHRIS.xml:S1:27108:12	I-AdverseReaction
levels	SAPHRIS.xml:S1:27121:6	I-AdverseReaction
for	SAPHRIS.xml:S1:27128:3	O
SAPHRIS	SAPHRIS.xml:S1:27132:7	O
-	SAPHRIS.xml:S1:27139:1	O
treated	SAPHRIS.xml:S1:27140:7	O
patients	SAPHRIS.xml:S1:27148:8	O
was	SAPHRIS.xml:S1:27157:3	O
1.6	SAPHRIS.xml:S1:27161:3	O
units	SAPHRIS.xml:S1:27165:5	O
L	SAPHRIS.xml:S1:27171:1	O
compared	SAPHRIS.xml:S1:27173:8	O
to	SAPHRIS.xml:S1:27182:2	O
a	SAPHRIS.xml:S1:27185:1	O
decrease	SAPHRIS.xml:S1:27187:8	O
of	SAPHRIS.xml:S1:27196:2	O
0.4	SAPHRIS.xml:S1:27199:3	O
units	SAPHRIS.xml:S1:27203:5	O
L	SAPHRIS.xml:S1:27209:1	O
for	SAPHRIS.xml:S1:27211:3	O
placebo	SAPHRIS.xml:S1:27215:7	O
-	SAPHRIS.xml:S1:27222:1	O
treated	SAPHRIS.xml:S1:27223:7	O
patients	SAPHRIS.xml:S1:27231:8	O
.	SAPHRIS.xml:S1:27239:1	O

The	SAPHRIS.xml:S1:27241:3	O
proportion	SAPHRIS.xml:S1:27245:10	O
of	SAPHRIS.xml:S1:27256:2	O
patients	SAPHRIS.xml:S1:27259:8	O
with	SAPHRIS.xml:S1:27268:4	O
transaminase	SAPHRIS.xml:S1:27273:12	B-AdverseReaction
elevations	SAPHRIS.xml:S1:27286:10	I-AdverseReaction
3	SAPHRIS.xml:S1:27299:1	B-Severity
times	SAPHRIS.xml:S1:27301:5	I-Severity
ULN	SAPHRIS.xml:S1:27307:3	I-Severity
(	SAPHRIS.xml:S1:27311:1	O
at	SAPHRIS.xml:S1:27312:2	O
Endpoint	SAPHRIS.xml:S1:27315:8	O
)	SAPHRIS.xml:S1:27323:1	O
was	SAPHRIS.xml:S1:27325:3	O
0.9%	SAPHRIS.xml:S1:27329:4	O
for	SAPHRIS.xml:S1:27334:3	O
SAPHRIS	SAPHRIS.xml:S1:27338:7	O
-	SAPHRIS.xml:S1:27345:1	O
treated	SAPHRIS.xml:S1:27346:7	O
patients	SAPHRIS.xml:S1:27354:8	O
versus	SAPHRIS.xml:S1:27363:6	O
1.3%	SAPHRIS.xml:S1:27370:4	O
for	SAPHRIS.xml:S1:27375:3	O
placebo	SAPHRIS.xml:S1:27379:7	O
-	SAPHRIS.xml:S1:27386:1	O
treated	SAPHRIS.xml:S1:27387:7	O
patients	SAPHRIS.xml:S1:27395:8	O
.	SAPHRIS.xml:S1:27403:1	O

In	SAPHRIS.xml:S1:27405:2	O
short	SAPHRIS.xml:S1:27408:5	O
-	SAPHRIS.xml:S1:27413:1	O
term	SAPHRIS.xml:S1:27414:4	O
,	SAPHRIS.xml:S1:27418:1	O
placebo	SAPHRIS.xml:S1:27420:7	O
-	SAPHRIS.xml:S1:27427:1	O
controlled	SAPHRIS.xml:S1:27428:10	O
bipolar	SAPHRIS.xml:S1:27439:7	O
adult	SAPHRIS.xml:S1:27447:5	O
mania	SAPHRIS.xml:S1:27453:5	O
trials	SAPHRIS.xml:S1:27459:6	O
,	SAPHRIS.xml:S1:27465:1	O
the	SAPHRIS.xml:S1:27467:3	O
mean	SAPHRIS.xml:S1:27471:4	O
increase	SAPHRIS.xml:S1:27476:8	B-AdverseReaction
in	SAPHRIS.xml:S1:27485:2	I-AdverseReaction
transaminase	SAPHRIS.xml:S1:27488:12	I-AdverseReaction
levels	SAPHRIS.xml:S1:27501:6	I-AdverseReaction
for	SAPHRIS.xml:S1:27508:3	O
SAPHRIS	SAPHRIS.xml:S1:27512:7	O
-	SAPHRIS.xml:S1:27519:1	O
treated	SAPHRIS.xml:S1:27520:7	O
patients	SAPHRIS.xml:S1:27528:8	O
was	SAPHRIS.xml:S1:27537:3	O
8.9	SAPHRIS.xml:S1:27541:3	O
units	SAPHRIS.xml:S1:27545:5	O
L	SAPHRIS.xml:S1:27551:1	O
compared	SAPHRIS.xml:S1:27553:8	O
to	SAPHRIS.xml:S1:27562:2	O
a	SAPHRIS.xml:S1:27565:1	O
decrease	SAPHRIS.xml:S1:27567:8	O
of	SAPHRIS.xml:S1:27576:2	O
4.9	SAPHRIS.xml:S1:27579:3	O
units	SAPHRIS.xml:S1:27583:5	O
L	SAPHRIS.xml:S1:27589:1	O
in	SAPHRIS.xml:S1:27591:2	O
placebo	SAPHRIS.xml:S1:27594:7	O
-	SAPHRIS.xml:S1:27601:1	O
treated	SAPHRIS.xml:S1:27602:7	O
patients	SAPHRIS.xml:S1:27610:8	O
.	SAPHRIS.xml:S1:27618:1	O

The	SAPHRIS.xml:S1:27620:3	O
proportion	SAPHRIS.xml:S1:27624:10	O
of	SAPHRIS.xml:S1:27635:2	O
patients	SAPHRIS.xml:S1:27638:8	O
with	SAPHRIS.xml:S1:27647:4	O
transaminase	SAPHRIS.xml:S1:27652:12	B-AdverseReaction
elevations	SAPHRIS.xml:S1:27665:10	I-AdverseReaction
3	SAPHRIS.xml:S1:27678:1	B-Severity
times	SAPHRIS.xml:S1:27680:5	I-Severity
upper	SAPHRIS.xml:S1:27686:5	I-Severity
limit	SAPHRIS.xml:S1:27692:5	I-Severity
of	SAPHRIS.xml:S1:27698:2	I-Severity
normal	SAPHRIS.xml:S1:27701:6	I-Severity
(	SAPHRIS.xml:S1:27708:1	I-Severity
ULN	SAPHRIS.xml:S1:27709:3	I-Severity
)	SAPHRIS.xml:S1:27712:1	I-Severity
(	SAPHRIS.xml:S1:27714:1	O
at	SAPHRIS.xml:S1:27715:2	O
Endpoint	SAPHRIS.xml:S1:27718:8	O
)	SAPHRIS.xml:S1:27726:1	O
was	SAPHRIS.xml:S1:27728:3	O
2.5%	SAPHRIS.xml:S1:27732:4	O
for	SAPHRIS.xml:S1:27737:3	O
SAPHRIS	SAPHRIS.xml:S1:27741:7	O
-	SAPHRIS.xml:S1:27748:1	O
treated	SAPHRIS.xml:S1:27749:7	O
patients	SAPHRIS.xml:S1:27757:8	O
versus	SAPHRIS.xml:S1:27766:6	O
0.6%	SAPHRIS.xml:S1:27773:4	O
for	SAPHRIS.xml:S1:27778:3	O
placebo	SAPHRIS.xml:S1:27782:7	O
-	SAPHRIS.xml:S1:27789:1	O
treated	SAPHRIS.xml:S1:27790:7	O
patients	SAPHRIS.xml:S1:27798:8	O
.	SAPHRIS.xml:S1:27806:1	O

In	SAPHRIS.xml:S1:27812:2	O
a	SAPHRIS.xml:S1:27815:1	O
52	SAPHRIS.xml:S1:27817:2	O
-	SAPHRIS.xml:S1:27819:1	O
week	SAPHRIS.xml:S1:27820:4	O
,	SAPHRIS.xml:S1:27824:1	O
double	SAPHRIS.xml:S1:27826:6	O
-	SAPHRIS.xml:S1:27832:1	O
blind	SAPHRIS.xml:S1:27833:5	O
,	SAPHRIS.xml:S1:27838:1	O
comparator	SAPHRIS.xml:S1:27840:10	O
-	SAPHRIS.xml:S1:27850:1	O
controlled	SAPHRIS.xml:S1:27851:10	O
trial	SAPHRIS.xml:S1:27862:5	O
that	SAPHRIS.xml:S1:27868:4	O
included	SAPHRIS.xml:S1:27873:8	O
primarily	SAPHRIS.xml:S1:27882:9	O
adult	SAPHRIS.xml:S1:27892:5	O
patients	SAPHRIS.xml:S1:27898:8	O
with	SAPHRIS.xml:S1:27907:4	O
schizophrenia	SAPHRIS.xml:S1:27912:13	O
,	SAPHRIS.xml:S1:27925:1	O
the	SAPHRIS.xml:S1:27927:3	O
mean	SAPHRIS.xml:S1:27931:4	O
increase	SAPHRIS.xml:S1:27936:8	B-AdverseReaction
from	SAPHRIS.xml:S1:27945:4	O
baseline	SAPHRIS.xml:S1:27950:8	O
of	SAPHRIS.xml:S1:27959:2	I-AdverseReaction
ALT	SAPHRIS.xml:S1:27962:3	I-AdverseReaction
was	SAPHRIS.xml:S1:27966:3	O
1.7	SAPHRIS.xml:S1:27970:3	B-Severity
units	SAPHRIS.xml:S1:27974:5	I-Severity
L.	SAPHRIS.xml:S1:27980:2	I-Severity

In	SAPHRIS.xml:S1:27987:2	O
a	SAPHRIS.xml:S1:27990:1	O
3	SAPHRIS.xml:S1:27992:1	O
-	SAPHRIS.xml:S1:27993:1	O
week	SAPHRIS.xml:S1:27994:4	O
,	SAPHRIS.xml:S1:27998:1	O
placebo	SAPHRIS.xml:S1:28000:7	O
-	SAPHRIS.xml:S1:28007:1	O
controlled	SAPHRIS.xml:S1:28008:10	O
pediatric	SAPHRIS.xml:S1:28019:9	O
trial	SAPHRIS.xml:S1:28029:5	O
with	SAPHRIS.xml:S1:28035:4	O
bipolar	SAPHRIS.xml:S1:28040:7	O
I	SAPHRIS.xml:S1:28048:1	O
disorder	SAPHRIS.xml:S1:28050:8	O
,	SAPHRIS.xml:S1:28058:1	O
transient	SAPHRIS.xml:S1:28060:9	O
elevations	SAPHRIS.xml:S1:28070:10	B-AdverseReaction
in	SAPHRIS.xml:S1:28081:2	I-AdverseReaction
serum	SAPHRIS.xml:S1:28084:5	I-AdverseReaction
transaminases	SAPHRIS.xml:S1:28090:13	I-AdverseReaction
(	SAPHRIS.xml:S1:28104:1	O
primarily	SAPHRIS.xml:S1:28105:9	O
ALT	SAPHRIS.xml:S1:28115:3	I-AdverseReaction
)	SAPHRIS.xml:S1:28118:1	O
were	SAPHRIS.xml:S1:28120:4	O
more	SAPHRIS.xml:S1:28125:4	O
common	SAPHRIS.xml:S1:28130:6	O
in	SAPHRIS.xml:S1:28137:2	O
treated	SAPHRIS.xml:S1:28140:7	O
patients	SAPHRIS.xml:S1:28148:8	O
.	SAPHRIS.xml:S1:28156:1	O

The	SAPHRIS.xml:S1:28158:3	O
proportion	SAPHRIS.xml:S1:28162:10	O
of	SAPHRIS.xml:S1:28173:2	O
pediatric	SAPHRIS.xml:S1:28176:9	O
patients	SAPHRIS.xml:S1:28186:8	O
with	SAPHRIS.xml:S1:28195:4	O
ALT	SAPHRIS.xml:S1:28200:3	B-AdverseReaction
elevations	SAPHRIS.xml:S1:28204:10	I-AdverseReaction
3	SAPHRIS.xml:S1:28217:1	B-Severity
times	SAPHRIS.xml:S1:28219:5	I-Severity
upper	SAPHRIS.xml:S1:28225:5	I-Severity
limit	SAPHRIS.xml:S1:28231:5	I-Severity
of	SAPHRIS.xml:S1:28237:2	I-Severity
normal	SAPHRIS.xml:S1:28240:6	I-Severity
(	SAPHRIS.xml:S1:28247:1	I-Severity
ULN	SAPHRIS.xml:S1:28248:3	I-Severity
)	SAPHRIS.xml:S1:28251:1	I-Severity
was	SAPHRIS.xml:S1:28253:3	O
2.4%	SAPHRIS.xml:S1:28257:4	O
for	SAPHRIS.xml:S1:28262:3	O
patients	SAPHRIS.xml:S1:28266:8	O
treated	SAPHRIS.xml:S1:28275:7	O
with	SAPHRIS.xml:S1:28283:4	O
SAPHRIS	SAPHRIS.xml:S1:28288:7	O
10	SAPHRIS.xml:S1:28296:2	O
mg	SAPHRIS.xml:S1:28299:2	O
twice	SAPHRIS.xml:S1:28302:5	O
daily	SAPHRIS.xml:S1:28308:5	O
versus	SAPHRIS.xml:S1:28314:6	O
none	SAPHRIS.xml:S1:28321:4	O
for	SAPHRIS.xml:S1:28326:3	O
the	SAPHRIS.xml:S1:28330:3	O
other	SAPHRIS.xml:S1:28334:5	O
SAPHRIS	SAPHRIS.xml:S1:28340:7	O
dose	SAPHRIS.xml:S1:28348:4	O
groups	SAPHRIS.xml:S1:28353:6	O
and	SAPHRIS.xml:S1:28360:3	O
placebo	SAPHRIS.xml:S1:28364:7	O
-	SAPHRIS.xml:S1:28371:1	O
treated	SAPHRIS.xml:S1:28372:7	O
patients	SAPHRIS.xml:S1:28380:8	O
.	SAPHRIS.xml:S1:28388:1	O

Prolactin	SAPHRIS.xml:S1:28398:9	O
:	SAPHRIS.xml:S1:28407:1	O
In	SAPHRIS.xml:S1:28410:2	O
short	SAPHRIS.xml:S1:28413:5	O
-	SAPHRIS.xml:S1:28418:1	O
term	SAPHRIS.xml:S1:28419:4	O
,	SAPHRIS.xml:S1:28423:1	O
placebo	SAPHRIS.xml:S1:28425:7	O
-	SAPHRIS.xml:S1:28432:1	O
controlled	SAPHRIS.xml:S1:28433:10	O
adult	SAPHRIS.xml:S1:28444:5	O
schizophrenia	SAPHRIS.xml:S1:28450:13	O
trials	SAPHRIS.xml:S1:28464:6	O
,	SAPHRIS.xml:S1:28470:1	O
the	SAPHRIS.xml:S1:28472:3	O
mean	SAPHRIS.xml:S1:28476:4	O
decreases	SAPHRIS.xml:S1:28481:9	B-AdverseReaction
in	SAPHRIS.xml:S1:28491:2	I-AdverseReaction
prolactin	SAPHRIS.xml:S1:28494:9	I-AdverseReaction
levels	SAPHRIS.xml:S1:28504:6	I-AdverseReaction
were	SAPHRIS.xml:S1:28511:4	O
6.5	SAPHRIS.xml:S1:28516:3	O
ng	SAPHRIS.xml:S1:28520:2	O
mL	SAPHRIS.xml:S1:28523:2	O
for	SAPHRIS.xml:S1:28526:3	O
SAPHRIS	SAPHRIS.xml:S1:28530:7	O
-	SAPHRIS.xml:S1:28537:1	O
treated	SAPHRIS.xml:S1:28538:7	O
patients	SAPHRIS.xml:S1:28546:8	O
compared	SAPHRIS.xml:S1:28555:8	O
to	SAPHRIS.xml:S1:28564:2	O
10.7	SAPHRIS.xml:S1:28567:4	O
ng	SAPHRIS.xml:S1:28572:2	O
mL	SAPHRIS.xml:S1:28575:2	O
for	SAPHRIS.xml:S1:28578:3	O
placebo	SAPHRIS.xml:S1:28582:7	O
-	SAPHRIS.xml:S1:28589:1	O
treated	SAPHRIS.xml:S1:28590:7	O
patients	SAPHRIS.xml:S1:28598:8	O
.	SAPHRIS.xml:S1:28606:1	O

The	SAPHRIS.xml:S1:28608:3	O
proportion	SAPHRIS.xml:S1:28612:10	O
of	SAPHRIS.xml:S1:28623:2	O
patients	SAPHRIS.xml:S1:28626:8	O
with	SAPHRIS.xml:S1:28635:4	O
prolactin	SAPHRIS.xml:S1:28640:9	B-AdverseReaction
elevations	SAPHRIS.xml:S1:28650:10	I-AdverseReaction
4	SAPHRIS.xml:S1:28663:1	B-Severity
times	SAPHRIS.xml:S1:28665:5	I-Severity
ULN	SAPHRIS.xml:S1:28671:3	I-Severity
(	SAPHRIS.xml:S1:28675:1	O
at	SAPHRIS.xml:S1:28676:2	O
Endpoint	SAPHRIS.xml:S1:28679:8	O
)	SAPHRIS.xml:S1:28687:1	O
were	SAPHRIS.xml:S1:28689:4	O
2.6%	SAPHRIS.xml:S1:28694:4	O
for	SAPHRIS.xml:S1:28699:3	O
SAPHRIS	SAPHRIS.xml:S1:28703:7	O
-	SAPHRIS.xml:S1:28710:1	O
treated	SAPHRIS.xml:S1:28711:7	O
patients	SAPHRIS.xml:S1:28719:8	O
versus	SAPHRIS.xml:S1:28728:6	O
0.6%	SAPHRIS.xml:S1:28735:4	O
for	SAPHRIS.xml:S1:28740:3	O
placebo	SAPHRIS.xml:S1:28744:7	O
-	SAPHRIS.xml:S1:28751:1	O
treated	SAPHRIS.xml:S1:28752:7	O
patients	SAPHRIS.xml:S1:28760:8	O
.	SAPHRIS.xml:S1:28768:1	O

In	SAPHRIS.xml:S1:28770:2	O
short	SAPHRIS.xml:S1:28773:5	O
-	SAPHRIS.xml:S1:28778:1	O
term	SAPHRIS.xml:S1:28779:4	O
,	SAPHRIS.xml:S1:28783:1	O
placebo	SAPHRIS.xml:S1:28785:7	O
-	SAPHRIS.xml:S1:28792:1	O
controlled	SAPHRIS.xml:S1:28793:10	O
bipolar	SAPHRIS.xml:S1:28804:7	O
mania	SAPHRIS.xml:S1:28812:5	O
adult	SAPHRIS.xml:S1:28818:5	O
trials	SAPHRIS.xml:S1:28824:6	O
,	SAPHRIS.xml:S1:28830:1	O
the	SAPHRIS.xml:S1:28832:3	O
mean	SAPHRIS.xml:S1:28836:4	O
increase	SAPHRIS.xml:S1:28841:8	B-AdverseReaction
in	SAPHRIS.xml:S1:28850:2	I-AdverseReaction
prolactin	SAPHRIS.xml:S1:28853:9	I-AdverseReaction
levels	SAPHRIS.xml:S1:28863:6	I-AdverseReaction
was	SAPHRIS.xml:S1:28870:3	O
4.9	SAPHRIS.xml:S1:28874:3	O
ng	SAPHRIS.xml:S1:28878:2	O
mL	SAPHRIS.xml:S1:28881:2	O
for	SAPHRIS.xml:S1:28884:3	O
SAPHRIS	SAPHRIS.xml:S1:28888:7	O
-	SAPHRIS.xml:S1:28895:1	O
treated	SAPHRIS.xml:S1:28896:7	O
patients	SAPHRIS.xml:S1:28904:8	O
compared	SAPHRIS.xml:S1:28913:8	O
to	SAPHRIS.xml:S1:28922:2	O
a	SAPHRIS.xml:S1:28925:1	O
decrease	SAPHRIS.xml:S1:28927:8	O
of	SAPHRIS.xml:S1:28936:2	O
0.2	SAPHRIS.xml:S1:28939:3	O
ng	SAPHRIS.xml:S1:28943:2	O
mL	SAPHRIS.xml:S1:28946:2	O
for	SAPHRIS.xml:S1:28949:3	O
placebo	SAPHRIS.xml:S1:28953:7	O
-	SAPHRIS.xml:S1:28960:1	O
treated	SAPHRIS.xml:S1:28961:7	O
patients	SAPHRIS.xml:S1:28969:8	O
.	SAPHRIS.xml:S1:28977:1	O

The	SAPHRIS.xml:S1:28979:3	O
proportion	SAPHRIS.xml:S1:28983:10	O
of	SAPHRIS.xml:S1:28994:2	O
patients	SAPHRIS.xml:S1:28997:8	O
with	SAPHRIS.xml:S1:29006:4	O
prolactin	SAPHRIS.xml:S1:29011:9	B-AdverseReaction
elevations	SAPHRIS.xml:S1:29021:10	I-AdverseReaction
4	SAPHRIS.xml:S1:29034:1	B-Severity
times	SAPHRIS.xml:S1:29036:5	I-Severity
ULN	SAPHRIS.xml:S1:29042:3	I-Severity
(	SAPHRIS.xml:S1:29046:1	O
at	SAPHRIS.xml:S1:29047:2	O
Endpoint	SAPHRIS.xml:S1:29050:8	O
)	SAPHRIS.xml:S1:29058:1	O
were	SAPHRIS.xml:S1:29060:4	O
2.3%	SAPHRIS.xml:S1:29065:4	O
for	SAPHRIS.xml:S1:29070:3	O
SAPHRIS	SAPHRIS.xml:S1:29074:7	O
-	SAPHRIS.xml:S1:29081:1	O
treated	SAPHRIS.xml:S1:29082:7	O
patients	SAPHRIS.xml:S1:29090:8	O
versus	SAPHRIS.xml:S1:29099:6	O
0.7%	SAPHRIS.xml:S1:29106:4	O
for	SAPHRIS.xml:S1:29111:3	O
placebo	SAPHRIS.xml:S1:29115:7	O
-	SAPHRIS.xml:S1:29122:1	O
treated	SAPHRIS.xml:S1:29123:7	O
patients	SAPHRIS.xml:S1:29131:8	O
.	SAPHRIS.xml:S1:29139:1	O

In	SAPHRIS.xml:S1:29145:2	O
a	SAPHRIS.xml:S1:29148:1	O
long	SAPHRIS.xml:S1:29150:4	O
-	SAPHRIS.xml:S1:29154:1	O
term	SAPHRIS.xml:S1:29155:4	O
(	SAPHRIS.xml:S1:29160:1	O
52	SAPHRIS.xml:S1:29161:2	O
-	SAPHRIS.xml:S1:29163:1	O
week	SAPHRIS.xml:S1:29164:4	O
)	SAPHRIS.xml:S1:29168:1	O
,	SAPHRIS.xml:S1:29169:1	O
double	SAPHRIS.xml:S1:29171:6	O
-	SAPHRIS.xml:S1:29177:1	O
blind	SAPHRIS.xml:S1:29178:5	O
,	SAPHRIS.xml:S1:29183:1	O
comparator	SAPHRIS.xml:S1:29185:10	O
-	SAPHRIS.xml:S1:29195:1	O
controlled	SAPHRIS.xml:S1:29196:10	O
adult	SAPHRIS.xml:S1:29207:5	O
trial	SAPHRIS.xml:S1:29213:5	O
that	SAPHRIS.xml:S1:29219:4	O
included	SAPHRIS.xml:S1:29224:8	O
primarily	SAPHRIS.xml:S1:29233:9	O
patients	SAPHRIS.xml:S1:29243:8	O
with	SAPHRIS.xml:S1:29252:4	O
schizophrenia	SAPHRIS.xml:S1:29257:13	O
,	SAPHRIS.xml:S1:29270:1	O
the	SAPHRIS.xml:S1:29272:3	O
mean	SAPHRIS.xml:S1:29276:4	O
decrease	SAPHRIS.xml:S1:29281:8	B-AdverseReaction
in	SAPHRIS.xml:S1:29290:2	I-AdverseReaction
prolactin	SAPHRIS.xml:S1:29293:9	I-AdverseReaction
from	SAPHRIS.xml:S1:29303:4	O
baseline	SAPHRIS.xml:S1:29308:8	O
for	SAPHRIS.xml:S1:29317:3	O
SAPHRIS	SAPHRIS.xml:S1:29321:7	O
-	SAPHRIS.xml:S1:29328:1	O
treated	SAPHRIS.xml:S1:29329:7	O
patients	SAPHRIS.xml:S1:29337:8	O
was	SAPHRIS.xml:S1:29346:3	O
26.9	SAPHRIS.xml:S1:29350:4	O
ng	SAPHRIS.xml:S1:29355:2	O
mL	SAPHRIS.xml:S1:29358:2	O
.	SAPHRIS.xml:S1:29360:1	O

In	SAPHRIS.xml:S1:29366:2	O
a	SAPHRIS.xml:S1:29369:1	O
3	SAPHRIS.xml:S1:29371:1	O
-	SAPHRIS.xml:S1:29372:1	O
week	SAPHRIS.xml:S1:29373:4	O
,	SAPHRIS.xml:S1:29377:1	O
placebo	SAPHRIS.xml:S1:29379:7	O
-	SAPHRIS.xml:S1:29386:1	O
controlled	SAPHRIS.xml:S1:29387:10	O
pediatric	SAPHRIS.xml:S1:29398:9	O
trial	SAPHRIS.xml:S1:29408:5	O
with	SAPHRIS.xml:S1:29414:4	O
bipolar	SAPHRIS.xml:S1:29419:7	O
I	SAPHRIS.xml:S1:29427:1	O
disorder	SAPHRIS.xml:S1:29429:8	O
,	SAPHRIS.xml:S1:29437:1	O
the	SAPHRIS.xml:S1:29439:3	O
mean	SAPHRIS.xml:S1:29443:4	O
increases	SAPHRIS.xml:S1:29448:9	B-AdverseReaction
(	SAPHRIS.xml:S1:29458:1	O
at	SAPHRIS.xml:S1:29459:2	O
Endpoint	SAPHRIS.xml:S1:29462:8	O
)	SAPHRIS.xml:S1:29470:1	O
in	SAPHRIS.xml:S1:29472:2	I-AdverseReaction
prolactin	SAPHRIS.xml:S1:29475:9	I-AdverseReaction
levels	SAPHRIS.xml:S1:29485:6	I-AdverseReaction
were	SAPHRIS.xml:S1:29492:4	O
3.2	SAPHRIS.xml:S1:29497:3	O
ng	SAPHRIS.xml:S1:29501:2	O
mL	SAPHRIS.xml:S1:29504:2	O
for	SAPHRIS.xml:S1:29507:3	O
patients	SAPHRIS.xml:S1:29511:8	O
treated	SAPHRIS.xml:S1:29520:7	O
with	SAPHRIS.xml:S1:29528:4	O
SAPHRIS	SAPHRIS.xml:S1:29533:7	O
2.5	SAPHRIS.xml:S1:29541:3	O
mg	SAPHRIS.xml:S1:29545:2	O
twice	SAPHRIS.xml:S1:29548:5	O
daily	SAPHRIS.xml:S1:29554:5	O
,	SAPHRIS.xml:S1:29559:1	O
2.1	SAPHRIS.xml:S1:29561:3	O
ng	SAPHRIS.xml:S1:29565:2	O
mL	SAPHRIS.xml:S1:29568:2	O
for	SAPHRIS.xml:S1:29571:3	O
patients	SAPHRIS.xml:S1:29575:8	O
treated	SAPHRIS.xml:S1:29584:7	O
with	SAPHRIS.xml:S1:29592:4	O
SAPHRIS	SAPHRIS.xml:S1:29597:7	O
5	SAPHRIS.xml:S1:29605:1	O
mg	SAPHRIS.xml:S1:29607:2	O
twice	SAPHRIS.xml:S1:29610:5	O
daily	SAPHRIS.xml:S1:29616:5	O
,	SAPHRIS.xml:S1:29621:1	O
and	SAPHRIS.xml:S1:29623:3	O
6.4	SAPHRIS.xml:S1:29627:3	O
ng	SAPHRIS.xml:S1:29631:2	O
mL	SAPHRIS.xml:S1:29634:2	O
for	SAPHRIS.xml:S1:29637:3	O
patients	SAPHRIS.xml:S1:29641:8	O
treated	SAPHRIS.xml:S1:29650:7	O
with	SAPHRIS.xml:S1:29658:4	O
SAPHRIS	SAPHRIS.xml:S1:29663:7	O
10	SAPHRIS.xml:S1:29671:2	O
mg	SAPHRIS.xml:S1:29674:2	O
twice	SAPHRIS.xml:S1:29677:5	O
daily	SAPHRIS.xml:S1:29683:5	O
compared	SAPHRIS.xml:S1:29689:8	O
to	SAPHRIS.xml:S1:29698:2	O
an	SAPHRIS.xml:S1:29701:2	O
increase	SAPHRIS.xml:S1:29704:8	O
of	SAPHRIS.xml:S1:29713:2	O
2.5	SAPHRIS.xml:S1:29716:3	O
ng	SAPHRIS.xml:S1:29720:2	O
mL	SAPHRIS.xml:S1:29723:2	O
for	SAPHRIS.xml:S1:29726:3	O
placebo	SAPHRIS.xml:S1:29730:7	O
-	SAPHRIS.xml:S1:29737:1	O
treated	SAPHRIS.xml:S1:29738:7	O
patients	SAPHRIS.xml:S1:29746:8	O
.	SAPHRIS.xml:S1:29754:1	O

There	SAPHRIS.xml:S1:29756:5	O
were	SAPHRIS.xml:S1:29762:4	O
no	SAPHRIS.xml:S1:29767:2	B-Negation
reports	SAPHRIS.xml:S1:29770:7	O
of	SAPHRIS.xml:S1:29778:2	O
prolactin	SAPHRIS.xml:S1:29781:9	B-AdverseReaction
elevations	SAPHRIS.xml:S1:29791:10	I-AdverseReaction
4	SAPHRIS.xml:S1:29804:1	B-Severity
times	SAPHRIS.xml:S1:29806:5	I-Severity
ULN	SAPHRIS.xml:S1:29812:3	I-Severity
(	SAPHRIS.xml:S1:29816:1	O
at	SAPHRIS.xml:S1:29817:2	O
Endpoint	SAPHRIS.xml:S1:29820:8	O
)	SAPHRIS.xml:S1:29828:1	O
for	SAPHRIS.xml:S1:29830:3	O
patients	SAPHRIS.xml:S1:29834:8	O
treated	SAPHRIS.xml:S1:29843:7	O
with	SAPHRIS.xml:S1:29851:4	O
SAPHRIS	SAPHRIS.xml:S1:29856:7	O
or	SAPHRIS.xml:S1:29864:2	O
placebo	SAPHRIS.xml:S1:29867:7	O
.	SAPHRIS.xml:S1:29874:1	O

Galactorrhea	SAPHRIS.xml:S1:29876:12	B-AdverseReaction
or	SAPHRIS.xml:S1:29889:2	O
dysmenorrhea	SAPHRIS.xml:S1:29892:12	B-AdverseReaction
were	SAPHRIS.xml:S1:29905:4	O
reported	SAPHRIS.xml:S1:29910:8	O
in	SAPHRIS.xml:S1:29919:2	O
0%	SAPHRIS.xml:S1:29922:2	O
of	SAPHRIS.xml:S1:29925:2	O
patients	SAPHRIS.xml:S1:29928:8	O
treated	SAPHRIS.xml:S1:29937:7	O
with	SAPHRIS.xml:S1:29945:4	O
SAPHRIS	SAPHRIS.xml:S1:29950:7	O
2.5	SAPHRIS.xml:S1:29958:3	O
mg	SAPHRIS.xml:S1:29962:2	O
twice	SAPHRIS.xml:S1:29965:5	O
daily	SAPHRIS.xml:S1:29971:5	O
,	SAPHRIS.xml:S1:29976:1	O
2%	SAPHRIS.xml:S1:29978:2	O
of	SAPHRIS.xml:S1:29981:2	O
patients	SAPHRIS.xml:S1:29984:8	O
treated	SAPHRIS.xml:S1:29993:7	O
with	SAPHRIS.xml:S1:30001:4	O
SAPHRIS	SAPHRIS.xml:S1:30006:7	O
5	SAPHRIS.xml:S1:30014:1	O
mg	SAPHRIS.xml:S1:30016:2	O
twice	SAPHRIS.xml:S1:30019:5	O
daily	SAPHRIS.xml:S1:30025:5	O
,	SAPHRIS.xml:S1:30030:1	O
and	SAPHRIS.xml:S1:30032:3	O
1%	SAPHRIS.xml:S1:30036:2	O
of	SAPHRIS.xml:S1:30039:2	O
patients	SAPHRIS.xml:S1:30042:8	O
treated	SAPHRIS.xml:S1:30051:7	O
with	SAPHRIS.xml:S1:30059:4	O
SAPHRIS	SAPHRIS.xml:S1:30064:7	O
10	SAPHRIS.xml:S1:30072:2	O
mg	SAPHRIS.xml:S1:30075:2	O
twice	SAPHRIS.xml:S1:30078:5	O
daily	SAPHRIS.xml:S1:30084:5	O
compared	SAPHRIS.xml:S1:30090:8	O
to	SAPHRIS.xml:S1:30099:2	O
1%	SAPHRIS.xml:S1:30102:2	O
of	SAPHRIS.xml:S1:30105:2	O
placebo	SAPHRIS.xml:S1:30108:7	O
-	SAPHRIS.xml:S1:30115:1	O
treated	SAPHRIS.xml:S1:30116:7	O
patients	SAPHRIS.xml:S1:30124:8	O
.	SAPHRIS.xml:S1:30132:1	O

There	SAPHRIS.xml:S1:30134:5	O
were	SAPHRIS.xml:S1:30140:4	O
no	SAPHRIS.xml:S1:30145:2	B-Negation
reports	SAPHRIS.xml:S1:30148:7	O
of	SAPHRIS.xml:S1:30156:2	O
gynecomastia	SAPHRIS.xml:S1:30159:12	B-AdverseReaction
in	SAPHRIS.xml:S1:30172:2	O
this	SAPHRIS.xml:S1:30175:4	O
trial	SAPHRIS.xml:S1:30180:5	O
.	SAPHRIS.xml:S1:30185:1	O

Creatine	SAPHRIS.xml:S1:30195:8	O
Kinase	SAPHRIS.xml:S1:30204:6	O
(	SAPHRIS.xml:S1:30211:1	O
CK	SAPHRIS.xml:S1:30212:2	O
)	SAPHRIS.xml:S1:30214:1	O
:	SAPHRIS.xml:S1:30215:1	O
The	SAPHRIS.xml:S1:30218:3	O
proportion	SAPHRIS.xml:S1:30222:10	O
of	SAPHRIS.xml:S1:30233:2	O
adult	SAPHRIS.xml:S1:30236:5	O
patients	SAPHRIS.xml:S1:30242:8	O
with	SAPHRIS.xml:S1:30251:4	O
CK	SAPHRIS.xml:S1:30256:2	B-AdverseReaction
elevations	SAPHRIS.xml:S1:30259:10	I-AdverseReaction
3	SAPHRIS.xml:S1:30271:1	B-Severity
times	SAPHRIS.xml:S1:30273:5	I-Severity
ULN	SAPHRIS.xml:S1:30279:3	I-Severity
at	SAPHRIS.xml:S1:30283:2	O
any	SAPHRIS.xml:S1:30286:3	O
time	SAPHRIS.xml:S1:30290:4	O
were	SAPHRIS.xml:S1:30295:4	O
6.4%	SAPHRIS.xml:S1:30300:4	O
and	SAPHRIS.xml:S1:30305:3	O
11.1%	SAPHRIS.xml:S1:30309:5	O
for	SAPHRIS.xml:S1:30315:3	O
patients	SAPHRIS.xml:S1:30319:8	O
treated	SAPHRIS.xml:S1:30328:7	O
with	SAPHRIS.xml:S1:30336:4	O
SAPHRIS	SAPHRIS.xml:S1:30341:7	O
5	SAPHRIS.xml:S1:30349:1	O
mg	SAPHRIS.xml:S1:30351:2	O
twice	SAPHRIS.xml:S1:30354:5	O
daily	SAPHRIS.xml:S1:30360:5	O
and	SAPHRIS.xml:S1:30366:3	O
10	SAPHRIS.xml:S1:30370:2	O
mg	SAPHRIS.xml:S1:30373:2	O
twice	SAPHRIS.xml:S1:30376:5	O
daily	SAPHRIS.xml:S1:30382:5	O
,	SAPHRIS.xml:S1:30387:1	O
respectively	SAPHRIS.xml:S1:30389:12	O
,	SAPHRIS.xml:S1:30401:1	O
as	SAPHRIS.xml:S1:30403:2	O
compared	SAPHRIS.xml:S1:30406:8	O
to	SAPHRIS.xml:S1:30415:2	O
6.7%	SAPHRIS.xml:S1:30418:4	O
for	SAPHRIS.xml:S1:30423:3	O
placebo	SAPHRIS.xml:S1:30427:7	O
-	SAPHRIS.xml:S1:30434:1	O
treated	SAPHRIS.xml:S1:30435:7	O
patients	SAPHRIS.xml:S1:30443:8	O
in	SAPHRIS.xml:S1:30452:2	O
short	SAPHRIS.xml:S1:30455:5	O
-	SAPHRIS.xml:S1:30460:1	O
term	SAPHRIS.xml:S1:30461:4	O
,	SAPHRIS.xml:S1:30465:1	O
fixed	SAPHRIS.xml:S1:30467:5	O
-	SAPHRIS.xml:S1:30472:1	O
dose	SAPHRIS.xml:S1:30473:4	O
trials	SAPHRIS.xml:S1:30478:6	O
in	SAPHRIS.xml:S1:30485:2	O
schizophrenia	SAPHRIS.xml:S1:30488:13	O
and	SAPHRIS.xml:S1:30502:3	O
bipolar	SAPHRIS.xml:S1:30506:7	O
mania	SAPHRIS.xml:S1:30514:5	O
.	SAPHRIS.xml:S1:30519:1	O

The	SAPHRIS.xml:S1:30521:3	O
clinical	SAPHRIS.xml:S1:30525:8	O
relevance	SAPHRIS.xml:S1:30534:9	O
of	SAPHRIS.xml:S1:30544:2	O
this	SAPHRIS.xml:S1:30547:4	O
finding	SAPHRIS.xml:S1:30552:7	O
is	SAPHRIS.xml:S1:30560:2	O
unknown	SAPHRIS.xml:S1:30563:7	O
.	SAPHRIS.xml:S1:30570:1	O

The	SAPHRIS.xml:S1:30576:3	O
proportion	SAPHRIS.xml:S1:30580:10	O
of	SAPHRIS.xml:S1:30591:2	O
patients	SAPHRIS.xml:S1:30594:8	O
with	SAPHRIS.xml:S1:30603:4	O
CK	SAPHRIS.xml:S1:30608:2	B-AdverseReaction
elevations	SAPHRIS.xml:S1:30611:10	I-AdverseReaction
3	SAPHRIS.xml:S1:30624:1	B-Severity
times	SAPHRIS.xml:S1:30626:5	I-Severity
ULN	SAPHRIS.xml:S1:30632:3	I-Severity
during	SAPHRIS.xml:S1:30636:6	O
a	SAPHRIS.xml:S1:30643:1	O
3	SAPHRIS.xml:S1:30645:1	O
-	SAPHRIS.xml:S1:30646:1	O
week	SAPHRIS.xml:S1:30647:4	O
trial	SAPHRIS.xml:S1:30652:5	O
in	SAPHRIS.xml:S1:30658:2	O
pediatric	SAPHRIS.xml:S1:30661:9	O
bipolar	SAPHRIS.xml:S1:30671:7	O
I	SAPHRIS.xml:S1:30679:1	O
disorder	SAPHRIS.xml:S1:30681:8	O
at	SAPHRIS.xml:S1:30690:2	O
any	SAPHRIS.xml:S1:30693:3	O
time	SAPHRIS.xml:S1:30697:4	O
were	SAPHRIS.xml:S1:30702:4	O
1%	SAPHRIS.xml:S1:30707:2	O
,	SAPHRIS.xml:S1:30709:1	O
0%	SAPHRIS.xml:S1:30711:2	O
,	SAPHRIS.xml:S1:30713:1	O
and	SAPHRIS.xml:S1:30715:3	O
1%	SAPHRIS.xml:S1:30719:2	O
for	SAPHRIS.xml:S1:30722:3	O
patients	SAPHRIS.xml:S1:30726:8	O
treated	SAPHRIS.xml:S1:30735:7	O
with	SAPHRIS.xml:S1:30743:4	O
SAPHRIS	SAPHRIS.xml:S1:30748:7	O
2.5	SAPHRIS.xml:S1:30756:3	O
mg	SAPHRIS.xml:S1:30760:2	O
,	SAPHRIS.xml:S1:30762:1	O
5	SAPHRIS.xml:S1:30764:1	O
mg	SAPHRIS.xml:S1:30766:2	O
,	SAPHRIS.xml:S1:30768:1	O
and	SAPHRIS.xml:S1:30770:3	O
10	SAPHRIS.xml:S1:30774:2	O
mg	SAPHRIS.xml:S1:30777:2	O
twice	SAPHRIS.xml:S1:30780:5	O
daily	SAPHRIS.xml:S1:30786:5	O
,	SAPHRIS.xml:S1:30791:1	O
respectively	SAPHRIS.xml:S1:30793:12	O
,	SAPHRIS.xml:S1:30805:1	O
versus	SAPHRIS.xml:S1:30807:6	O
3%	SAPHRIS.xml:S1:30814:2	O
for	SAPHRIS.xml:S1:30817:3	O
placebo	SAPHRIS.xml:S1:30821:7	O
-	SAPHRIS.xml:S1:30828:1	O
treated	SAPHRIS.xml:S1:30829:7	O
patients	SAPHRIS.xml:S1:30837:8	O
.	SAPHRIS.xml:S1:30845:1	O

Other	SAPHRIS.xml:S1:30855:5	O
Adverse	SAPHRIS.xml:S1:30861:7	O
Reactions	SAPHRIS.xml:S1:30869:9	O
Observed	SAPHRIS.xml:S1:30879:8	O
During	SAPHRIS.xml:S1:30888:6	O
the	SAPHRIS.xml:S1:30895:3	O
Premarketing	SAPHRIS.xml:S1:30899:12	O
Evaluation	SAPHRIS.xml:S1:30912:10	O
of	SAPHRIS.xml:S1:30923:2	O
SAPHRIS	SAPHRIS.xml:S1:30926:7	O
:	SAPHRIS.xml:S1:30933:1	O
Following	SAPHRIS.xml:S1:30936:9	O
is	SAPHRIS.xml:S1:30946:2	O
a	SAPHRIS.xml:S1:30949:1	O
list	SAPHRIS.xml:S1:30951:4	O
of	SAPHRIS.xml:S1:30956:2	O
MedDRA	SAPHRIS.xml:S1:30959:6	O
terms	SAPHRIS.xml:S1:30966:5	O
that	SAPHRIS.xml:S1:30972:4	O
reflect	SAPHRIS.xml:S1:30977:7	O
adverse	SAPHRIS.xml:S1:30985:7	O
reactions	SAPHRIS.xml:S1:30993:9	O
reported	SAPHRIS.xml:S1:31003:8	O
by	SAPHRIS.xml:S1:31012:2	O
patients	SAPHRIS.xml:S1:31015:8	O
treated	SAPHRIS.xml:S1:31024:7	O
with	SAPHRIS.xml:S1:31032:4	O
sublingual	SAPHRIS.xml:S1:31037:10	O
SAPHRIS	SAPHRIS.xml:S1:31048:7	O
at	SAPHRIS.xml:S1:31056:2	O
multiple	SAPHRIS.xml:S1:31059:8	O
doses	SAPHRIS.xml:S1:31068:5	O
of	SAPHRIS.xml:S1:31074:2	O
5	SAPHRIS.xml:S1:31079:1	O
mg	SAPHRIS.xml:S1:31081:2	O
twice	SAPHRIS.xml:S1:31084:5	O
daily	SAPHRIS.xml:S1:31090:5	O
during	SAPHRIS.xml:S1:31096:6	O
any	SAPHRIS.xml:S1:31103:3	O
phase	SAPHRIS.xml:S1:31107:5	O
of	SAPHRIS.xml:S1:31113:2	O
a	SAPHRIS.xml:S1:31116:1	O
trial	SAPHRIS.xml:S1:31118:5	O
within	SAPHRIS.xml:S1:31124:6	O
the	SAPHRIS.xml:S1:31131:3	O
database	SAPHRIS.xml:S1:31135:8	O
of	SAPHRIS.xml:S1:31144:2	O
adult	SAPHRIS.xml:S1:31147:5	O
patients	SAPHRIS.xml:S1:31153:8	O
.	SAPHRIS.xml:S1:31161:1	O

The	SAPHRIS.xml:S1:31163:3	O
reactions	SAPHRIS.xml:S1:31167:9	O
listed	SAPHRIS.xml:S1:31177:6	O
are	SAPHRIS.xml:S1:31184:3	O
those	SAPHRIS.xml:S1:31188:5	O
that	SAPHRIS.xml:S1:31194:4	O
could	SAPHRIS.xml:S1:31199:5	O
be	SAPHRIS.xml:S1:31205:2	O
of	SAPHRIS.xml:S1:31208:2	O
clinical	SAPHRIS.xml:S1:31211:8	O
importance	SAPHRIS.xml:S1:31220:10	O
,	SAPHRIS.xml:S1:31230:1	O
as	SAPHRIS.xml:S1:31232:2	O
well	SAPHRIS.xml:S1:31235:4	O
as	SAPHRIS.xml:S1:31240:2	O
reactions	SAPHRIS.xml:S1:31243:9	O
that	SAPHRIS.xml:S1:31253:4	O
are	SAPHRIS.xml:S1:31258:3	O
plausibly	SAPHRIS.xml:S1:31262:9	O
drug	SAPHRIS.xml:S1:31272:4	O
-	SAPHRIS.xml:S1:31276:1	O
related	SAPHRIS.xml:S1:31277:7	O
on	SAPHRIS.xml:S1:31285:2	O
pharmacologic	SAPHRIS.xml:S1:31288:13	O
or	SAPHRIS.xml:S1:31302:2	O
other	SAPHRIS.xml:S1:31305:5	O
grounds	SAPHRIS.xml:S1:31311:7	O
.	SAPHRIS.xml:S1:31318:1	O

Reactions	SAPHRIS.xml:S1:31320:9	O
already	SAPHRIS.xml:S1:31330:7	O
listed	SAPHRIS.xml:S1:31338:6	O
for	SAPHRIS.xml:S1:31345:3	O
either	SAPHRIS.xml:S1:31349:6	O
adults	SAPHRIS.xml:S1:31356:6	O
or	SAPHRIS.xml:S1:31363:2	O
pediatric	SAPHRIS.xml:S1:31366:9	O
patients	SAPHRIS.xml:S1:31376:8	O
in	SAPHRIS.xml:S1:31385:2	O
other	SAPHRIS.xml:S1:31388:5	O
parts	SAPHRIS.xml:S1:31394:5	O
of	SAPHRIS.xml:S1:31400:2	O
Adverse	SAPHRIS.xml:S1:31404:7	O
Reactions	SAPHRIS.xml:S1:31412:9	O
(	SAPHRIS.xml:S1:31422:1	O
6	SAPHRIS.xml:S1:31423:1	O
)	SAPHRIS.xml:S1:31424:1	O
,	SAPHRIS.xml:S1:31427:1	O
or	SAPHRIS.xml:S1:31429:2	O
those	SAPHRIS.xml:S1:31432:5	O
considered	SAPHRIS.xml:S1:31438:10	O
in	SAPHRIS.xml:S1:31449:2	O
Contraindications	SAPHRIS.xml:S1:31453:17	O
(	SAPHRIS.xml:S1:31471:1	O
4	SAPHRIS.xml:S1:31472:1	O
)	SAPHRIS.xml:S1:31473:1	O
,	SAPHRIS.xml:S1:31474:1	O
Warnings	SAPHRIS.xml:S1:31476:8	O
and	SAPHRIS.xml:S1:31485:3	O
Precautions	SAPHRIS.xml:S1:31489:11	O
(	SAPHRIS.xml:S1:31501:1	O
5	SAPHRIS.xml:S1:31502:1	O
)	SAPHRIS.xml:S1:31503:1	O
or	SAPHRIS.xml:S1:31506:2	O
Overdosage	SAPHRIS.xml:S1:31510:10	O
(	SAPHRIS.xml:S1:31521:1	O
10	SAPHRIS.xml:S1:31522:2	O
)	SAPHRIS.xml:S1:31524:1	O
are	SAPHRIS.xml:S1:31527:3	O
not	SAPHRIS.xml:S1:31531:3	O
included	SAPHRIS.xml:S1:31535:8	O
.	SAPHRIS.xml:S1:31543:1	O

Reactions	SAPHRIS.xml:S1:31545:9	O
are	SAPHRIS.xml:S1:31555:3	O
further	SAPHRIS.xml:S1:31559:7	O
categorized	SAPHRIS.xml:S1:31567:11	O
by	SAPHRIS.xml:S1:31579:2	O
MedDRA	SAPHRIS.xml:S1:31582:6	O
system	SAPHRIS.xml:S1:31589:6	O
organ	SAPHRIS.xml:S1:31596:5	O
class	SAPHRIS.xml:S1:31602:5	O
and	SAPHRIS.xml:S1:31608:3	O
listed	SAPHRIS.xml:S1:31612:6	O
in	SAPHRIS.xml:S1:31619:2	O
order	SAPHRIS.xml:S1:31622:5	O
of	SAPHRIS.xml:S1:31628:2	O
decreasing	SAPHRIS.xml:S1:31631:10	O
frequency	SAPHRIS.xml:S1:31642:9	O
according	SAPHRIS.xml:S1:31652:9	O
to	SAPHRIS.xml:S1:31662:2	O
the	SAPHRIS.xml:S1:31665:3	O
following	SAPHRIS.xml:S1:31669:9	O
definitions	SAPHRIS.xml:S1:31679:11	O
:	SAPHRIS.xml:S1:31690:1	O
those	SAPHRIS.xml:S1:31692:5	O
occurring	SAPHRIS.xml:S1:31698:9	O
in	SAPHRIS.xml:S1:31708:2	O
at	SAPHRIS.xml:S1:31711:2	O
least	SAPHRIS.xml:S1:31714:5	O
1	SAPHRIS.xml:S1:31720:1	O
100	SAPHRIS.xml:S1:31722:3	O
patients	SAPHRIS.xml:S1:31726:8	O
(	SAPHRIS.xml:S1:31735:1	O
frequent	SAPHRIS.xml:S1:31736:8	O
)	SAPHRIS.xml:S1:31744:1	O
(	SAPHRIS.xml:S1:31746:1	O
only	SAPHRIS.xml:S1:31747:4	O
those	SAPHRIS.xml:S1:31752:5	O
not	SAPHRIS.xml:S1:31758:3	O
already	SAPHRIS.xml:S1:31762:7	O
listed	SAPHRIS.xml:S1:31770:6	O
in	SAPHRIS.xml:S1:31777:2	O
the	SAPHRIS.xml:S1:31780:3	O
tabulated	SAPHRIS.xml:S1:31784:9	O
results	SAPHRIS.xml:S1:31794:7	O
from	SAPHRIS.xml:S1:31802:4	O
placebo	SAPHRIS.xml:S1:31807:7	O
-	SAPHRIS.xml:S1:31814:1	O
controlled	SAPHRIS.xml:S1:31815:10	O
trials	SAPHRIS.xml:S1:31826:6	O
appear	SAPHRIS.xml:S1:31833:6	O
in	SAPHRIS.xml:S1:31840:2	O
this	SAPHRIS.xml:S1:31843:4	O
listing	SAPHRIS.xml:S1:31848:7	O
)	SAPHRIS.xml:S1:31855:1	O
;	SAPHRIS.xml:S1:31856:1	O
those	SAPHRIS.xml:S1:31858:5	O
occurring	SAPHRIS.xml:S1:31864:9	O
in	SAPHRIS.xml:S1:31874:2	O
1	SAPHRIS.xml:S1:31877:1	O
100	SAPHRIS.xml:S1:31879:3	O
to	SAPHRIS.xml:S1:31883:2	O
1	SAPHRIS.xml:S1:31886:1	O
1000	SAPHRIS.xml:S1:31888:4	O
patients	SAPHRIS.xml:S1:31893:8	O
(	SAPHRIS.xml:S1:31902:1	O
infrequent	SAPHRIS.xml:S1:31903:10	O
)	SAPHRIS.xml:S1:31913:1	O
;	SAPHRIS.xml:S1:31914:1	O
and	SAPHRIS.xml:S1:31916:3	O
those	SAPHRIS.xml:S1:31920:5	O
occurring	SAPHRIS.xml:S1:31926:9	O
in	SAPHRIS.xml:S1:31936:2	O
fewer	SAPHRIS.xml:S1:31939:5	O
than	SAPHRIS.xml:S1:31945:4	O
1	SAPHRIS.xml:S1:31950:1	O
1000	SAPHRIS.xml:S1:31952:4	O
patients	SAPHRIS.xml:S1:31957:8	O
(	SAPHRIS.xml:S1:31966:1	O
rare	SAPHRIS.xml:S1:31967:4	O
)	SAPHRIS.xml:S1:31971:1	O
.	SAPHRIS.xml:S1:31972:1	O

Blood	SAPHRIS.xml:S1:31985:5	O
and	SAPHRIS.xml:S1:31991:3	O
lymphatic	SAPHRIS.xml:S1:31995:9	O
disorders	SAPHRIS.xml:S1:32005:9	O
:	SAPHRIS.xml:S1:32014:1	O
infrequent	SAPHRIS.xml:S1:32017:10	O
:	SAPHRIS.xml:S1:32027:1	O
anemia	SAPHRIS.xml:S1:32029:6	B-AdverseReaction
;	SAPHRIS.xml:S1:32035:1	O
rare	SAPHRIS.xml:S1:32037:4	O
:	SAPHRIS.xml:S1:32041:1	O
thrombocytopenia	SAPHRIS.xml:S1:32043:16	B-AdverseReaction

Cardiac	SAPHRIS.xml:S1:32069:7	O
disorders	SAPHRIS.xml:S1:32077:9	O
:	SAPHRIS.xml:S1:32086:1	O
infrequent	SAPHRIS.xml:S1:32089:10	O
:	SAPHRIS.xml:S1:32099:1	O
temporary	SAPHRIS.xml:S1:32101:9	B-AdverseReaction
bundle	SAPHRIS.xml:S1:32111:6	I-AdverseReaction
branch	SAPHRIS.xml:S1:32118:6	I-AdverseReaction
block	SAPHRIS.xml:S1:32125:5	I-AdverseReaction

Eye	SAPHRIS.xml:S1:32140:3	O
disorders	SAPHRIS.xml:S1:32144:9	O
:	SAPHRIS.xml:S1:32153:1	O
infrequent	SAPHRIS.xml:S1:32156:10	O
:	SAPHRIS.xml:S1:32166:1	O
accommodation	SAPHRIS.xml:S1:32168:13	B-AdverseReaction
disorder	SAPHRIS.xml:S1:32182:8	I-AdverseReaction

Gastrointestinal	SAPHRIS.xml:S1:32200:16	O
disorders	SAPHRIS.xml:S1:32217:9	O
:	SAPHRIS.xml:S1:32226:1	O
infrequent	SAPHRIS.xml:S1:32229:10	O
:	SAPHRIS.xml:S1:32239:1	O
swollen	SAPHRIS.xml:S1:32241:7	B-AdverseReaction
tongue	SAPHRIS.xml:S1:32249:6	I-AdverseReaction

General	SAPHRIS.xml:S1:32265:7	O
disorders	SAPHRIS.xml:S1:32273:9	O
:	SAPHRIS.xml:S1:32282:1	O
rare	SAPHRIS.xml:S1:32285:4	O
:	SAPHRIS.xml:S1:32289:1	O
idiosyncratic	SAPHRIS.xml:S1:32291:13	B-AdverseReaction
drug	SAPHRIS.xml:S1:32305:4	I-AdverseReaction
reaction	SAPHRIS.xml:S1:32310:8	I-AdverseReaction

Investigations	SAPHRIS.xml:S1:32328:14	O
:	SAPHRIS.xml:S1:32342:1	O
infrequent	SAPHRIS.xml:S1:32345:10	O
:	SAPHRIS.xml:S1:32355:1	O
hyponatremia	SAPHRIS.xml:S1:32357:12	B-AdverseReaction

Nervous	SAPHRIS.xml:S1:32379:7	O
system	SAPHRIS.xml:S1:32387:6	O
disorders	SAPHRIS.xml:S1:32394:9	O
:	SAPHRIS.xml:S1:32403:1	O
infrequent	SAPHRIS.xml:S1:32406:10	O
:	SAPHRIS.xml:S1:32416:1	O
dysarthria	SAPHRIS.xml:S1:32418:10	B-AdverseReaction

Following	SAPHRIS.xml:S1:32434:9	O
is	SAPHRIS.xml:S1:32444:2	O
a	SAPHRIS.xml:S1:32447:1	O
list	SAPHRIS.xml:S1:32449:4	O
of	SAPHRIS.xml:S1:32454:2	O
MedDRA	SAPHRIS.xml:S1:32457:6	O
terms	SAPHRIS.xml:S1:32464:5	O
not	SAPHRIS.xml:S1:32470:3	O
already	SAPHRIS.xml:S1:32474:7	O
listed	SAPHRIS.xml:S1:32482:6	O
either	SAPHRIS.xml:S1:32489:6	O
for	SAPHRIS.xml:S1:32496:3	O
adults	SAPHRIS.xml:S1:32500:6	O
or	SAPHRIS.xml:S1:32507:2	O
pediatric	SAPHRIS.xml:S1:32510:9	O
patients	SAPHRIS.xml:S1:32520:8	O
in	SAPHRIS.xml:S1:32529:2	O
other	SAPHRIS.xml:S1:32532:5	O
parts	SAPHRIS.xml:S1:32538:5	O
of	SAPHRIS.xml:S1:32544:2	O
Adverse	SAPHRIS.xml:S1:32548:7	O
Reactions	SAPHRIS.xml:S1:32556:9	O
(	SAPHRIS.xml:S1:32566:1	O
6	SAPHRIS.xml:S1:32567:1	O
)	SAPHRIS.xml:S1:32568:1	O
,	SAPHRIS.xml:S1:32571:1	O
or	SAPHRIS.xml:S1:32573:2	O
those	SAPHRIS.xml:S1:32576:5	O
considered	SAPHRIS.xml:S1:32582:10	O
in	SAPHRIS.xml:S1:32593:2	O
Contraindications	SAPHRIS.xml:S1:32597:17	O
(	SAPHRIS.xml:S1:32615:1	O
4	SAPHRIS.xml:S1:32616:1	O
)	SAPHRIS.xml:S1:32617:1	O
,	SAPHRIS.xml:S1:32618:1	O
Warnings	SAPHRIS.xml:S1:32620:8	O
and	SAPHRIS.xml:S1:32629:3	O
Precautions	SAPHRIS.xml:S1:32633:11	O
(	SAPHRIS.xml:S1:32645:1	O
5	SAPHRIS.xml:S1:32646:1	O
)	SAPHRIS.xml:S1:32647:1	O
or	SAPHRIS.xml:S1:32650:2	O
Overdosage	SAPHRIS.xml:S1:32654:10	O
(	SAPHRIS.xml:S1:32665:1	O
10	SAPHRIS.xml:S1:32666:2	O
)	SAPHRIS.xml:S1:32668:1	O
that	SAPHRIS.xml:S1:32671:4	O
reflect	SAPHRIS.xml:S1:32676:7	O
adverse	SAPHRIS.xml:S1:32684:7	O
reactions	SAPHRIS.xml:S1:32692:9	O
reported	SAPHRIS.xml:S1:32702:8	O
by	SAPHRIS.xml:S1:32711:2	O
pediatric	SAPHRIS.xml:S1:32714:9	O
patients	SAPHRIS.xml:S1:32724:8	O
(	SAPHRIS.xml:S1:32733:1	O
Ages	SAPHRIS.xml:S1:32734:4	O
10	SAPHRIS.xml:S1:32739:2	O
to	SAPHRIS.xml:S1:32742:2	O
17	SAPHRIS.xml:S1:32745:2	O
years	SAPHRIS.xml:S1:32748:5	O
)	SAPHRIS.xml:S1:32753:1	O
treated	SAPHRIS.xml:S1:32755:7	O
with	SAPHRIS.xml:S1:32763:4	O
sublingual	SAPHRIS.xml:S1:32768:10	O
SAPHRIS	SAPHRIS.xml:S1:32779:7	O
at	SAPHRIS.xml:S1:32787:2	O
doses	SAPHRIS.xml:S1:32790:5	O
of	SAPHRIS.xml:S1:32796:2	O
2.5	SAPHRIS.xml:S1:32799:3	O
mg	SAPHRIS.xml:S1:32803:2	O
,	SAPHRIS.xml:S1:32805:1	O
5	SAPHRIS.xml:S1:32807:1	O
mg	SAPHRIS.xml:S1:32809:2	O
,	SAPHRIS.xml:S1:32811:1	O
or	SAPHRIS.xml:S1:32813:2	O
10	SAPHRIS.xml:S1:32816:2	O
mg	SAPHRIS.xml:S1:32819:2	O
twice	SAPHRIS.xml:S1:32822:5	O
daily	SAPHRIS.xml:S1:32828:5	O
during	SAPHRIS.xml:S1:32834:6	O
any	SAPHRIS.xml:S1:32841:3	O
phase	SAPHRIS.xml:S1:32845:5	O
of	SAPHRIS.xml:S1:32851:2	O
a	SAPHRIS.xml:S1:32854:1	O
trial	SAPHRIS.xml:S1:32856:5	O
within	SAPHRIS.xml:S1:32862:6	O
the	SAPHRIS.xml:S1:32869:3	O
database	SAPHRIS.xml:S1:32873:8	O
of	SAPHRIS.xml:S1:32882:2	O
pediatric	SAPHRIS.xml:S1:32885:9	O
patients	SAPHRIS.xml:S1:32895:8	O
.	SAPHRIS.xml:S1:32903:1	O

Eye	SAPHRIS.xml:S1:32916:3	O

disorders	SAPHRIS.xml:S1:32920:9	O
:	SAPHRIS.xml:S1:32929:1	O
infrequent	SAPHRIS.xml:S1:32932:10	O
:	SAPHRIS.xml:S1:32942:1	O
diplopia	SAPHRIS.xml:S1:32944:8	B-AdverseReaction
,	SAPHRIS.xml:S1:32952:1	O
vision	SAPHRIS.xml:S1:32954:6	B-AdverseReaction
blurred	SAPHRIS.xml:S1:32961:7	I-AdverseReaction

Gastrointestinal	SAPHRIS.xml:S1:32978:16	O
disorders	SAPHRIS.xml:S1:32995:9	O
:	SAPHRIS.xml:S1:33004:1	O
infrequent	SAPHRIS.xml:S1:33007:10	O
:	SAPHRIS.xml:S1:33017:1	O
gastroesophageal	SAPHRIS.xml:S1:33019:16	B-AdverseReaction
reflux	SAPHRIS.xml:S1:33036:6	I-AdverseReaction
disease	SAPHRIS.xml:S1:33043:7	I-AdverseReaction

Injury	SAPHRIS.xml:S1:33060:6	O
,	SAPHRIS.xml:S1:33066:1	O
Poisoning	SAPHRIS.xml:S1:33068:9	O
,	SAPHRIS.xml:S1:33077:1	O
and	SAPHRIS.xml:S1:33079:3	O
Procedural	SAPHRIS.xml:S1:33083:10	O
Complications	SAPHRIS.xml:S1:33094:13	O
:	SAPHRIS.xml:S1:33107:1	O
infrequent	SAPHRIS.xml:S1:33110:10	O
:	SAPHRIS.xml:S1:33121:1	O
fall	SAPHRIS.xml:S1:33123:4	B-AdverseReaction

Skin	SAPHRIS.xml:S1:33137:4	O
and	SAPHRIS.xml:S1:33142:3	O
subcutaneous	SAPHRIS.xml:S1:33146:12	O
tissue	SAPHRIS.xml:S1:33159:6	O
disorders	SAPHRIS.xml:S1:33166:9	O
:	SAPHRIS.xml:S1:33175:1	O
infrequent	SAPHRIS.xml:S1:33178:10	O
:	SAPHRIS.xml:S1:33188:1	O
photosensitivity	SAPHRIS.xml:S1:33190:16	B-AdverseReaction
reaction	SAPHRIS.xml:S1:33207:8	I-AdverseReaction

Renal	SAPHRIS.xml:S1:33225:5	O
and	SAPHRIS.xml:S1:33231:3	O
urinary	SAPHRIS.xml:S1:33235:7	O
disorders	SAPHRIS.xml:S1:33243:9	O
:	SAPHRIS.xml:S1:33252:1	O
infrequent	SAPHRIS.xml:S1:33254:10	O
:	SAPHRIS.xml:S1:33264:1	O
enuresis	SAPHRIS.xml:S1:33267:8	B-AdverseReaction

6.2	SAPHRIS.xml:S1:33284:3	O
Postmarketing	SAPHRIS.xml:S1:33288:13	O
Experience	SAPHRIS.xml:S1:33302:10	O

The	SAPHRIS.xml:S1:33316:3	O
following	SAPHRIS.xml:S1:33320:9	O
adverse	SAPHRIS.xml:S1:33330:7	O
reactions	SAPHRIS.xml:S1:33338:9	O
have	SAPHRIS.xml:S1:33348:4	O
been	SAPHRIS.xml:S1:33353:4	O
identified	SAPHRIS.xml:S1:33358:10	O
during	SAPHRIS.xml:S1:33369:6	O
post	SAPHRIS.xml:S1:33376:4	O
-	SAPHRIS.xml:S1:33380:1	O
approval	SAPHRIS.xml:S1:33381:8	O
use	SAPHRIS.xml:S1:33390:3	O
of	SAPHRIS.xml:S1:33394:2	O
SAPHRIS	SAPHRIS.xml:S1:33397:7	O
.	SAPHRIS.xml:S1:33404:1	O

Because	SAPHRIS.xml:S1:33406:7	O
these	SAPHRIS.xml:S1:33414:5	O
reactions	SAPHRIS.xml:S1:33420:9	O
are	SAPHRIS.xml:S1:33430:3	O
reported	SAPHRIS.xml:S1:33434:8	O
voluntarily	SAPHRIS.xml:S1:33443:11	O
from	SAPHRIS.xml:S1:33455:4	O
a	SAPHRIS.xml:S1:33460:1	O
population	SAPHRIS.xml:S1:33462:10	O
of	SAPHRIS.xml:S1:33473:2	O
uncertain	SAPHRIS.xml:S1:33476:9	O
size	SAPHRIS.xml:S1:33486:4	O
,	SAPHRIS.xml:S1:33490:1	O
it	SAPHRIS.xml:S1:33492:2	O
is	SAPHRIS.xml:S1:33495:2	O
not	SAPHRIS.xml:S1:33498:3	O
always	SAPHRIS.xml:S1:33502:6	O
possible	SAPHRIS.xml:S1:33509:8	O
to	SAPHRIS.xml:S1:33518:2	O
establish	SAPHRIS.xml:S1:33521:9	O
a	SAPHRIS.xml:S1:33531:1	O
causal	SAPHRIS.xml:S1:33533:6	O
relationship	SAPHRIS.xml:S1:33540:12	O
to	SAPHRIS.xml:S1:33553:2	O
drug	SAPHRIS.xml:S1:33556:4	O
exposure	SAPHRIS.xml:S1:33561:8	O
.	SAPHRIS.xml:S1:33569:1	O

In	SAPHRIS.xml:S1:33571:2	O
many	SAPHRIS.xml:S1:33574:4	O
cases	SAPHRIS.xml:S1:33579:5	O
,	SAPHRIS.xml:S1:33584:1	O
the	SAPHRIS.xml:S1:33586:3	O
occurrence	SAPHRIS.xml:S1:33590:10	O
of	SAPHRIS.xml:S1:33601:2	O
these	SAPHRIS.xml:S1:33604:5	O
adverse	SAPHRIS.xml:S1:33610:7	O
reactions	SAPHRIS.xml:S1:33618:9	O
led	SAPHRIS.xml:S1:33628:3	O
to	SAPHRIS.xml:S1:33632:2	O
discontinuation	SAPHRIS.xml:S1:33635:15	O
of	SAPHRIS.xml:S1:33651:2	O
therapy	SAPHRIS.xml:S1:33654:7	O
.	SAPHRIS.xml:S1:33661:1	O

Application	SAPHRIS.xml:S1:33670:11	B-AdverseReaction
site	SAPHRIS.xml:S1:33682:4	I-AdverseReaction
reactions	SAPHRIS.xml:S1:33687:9	I-AdverseReaction
,	SAPHRIS.xml:S1:33696:1	O
primarily	SAPHRIS.xml:S1:33698:9	O
in	SAPHRIS.xml:S1:33708:2	O
the	SAPHRIS.xml:S1:33711:3	O
sublingual	SAPHRIS.xml:S1:33715:10	I-AdverseReaction
area	SAPHRIS.xml:S1:33726:4	I-AdverseReaction
,	SAPHRIS.xml:S1:33730:1	O
have	SAPHRIS.xml:S1:33732:4	O
been	SAPHRIS.xml:S1:33737:4	O
reported	SAPHRIS.xml:S1:33742:8	O
.	SAPHRIS.xml:S1:33750:1	O

These	SAPHRIS.xml:S1:33752:5	O
application	SAPHRIS.xml:S1:33758:11	B-AdverseReaction
site	SAPHRIS.xml:S1:33770:4	I-AdverseReaction
reactions	SAPHRIS.xml:S1:33775:9	I-AdverseReaction
included	SAPHRIS.xml:S1:33785:8	O
oral	SAPHRIS.xml:S1:33794:4	I-AdverseReaction
ulcers	SAPHRIS.xml:S1:33799:6	I-AdverseReaction
,	SAPHRIS.xml:S1:33805:1	O
blisters	SAPHRIS.xml:S1:33807:8	I-AdverseReaction
,	SAPHRIS.xml:S1:33815:1	O
peeling	SAPHRIS.xml:S1:33817:7	I-AdverseReaction
sloughing	SAPHRIS.xml:S1:33825:9	I-AdverseReaction
,	SAPHRIS.xml:S1:33834:1	O
and	SAPHRIS.xml:S1:33836:3	O
inflammation	SAPHRIS.xml:S1:33840:12	I-AdverseReaction
.	SAPHRIS.xml:S1:33852:1	O

Choking	SAPHRIS.xml:S1:33859:7	B-AdverseReaction
has	SAPHRIS.xml:S1:33867:3	O
been	SAPHRIS.xml:S1:33871:4	O
reported	SAPHRIS.xml:S1:33876:8	O
by	SAPHRIS.xml:S1:33885:2	O
patients	SAPHRIS.xml:S1:33888:8	O
,	SAPHRIS.xml:S1:33896:1	O
some	SAPHRIS.xml:S1:33898:4	O
of	SAPHRIS.xml:S1:33903:2	O
whom	SAPHRIS.xml:S1:33906:4	O
may	SAPHRIS.xml:S1:33911:3	B-Factor
have	SAPHRIS.xml:S1:33915:4	O
also	SAPHRIS.xml:S1:33920:4	O
experienced	SAPHRIS.xml:S1:33925:11	O
oropharyngeal	SAPHRIS.xml:S1:33937:13	B-AdverseReaction
muscular	SAPHRIS.xml:S1:33951:8	I-AdverseReaction
dysfunction	SAPHRIS.xml:S1:33960:11	I-AdverseReaction
or	SAPHRIS.xml:S1:33972:2	O
hypoesthesia	SAPHRIS.xml:S1:33975:12	B-AdverseReaction
.	SAPHRIS.xml:S1:33987:1	O
\n\n	SAPHRIS.xml:S2:0:2	O
BOXED	SAPHRIS.xml:S2:6:5	O
WARNING	SAPHRIS.xml:S2:12:7	O
:	SAPHRIS.xml:S2:19:1	O
WARNING	SAPHRIS.xml:S2:21:7	O
:	SAPHRIS.xml:S2:28:1	O
INCREASED	SAPHRIS.xml:S2:30:9	B-AdverseReaction
MORTALITY	SAPHRIS.xml:S2:40:9	I-AdverseReaction
IN	SAPHRIS.xml:S2:50:2	O
ELDERLY	SAPHRIS.xml:S2:53:7	O
PATIENTS	SAPHRIS.xml:S2:61:8	O
WITH	SAPHRIS.xml:S2:70:4	O
DEMENTIA	SAPHRIS.xml:S2:75:8	O
-	SAPHRIS.xml:S2:83:1	O
RELATED	SAPHRIS.xml:S2:84:7	O
PSYCHOSIS	SAPHRIS.xml:S2:92:9	O
\n\n\n\n	SAPHRIS.xml:S2:101:4	O
WARNING	SAPHRIS.xml:S2:107:7	O
:	SAPHRIS.xml:S2:114:1	O
INCREASED	SAPHRIS.xml:S2:116:9	B-AdverseReaction
MORTALITY	SAPHRIS.xml:S2:126:9	I-AdverseReaction
IN	SAPHRIS.xml:S2:136:2	O
ELDERLY	SAPHRIS.xml:S2:139:7	O
PATIENTS	SAPHRIS.xml:S2:147:8	O
WITH	SAPHRIS.xml:S2:156:4	O
DEMENTIA	SAPHRIS.xml:S2:161:8	O
-	SAPHRIS.xml:S2:169:1	O
RELATED	SAPHRIS.xml:S2:170:7	O
PSYCHOSIS	SAPHRIS.xml:S2:178:9	O
\n\n\n\n	SAPHRIS.xml:S2:187:4	O
Elderly	SAPHRIS.xml:S2:195:7	O
patients	SAPHRIS.xml:S2:203:8	O
with	SAPHRIS.xml:S2:212:4	O
dementia	SAPHRIS.xml:S2:217:8	O
-	SAPHRIS.xml:S2:225:1	O
related	SAPHRIS.xml:S2:226:7	O
psychosis	SAPHRIS.xml:S2:234:9	O
treated	SAPHRIS.xml:S2:244:7	O
with	SAPHRIS.xml:S2:252:4	O
antipsychotic	SAPHRIS.xml:S2:257:13	B-DrugClass
drugs	SAPHRIS.xml:S2:271:5	I-DrugClass
are	SAPHRIS.xml:S2:277:3	O
at	SAPHRIS.xml:S2:281:2	O
an	SAPHRIS.xml:S2:284:2	O
increased	SAPHRIS.xml:S2:287:9	O
risk	SAPHRIS.xml:S2:297:4	B-Factor
of	SAPHRIS.xml:S2:302:2	O
death	SAPHRIS.xml:S2:305:5	B-AdverseReaction
.	SAPHRIS.xml:S2:310:1	O

SAPHRIS	SAPHRIS.xml:S2:312:7	O
(	SAPHRIS.xml:S2:323:1	O
r	SAPHRIS.xml:S2:324:1	O
)\n\n	SAPHRIS.xml:S2:325:3	O
(	SAPHRIS.xml:S2:332:1	O
asenapine	SAPHRIS.xml:S2:333:9	O
)	SAPHRIS.xml:S2:342:1	O
is	SAPHRIS.xml:S2:344:2	O
not	SAPHRIS.xml:S2:347:3	O
approved	SAPHRIS.xml:S2:351:8	O
for	SAPHRIS.xml:S2:360:3	O
the	SAPHRIS.xml:S2:364:3	O
treatment	SAPHRIS.xml:S2:368:9	O
of	SAPHRIS.xml:S2:378:2	O
patients	SAPHRIS.xml:S2:381:8	O
with	SAPHRIS.xml:S2:390:4	O
dementia	SAPHRIS.xml:S2:395:8	O
-	SAPHRIS.xml:S2:403:1	O
related	SAPHRIS.xml:S2:404:7	O
psychosis	SAPHRIS.xml:S2:412:9	O
\n\n	SAPHRIS.xml:S2:421:2	O
[	SAPHRIS.xml:S2:427:1	O
see	SAPHRIS.xml:S2:428:3	O
Warnings	SAPHRIS.xml:S2:432:8	O
and	SAPHRIS.xml:S2:441:3	O
Precautions	SAPHRIS.xml:S2:445:11	O
(	SAPHRIS.xml:S2:457:1	O
5.1	SAPHRIS.xml:S2:458:3	O
,	SAPHRIS.xml:S2:461:1	O
5.2	SAPHRIS.xml:S2:463:3	O
)]	SAPHRIS.xml:S2:466:2	O
.	SAPHRIS.xml:S2:470:1	O

WARNING	SAPHRIS.xml:S2:482:7	O
:	SAPHRIS.xml:S2:489:1	O
INCREASED	SAPHRIS.xml:S2:491:9	B-AdverseReaction
MORTALITY	SAPHRIS.xml:S2:501:9	I-AdverseReaction
IN	SAPHRIS.xml:S2:511:2	O
ELDERLY	SAPHRIS.xml:S2:514:7	O
PATIENTS	SAPHRIS.xml:S2:522:8	O
WITH	SAPHRIS.xml:S2:531:4	O
DEMENTIA	SAPHRIS.xml:S2:536:8	O
-	SAPHRIS.xml:S2:544:1	O
RELATED	SAPHRIS.xml:S2:545:7	O
PSYCHOSIS	SAPHRIS.xml:S2:553:9	O
\n\n\n\n	SAPHRIS.xml:S2:564:4	O
See	SAPHRIS.xml:S2:571:3	O
full	SAPHRIS.xml:S2:575:4	O
prescribing	SAPHRIS.xml:S2:580:11	O
information	SAPHRIS.xml:S2:592:11	O
for	SAPHRIS.xml:S2:604:3	O
complete	SAPHRIS.xml:S2:608:8	O
boxed	SAPHRIS.xml:S2:617:5	O
warning	SAPHRIS.xml:S2:623:7	O
.	SAPHRIS.xml:S2:630:1	O

Elderly	SAPHRIS.xml:S2:640:7	O
patients	SAPHRIS.xml:S2:648:8	O
with	SAPHRIS.xml:S2:657:4	O
dementia	SAPHRIS.xml:S2:662:8	O
-	SAPHRIS.xml:S2:670:1	O
related	SAPHRIS.xml:S2:671:7	O
psychosis	SAPHRIS.xml:S2:679:9	O
treated	SAPHRIS.xml:S2:689:7	O
with	SAPHRIS.xml:S2:697:4	O
antipsychotic	SAPHRIS.xml:S2:702:13	B-DrugClass
drugs	SAPHRIS.xml:S2:716:5	I-DrugClass
are	SAPHRIS.xml:S2:722:3	O
at	SAPHRIS.xml:S2:726:2	O
an	SAPHRIS.xml:S2:729:2	O
increased	SAPHRIS.xml:S2:732:9	O
risk	SAPHRIS.xml:S2:742:4	O
of	SAPHRIS.xml:S2:747:2	O
death	SAPHRIS.xml:S2:750:5	B-AdverseReaction
.	SAPHRIS.xml:S2:755:1	O

SAPHRIS	SAPHRIS.xml:S2:757:7	O
is	SAPHRIS.xml:S2:765:2	O
not	SAPHRIS.xml:S2:768:3	O
approved	SAPHRIS.xml:S2:772:8	O
for	SAPHRIS.xml:S2:781:3	O
the	SAPHRIS.xml:S2:785:3	O
treatment	SAPHRIS.xml:S2:789:9	O
of	SAPHRIS.xml:S2:799:2	O
patients	SAPHRIS.xml:S2:802:8	O
with	SAPHRIS.xml:S2:811:4	O
dementia	SAPHRIS.xml:S2:816:8	O
-	SAPHRIS.xml:S2:824:1	O
related	SAPHRIS.xml:S2:825:7	O
psychosis	SAPHRIS.xml:S2:833:9	O
.	SAPHRIS.xml:S2:842:1	O

(	SAPHRIS.xml:S2:844:1	O
5.1	SAPHRIS.xml:S2:845:3	O
,	SAPHRIS.xml:S2:848:1	O
5.2	SAPHRIS.xml:S2:850:3	O
)	SAPHRIS.xml:S2:853:1	O
\n	SAPHRIS.xml:S2:856:1	O
5	SAPHRIS.xml:S3:8:1	O
WARNINGS	SAPHRIS.xml:S3:10:8	O
AND	SAPHRIS.xml:S3:19:3	O
PRECAUTIONS	SAPHRIS.xml:S3:23:11	O

EXCERPT	SAPHRIS.xml:S3:39:7	O
:	SAPHRIS.xml:S3:46:1	O
Cerebrovascular	SAPHRIS.xml:S3:55:15	B-AdverseReaction
Adverse	SAPHRIS.xml:S3:71:7	I-AdverseReaction
Events	SAPHRIS.xml:S3:79:6	I-AdverseReaction
:	SAPHRIS.xml:S3:85:1	O
An	SAPHRIS.xml:S3:87:2	O
increased	SAPHRIS.xml:S3:90:9	O
incidence	SAPHRIS.xml:S3:100:9	O
of	SAPHRIS.xml:S3:110:2	O
cerebrovascular	SAPHRIS.xml:S3:113:15	B-AdverseReaction
adverse	SAPHRIS.xml:S3:129:7	I-AdverseReaction
events	SAPHRIS.xml:S3:137:6	I-AdverseReaction
(	SAPHRIS.xml:S3:144:1	O
e	SAPHRIS.xml:S3:145:1	O
.	SAPHRIS.xml:S3:146:1	O
g	SAPHRIS.xml:S3:147:1	O
.	SAPHRIS.xml:S3:148:1	O
,	SAPHRIS.xml:S3:149:1	O
stroke	SAPHRIS.xml:S3:151:6	B-AdverseReaction
,	SAPHRIS.xml:S3:157:1	O
transient	SAPHRIS.xml:S3:159:9	B-AdverseReaction
ischemic	SAPHRIS.xml:S3:169:8	I-AdverseReaction
attack	SAPHRIS.xml:S3:178:6	I-AdverseReaction
)	SAPHRIS.xml:S3:184:1	O
has	SAPHRIS.xml:S3:186:3	O
been	SAPHRIS.xml:S3:190:4	O
seen	SAPHRIS.xml:S3:195:4	O
in	SAPHRIS.xml:S3:200:2	O
elderly	SAPHRIS.xml:S3:203:7	O
patients	SAPHRIS.xml:S3:211:8	O
with	SAPHRIS.xml:S3:220:4	O
dementia	SAPHRIS.xml:S3:225:8	O
-	SAPHRIS.xml:S3:233:1	O
related	SAPHRIS.xml:S3:234:7	O
psychoses	SAPHRIS.xml:S3:242:9	O
treated	SAPHRIS.xml:S3:252:7	O
with	SAPHRIS.xml:S3:260:4	O
atypical	SAPHRIS.xml:S3:265:8	B-DrugClass
antipsychotic	SAPHRIS.xml:S3:274:13	I-DrugClass
drugs	SAPHRIS.xml:S3:288:5	I-DrugClass
.	SAPHRIS.xml:S3:293:1	O

(	SAPHRIS.xml:S3:295:1	O
5.2	SAPHRIS.xml:S3:296:3	O
)	SAPHRIS.xml:S3:299:1	O

Neuroleptic	SAPHRIS.xml:S3:307:11	B-AdverseReaction
Malignant	SAPHRIS.xml:S3:319:9	I-AdverseReaction
Syndrome	SAPHRIS.xml:S3:329:8	I-AdverseReaction
:	SAPHRIS.xml:S3:337:1	O
Manage	SAPHRIS.xml:S3:339:6	O
with	SAPHRIS.xml:S3:346:4	O
immediate	SAPHRIS.xml:S3:351:9	O
discontinuation	SAPHRIS.xml:S3:361:15	O
and	SAPHRIS.xml:S3:377:3	O
close	SAPHRIS.xml:S3:381:5	O
monitoring	SAPHRIS.xml:S3:387:10	O
.	SAPHRIS.xml:S3:397:1	O

(	SAPHRIS.xml:S3:399:1	O
5.3	SAPHRIS.xml:S3:400:3	O
)	SAPHRIS.xml:S3:403:1	O

Tardive	SAPHRIS.xml:S3:411:7	B-AdverseReaction
Dyskinesia	SAPHRIS.xml:S3:419:10	I-AdverseReaction
:	SAPHRIS.xml:S3:429:1	O
Discontinue	SAPHRIS.xml:S3:431:11	O
if	SAPHRIS.xml:S3:443:2	O
clinically	SAPHRIS.xml:S3:446:10	O
appropriate	SAPHRIS.xml:S3:457:11	O
.	SAPHRIS.xml:S3:468:1	O

(	SAPHRIS.xml:S3:470:1	O
5.4	SAPHRIS.xml:S3:471:3	O
)	SAPHRIS.xml:S3:474:1	O

dispatch	SAPHRIS.xml:S3:480:8	O
:	SAPHRIS.xml:S3:488:1	O
unexpected	SAPHRIS.xml:S3:490:10	O
key	SAPHRIS.xml:S3:501:3	O
:	SAPHRIS.xml:S3:504:1	O
list	SAPHRIS.xml:S3:506:4	O
in	SAPHRIS.xml:S3:511:2	O
dispatch	SAPHRIS.xml:S3:514:8	O
table	SAPHRIS.xml:S3:523:5	O
:	SAPHRIS.xml:S3:528:1	O
caption	SAPHRIS.xml:S3:532:7	O
:	SAPHRIS.xml:S3:540:1	O
function	SAPHRIS.xml:S3:543:8	O
print_caption	SAPHRIS.xml:S3:552:13	O
at	SAPHRIS.xml:S3:566:2	O
0	SAPHRIS.xml:S3:569:1	O
x1c6c8c0	SAPHRIS.xml:S3:570:8	O
,	SAPHRIS.xml:S3:579:1	O
text	SAPHRIS.xml:S3:582:4	O
:	SAPHRIS.xml:S3:587:1	O
function	SAPHRIS.xml:S3:590:8	O
print_text	SAPHRIS.xml:S3:599:10	O
at	SAPHRIS.xml:S3:610:2	O
0	SAPHRIS.xml:S3:613:1	O
x1c6c500	SAPHRIS.xml:S3:614:8	O

Metabolic	SAPHRIS.xml:S3:627:9	B-AdverseReaction
Changes	SAPHRIS.xml:S3:637:7	I-AdverseReaction
:	SAPHRIS.xml:S3:644:1	O
Atypical	SAPHRIS.xml:S3:646:8	B-DrugClass
antipsychotic	SAPHRIS.xml:S3:655:13	I-DrugClass
drugs	SAPHRIS.xml:S3:669:5	I-DrugClass
have	SAPHRIS.xml:S3:675:4	O
been	SAPHRIS.xml:S3:680:4	O
associated	SAPHRIS.xml:S3:685:10	O
with	SAPHRIS.xml:S3:696:4	O
metabolic	SAPHRIS.xml:S3:701:9	B-AdverseReaction
changes	SAPHRIS.xml:S3:711:7	I-AdverseReaction
that	SAPHRIS.xml:S3:719:4	O
may	SAPHRIS.xml:S3:724:3	O
increase	SAPHRIS.xml:S3:728:8	O
cardiovascular	SAPHRIS.xml:S3:737:14	B-AdverseReaction
cerebrovascular	SAPHRIS.xml:S3:752:15	B-AdverseReaction
risk	SAPHRIS.xml:S3:768:4	I-AdverseReaction
.	SAPHRIS.xml:S3:772:1	O

These	SAPHRIS.xml:S3:774:5	O
metabolic	SAPHRIS.xml:S3:780:9	B-AdverseReaction
changes	SAPHRIS.xml:S3:790:7	I-AdverseReaction
include	SAPHRIS.xml:S3:798:7	O
hyperglycemia	SAPHRIS.xml:S3:806:13	B-AdverseReaction
,	SAPHRIS.xml:S3:819:1	O
dyslipidemia	SAPHRIS.xml:S3:821:12	B-AdverseReaction
,	SAPHRIS.xml:S3:833:1	O
and	SAPHRIS.xml:S3:835:3	O
weight	SAPHRIS.xml:S3:839:6	B-AdverseReaction
gain	SAPHRIS.xml:S3:846:4	I-AdverseReaction
.	SAPHRIS.xml:S3:850:1	O

(	SAPHRIS.xml:S3:852:1	O
5.5	SAPHRIS.xml:S3:853:3	O
)	SAPHRIS.xml:S3:856:1	O

Hypersensitivity	SAPHRIS.xml:S3:864:16	B-AdverseReaction
Reactions	SAPHRIS.xml:S3:881:9	I-AdverseReaction
:	SAPHRIS.xml:S3:890:1	O
Hypersensitivity	SAPHRIS.xml:S3:892:16	B-AdverseReaction
reactions	SAPHRIS.xml:S3:909:9	I-AdverseReaction
,	SAPHRIS.xml:S3:918:1	O
including	SAPHRIS.xml:S3:920:9	O
anaphylaxis	SAPHRIS.xml:S3:930:11	B-AdverseReaction
and	SAPHRIS.xml:S3:942:3	O
angioedema	SAPHRIS.xml:S3:946:10	B-AdverseReaction
,	SAPHRIS.xml:S3:956:1	O
have	SAPHRIS.xml:S3:958:4	O
been	SAPHRIS.xml:S3:963:4	O
observed	SAPHRIS.xml:S3:968:8	O
.	SAPHRIS.xml:S3:976:1	O

(	SAPHRIS.xml:S3:978:1	O
5.6	SAPHRIS.xml:S3:979:3	O
)	SAPHRIS.xml:S3:982:1	O

Orthostatic	SAPHRIS.xml:S3:990:11	B-AdverseReaction
Hypotension	SAPHRIS.xml:S3:1002:11	I-AdverseReaction
,	SAPHRIS.xml:S3:1013:1	O
Syncope	SAPHRIS.xml:S3:1015:7	B-AdverseReaction
,	SAPHRIS.xml:S3:1022:1	O
and	SAPHRIS.xml:S3:1024:3	O
Other	SAPHRIS.xml:S3:1028:5	O
Hemodynamic	SAPHRIS.xml:S3:1034:11	B-AdverseReaction
Effects	SAPHRIS.xml:S3:1046:7	I-AdverseReaction
:	SAPHRIS.xml:S3:1053:1	O
Dizziness	SAPHRIS.xml:S3:1055:9	B-AdverseReaction
,	SAPHRIS.xml:S3:1064:1	O
tachycardia	SAPHRIS.xml:S3:1066:11	B-AdverseReaction
or	SAPHRIS.xml:S3:1078:2	O
bradycardia	SAPHRIS.xml:S3:1081:11	B-AdverseReaction
,	SAPHRIS.xml:S3:1092:1	O
and	SAPHRIS.xml:S3:1094:3	O
syncope	SAPHRIS.xml:S3:1098:7	B-AdverseReaction
may	SAPHRIS.xml:S3:1106:3	B-Factor
occur	SAPHRIS.xml:S3:1110:5	O
,	SAPHRIS.xml:S3:1115:1	O
especially	SAPHRIS.xml:S3:1117:10	O
early	SAPHRIS.xml:S3:1128:5	O
in	SAPHRIS.xml:S3:1134:2	O
treatment	SAPHRIS.xml:S3:1137:9	O
.	SAPHRIS.xml:S3:1146:1	O

Use	SAPHRIS.xml:S3:1148:3	O
with	SAPHRIS.xml:S3:1152:4	O
caution	SAPHRIS.xml:S3:1157:7	O
in	SAPHRIS.xml:S3:1165:2	O
patients	SAPHRIS.xml:S3:1168:8	O
with	SAPHRIS.xml:S3:1177:4	O
known	SAPHRIS.xml:S3:1182:5	O
cardiovascular	SAPHRIS.xml:S3:1188:14	O
or	SAPHRIS.xml:S3:1203:2	O
cerebrovascular	SAPHRIS.xml:S3:1206:15	O
disease	SAPHRIS.xml:S3:1222:7	O
,	SAPHRIS.xml:S3:1229:1	O
and	SAPHRIS.xml:S3:1231:3	O
in	SAPHRIS.xml:S3:1235:2	O
antipsychotic	SAPHRIS.xml:S3:1238:13	O
-	SAPHRIS.xml:S3:1251:1	O
naive	SAPHRIS.xml:S3:1252:5	O
patients	SAPHRIS.xml:S3:1258:8	O
.	SAPHRIS.xml:S3:1266:1	O

(	SAPHRIS.xml:S3:1268:1	O
5.7	SAPHRIS.xml:S3:1269:3	O
)	SAPHRIS.xml:S3:1272:1	O

Leukopenia	SAPHRIS.xml:S3:1280:10	B-AdverseReaction
,	SAPHRIS.xml:S3:1290:1	O
Neutropenia	SAPHRIS.xml:S3:1292:11	B-AdverseReaction
,	SAPHRIS.xml:S3:1303:1	O
and	SAPHRIS.xml:S3:1305:3	O
Agranulocytosis	SAPHRIS.xml:S3:1309:15	B-AdverseReaction
have	SAPHRIS.xml:S3:1325:4	O
been	SAPHRIS.xml:S3:1330:4	O
reported	SAPHRIS.xml:S3:1335:8	O
with	SAPHRIS.xml:S3:1344:4	O
antipsychotics	SAPHRIS.xml:S3:1349:14	B-DrugClass
.	SAPHRIS.xml:S3:1363:1	O

Patients	SAPHRIS.xml:S3:1365:8	O
with	SAPHRIS.xml:S3:1374:4	O
a	SAPHRIS.xml:S3:1379:1	O
pre	SAPHRIS.xml:S3:1381:3	O
-	SAPHRIS.xml:S3:1384:1	O
existing	SAPHRIS.xml:S3:1385:8	O
low	SAPHRIS.xml:S3:1394:3	O
white	SAPHRIS.xml:S3:1398:5	O
blood	SAPHRIS.xml:S3:1404:5	O
cell	SAPHRIS.xml:S3:1410:4	O
count	SAPHRIS.xml:S3:1415:5	O
(	SAPHRIS.xml:S3:1421:1	O
WBC	SAPHRIS.xml:S3:1422:3	O
)	SAPHRIS.xml:S3:1425:1	O
or	SAPHRIS.xml:S3:1427:2	O
a	SAPHRIS.xml:S3:1430:1	O
history	SAPHRIS.xml:S3:1432:7	O
of	SAPHRIS.xml:S3:1440:2	O
leukopenia	SAPHRIS.xml:S3:1443:10	O
neutropenia	SAPHRIS.xml:S3:1454:11	O
should	SAPHRIS.xml:S3:1466:6	O
have	SAPHRIS.xml:S3:1473:4	O
their	SAPHRIS.xml:S3:1478:5	O
complete	SAPHRIS.xml:S3:1484:8	O
blood	SAPHRIS.xml:S3:1493:5	O
count	SAPHRIS.xml:S3:1499:5	O
(	SAPHRIS.xml:S3:1505:1	O
CBC	SAPHRIS.xml:S3:1506:3	O
)	SAPHRIS.xml:S3:1509:1	O
monitored	SAPHRIS.xml:S3:1511:9	O
frequently	SAPHRIS.xml:S3:1521:10	O
during	SAPHRIS.xml:S3:1532:6	O
the	SAPHRIS.xml:S3:1539:3	O
first	SAPHRIS.xml:S3:1543:5	O
few	SAPHRIS.xml:S3:1549:3	O
months	SAPHRIS.xml:S3:1553:6	O
of	SAPHRIS.xml:S3:1560:2	O
therapy	SAPHRIS.xml:S3:1563:7	O
and	SAPHRIS.xml:S3:1571:3	O
SAPHRIS	SAPHRIS.xml:S3:1575:7	O
should	SAPHRIS.xml:S3:1583:6	O
be	SAPHRIS.xml:S3:1590:2	O
discontinued	SAPHRIS.xml:S3:1593:12	O
at	SAPHRIS.xml:S3:1606:2	O
the	SAPHRIS.xml:S3:1609:3	O
first	SAPHRIS.xml:S3:1613:5	O
sign	SAPHRIS.xml:S3:1619:4	O
of	SAPHRIS.xml:S3:1624:2	O
a	SAPHRIS.xml:S3:1627:1	O
decline	SAPHRIS.xml:S3:1629:7	O
in	SAPHRIS.xml:S3:1637:2	O
WBC	SAPHRIS.xml:S3:1640:3	O
in	SAPHRIS.xml:S3:1644:2	O
the	SAPHRIS.xml:S3:1647:3	O
absence	SAPHRIS.xml:S3:1651:7	O
of	SAPHRIS.xml:S3:1659:2	O
other	SAPHRIS.xml:S3:1662:5	O
causative	SAPHRIS.xml:S3:1668:9	O
factors	SAPHRIS.xml:S3:1678:7	O
.	SAPHRIS.xml:S3:1685:1	O

(	SAPHRIS.xml:S3:1687:1	O
5.8	SAPHRIS.xml:S3:1688:3	O
)	SAPHRIS.xml:S3:1691:1	O

QT	SAPHRIS.xml:S3:1699:2	B-AdverseReaction
Prolongation	SAPHRIS.xml:S3:1702:12	I-AdverseReaction
:	SAPHRIS.xml:S3:1714:1	O
Increases	SAPHRIS.xml:S3:1716:9	B-AdverseReaction
in	SAPHRIS.xml:S3:1726:2	I-AdverseReaction
QT	SAPHRIS.xml:S3:1729:2	I-AdverseReaction
interval	SAPHRIS.xml:S3:1732:8	I-AdverseReaction
;	SAPHRIS.xml:S3:1740:1	O
avoid	SAPHRIS.xml:S3:1742:5	O
use	SAPHRIS.xml:S3:1748:3	O
with	SAPHRIS.xml:S3:1752:4	O
drugs	SAPHRIS.xml:S3:1757:5	O
that	SAPHRIS.xml:S3:1763:4	O
also	SAPHRIS.xml:S3:1768:4	O
increase	SAPHRIS.xml:S3:1773:8	O
the	SAPHRIS.xml:S3:1782:3	O
QT	SAPHRIS.xml:S3:1786:2	O
interval	SAPHRIS.xml:S3:1789:8	O
and	SAPHRIS.xml:S3:1798:3	O
in	SAPHRIS.xml:S3:1802:2	O
patients	SAPHRIS.xml:S3:1805:8	O
with	SAPHRIS.xml:S3:1814:4	O
risk	SAPHRIS.xml:S3:1819:4	O
factors	SAPHRIS.xml:S3:1824:7	O
for	SAPHRIS.xml:S3:1832:3	O
prolonged	SAPHRIS.xml:S3:1836:9	O
QT	SAPHRIS.xml:S3:1846:2	O
interval	SAPHRIS.xml:S3:1849:8	O
.	SAPHRIS.xml:S3:1857:1	O

(	SAPHRIS.xml:S3:1859:1	O
5.9	SAPHRIS.xml:S3:1860:3	O
)	SAPHRIS.xml:S3:1863:1	O

Seizures	SAPHRIS.xml:S3:1871:8	B-AdverseReaction
:	SAPHRIS.xml:S3:1879:1	O
Use	SAPHRIS.xml:S3:1881:3	O
cautiously	SAPHRIS.xml:S3:1885:10	O
in	SAPHRIS.xml:S3:1896:2	O
patients	SAPHRIS.xml:S3:1899:8	O
with	SAPHRIS.xml:S3:1908:4	O
a	SAPHRIS.xml:S3:1913:1	O
history	SAPHRIS.xml:S3:1915:7	O
of	SAPHRIS.xml:S3:1923:2	O
seizures	SAPHRIS.xml:S3:1926:8	O
or	SAPHRIS.xml:S3:1935:2	O
with	SAPHRIS.xml:S3:1938:4	O
conditions	SAPHRIS.xml:S3:1943:10	O
that	SAPHRIS.xml:S3:1954:4	O
lower	SAPHRIS.xml:S3:1959:5	O
the	SAPHRIS.xml:S3:1965:3	O
seizure	SAPHRIS.xml:S3:1969:7	O
threshold	SAPHRIS.xml:S3:1977:9	O
.	SAPHRIS.xml:S3:1986:1	O

(	SAPHRIS.xml:S3:1988:1	O
5.11	SAPHRIS.xml:S3:1989:4	O
)	SAPHRIS.xml:S3:1993:1	O

Potential	SAPHRIS.xml:S3:2001:9	B-Factor
for	SAPHRIS.xml:S3:2011:3	O
Cognitive	SAPHRIS.xml:S3:2015:9	B-AdverseReaction
and	SAPHRIS.xml:S3:2025:3	O
Motor	SAPHRIS.xml:S3:2029:5	B-AdverseReaction
Impairment	SAPHRIS.xml:S3:2035:10	I-AdverseReaction
:	SAPHRIS.xml:S3:2045:1	O
Use	SAPHRIS.xml:S3:2047:3	O
caution	SAPHRIS.xml:S3:2051:7	O
when	SAPHRIS.xml:S3:2059:4	O
operating	SAPHRIS.xml:S3:2064:9	O
machinery	SAPHRIS.xml:S3:2074:9	O
.	SAPHRIS.xml:S3:2083:1	O

(	SAPHRIS.xml:S3:2085:1	O
5.12	SAPHRIS.xml:S3:2086:4	O
)	SAPHRIS.xml:S3:2090:1	O

Suicide	SAPHRIS.xml:S3:2098:7	B-AdverseReaction
:	SAPHRIS.xml:S3:2105:1	O
The	SAPHRIS.xml:S3:2107:3	O
possibility	SAPHRIS.xml:S3:2111:11	O
of	SAPHRIS.xml:S3:2123:2	O
a	SAPHRIS.xml:S3:2126:1	O
suicide	SAPHRIS.xml:S3:2128:7	O
attempt	SAPHRIS.xml:S3:2136:7	O
is	SAPHRIS.xml:S3:2144:2	O
inherent	SAPHRIS.xml:S3:2147:8	O
in	SAPHRIS.xml:S3:2156:2	O
schizophrenia	SAPHRIS.xml:S3:2159:13	O
and	SAPHRIS.xml:S3:2173:3	O
bipolar	SAPHRIS.xml:S3:2177:7	O
disorder	SAPHRIS.xml:S3:2185:8	O
.	SAPHRIS.xml:S3:2193:1	O

Closely	SAPHRIS.xml:S3:2195:7	O
supervise	SAPHRIS.xml:S3:2203:9	O
high	SAPHRIS.xml:S3:2213:4	O
-	SAPHRIS.xml:S3:2217:1	O
risk	SAPHRIS.xml:S3:2218:4	O
patients	SAPHRIS.xml:S3:2223:8	O
.	SAPHRIS.xml:S3:2231:1	O

(	SAPHRIS.xml:S3:2233:1	O
5.14	SAPHRIS.xml:S3:2234:4	O
)	SAPHRIS.xml:S3:2238:1	O

5.1	SAPHRIS.xml:S3:2253:3	O

Increased	SAPHRIS.xml:S3:2257:9	O
Mortality	SAPHRIS.xml:S3:2267:9	O
in	SAPHRIS.xml:S3:2277:2	O
Elderly	SAPHRIS.xml:S3:2280:7	O
Patients	SAPHRIS.xml:S3:2288:8	O
with	SAPHRIS.xml:S3:2297:4	O
Dementia	SAPHRIS.xml:S3:2302:8	O
-	SAPHRIS.xml:S3:2310:1	O
Related	SAPHRIS.xml:S3:2311:7	O
Psychosis	SAPHRIS.xml:S3:2319:9	O

Elderly	SAPHRIS.xml:S3:2336:7	O
patients	SAPHRIS.xml:S3:2344:8	O
with	SAPHRIS.xml:S3:2353:4	O
dementia	SAPHRIS.xml:S3:2358:8	O
-	SAPHRIS.xml:S3:2366:1	O
related	SAPHRIS.xml:S3:2367:7	O
psychosis	SAPHRIS.xml:S3:2375:9	O
treated	SAPHRIS.xml:S3:2385:7	O
with	SAPHRIS.xml:S3:2393:4	O
antipsychotic	SAPHRIS.xml:S3:2398:13	B-DrugClass
drugs	SAPHRIS.xml:S3:2412:5	I-DrugClass
are	SAPHRIS.xml:S3:2418:3	O
at	SAPHRIS.xml:S3:2422:2	O
an	SAPHRIS.xml:S3:2425:2	O
increased	SAPHRIS.xml:S3:2428:9	O
risk	SAPHRIS.xml:S3:2438:4	O
of	SAPHRIS.xml:S3:2443:2	O
death	SAPHRIS.xml:S3:2446:5	B-AdverseReaction
.	SAPHRIS.xml:S3:2451:1	O

Analyses	SAPHRIS.xml:S3:2453:8	O
of	SAPHRIS.xml:S3:2462:2	O
17	SAPHRIS.xml:S3:2465:2	O
placebo	SAPHRIS.xml:S3:2468:7	O
-	SAPHRIS.xml:S3:2475:1	O
controlled	SAPHRIS.xml:S3:2476:10	O
trials	SAPHRIS.xml:S3:2487:6	O
(	SAPHRIS.xml:S3:2494:1	O
modal	SAPHRIS.xml:S3:2495:5	O
duration	SAPHRIS.xml:S3:2501:8	O
of	SAPHRIS.xml:S3:2510:2	O
10	SAPHRIS.xml:S3:2513:2	O
weeks	SAPHRIS.xml:S3:2516:5	O
)	SAPHRIS.xml:S3:2521:1	O
,	SAPHRIS.xml:S3:2522:1	O
largely	SAPHRIS.xml:S3:2524:7	O
in	SAPHRIS.xml:S3:2532:2	O
patients	SAPHRIS.xml:S3:2535:8	O
taking	SAPHRIS.xml:S3:2544:6	O
atypical	SAPHRIS.xml:S3:2551:8	B-DrugClass
antipsychotic	SAPHRIS.xml:S3:2560:13	I-DrugClass
drugs	SAPHRIS.xml:S3:2574:5	I-DrugClass
,	SAPHRIS.xml:S3:2579:1	O
revealed	SAPHRIS.xml:S3:2581:8	O
a	SAPHRIS.xml:S3:2590:1	O
risk	SAPHRIS.xml:S3:2592:4	O
of	SAPHRIS.xml:S3:2597:2	O
death	SAPHRIS.xml:S3:2600:5	B-AdverseReaction
in	SAPHRIS.xml:S3:2606:2	O
the	SAPHRIS.xml:S3:2609:3	O
drug	SAPHRIS.xml:S3:2613:4	O
-	SAPHRIS.xml:S3:2617:1	O
treated	SAPHRIS.xml:S3:2618:7	O
patients	SAPHRIS.xml:S3:2626:8	O
of	SAPHRIS.xml:S3:2635:2	O
between	SAPHRIS.xml:S3:2638:7	O
1.6	SAPHRIS.xml:S3:2646:3	O
to	SAPHRIS.xml:S3:2650:2	O
1.7	SAPHRIS.xml:S3:2653:3	O
times	SAPHRIS.xml:S3:2657:5	O
that	SAPHRIS.xml:S3:2663:4	O
seen	SAPHRIS.xml:S3:2668:4	O
in	SAPHRIS.xml:S3:2673:2	O
placebo	SAPHRIS.xml:S3:2676:7	O
-	SAPHRIS.xml:S3:2683:1	O
treated	SAPHRIS.xml:S3:2684:7	O
patients	SAPHRIS.xml:S3:2692:8	O
.	SAPHRIS.xml:S3:2700:1	O

Over	SAPHRIS.xml:S3:2702:4	O
the	SAPHRIS.xml:S3:2707:3	O
course	SAPHRIS.xml:S3:2711:6	O
of	SAPHRIS.xml:S3:2718:2	O
a	SAPHRIS.xml:S3:2721:1	O
typical	SAPHRIS.xml:S3:2723:7	O
10	SAPHRIS.xml:S3:2731:2	O
-	SAPHRIS.xml:S3:2733:1	O
week	SAPHRIS.xml:S3:2734:4	O
controlled	SAPHRIS.xml:S3:2739:10	O
trial	SAPHRIS.xml:S3:2750:5	O
,	SAPHRIS.xml:S3:2755:1	O
the	SAPHRIS.xml:S3:2757:3	O
rate	SAPHRIS.xml:S3:2761:4	O
of	SAPHRIS.xml:S3:2766:2	O
death	SAPHRIS.xml:S3:2769:5	B-AdverseReaction
in	SAPHRIS.xml:S3:2775:2	O
drug	SAPHRIS.xml:S3:2778:4	O
-	SAPHRIS.xml:S3:2782:1	O
treated	SAPHRIS.xml:S3:2783:7	O
patients	SAPHRIS.xml:S3:2791:8	O
was	SAPHRIS.xml:S3:2800:3	O
about	SAPHRIS.xml:S3:2804:5	O
4.5%	SAPHRIS.xml:S3:2810:4	O
,	SAPHRIS.xml:S3:2814:1	O
compared	SAPHRIS.xml:S3:2816:8	O
to	SAPHRIS.xml:S3:2825:2	O
a	SAPHRIS.xml:S3:2828:1	O
rate	SAPHRIS.xml:S3:2830:4	O
of	SAPHRIS.xml:S3:2835:2	O
about	SAPHRIS.xml:S3:2838:5	O
2.6%	SAPHRIS.xml:S3:2844:4	O
in	SAPHRIS.xml:S3:2849:2	O
the	SAPHRIS.xml:S3:2852:3	O
placebo	SAPHRIS.xml:S3:2856:7	O
group	SAPHRIS.xml:S3:2864:5	O
.	SAPHRIS.xml:S3:2869:1	O

Although	SAPHRIS.xml:S3:2871:8	O
the	SAPHRIS.xml:S3:2880:3	O
causes	SAPHRIS.xml:S3:2884:6	O
of	SAPHRIS.xml:S3:2891:2	O
death	SAPHRIS.xml:S3:2894:5	B-AdverseReaction
were	SAPHRIS.xml:S3:2900:4	O
varied	SAPHRIS.xml:S3:2905:6	O
,	SAPHRIS.xml:S3:2911:1	O
most	SAPHRIS.xml:S3:2913:4	O
of	SAPHRIS.xml:S3:2918:2	O
the	SAPHRIS.xml:S3:2921:3	O
deaths	SAPHRIS.xml:S3:2925:6	B-AdverseReaction
appeared	SAPHRIS.xml:S3:2932:8	O
to	SAPHRIS.xml:S3:2941:2	O
be	SAPHRIS.xml:S3:2944:2	O
either	SAPHRIS.xml:S3:2947:6	O
cardiovascular	SAPHRIS.xml:S3:2954:14	O
(	SAPHRIS.xml:S3:2969:1	O
e	SAPHRIS.xml:S3:2970:1	O
.	SAPHRIS.xml:S3:2971:1	O
g	SAPHRIS.xml:S3:2972:1	O
.	SAPHRIS.xml:S3:2973:1	O
,	SAPHRIS.xml:S3:2974:1	O
heart	SAPHRIS.xml:S3:2976:5	B-AdverseReaction
failure	SAPHRIS.xml:S3:2982:7	I-AdverseReaction
,	SAPHRIS.xml:S3:2989:1	O
sudden	SAPHRIS.xml:S3:2991:6	B-AdverseReaction
death	SAPHRIS.xml:S3:2998:5	I-AdverseReaction
)	SAPHRIS.xml:S3:3003:1	O
or	SAPHRIS.xml:S3:3005:2	O
infectious	SAPHRIS.xml:S3:3008:10	O
(	SAPHRIS.xml:S3:3019:1	O
e	SAPHRIS.xml:S3:3020:1	O
.	SAPHRIS.xml:S3:3021:1	O
g	SAPHRIS.xml:S3:3022:1	O
.	SAPHRIS.xml:S3:3023:1	O
,	SAPHRIS.xml:S3:3024:1	O
pneumonia	SAPHRIS.xml:S3:3026:9	B-AdverseReaction
)	SAPHRIS.xml:S3:3035:1	O
in	SAPHRIS.xml:S3:3037:2	O
nature	SAPHRIS.xml:S3:3040:6	O
.	SAPHRIS.xml:S3:3046:1	O

Observational	SAPHRIS.xml:S3:3048:13	O
studies	SAPHRIS.xml:S3:3062:7	O
suggest	SAPHRIS.xml:S3:3070:7	O
that	SAPHRIS.xml:S3:3078:4	O
,	SAPHRIS.xml:S3:3082:1	O
similar	SAPHRIS.xml:S3:3084:7	O
to	SAPHRIS.xml:S3:3092:2	O
atypical	SAPHRIS.xml:S3:3095:8	O
antipsychotic	SAPHRIS.xml:S3:3104:13	O
drugs	SAPHRIS.xml:S3:3118:5	O
,	SAPHRIS.xml:S3:3123:1	O
treatment	SAPHRIS.xml:S3:3125:9	O
with	SAPHRIS.xml:S3:3135:4	O
conventional	SAPHRIS.xml:S3:3140:12	O
antipsychotic	SAPHRIS.xml:S3:3153:13	O
drugs	SAPHRIS.xml:S3:3167:5	O
may	SAPHRIS.xml:S3:3173:3	O
increase	SAPHRIS.xml:S3:3177:8	O
mortality	SAPHRIS.xml:S3:3186:9	O
.	SAPHRIS.xml:S3:3195:1	O

The	SAPHRIS.xml:S3:3197:3	O
extent	SAPHRIS.xml:S3:3201:6	O
to	SAPHRIS.xml:S3:3208:2	O
which	SAPHRIS.xml:S3:3211:5	O
the	SAPHRIS.xml:S3:3217:3	O
findings	SAPHRIS.xml:S3:3221:8	O
of	SAPHRIS.xml:S3:3230:2	O
increased	SAPHRIS.xml:S3:3233:9	B-AdverseReaction
mortality	SAPHRIS.xml:S3:3243:9	I-AdverseReaction
in	SAPHRIS.xml:S3:3253:2	O
observational	SAPHRIS.xml:S3:3256:13	O
studies	SAPHRIS.xml:S3:3270:7	O
may	SAPHRIS.xml:S3:3278:3	O
be	SAPHRIS.xml:S3:3282:2	O
attributed	SAPHRIS.xml:S3:3285:10	O
to	SAPHRIS.xml:S3:3296:2	O
the	SAPHRIS.xml:S3:3299:3	O
antipsychotic	SAPHRIS.xml:S3:3303:13	B-DrugClass
drug	SAPHRIS.xml:S3:3317:4	I-DrugClass
as	SAPHRIS.xml:S3:3322:2	O
opposed	SAPHRIS.xml:S3:3325:7	O
to	SAPHRIS.xml:S3:3333:2	O
some	SAPHRIS.xml:S3:3336:4	O
characteristic	SAPHRIS.xml:S3:3341:14	O
(	SAPHRIS.xml:S3:3355:1	O
s	SAPHRIS.xml:S3:3356:1	O
)	SAPHRIS.xml:S3:3357:1	O
of	SAPHRIS.xml:S3:3359:2	O
the	SAPHRIS.xml:S3:3362:3	O
patients	SAPHRIS.xml:S3:3366:8	O
is	SAPHRIS.xml:S3:3375:2	O
not	SAPHRIS.xml:S3:3378:3	O
clear	SAPHRIS.xml:S3:3382:5	O
.	SAPHRIS.xml:S3:3387:1	O

SAPHRIS	SAPHRIS.xml:S3:3389:7	O
is	SAPHRIS.xml:S3:3397:2	O
not	SAPHRIS.xml:S3:3400:3	O
approved	SAPHRIS.xml:S3:3404:8	O
for	SAPHRIS.xml:S3:3413:3	O
the	SAPHRIS.xml:S3:3417:3	O
treatment	SAPHRIS.xml:S3:3421:9	O
of	SAPHRIS.xml:S3:3431:2	O
patients	SAPHRIS.xml:S3:3434:8	O
with	SAPHRIS.xml:S3:3443:4	O
dementia	SAPHRIS.xml:S3:3448:8	O
-	SAPHRIS.xml:S3:3456:1	O
related	SAPHRIS.xml:S3:3457:7	O
psychosis	SAPHRIS.xml:S3:3465:9	O
[	SAPHRIS.xml:S3:3476:1	O
seeBoxed	SAPHRIS.xml:S3:3477:8	O
Warningand	SAPHRIS.xml:S3:3486:10	O
Warnings	SAPHRIS.xml:S3:3497:8	O
and	SAPHRIS.xml:S3:3506:3	O
Precautions	SAPHRIS.xml:S3:3510:11	O
(	SAPHRIS.xml:S3:3522:1	O
5.2	SAPHRIS.xml:S3:3523:3	O
)]	SAPHRIS.xml:S3:3526:2	O
.	SAPHRIS.xml:S3:3530:1	O

5.2	SAPHRIS.xml:S3:3542:3	O
Cerebrovascular	SAPHRIS.xml:S3:3546:15	O
Adverse	SAPHRIS.xml:S3:3562:7	O
Events	SAPHRIS.xml:S3:3570:6	O
,	SAPHRIS.xml:S3:3576:1	O
Including	SAPHRIS.xml:S3:3578:9	O
Stroke	SAPHRIS.xml:S3:3588:6	O
,	SAPHRIS.xml:S3:3594:1	O
In	SAPHRIS.xml:S3:3596:2	O
Elderly	SAPHRIS.xml:S3:3599:7	O
Patients	SAPHRIS.xml:S3:3607:8	O
with	SAPHRIS.xml:S3:3616:4	O
Dementia	SAPHRIS.xml:S3:3621:8	O
-	SAPHRIS.xml:S3:3629:1	O
Related	SAPHRIS.xml:S3:3630:7	O
Psychosis	SAPHRIS.xml:S3:3638:9	O

In	SAPHRIS.xml:S3:3655:2	O
placebo	SAPHRIS.xml:S3:3658:7	O
-	SAPHRIS.xml:S3:3665:1	O
controlled	SAPHRIS.xml:S3:3666:10	O
trials	SAPHRIS.xml:S3:3677:6	O
with	SAPHRIS.xml:S3:3684:4	O
risperidone	SAPHRIS.xml:S3:3689:11	B-DrugClass
,	SAPHRIS.xml:S3:3700:1	O
aripiprazole	SAPHRIS.xml:S3:3702:12	B-DrugClass
,	SAPHRIS.xml:S3:3714:1	O
and	SAPHRIS.xml:S3:3716:3	O
olanzapine	SAPHRIS.xml:S3:3720:10	B-DrugClass
in	SAPHRIS.xml:S3:3731:2	O
elderly	SAPHRIS.xml:S3:3734:7	O
subjects	SAPHRIS.xml:S3:3742:8	O
with	SAPHRIS.xml:S3:3751:4	O
dementia	SAPHRIS.xml:S3:3756:8	O
,	SAPHRIS.xml:S3:3764:1	O
there	SAPHRIS.xml:S3:3766:5	O
was	SAPHRIS.xml:S3:3772:3	O
a	SAPHRIS.xml:S3:3776:1	O
higher	SAPHRIS.xml:S3:3778:6	O
incidence	SAPHRIS.xml:S3:3785:9	O
of	SAPHRIS.xml:S3:3795:2	O
cerebrovascular	SAPHRIS.xml:S3:3798:15	B-AdverseReaction
adverse	SAPHRIS.xml:S3:3814:7	I-AdverseReaction
reactions	SAPHRIS.xml:S3:3822:9	I-AdverseReaction
(	SAPHRIS.xml:S3:3832:1	O
cerebrovascular	SAPHRIS.xml:S3:3833:15	B-AdverseReaction
accidents	SAPHRIS.xml:S3:3849:9	I-AdverseReaction
and	SAPHRIS.xml:S3:3859:3	O
transient	SAPHRIS.xml:S3:3863:9	B-AdverseReaction
ischemic	SAPHRIS.xml:S3:3873:8	I-AdverseReaction
attacks	SAPHRIS.xml:S3:3882:7	I-AdverseReaction
)	SAPHRIS.xml:S3:3889:1	O
including	SAPHRIS.xml:S3:3891:9	O
fatalities	SAPHRIS.xml:S3:3901:10	B-AdverseReaction
compared	SAPHRIS.xml:S3:3912:8	O
to	SAPHRIS.xml:S3:3921:2	O
placebo	SAPHRIS.xml:S3:3924:7	O
-	SAPHRIS.xml:S3:3931:1	O
treated	SAPHRIS.xml:S3:3932:7	O
subjects	SAPHRIS.xml:S3:3940:8	O
.	SAPHRIS.xml:S3:3948:1	O

SAPHRIS	SAPHRIS.xml:S3:3950:7	O
is	SAPHRIS.xml:S3:3958:2	O
not	SAPHRIS.xml:S3:3961:3	O
approved	SAPHRIS.xml:S3:3965:8	O
for	SAPHRIS.xml:S3:3974:3	O
the	SAPHRIS.xml:S3:3978:3	O
treatment	SAPHRIS.xml:S3:3982:9	O
of	SAPHRIS.xml:S3:3992:2	O
patients	SAPHRIS.xml:S3:3995:8	O
with	SAPHRIS.xml:S3:4004:4	O
dementia	SAPHRIS.xml:S3:4009:8	O
-	SAPHRIS.xml:S3:4017:1	O
related	SAPHRIS.xml:S3:4018:7	O
psychosis	SAPHRIS.xml:S3:4026:9	O
[	SAPHRIS.xml:S3:4037:1	O
see	SAPHRIS.xml:S3:4038:3	O
alsoBoxed	SAPHRIS.xml:S3:4042:9	O
Warningand	SAPHRIS.xml:S3:4052:10	O
Warnings	SAPHRIS.xml:S3:4063:8	O
and	SAPHRIS.xml:S3:4072:3	O
Precautions	SAPHRIS.xml:S3:4076:11	O
(	SAPHRIS.xml:S3:4088:1	O
5.1	SAPHRIS.xml:S3:4089:3	O
)]	SAPHRIS.xml:S3:4092:2	O
.	SAPHRIS.xml:S3:4096:1	O

5.3	SAPHRIS.xml:S3:4108:3	O
Neuroleptic	SAPHRIS.xml:S3:4112:11	O
Malignant	SAPHRIS.xml:S3:4124:9	O
Syndrome	SAPHRIS.xml:S3:4134:8	O

A	SAPHRIS.xml:S3:4150:1	O
potentially	SAPHRIS.xml:S3:4152:11	B-Factor
fatal	SAPHRIS.xml:S3:4164:5	B-AdverseReaction
symptom	SAPHRIS.xml:S3:4170:7	O
complex	SAPHRIS.xml:S3:4178:7	O
sometimes	SAPHRIS.xml:S3:4186:9	O
referred	SAPHRIS.xml:S3:4196:8	O
to	SAPHRIS.xml:S3:4205:2	O
as	SAPHRIS.xml:S3:4208:2	O
Neuroleptic	SAPHRIS.xml:S3:4211:11	B-AdverseReaction
Malignant	SAPHRIS.xml:S3:4223:9	I-AdverseReaction
Syndrome	SAPHRIS.xml:S3:4233:8	I-AdverseReaction
(	SAPHRIS.xml:S3:4242:1	O
NMS	SAPHRIS.xml:S3:4243:3	B-AdverseReaction
)	SAPHRIS.xml:S3:4246:1	O
has	SAPHRIS.xml:S3:4248:3	O
been	SAPHRIS.xml:S3:4252:4	O
reported	SAPHRIS.xml:S3:4257:8	O
in	SAPHRIS.xml:S3:4266:2	O
association	SAPHRIS.xml:S3:4269:11	O
with	SAPHRIS.xml:S3:4281:4	O
administration	SAPHRIS.xml:S3:4286:14	O
of	SAPHRIS.xml:S3:4301:2	O
antipsychotic	SAPHRIS.xml:S3:4304:13	O
drugs	SAPHRIS.xml:S3:4318:5	O
,	SAPHRIS.xml:S3:4323:1	O
including	SAPHRIS.xml:S3:4325:9	O
SAPHRIS	SAPHRIS.xml:S3:4335:7	O
.	SAPHRIS.xml:S3:4342:1	O

Clinical	SAPHRIS.xml:S3:4344:8	O
manifestations	SAPHRIS.xml:S3:4353:14	O
of	SAPHRIS.xml:S3:4368:2	O
NMS	SAPHRIS.xml:S3:4371:3	B-AdverseReaction
are	SAPHRIS.xml:S3:4375:3	O
hyperpyrexia	SAPHRIS.xml:S3:4379:12	B-AdverseReaction
,	SAPHRIS.xml:S3:4391:1	O
muscle	SAPHRIS.xml:S3:4393:6	B-AdverseReaction
rigidity	SAPHRIS.xml:S3:4400:8	I-AdverseReaction
,	SAPHRIS.xml:S3:4408:1	O
altered	SAPHRIS.xml:S3:4410:7	B-AdverseReaction
mental	SAPHRIS.xml:S3:4418:6	I-AdverseReaction
status	SAPHRIS.xml:S3:4425:6	I-AdverseReaction
,	SAPHRIS.xml:S3:4431:1	O
and	SAPHRIS.xml:S3:4433:3	O
evidence	SAPHRIS.xml:S3:4437:8	O
of	SAPHRIS.xml:S3:4446:2	O
autonomic	SAPHRIS.xml:S3:4449:9	B-AdverseReaction
instability	SAPHRIS.xml:S3:4459:11	I-AdverseReaction
(	SAPHRIS.xml:S3:4471:1	O
irregular	SAPHRIS.xml:S3:4472:9	B-AdverseReaction
pulse	SAPHRIS.xml:S3:4482:5	I-AdverseReaction
or	SAPHRIS.xml:S3:4488:2	O
blood	SAPHRIS.xml:S3:4491:5	I-AdverseReaction
pressure	SAPHRIS.xml:S3:4497:8	I-AdverseReaction
,	SAPHRIS.xml:S3:4505:1	O
tachycardia	SAPHRIS.xml:S3:4507:11	B-AdverseReaction
,	SAPHRIS.xml:S3:4518:1	O
diaphoresis	SAPHRIS.xml:S3:4520:11	B-AdverseReaction
,	SAPHRIS.xml:S3:4531:1	O
and	SAPHRIS.xml:S3:4533:3	O
cardiac	SAPHRIS.xml:S3:4537:7	B-AdverseReaction
dysrhythmia	SAPHRIS.xml:S3:4545:11	I-AdverseReaction
)	SAPHRIS.xml:S3:4556:1	O
.	SAPHRIS.xml:S3:4557:1	O

Additional	SAPHRIS.xml:S3:4559:10	O
signs	SAPHRIS.xml:S3:4570:5	O
may	SAPHRIS.xml:S3:4576:3	B-Factor
include	SAPHRIS.xml:S3:4580:7	O
elevated	SAPHRIS.xml:S3:4588:8	B-AdverseReaction
creatine	SAPHRIS.xml:S3:4597:8	I-AdverseReaction
phosphokinase	SAPHRIS.xml:S3:4606:13	I-AdverseReaction
,	SAPHRIS.xml:S3:4619:1	O
myoglobinuria	SAPHRIS.xml:S3:4621:13	B-AdverseReaction
(	SAPHRIS.xml:S3:4635:1	O
rhabdomyolysis	SAPHRIS.xml:S3:4636:14	B-AdverseReaction
)	SAPHRIS.xml:S3:4650:1	O
,	SAPHRIS.xml:S3:4651:1	O
and	SAPHRIS.xml:S3:4653:3	O
acute	SAPHRIS.xml:S3:4657:5	B-AdverseReaction
renal	SAPHRIS.xml:S3:4663:5	I-AdverseReaction
failure	SAPHRIS.xml:S3:4669:7	I-AdverseReaction
.	SAPHRIS.xml:S3:4676:1	O

The	SAPHRIS.xml:S3:4686:3	O
diagnostic	SAPHRIS.xml:S3:4690:10	O
evaluation	SAPHRIS.xml:S3:4701:10	O
of	SAPHRIS.xml:S3:4712:2	O
patients	SAPHRIS.xml:S3:4715:8	O
with	SAPHRIS.xml:S3:4724:4	O
this	SAPHRIS.xml:S3:4729:4	O
syndrome	SAPHRIS.xml:S3:4734:8	O
is	SAPHRIS.xml:S3:4743:2	O
complicated	SAPHRIS.xml:S3:4746:11	O
.	SAPHRIS.xml:S3:4757:1	O

It	SAPHRIS.xml:S3:4759:2	O
is	SAPHRIS.xml:S3:4762:2	O
important	SAPHRIS.xml:S3:4765:9	O
to	SAPHRIS.xml:S3:4775:2	O
exclude	SAPHRIS.xml:S3:4778:7	O
cases	SAPHRIS.xml:S3:4786:5	O
where	SAPHRIS.xml:S3:4792:5	O
the	SAPHRIS.xml:S3:4798:3	O
clinical	SAPHRIS.xml:S3:4802:8	O
presentation	SAPHRIS.xml:S3:4811:12	O
includes	SAPHRIS.xml:S3:4824:8	O
both	SAPHRIS.xml:S3:4833:4	O
serious	SAPHRIS.xml:S3:4838:7	O
medical	SAPHRIS.xml:S3:4846:7	O
illness	SAPHRIS.xml:S3:4854:7	O
(	SAPHRIS.xml:S3:4862:1	O
e	SAPHRIS.xml:S3:4863:1	O
.	SAPHRIS.xml:S3:4864:1	O
g	SAPHRIS.xml:S3:4865:1	O
.	SAPHRIS.xml:S3:4866:1	O

pneumonia	SAPHRIS.xml:S3:4868:9	O
,	SAPHRIS.xml:S3:4877:1	O
systemic	SAPHRIS.xml:S3:4879:8	O
infection	SAPHRIS.xml:S3:4888:9	O
)	SAPHRIS.xml:S3:4897:1	O
and	SAPHRIS.xml:S3:4899:3	O
untreated	SAPHRIS.xml:S3:4903:9	O
or	SAPHRIS.xml:S3:4913:2	O
inadequately	SAPHRIS.xml:S3:4916:12	O
treated	SAPHRIS.xml:S3:4929:7	O
extrapyramidal	SAPHRIS.xml:S3:4937:14	O
signs	SAPHRIS.xml:S3:4952:5	O
and	SAPHRIS.xml:S3:4958:3	O
symptoms	SAPHRIS.xml:S3:4962:8	O
(	SAPHRIS.xml:S3:4971:1	O
EPS	SAPHRIS.xml:S3:4972:3	O
)	SAPHRIS.xml:S3:4975:1	O
.	SAPHRIS.xml:S3:4976:1	O

Other	SAPHRIS.xml:S3:4978:5	O
important	SAPHRIS.xml:S3:4984:9	O
considerations	SAPHRIS.xml:S3:4994:14	O
in	SAPHRIS.xml:S3:5009:2	O
the	SAPHRIS.xml:S3:5012:3	O
differential	SAPHRIS.xml:S3:5016:12	O
diagnosis	SAPHRIS.xml:S3:5029:9	O
include	SAPHRIS.xml:S3:5039:7	O
central	SAPHRIS.xml:S3:5047:7	O
anticholinergic	SAPHRIS.xml:S3:5055:15	O
toxicity	SAPHRIS.xml:S3:5071:8	O
,	SAPHRIS.xml:S3:5079:1	O
heat	SAPHRIS.xml:S3:5081:4	O
stroke	SAPHRIS.xml:S3:5086:6	O
,	SAPHRIS.xml:S3:5092:1	O
drug	SAPHRIS.xml:S3:5094:4	O
fever	SAPHRIS.xml:S3:5099:5	O
,	SAPHRIS.xml:S3:5104:1	O
and	SAPHRIS.xml:S3:5106:3	O
primary	SAPHRIS.xml:S3:5110:7	O
central	SAPHRIS.xml:S3:5118:7	O
nervous	SAPHRIS.xml:S3:5126:7	O
system	SAPHRIS.xml:S3:5134:6	O
pathology	SAPHRIS.xml:S3:5141:9	O
.	SAPHRIS.xml:S3:5150:1	O

The	SAPHRIS.xml:S3:5160:3	O
management	SAPHRIS.xml:S3:5164:10	O
of	SAPHRIS.xml:S3:5175:2	O
NMS	SAPHRIS.xml:S3:5178:3	O
should	SAPHRIS.xml:S3:5182:6	O
include	SAPHRIS.xml:S3:5189:7	O
:	SAPHRIS.xml:S3:5196:1	O
1	SAPHRIS.xml:S3:5198:1	O
)	SAPHRIS.xml:S3:5199:1	O
immediate	SAPHRIS.xml:S3:5201:9	O
discontinuation	SAPHRIS.xml:S3:5211:15	O
of	SAPHRIS.xml:S3:5227:2	O
antipsychotic	SAPHRIS.xml:S3:5230:13	O
drugs	SAPHRIS.xml:S3:5244:5	O
and	SAPHRIS.xml:S3:5250:3	O
other	SAPHRIS.xml:S3:5254:5	O
drugs	SAPHRIS.xml:S3:5260:5	O
not	SAPHRIS.xml:S3:5266:3	O
essential	SAPHRIS.xml:S3:5270:9	O
to	SAPHRIS.xml:S3:5280:2	O
concurrent	SAPHRIS.xml:S3:5283:10	O
therapy	SAPHRIS.xml:S3:5294:7	O
;	SAPHRIS.xml:S3:5301:1	O
2	SAPHRIS.xml:S3:5303:1	O
)	SAPHRIS.xml:S3:5304:1	O
intensive	SAPHRIS.xml:S3:5306:9	O
symptomatic	SAPHRIS.xml:S3:5316:11	O
treatment	SAPHRIS.xml:S3:5328:9	O
and	SAPHRIS.xml:S3:5338:3	O
medical	SAPHRIS.xml:S3:5342:7	O
monitoring	SAPHRIS.xml:S3:5350:10	O
;	SAPHRIS.xml:S3:5360:1	O
and	SAPHRIS.xml:S3:5362:3	O
3	SAPHRIS.xml:S3:5366:1	O
)	SAPHRIS.xml:S3:5367:1	O
treatment	SAPHRIS.xml:S3:5369:9	O
of	SAPHRIS.xml:S3:5379:2	O
any	SAPHRIS.xml:S3:5382:3	O
concomitant	SAPHRIS.xml:S3:5386:11	O
serious	SAPHRIS.xml:S3:5398:7	O
medical	SAPHRIS.xml:S3:5406:7	O
problems	SAPHRIS.xml:S3:5414:8	O
for	SAPHRIS.xml:S3:5423:3	O
which	SAPHRIS.xml:S3:5427:5	O
specific	SAPHRIS.xml:S3:5433:8	O
treatments	SAPHRIS.xml:S3:5442:10	O
are	SAPHRIS.xml:S3:5453:3	O
available	SAPHRIS.xml:S3:5457:9	O
.	SAPHRIS.xml:S3:5466:1	O

There	SAPHRIS.xml:S3:5468:5	O
is	SAPHRIS.xml:S3:5474:2	O
no	SAPHRIS.xml:S3:5477:2	O
general	SAPHRIS.xml:S3:5480:7	O
agreement	SAPHRIS.xml:S3:5488:9	O
about	SAPHRIS.xml:S3:5498:5	O
specific	SAPHRIS.xml:S3:5504:8	O
pharmacological	SAPHRIS.xml:S3:5513:15	O
treatment	SAPHRIS.xml:S3:5529:9	O
regimens	SAPHRIS.xml:S3:5539:8	O
for	SAPHRIS.xml:S3:5548:3	O
NMS	SAPHRIS.xml:S3:5552:3	O
.	SAPHRIS.xml:S3:5555:1	O

If	SAPHRIS.xml:S3:5565:2	O
a	SAPHRIS.xml:S3:5568:1	O
patient	SAPHRIS.xml:S3:5570:7	O
requires	SAPHRIS.xml:S3:5578:8	O
antipsychotic	SAPHRIS.xml:S3:5587:13	O
drug	SAPHRIS.xml:S3:5601:4	O
treatment	SAPHRIS.xml:S3:5606:9	O
after	SAPHRIS.xml:S3:5616:5	O
recovery	SAPHRIS.xml:S3:5622:8	O
from	SAPHRIS.xml:S3:5631:4	O
NMS	SAPHRIS.xml:S3:5636:3	O
,	SAPHRIS.xml:S3:5639:1	O
the	SAPHRIS.xml:S3:5641:3	O
potential	SAPHRIS.xml:S3:5645:9	O
reintroduction	SAPHRIS.xml:S3:5655:14	O
of	SAPHRIS.xml:S3:5670:2	O
drug	SAPHRIS.xml:S3:5673:4	O
therapy	SAPHRIS.xml:S3:5678:7	O
should	SAPHRIS.xml:S3:5686:6	O
be	SAPHRIS.xml:S3:5693:2	O
carefully	SAPHRIS.xml:S3:5696:9	O
considered	SAPHRIS.xml:S3:5706:10	O
.	SAPHRIS.xml:S3:5716:1	O

The	SAPHRIS.xml:S3:5718:3	O
patient	SAPHRIS.xml:S3:5722:7	O
should	SAPHRIS.xml:S3:5730:6	O
be	SAPHRIS.xml:S3:5737:2	O
carefully	SAPHRIS.xml:S3:5740:9	O
monitored	SAPHRIS.xml:S3:5750:9	O
,	SAPHRIS.xml:S3:5759:1	O
since	SAPHRIS.xml:S3:5761:5	O
recurrences	SAPHRIS.xml:S3:5767:11	O
of	SAPHRIS.xml:S3:5779:2	O
NMS	SAPHRIS.xml:S3:5782:3	O
have	SAPHRIS.xml:S3:5786:4	O
been	SAPHRIS.xml:S3:5791:4	O
reported	SAPHRIS.xml:S3:5796:8	O
.	SAPHRIS.xml:S3:5804:1	O

5.4	SAPHRIS.xml:S3:5816:3	O
Tardive	SAPHRIS.xml:S3:5820:7	O
Dyskinesia	SAPHRIS.xml:S3:5828:10	O

A	SAPHRIS.xml:S3:5846:1	O
syndrome	SAPHRIS.xml:S3:5848:8	O
of	SAPHRIS.xml:S3:5857:2	O
potentially	SAPHRIS.xml:S3:5860:11	B-Severity
irreversible	SAPHRIS.xml:S3:5872:12	I-Severity
,	SAPHRIS.xml:S3:5884:1	O
involuntary	SAPHRIS.xml:S3:5886:11	B-AdverseReaction
,	SAPHRIS.xml:S3:5897:1	I-AdverseReaction
dyskinetic	SAPHRIS.xml:S3:5899:10	I-AdverseReaction
movements	SAPHRIS.xml:S3:5910:9	I-AdverseReaction
can	SAPHRIS.xml:S3:5920:3	O
develop	SAPHRIS.xml:S3:5924:7	O
in	SAPHRIS.xml:S3:5932:2	O
patients	SAPHRIS.xml:S3:5935:8	O
treated	SAPHRIS.xml:S3:5944:7	O
with	SAPHRIS.xml:S3:5952:4	O
antipsychotic	SAPHRIS.xml:S3:5957:13	B-DrugClass
drugs	SAPHRIS.xml:S3:5971:5	I-DrugClass
.	SAPHRIS.xml:S3:5976:1	O

Although	SAPHRIS.xml:S3:5978:8	O
the	SAPHRIS.xml:S3:5987:3	O
prevalence	SAPHRIS.xml:S3:5991:10	O
of	SAPHRIS.xml:S3:6002:2	O
the	SAPHRIS.xml:S3:6005:3	O
syndrome	SAPHRIS.xml:S3:6009:8	O
appears	SAPHRIS.xml:S3:6018:7	O
to	SAPHRIS.xml:S3:6026:2	O
be	SAPHRIS.xml:S3:6029:2	O
highest	SAPHRIS.xml:S3:6032:7	O
among	SAPHRIS.xml:S3:6040:5	O
the	SAPHRIS.xml:S3:6046:3	O
elderly	SAPHRIS.xml:S3:6050:7	O
,	SAPHRIS.xml:S3:6057:1	O
especially	SAPHRIS.xml:S3:6059:10	O
elderly	SAPHRIS.xml:S3:6070:7	O
women	SAPHRIS.xml:S3:6078:5	O
,	SAPHRIS.xml:S3:6083:1	O
it	SAPHRIS.xml:S3:6085:2	O
is	SAPHRIS.xml:S3:6088:2	O
impossible	SAPHRIS.xml:S3:6091:10	O
to	SAPHRIS.xml:S3:6102:2	O
rely	SAPHRIS.xml:S3:6105:4	O
upon	SAPHRIS.xml:S3:6110:4	O
prevalence	SAPHRIS.xml:S3:6115:10	O
estimates	SAPHRIS.xml:S3:6126:9	O
to	SAPHRIS.xml:S3:6136:2	O
predict	SAPHRIS.xml:S3:6139:7	O
,	SAPHRIS.xml:S3:6146:1	O
at	SAPHRIS.xml:S3:6148:2	O
the	SAPHRIS.xml:S3:6151:3	O
inception	SAPHRIS.xml:S3:6155:9	O
of	SAPHRIS.xml:S3:6165:2	O
antipsychotic	SAPHRIS.xml:S3:6168:13	O
treatment	SAPHRIS.xml:S3:6182:9	O
,	SAPHRIS.xml:S3:6191:1	O
which	SAPHRIS.xml:S3:6193:5	O
patients	SAPHRIS.xml:S3:6199:8	O
are	SAPHRIS.xml:S3:6208:3	O
likely	SAPHRIS.xml:S3:6212:6	O
to	SAPHRIS.xml:S3:6219:2	O
develop	SAPHRIS.xml:S3:6222:7	O
the	SAPHRIS.xml:S3:6230:3	O
syndrome	SAPHRIS.xml:S3:6234:8	O
.	SAPHRIS.xml:S3:6242:1	O

Whether	SAPHRIS.xml:S3:6244:7	O
antipsychotic	SAPHRIS.xml:S3:6252:13	B-DrugClass
drug	SAPHRIS.xml:S3:6266:4	I-DrugClass
products	SAPHRIS.xml:S3:6271:8	O
differ	SAPHRIS.xml:S3:6280:6	O
in	SAPHRIS.xml:S3:6287:2	O
their	SAPHRIS.xml:S3:6290:5	O
potential	SAPHRIS.xml:S3:6296:9	O
to	SAPHRIS.xml:S3:6306:2	O
cause	SAPHRIS.xml:S3:6309:5	O
Tardive	SAPHRIS.xml:S3:6315:7	B-AdverseReaction
Dyskinesia	SAPHRIS.xml:S3:6323:10	I-AdverseReaction
(	SAPHRIS.xml:S3:6334:1	O
TD	SAPHRIS.xml:S3:6335:2	B-AdverseReaction
)	SAPHRIS.xml:S3:6337:1	O
is	SAPHRIS.xml:S3:6339:2	O
unknown	SAPHRIS.xml:S3:6342:7	O
.	SAPHRIS.xml:S3:6349:1	O

The	SAPHRIS.xml:S3:6359:3	O
risk	SAPHRIS.xml:S3:6363:4	O
of	SAPHRIS.xml:S3:6368:2	O
developing	SAPHRIS.xml:S3:6371:10	O
TD	SAPHRIS.xml:S3:6382:2	B-AdverseReaction
and	SAPHRIS.xml:S3:6385:3	O
the	SAPHRIS.xml:S3:6389:3	O
likelihood	SAPHRIS.xml:S3:6393:10	O
that	SAPHRIS.xml:S3:6404:4	O
it	SAPHRIS.xml:S3:6409:2	O
will	SAPHRIS.xml:S3:6412:4	O
become	SAPHRIS.xml:S3:6417:6	O
irreversible	SAPHRIS.xml:S3:6424:12	B-Severity
are	SAPHRIS.xml:S3:6437:3	O
believed	SAPHRIS.xml:S3:6441:8	O
to	SAPHRIS.xml:S3:6450:2	O
increase	SAPHRIS.xml:S3:6453:8	O
as	SAPHRIS.xml:S3:6462:2	O
the	SAPHRIS.xml:S3:6465:3	O
duration	SAPHRIS.xml:S3:6469:8	O
of	SAPHRIS.xml:S3:6478:2	O
treatment	SAPHRIS.xml:S3:6481:9	O
and	SAPHRIS.xml:S3:6491:3	O
the	SAPHRIS.xml:S3:6495:3	O
total	SAPHRIS.xml:S3:6499:5	O
cumulative	SAPHRIS.xml:S3:6505:10	O
dose	SAPHRIS.xml:S3:6516:4	O
of	SAPHRIS.xml:S3:6521:2	O
antipsychotic	SAPHRIS.xml:S3:6524:13	B-DrugClass
drugs	SAPHRIS.xml:S3:6538:5	I-DrugClass
administered	SAPHRIS.xml:S3:6544:12	O
to	SAPHRIS.xml:S3:6557:2	O
the	SAPHRIS.xml:S3:6560:3	O
patient	SAPHRIS.xml:S3:6564:7	O
increase	SAPHRIS.xml:S3:6572:8	O
.	SAPHRIS.xml:S3:6580:1	O

However	SAPHRIS.xml:S3:6582:7	O
,	SAPHRIS.xml:S3:6589:1	O
the	SAPHRIS.xml:S3:6591:3	O
syndrome	SAPHRIS.xml:S3:6595:8	O
can	SAPHRIS.xml:S3:6604:3	O
develop	SAPHRIS.xml:S3:6608:7	O
,	SAPHRIS.xml:S3:6615:1	O
although	SAPHRIS.xml:S3:6617:8	O
much	SAPHRIS.xml:S3:6626:4	O
less	SAPHRIS.xml:S3:6631:4	O
commonly	SAPHRIS.xml:S3:6636:8	O
,	SAPHRIS.xml:S3:6644:1	O
after	SAPHRIS.xml:S3:6646:5	O
relatively	SAPHRIS.xml:S3:6652:10	O
brief	SAPHRIS.xml:S3:6663:5	O
treatment	SAPHRIS.xml:S3:6669:9	O
periods	SAPHRIS.xml:S3:6679:7	O
at	SAPHRIS.xml:S3:6687:2	O
low	SAPHRIS.xml:S3:6690:3	O
doses	SAPHRIS.xml:S3:6694:5	O
.	SAPHRIS.xml:S3:6699:1	O

There	SAPHRIS.xml:S3:6709:5	O
is	SAPHRIS.xml:S3:6715:2	O
no	SAPHRIS.xml:S3:6718:2	O
known	SAPHRIS.xml:S3:6721:5	O
treatment	SAPHRIS.xml:S3:6727:9	O
for	SAPHRIS.xml:S3:6737:3	O
established	SAPHRIS.xml:S3:6741:11	O
cases	SAPHRIS.xml:S3:6753:5	O
of	SAPHRIS.xml:S3:6759:2	O
TD	SAPHRIS.xml:S3:6762:2	O
,	SAPHRIS.xml:S3:6764:1	O
although	SAPHRIS.xml:S3:6766:8	O
the	SAPHRIS.xml:S3:6775:3	O
syndrome	SAPHRIS.xml:S3:6779:8	O
may	SAPHRIS.xml:S3:6788:3	O
remit	SAPHRIS.xml:S3:6792:5	O
,	SAPHRIS.xml:S3:6797:1	O
partially	SAPHRIS.xml:S3:6799:9	O
or	SAPHRIS.xml:S3:6809:2	O
completely	SAPHRIS.xml:S3:6812:10	O
,	SAPHRIS.xml:S3:6822:1	O
if	SAPHRIS.xml:S3:6824:2	O
antipsychotic	SAPHRIS.xml:S3:6827:13	O
treatment	SAPHRIS.xml:S3:6841:9	O
is	SAPHRIS.xml:S3:6851:2	O
withdrawn	SAPHRIS.xml:S3:6854:9	O
.	SAPHRIS.xml:S3:6863:1	O

Antipsychotic	SAPHRIS.xml:S3:6865:13	O
treatment	SAPHRIS.xml:S3:6879:9	O
,	SAPHRIS.xml:S3:6888:1	O
itself	SAPHRIS.xml:S3:6890:6	O
,	SAPHRIS.xml:S3:6896:1	O
however	SAPHRIS.xml:S3:6898:7	O
,	SAPHRIS.xml:S3:6905:1	O
may	SAPHRIS.xml:S3:6907:3	O
suppress	SAPHRIS.xml:S3:6911:8	O
(	SAPHRIS.xml:S3:6920:1	O
or	SAPHRIS.xml:S3:6921:2	O
partially	SAPHRIS.xml:S3:6924:9	O
suppress	SAPHRIS.xml:S3:6934:8	O
)	SAPHRIS.xml:S3:6942:1	O
the	SAPHRIS.xml:S3:6944:3	O
signs	SAPHRIS.xml:S3:6948:5	O
and	SAPHRIS.xml:S3:6954:3	O
symptoms	SAPHRIS.xml:S3:6958:8	O
of	SAPHRIS.xml:S3:6967:2	O
the	SAPHRIS.xml:S3:6970:3	O
syndrome	SAPHRIS.xml:S3:6974:8	O
and	SAPHRIS.xml:S3:6983:3	O
thereby	SAPHRIS.xml:S3:6987:7	O
may	SAPHRIS.xml:S3:6995:3	O
possibly	SAPHRIS.xml:S3:6999:8	O
mask	SAPHRIS.xml:S3:7008:4	O
the	SAPHRIS.xml:S3:7013:3	O
underlying	SAPHRIS.xml:S3:7017:10	O
process	SAPHRIS.xml:S3:7028:7	O
.	SAPHRIS.xml:S3:7035:1	O

The	SAPHRIS.xml:S3:7037:3	O
effect	SAPHRIS.xml:S3:7041:6	O
that	SAPHRIS.xml:S3:7048:4	O
symptomatic	SAPHRIS.xml:S3:7053:11	O
suppression	SAPHRIS.xml:S3:7065:11	O
has	SAPHRIS.xml:S3:7077:3	O
upon	SAPHRIS.xml:S3:7081:4	O
the	SAPHRIS.xml:S3:7086:3	O
long	SAPHRIS.xml:S3:7090:4	O
-	SAPHRIS.xml:S3:7094:1	O
term	SAPHRIS.xml:S3:7095:4	O
course	SAPHRIS.xml:S3:7100:6	O
of	SAPHRIS.xml:S3:7107:2	O
the	SAPHRIS.xml:S3:7110:3	O
syndrome	SAPHRIS.xml:S3:7114:8	O
is	SAPHRIS.xml:S3:7123:2	O
unknown	SAPHRIS.xml:S3:7126:7	O
.	SAPHRIS.xml:S3:7133:1	O

Given	SAPHRIS.xml:S3:7143:5	O
these	SAPHRIS.xml:S3:7149:5	O
considerations	SAPHRIS.xml:S3:7155:14	O
,	SAPHRIS.xml:S3:7169:1	O
SAPHRIS	SAPHRIS.xml:S3:7171:7	O
should	SAPHRIS.xml:S3:7179:6	O
be	SAPHRIS.xml:S3:7186:2	O
prescribed	SAPHRIS.xml:S3:7189:10	O
in	SAPHRIS.xml:S3:7200:2	O
a	SAPHRIS.xml:S3:7203:1	O
manner	SAPHRIS.xml:S3:7205:6	O
that	SAPHRIS.xml:S3:7212:4	O
is	SAPHRIS.xml:S3:7217:2	O
most	SAPHRIS.xml:S3:7220:4	O
likely	SAPHRIS.xml:S3:7225:6	O
to	SAPHRIS.xml:S3:7232:2	O
minimize	SAPHRIS.xml:S3:7235:8	O
the	SAPHRIS.xml:S3:7244:3	O
occurrence	SAPHRIS.xml:S3:7248:10	O
of	SAPHRIS.xml:S3:7259:2	O
TD	SAPHRIS.xml:S3:7262:2	O
.	SAPHRIS.xml:S3:7264:1	O

Chronic	SAPHRIS.xml:S3:7266:7	O
antipsychotic	SAPHRIS.xml:S3:7274:13	O
treatment	SAPHRIS.xml:S3:7288:9	O
should	SAPHRIS.xml:S3:7298:6	O
generally	SAPHRIS.xml:S3:7305:9	O
be	SAPHRIS.xml:S3:7315:2	O
reserved	SAPHRIS.xml:S3:7318:8	O
for	SAPHRIS.xml:S3:7327:3	O
patients	SAPHRIS.xml:S3:7331:8	O
who	SAPHRIS.xml:S3:7340:3	O
suffer	SAPHRIS.xml:S3:7344:6	O
from	SAPHRIS.xml:S3:7351:4	O
a	SAPHRIS.xml:S3:7356:1	O
chronic	SAPHRIS.xml:S3:7358:7	O
illness	SAPHRIS.xml:S3:7366:7	O
that	SAPHRIS.xml:S3:7374:4	O
(	SAPHRIS.xml:S3:7379:1	O
1	SAPHRIS.xml:S3:7380:1	O
)	SAPHRIS.xml:S3:7381:1	O
is	SAPHRIS.xml:S3:7383:2	O
known	SAPHRIS.xml:S3:7386:5	O
to	SAPHRIS.xml:S3:7392:2	O
respond	SAPHRIS.xml:S3:7395:7	O
to	SAPHRIS.xml:S3:7403:2	O
antipsychotic	SAPHRIS.xml:S3:7406:13	O
drugs	SAPHRIS.xml:S3:7420:5	O
,	SAPHRIS.xml:S3:7425:1	O
and	SAPHRIS.xml:S3:7427:3	O
(	SAPHRIS.xml:S3:7431:1	O
2	SAPHRIS.xml:S3:7432:1	O
)	SAPHRIS.xml:S3:7433:1	O
for	SAPHRIS.xml:S3:7435:3	O
whom	SAPHRIS.xml:S3:7439:4	O
alternative	SAPHRIS.xml:S3:7444:11	O
,	SAPHRIS.xml:S3:7455:1	O
equally	SAPHRIS.xml:S3:7457:7	O
effective	SAPHRIS.xml:S3:7465:9	O
,	SAPHRIS.xml:S3:7474:1	O
but	SAPHRIS.xml:S3:7476:3	O
potentially	SAPHRIS.xml:S3:7480:11	O
less	SAPHRIS.xml:S3:7492:4	O
harmful	SAPHRIS.xml:S3:7497:7	O
treatments	SAPHRIS.xml:S3:7505:10	O
are	SAPHRIS.xml:S3:7516:3	O
not	SAPHRIS.xml:S3:7520:3	O
available	SAPHRIS.xml:S3:7524:9	O
or	SAPHRIS.xml:S3:7534:2	O
appropriate	SAPHRIS.xml:S3:7537:11	O
.	SAPHRIS.xml:S3:7548:1	O

In	SAPHRIS.xml:S3:7550:2	O
patients	SAPHRIS.xml:S3:7553:8	O
who	SAPHRIS.xml:S3:7562:3	O
do	SAPHRIS.xml:S3:7566:2	O
require	SAPHRIS.xml:S3:7569:7	O
chronic	SAPHRIS.xml:S3:7577:7	O
treatment	SAPHRIS.xml:S3:7585:9	O
,	SAPHRIS.xml:S3:7594:1	O
the	SAPHRIS.xml:S3:7596:3	O
smallest	SAPHRIS.xml:S3:7600:8	O
dose	SAPHRIS.xml:S3:7609:4	O
and	SAPHRIS.xml:S3:7614:3	O
the	SAPHRIS.xml:S3:7618:3	O
shortest	SAPHRIS.xml:S3:7622:8	O
duration	SAPHRIS.xml:S3:7631:8	O
of	SAPHRIS.xml:S3:7640:2	O
treatment	SAPHRIS.xml:S3:7643:9	O
producing	SAPHRIS.xml:S3:7653:9	O
a	SAPHRIS.xml:S3:7663:1	O
satisfactory	SAPHRIS.xml:S3:7665:12	O
clinical	SAPHRIS.xml:S3:7678:8	O
response	SAPHRIS.xml:S3:7687:8	O
should	SAPHRIS.xml:S3:7696:6	O
be	SAPHRIS.xml:S3:7703:2	O
sought	SAPHRIS.xml:S3:7706:6	O
.	SAPHRIS.xml:S3:7712:1	O

The	SAPHRIS.xml:S3:7714:3	O
need	SAPHRIS.xml:S3:7718:4	O
for	SAPHRIS.xml:S3:7723:3	O
continued	SAPHRIS.xml:S3:7727:9	O
treatment	SAPHRIS.xml:S3:7737:9	O
should	SAPHRIS.xml:S3:7747:6	O
be	SAPHRIS.xml:S3:7754:2	O
reassessed	SAPHRIS.xml:S3:7757:10	O
periodically	SAPHRIS.xml:S3:7768:12	O
.	SAPHRIS.xml:S3:7780:1	O

If	SAPHRIS.xml:S3:7790:2	O
signs	SAPHRIS.xml:S3:7793:5	O
and	SAPHRIS.xml:S3:7799:3	O
symptoms	SAPHRIS.xml:S3:7803:8	O
of	SAPHRIS.xml:S3:7812:2	O
TD	SAPHRIS.xml:S3:7815:2	O
appear	SAPHRIS.xml:S3:7818:6	O
in	SAPHRIS.xml:S3:7825:2	O
a	SAPHRIS.xml:S3:7828:1	O
patient	SAPHRIS.xml:S3:7830:7	O
on	SAPHRIS.xml:S3:7838:2	O
SAPHRIS	SAPHRIS.xml:S3:7841:7	O
,	SAPHRIS.xml:S3:7848:1	O
drug	SAPHRIS.xml:S3:7850:4	O
discontinuation	SAPHRIS.xml:S3:7855:15	O
should	SAPHRIS.xml:S3:7871:6	O
be	SAPHRIS.xml:S3:7878:2	O
considered	SAPHRIS.xml:S3:7881:10	O
.	SAPHRIS.xml:S3:7891:1	O

However	SAPHRIS.xml:S3:7893:7	O
,	SAPHRIS.xml:S3:7900:1	O
some	SAPHRIS.xml:S3:7902:4	O
patients	SAPHRIS.xml:S3:7907:8	O
may	SAPHRIS.xml:S3:7916:3	O
require	SAPHRIS.xml:S3:7920:7	O
treatment	SAPHRIS.xml:S3:7928:9	O
with	SAPHRIS.xml:S3:7938:4	O
SAPHRIS	SAPHRIS.xml:S3:7943:7	O
despite	SAPHRIS.xml:S3:7951:7	O
the	SAPHRIS.xml:S3:7959:3	O
presence	SAPHRIS.xml:S3:7963:8	O
of	SAPHRIS.xml:S3:7972:2	O
the	SAPHRIS.xml:S3:7975:3	O
syndrome	SAPHRIS.xml:S3:7979:8	O
.	SAPHRIS.xml:S3:7987:1	O

5.5	SAPHRIS.xml:S3:7999:3	O
Metabolic	SAPHRIS.xml:S3:8003:9	O
Changes	SAPHRIS.xml:S3:8013:7	O

Atypical	SAPHRIS.xml:S3:8028:8	B-DrugClass
antipsychotic	SAPHRIS.xml:S3:8037:13	I-DrugClass
drugs	SAPHRIS.xml:S3:8051:5	I-DrugClass
have	SAPHRIS.xml:S3:8057:4	O
been	SAPHRIS.xml:S3:8062:4	O
associated	SAPHRIS.xml:S3:8067:10	O
with	SAPHRIS.xml:S3:8078:4	O
metabolic	SAPHRIS.xml:S3:8083:9	B-AdverseReaction
changes	SAPHRIS.xml:S3:8093:7	I-AdverseReaction
that	SAPHRIS.xml:S3:8101:4	O
may	SAPHRIS.xml:S3:8106:3	O
increase	SAPHRIS.xml:S3:8110:8	B-AdverseReaction
cardiovascular	SAPHRIS.xml:S3:8119:14	I-AdverseReaction
cerebrovascular	SAPHRIS.xml:S3:8134:15	I-AdverseReaction
risk	SAPHRIS.xml:S3:8150:4	I-AdverseReaction
.	SAPHRIS.xml:S3:8154:1	O

These	SAPHRIS.xml:S3:8156:5	O
metabolic	SAPHRIS.xml:S3:8162:9	B-AdverseReaction
changes	SAPHRIS.xml:S3:8172:7	I-AdverseReaction
include	SAPHRIS.xml:S3:8180:7	O
hyperglycemia	SAPHRIS.xml:S3:8188:13	B-AdverseReaction
,	SAPHRIS.xml:S3:8201:1	O
dyslipidemia	SAPHRIS.xml:S3:8203:12	B-AdverseReaction
,	SAPHRIS.xml:S3:8215:1	O
and	SAPHRIS.xml:S3:8217:3	O
body	SAPHRIS.xml:S3:8221:4	B-AdverseReaction
weight	SAPHRIS.xml:S3:8226:6	I-AdverseReaction
gain	SAPHRIS.xml:S3:8233:4	I-AdverseReaction
.	SAPHRIS.xml:S3:8237:1	O

While	SAPHRIS.xml:S3:8239:5	O
all	SAPHRIS.xml:S3:8245:3	O
of	SAPHRIS.xml:S3:8249:2	O
the	SAPHRIS.xml:S3:8252:3	O
drugs	SAPHRIS.xml:S3:8256:5	B-DrugClass
in	SAPHRIS.xml:S3:8262:2	I-DrugClass
the	SAPHRIS.xml:S3:8265:3	I-DrugClass
class	SAPHRIS.xml:S3:8269:5	I-DrugClass
have	SAPHRIS.xml:S3:8275:4	O
been	SAPHRIS.xml:S3:8280:4	O
shown	SAPHRIS.xml:S3:8285:5	O
to	SAPHRIS.xml:S3:8291:2	O
produce	SAPHRIS.xml:S3:8294:7	O
some	SAPHRIS.xml:S3:8302:4	O
metabolic	SAPHRIS.xml:S3:8307:9	B-AdverseReaction
changes	SAPHRIS.xml:S3:8317:7	I-AdverseReaction
,	SAPHRIS.xml:S3:8324:1	O
each	SAPHRIS.xml:S3:8326:4	O
drug	SAPHRIS.xml:S3:8331:4	O
has	SAPHRIS.xml:S3:8336:3	O
its	SAPHRIS.xml:S3:8340:3	O
own	SAPHRIS.xml:S3:8344:3	O
specific	SAPHRIS.xml:S3:8348:8	O
risk	SAPHRIS.xml:S3:8357:4	O
profile	SAPHRIS.xml:S3:8362:7	O
.	SAPHRIS.xml:S3:8369:1	O

Hyperglycemia	SAPHRIS.xml:S3:8383:13	O
and	SAPHRIS.xml:S3:8397:3	O
Diabetes	SAPHRIS.xml:S3:8401:8	O
Mellitus	SAPHRIS.xml:S3:8410:8	O

Hyperglycemia	SAPHRIS.xml:S3:8429:13	B-AdverseReaction
,	SAPHRIS.xml:S3:8442:1	O
in	SAPHRIS.xml:S3:8444:2	O
some	SAPHRIS.xml:S3:8447:4	O
cases	SAPHRIS.xml:S3:8452:5	O
extreme	SAPHRIS.xml:S3:8458:7	B-Severity
and	SAPHRIS.xml:S3:8466:3	O
associated	SAPHRIS.xml:S3:8470:10	O
with	SAPHRIS.xml:S3:8481:4	O
ketoacidosis	SAPHRIS.xml:S3:8486:12	B-AdverseReaction
or	SAPHRIS.xml:S3:8499:2	O
hyperosmolar	SAPHRIS.xml:S3:8502:12	B-AdverseReaction
coma	SAPHRIS.xml:S3:8515:4	I-AdverseReaction
or	SAPHRIS.xml:S3:8520:2	O
death	SAPHRIS.xml:S3:8523:5	B-AdverseReaction
,	SAPHRIS.xml:S3:8528:1	O
has	SAPHRIS.xml:S3:8530:3	O
been	SAPHRIS.xml:S3:8534:4	O
reported	SAPHRIS.xml:S3:8539:8	O
in	SAPHRIS.xml:S3:8548:2	O
patients	SAPHRIS.xml:S3:8551:8	O
treated	SAPHRIS.xml:S3:8560:7	O
with	SAPHRIS.xml:S3:8568:4	O
atypical	SAPHRIS.xml:S3:8573:8	B-DrugClass
antipsychotics	SAPHRIS.xml:S3:8582:14	I-DrugClass
.	SAPHRIS.xml:S3:8596:1	O

Assessment	SAPHRIS.xml:S3:8598:10	O
of	SAPHRIS.xml:S3:8609:2	O
the	SAPHRIS.xml:S3:8612:3	O
relationship	SAPHRIS.xml:S3:8616:12	O
between	SAPHRIS.xml:S3:8629:7	O
atypical	SAPHRIS.xml:S3:8637:8	O
antipsychotic	SAPHRIS.xml:S3:8646:13	O
use	SAPHRIS.xml:S3:8660:3	O
and	SAPHRIS.xml:S3:8664:3	O
glucose	SAPHRIS.xml:S3:8668:7	O
abnormalities	SAPHRIS.xml:S3:8676:13	O
is	SAPHRIS.xml:S3:8690:2	O
complicated	SAPHRIS.xml:S3:8693:11	O
by	SAPHRIS.xml:S3:8705:2	O
the	SAPHRIS.xml:S3:8708:3	O
possibility	SAPHRIS.xml:S3:8712:11	O
of	SAPHRIS.xml:S3:8724:2	O
an	SAPHRIS.xml:S3:8727:2	O
increased	SAPHRIS.xml:S3:8730:9	O
background	SAPHRIS.xml:S3:8740:10	O
risk	SAPHRIS.xml:S3:8751:4	O
of	SAPHRIS.xml:S3:8756:2	O
diabetes	SAPHRIS.xml:S3:8759:8	O
mellitus	SAPHRIS.xml:S3:8768:8	O
in	SAPHRIS.xml:S3:8777:2	O
patients	SAPHRIS.xml:S3:8780:8	O
with	SAPHRIS.xml:S3:8789:4	O
schizophrenia	SAPHRIS.xml:S3:8794:13	O
and	SAPHRIS.xml:S3:8808:3	O
the	SAPHRIS.xml:S3:8812:3	O
increasing	SAPHRIS.xml:S3:8816:10	O
incidence	SAPHRIS.xml:S3:8827:9	O
of	SAPHRIS.xml:S3:8837:2	O
diabetes	SAPHRIS.xml:S3:8840:8	O
mellitus	SAPHRIS.xml:S3:8849:8	O
in	SAPHRIS.xml:S3:8858:2	O
the	SAPHRIS.xml:S3:8861:3	O
general	SAPHRIS.xml:S3:8865:7	O
population	SAPHRIS.xml:S3:8873:10	O
.	SAPHRIS.xml:S3:8883:1	O

Given	SAPHRIS.xml:S3:8885:5	O
these	SAPHRIS.xml:S3:8891:5	O
confounders	SAPHRIS.xml:S3:8897:11	O
,	SAPHRIS.xml:S3:8908:1	O
the	SAPHRIS.xml:S3:8910:3	O
relationship	SAPHRIS.xml:S3:8914:12	O
between	SAPHRIS.xml:S3:8927:7	O
atypical	SAPHRIS.xml:S3:8935:8	B-DrugClass
antipsychotic	SAPHRIS.xml:S3:8944:13	I-DrugClass
use	SAPHRIS.xml:S3:8958:3	O
and	SAPHRIS.xml:S3:8962:3	O
hyperglycemia	SAPHRIS.xml:S3:8966:13	B-AdverseReaction
-	SAPHRIS.xml:S3:8979:1	O
related	SAPHRIS.xml:S3:8980:7	O
adverse	SAPHRIS.xml:S3:8988:7	O
reactions	SAPHRIS.xml:S3:8996:9	O
is	SAPHRIS.xml:S3:9006:2	O
not	SAPHRIS.xml:S3:9009:3	O
completely	SAPHRIS.xml:S3:9013:10	O
understood	SAPHRIS.xml:S3:9024:10	O
.	SAPHRIS.xml:S3:9034:1	O

However	SAPHRIS.xml:S3:9036:7	O
,	SAPHRIS.xml:S3:9043:1	O
epidemiological	SAPHRIS.xml:S3:9045:15	O
studies	SAPHRIS.xml:S3:9061:7	O
suggest	SAPHRIS.xml:S3:9069:7	O
an	SAPHRIS.xml:S3:9077:2	O
increased	SAPHRIS.xml:S3:9080:9	O
risk	SAPHRIS.xml:S3:9090:4	O
of	SAPHRIS.xml:S3:9095:2	O
treatment	SAPHRIS.xml:S3:9098:9	O
-	SAPHRIS.xml:S3:9107:1	O
emergent	SAPHRIS.xml:S3:9108:8	O
hyperglycemia	SAPHRIS.xml:S3:9117:13	B-AdverseReaction
-	SAPHRIS.xml:S3:9130:1	O
related	SAPHRIS.xml:S3:9131:7	O
adverse	SAPHRIS.xml:S3:9139:7	O
events	SAPHRIS.xml:S3:9147:6	O
in	SAPHRIS.xml:S3:9154:2	O
patients	SAPHRIS.xml:S3:9157:8	O
treated	SAPHRIS.xml:S3:9166:7	O
with	SAPHRIS.xml:S3:9174:4	O
the	SAPHRIS.xml:S3:9179:3	O
atypical	SAPHRIS.xml:S3:9183:8	B-DrugClass
antipsychotics	SAPHRIS.xml:S3:9192:14	I-DrugClass
included	SAPHRIS.xml:S3:9207:8	O
in	SAPHRIS.xml:S3:9216:2	O
these	SAPHRIS.xml:S3:9219:5	O
studies	SAPHRIS.xml:S3:9225:7	O
.	SAPHRIS.xml:S3:9232:1	O

Precise	SAPHRIS.xml:S3:9234:7	O
risk	SAPHRIS.xml:S3:9242:4	O
estimates	SAPHRIS.xml:S3:9247:9	O
for	SAPHRIS.xml:S3:9257:3	O
hyperglycemia	SAPHRIS.xml:S3:9261:13	B-AdverseReaction
-	SAPHRIS.xml:S3:9274:1	O
related	SAPHRIS.xml:S3:9275:7	O
adverse	SAPHRIS.xml:S3:9283:7	O
events	SAPHRIS.xml:S3:9291:6	O
in	SAPHRIS.xml:S3:9298:2	O
patients	SAPHRIS.xml:S3:9301:8	O
treated	SAPHRIS.xml:S3:9310:7	O
with	SAPHRIS.xml:S3:9318:4	O
atypical	SAPHRIS.xml:S3:9323:8	B-DrugClass
antipsychotics	SAPHRIS.xml:S3:9332:14	I-DrugClass
are	SAPHRIS.xml:S3:9347:3	O
not	SAPHRIS.xml:S3:9351:3	O
available	SAPHRIS.xml:S3:9355:9	O
.	SAPHRIS.xml:S3:9364:1	O

Patients	SAPHRIS.xml:S3:9374:8	O
with	SAPHRIS.xml:S3:9383:4	O
an	SAPHRIS.xml:S3:9388:2	O
established	SAPHRIS.xml:S3:9391:11	O
diagnosis	SAPHRIS.xml:S3:9403:9	O
of	SAPHRIS.xml:S3:9413:2	O
diabetes	SAPHRIS.xml:S3:9416:8	O
mellitus	SAPHRIS.xml:S3:9425:8	O
who	SAPHRIS.xml:S3:9434:3	O
are	SAPHRIS.xml:S3:9438:3	O
started	SAPHRIS.xml:S3:9442:7	O
on	SAPHRIS.xml:S3:9450:2	O
atypical	SAPHRIS.xml:S3:9453:8	O
antipsychotics	SAPHRIS.xml:S3:9462:14	O
should	SAPHRIS.xml:S3:9477:6	O
be	SAPHRIS.xml:S3:9484:2	O
monitored	SAPHRIS.xml:S3:9487:9	O
regularly	SAPHRIS.xml:S3:9497:9	O
for	SAPHRIS.xml:S3:9507:3	O
worsening	SAPHRIS.xml:S3:9511:9	O
of	SAPHRIS.xml:S3:9521:2	O
glucose	SAPHRIS.xml:S3:9524:7	O
control	SAPHRIS.xml:S3:9532:7	O
.	SAPHRIS.xml:S3:9539:1	O

Patients	SAPHRIS.xml:S3:9541:8	O
with	SAPHRIS.xml:S3:9550:4	O
risk	SAPHRIS.xml:S3:9555:4	O
factors	SAPHRIS.xml:S3:9560:7	O
for	SAPHRIS.xml:S3:9568:3	O
diabetes	SAPHRIS.xml:S3:9572:8	O
mellitus	SAPHRIS.xml:S3:9581:8	O
(	SAPHRIS.xml:S3:9590:1	O
e	SAPHRIS.xml:S3:9591:1	O
.	SAPHRIS.xml:S3:9592:1	O
g	SAPHRIS.xml:S3:9593:1	O
.	SAPHRIS.xml:S3:9594:1	O
,	SAPHRIS.xml:S3:9595:1	O
obesity	SAPHRIS.xml:S3:9597:7	O
,	SAPHRIS.xml:S3:9604:1	O
family	SAPHRIS.xml:S3:9606:6	O
history	SAPHRIS.xml:S3:9613:7	O
of	SAPHRIS.xml:S3:9621:2	O
diabetes	SAPHRIS.xml:S3:9624:8	O
)	SAPHRIS.xml:S3:9632:1	O
who	SAPHRIS.xml:S3:9634:3	O
are	SAPHRIS.xml:S3:9638:3	O
starting	SAPHRIS.xml:S3:9642:8	O
treatment	SAPHRIS.xml:S3:9651:9	O
with	SAPHRIS.xml:S3:9661:4	O
atypical	SAPHRIS.xml:S3:9666:8	O
antipsychotics	SAPHRIS.xml:S3:9675:14	O
should	SAPHRIS.xml:S3:9690:6	O
undergo	SAPHRIS.xml:S3:9697:7	O
fasting	SAPHRIS.xml:S3:9705:7	O
blood	SAPHRIS.xml:S3:9713:5	O
glucose	SAPHRIS.xml:S3:9719:7	O
testing	SAPHRIS.xml:S3:9727:7	O
at	SAPHRIS.xml:S3:9735:2	O
the	SAPHRIS.xml:S3:9738:3	O
beginning	SAPHRIS.xml:S3:9742:9	O
of	SAPHRIS.xml:S3:9752:2	O
treatment	SAPHRIS.xml:S3:9755:9	O
and	SAPHRIS.xml:S3:9765:3	O
periodically	SAPHRIS.xml:S3:9769:12	O
during	SAPHRIS.xml:S3:9782:6	O
treatment	SAPHRIS.xml:S3:9789:9	O
.	SAPHRIS.xml:S3:9798:1	O

Any	SAPHRIS.xml:S3:9800:3	O
patient	SAPHRIS.xml:S3:9804:7	O
treated	SAPHRIS.xml:S3:9812:7	O
with	SAPHRIS.xml:S3:9820:4	O
atypical	SAPHRIS.xml:S3:9825:8	O
antipsychotics	SAPHRIS.xml:S3:9834:14	O
should	SAPHRIS.xml:S3:9849:6	O
be	SAPHRIS.xml:S3:9856:2	O
monitored	SAPHRIS.xml:S3:9859:9	O
for	SAPHRIS.xml:S3:9869:3	O
symptoms	SAPHRIS.xml:S3:9873:8	O
of	SAPHRIS.xml:S3:9882:2	O
hyperglycemia	SAPHRIS.xml:S3:9885:13	O
including	SAPHRIS.xml:S3:9899:9	O
polydipsia	SAPHRIS.xml:S3:9909:10	O
,	SAPHRIS.xml:S3:9919:1	O
polyuria	SAPHRIS.xml:S3:9921:8	O
,	SAPHRIS.xml:S3:9929:1	O
polyphagia	SAPHRIS.xml:S3:9931:10	O
,	SAPHRIS.xml:S3:9941:1	O
and	SAPHRIS.xml:S3:9943:3	O
weakness	SAPHRIS.xml:S3:9947:8	O
.	SAPHRIS.xml:S3:9955:1	O

Patients	SAPHRIS.xml:S3:9957:8	O
who	SAPHRIS.xml:S3:9966:3	O
develop	SAPHRIS.xml:S3:9970:7	O
symptoms	SAPHRIS.xml:S3:9978:8	O
of	SAPHRIS.xml:S3:9987:2	O
hyperglycemia	SAPHRIS.xml:S3:9990:13	O
during	SAPHRIS.xml:S3:10004:6	O
treatment	SAPHRIS.xml:S3:10011:9	O
with	SAPHRIS.xml:S3:10021:4	O
atypical	SAPHRIS.xml:S3:10026:8	O
antipsychotics	SAPHRIS.xml:S3:10035:14	O
should	SAPHRIS.xml:S3:10050:6	O
undergo	SAPHRIS.xml:S3:10057:7	O
fasting	SAPHRIS.xml:S3:10065:7	O
blood	SAPHRIS.xml:S3:10073:5	O
glucose	SAPHRIS.xml:S3:10079:7	O
testing	SAPHRIS.xml:S3:10087:7	O
.	SAPHRIS.xml:S3:10094:1	O

In	SAPHRIS.xml:S3:10096:2	O
some	SAPHRIS.xml:S3:10099:4	O
cases	SAPHRIS.xml:S3:10104:5	O
,	SAPHRIS.xml:S3:10109:1	O
hyperglycemia	SAPHRIS.xml:S3:10111:13	O
has	SAPHRIS.xml:S3:10125:3	O
resolved	SAPHRIS.xml:S3:10129:8	O
when	SAPHRIS.xml:S3:10138:4	O
the	SAPHRIS.xml:S3:10143:3	O
atypical	SAPHRIS.xml:S3:10147:8	O
antipsychotic	SAPHRIS.xml:S3:10156:13	O
was	SAPHRIS.xml:S3:10170:3	O
discontinued	SAPHRIS.xml:S3:10174:12	O
;	SAPHRIS.xml:S3:10186:1	O
however	SAPHRIS.xml:S3:10188:7	O
,	SAPHRIS.xml:S3:10195:1	O
some	SAPHRIS.xml:S3:10197:4	O
patients	SAPHRIS.xml:S3:10202:8	O
required	SAPHRIS.xml:S3:10211:8	O
continuation	SAPHRIS.xml:S3:10220:12	O
of	SAPHRIS.xml:S3:10233:2	O
anti	SAPHRIS.xml:S3:10236:4	O
-	SAPHRIS.xml:S3:10240:1	O
diabetic	SAPHRIS.xml:S3:10241:8	O
treatment	SAPHRIS.xml:S3:10250:9	O
despite	SAPHRIS.xml:S3:10260:7	O
discontinuation	SAPHRIS.xml:S3:10268:15	O
of	SAPHRIS.xml:S3:10284:2	O
the	SAPHRIS.xml:S3:10287:3	O
antipsychotic	SAPHRIS.xml:S3:10291:13	O
drug	SAPHRIS.xml:S3:10305:4	O
.	SAPHRIS.xml:S3:10309:1	O

Adult	SAPHRIS.xml:S3:10321:5	O
Patients	SAPHRIS.xml:S3:10327:8	O
:	SAPHRIS.xml:S3:10335:1	O
Pooled	SAPHRIS.xml:S3:10338:6	O
data	SAPHRIS.xml:S3:10345:4	O
from	SAPHRIS.xml:S3:10350:4	O
the	SAPHRIS.xml:S3:10355:3	O
short	SAPHRIS.xml:S3:10359:5	O
-	SAPHRIS.xml:S3:10364:1	O
term	SAPHRIS.xml:S3:10365:4	O
placebo	SAPHRIS.xml:S3:10370:7	O
-	SAPHRIS.xml:S3:10377:1	O
controlled	SAPHRIS.xml:S3:10378:10	O
schizophrenia	SAPHRIS.xml:S3:10389:13	O
and	SAPHRIS.xml:S3:10403:3	O
bipolar	SAPHRIS.xml:S3:10407:7	O
mania	SAPHRIS.xml:S3:10415:5	O
trials	SAPHRIS.xml:S3:10421:6	O
are	SAPHRIS.xml:S3:10428:3	O
presented	SAPHRIS.xml:S3:10432:9	O
in	SAPHRIS.xml:S3:10442:2	O
Table	SAPHRIS.xml:S3:10446:5	O
1	SAPHRIS.xml:S3:10452:1	O
.	SAPHRIS.xml:S3:10453:1	O

TABLE	SAPHRIS.xml:S3:10461:5	O
1	SAPHRIS.xml:S3:10467:1	O
:	SAPHRIS.xml:S3:10468:1	O
Changes	SAPHRIS.xml:S3:10470:7	O
in	SAPHRIS.xml:S3:10478:2	O
Fasting	SAPHRIS.xml:S3:10481:7	O
Glucose	SAPHRIS.xml:S3:10489:7	O
in	SAPHRIS.xml:S3:10497:2	O
Adult	SAPHRIS.xml:S3:10500:5	O
Patients	SAPHRIS.xml:S3:10506:8	O

N	SAPHRIS.xml:S3:10518:1	O
Number	SAPHRIS.xml:S3:10523:6	O
of	SAPHRIS.xml:S3:10530:2	O
patients	SAPHRIS.xml:S3:10533:8	O
who	SAPHRIS.xml:S3:10542:3	O
had	SAPHRIS.xml:S3:10546:3	O
assessments	SAPHRIS.xml:S3:10550:11	O
at	SAPHRIS.xml:S3:10562:2	O
both	SAPHRIS.xml:S3:10565:4	O
Baseline	SAPHRIS.xml:S3:10570:8	O
and	SAPHRIS.xml:S3:10579:3	O
Endpoint	SAPHRIS.xml:S3:10583:8	O
.	SAPHRIS.xml:S3:10591:1	O

N	SAPHRIS.xml:S3:10599:1	O
Number	SAPHRIS.xml:S3:10605:6	O
of	SAPHRIS.xml:S3:10612:2	O
patients	SAPHRIS.xml:S3:10615:8	O
at	SAPHRIS.xml:S3:10624:2	O
risk	SAPHRIS.xml:S3:10627:4	O
at	SAPHRIS.xml:S3:10632:2	O
Baseline	SAPHRIS.xml:S3:10635:8	O
with	SAPHRIS.xml:S3:10644:4	O
assessments	SAPHRIS.xml:S3:10649:11	O
at	SAPHRIS.xml:S3:10661:2	O
both	SAPHRIS.xml:S3:10664:4	O
Baseline	SAPHRIS.xml:S3:10669:8	O
and	SAPHRIS.xml:S3:10678:3	O
Endpoint	SAPHRIS.xml:S3:10682:8	O
.	SAPHRIS.xml:S3:10690:1	O

S	SAPHRIS.xml:S3:10698:1	O
Includes	SAPHRIS.xml:S3:10700:8	O
patients	SAPHRIS.xml:S3:10709:8	O
treated	SAPHRIS.xml:S3:10718:7	O
with	SAPHRIS.xml:S3:10726:4	O
flexible	SAPHRIS.xml:S3:10731:8	O
dose	SAPHRIS.xml:S3:10740:4	O
of	SAPHRIS.xml:S3:10745:2	O
SAPHRIS	SAPHRIS.xml:S3:10748:7	O
5	SAPHRIS.xml:S3:10756:1	O
or	SAPHRIS.xml:S3:10758:2	O
10	SAPHRIS.xml:S3:10761:2	O
mg	SAPHRIS.xml:S3:10764:2	O
twice	SAPHRIS.xml:S3:10767:5	O
daily	SAPHRIS.xml:S3:10773:5	O
(	SAPHRIS.xml:S3:10779:1	O
N	SAPHRIS.xml:S3:10780:1	O
90	SAPHRIS.xml:S3:10782:2	O
)	SAPHRIS.xml:S3:10784:1	O
.	SAPHRIS.xml:S3:10785:1	O

SAPHRIS	SAPHRIS.xml:S3:10793:7	O
5	SAPHRIS.xml:S3:10801:1	O
mg	SAPHRIS.xml:S3:10803:2	O
or	SAPHRIS.xml:S3:10806:2	O
10	SAPHRIS.xml:S3:10809:2	O
mg	SAPHRIS.xml:S3:10812:2	O
twice	SAPHRIS.xml:S3:10815:5	O
daily	SAPHRIS.xml:S3:10821:5	O
with	SAPHRIS.xml:S3:10827:4	O
flexible	SAPHRIS.xml:S3:10832:8	O
dosing	SAPHRIS.xml:S3:10841:6	O
.	SAPHRIS.xml:S3:10847:1	O

Schizophrenia	SAPHRIS.xml:S3:10878:13	O

(	SAPHRIS.xml:S3:10892:1	O
6	SAPHRIS.xml:S3:10893:1	O
-	SAPHRIS.xml:S3:10894:1	O
weeks	SAPHRIS.xml:S3:10895:5	O
)	SAPHRIS.xml:S3:10900:1	O
Bipolar	SAPHRIS.xml:S3:10903:7	O
(	SAPHRIS.xml:S3:10911:1	O
3	SAPHRIS.xml:S3:10912:1	O
-	SAPHRIS.xml:S3:10913:1	O
weeks	SAPHRIS.xml:S3:10914:5	O
)	SAPHRIS.xml:S3:10919:1	O

Placebo	SAPHRIS.xml:S3:10925:7	O
SAPHRIS	SAPHRIS.xml:S3:10946:7	O
Placebo	SAPHRIS.xml:S3:10960:7	O
SAPHRIS5	SAPHRIS.xml:S3:10972:8	O
or	SAPHRIS.xml:S3:10981:2	O
10	SAPHRIS.xml:S3:10984:2	O
mgtwice	SAPHRIS.xml:S3:10987:7	O
daily	SAPHRIS.xml:S3:10995:5	O

5	SAPHRIS.xml:S3:11009:1	O
mgtwice	SAPHRIS.xml:S3:11011:7	O
daily	SAPHRIS.xml:S3:11019:5	O
10	SAPHRIS.xml:S3:11030:2	O
mgtwice	SAPHRIS.xml:S3:11033:7	O
daily	SAPHRIS.xml:S3:11041:5	O
5	SAPHRIS.xml:S3:11048:1	O
or	SAPHRIS.xml:S3:11050:2	O
10	SAPHRIS.xml:S3:11053:2	O
mgtwice	SAPHRIS.xml:S3:11056:7	O
daily	SAPHRIS.xml:S3:11064:5	O
S	SAPHRIS.xml:S3:11071:1	O

Mean	SAPHRIS.xml:S3:11079:4	O
Change	SAPHRIS.xml:S3:11084:6	O
from	SAPHRIS.xml:S3:11091:4	O
Baseline	SAPHRIS.xml:S3:11096:8	O
in	SAPHRIS.xml:S3:11105:2	O
Fasting	SAPHRIS.xml:S3:11108:7	O
Glucose	SAPHRIS.xml:S3:11116:7	O
at	SAPHRIS.xml:S3:11124:2	O
Endpoint	SAPHRIS.xml:S3:11127:8	O

Change	SAPHRIS.xml:S3:11247:6	O

from	SAPHRIS.xml:S3:11254:4	O
Baseline	SAPHRIS.xml:S3:11259:8	O
(	SAPHRIS.xml:S3:11268:1	O
mg	SAPHRIS.xml:S3:11269:2	O
dL	SAPHRIS.xml:S3:11272:2	O
)	SAPHRIS.xml:S3:11274:1	O
(	SAPHRIS.xml:S3:11276:1	O
N	SAPHRIS.xml:S3:11277:1	O
)	SAPHRIS.xml:S3:11279:1	O
-	SAPHRIS.xml:S3:11282:1	O
0.2	SAPHRIS.xml:S3:11283:3	O
(	SAPHRIS.xml:S3:11286:1	O
232	SAPHRIS.xml:S3:11287:3	O
)	SAPHRIS.xml:S3:11290:1	O
3.8	SAPHRIS.xml:S3:11296:3	O
(	SAPHRIS.xml:S3:11299:1	O
158	SAPHRIS.xml:S3:11300:3	O
)	SAPHRIS.xml:S3:11303:1	O
1.1	SAPHRIS.xml:S3:11308:3	O
(	SAPHRIS.xml:S3:11311:1	O
153	SAPHRIS.xml:S3:11312:3	O
)	SAPHRIS.xml:S3:11315:1	O
3.2	SAPHRIS.xml:S3:11323:3	O
(	SAPHRIS.xml:S3:11326:1	O
377	SAPHRIS.xml:S3:11327:3	O
)	SAPHRIS.xml:S3:11330:1	O
-	SAPHRIS.xml:S3:11335:1	O
0.6	SAPHRIS.xml:S3:11336:3	O
(	SAPHRIS.xml:S3:11339:1	O
89	SAPHRIS.xml:S3:11340:2	O
)	SAPHRIS.xml:S3:11342:1	O
-	SAPHRIS.xml:S3:11350:1	O
0.6	SAPHRIS.xml:S3:11351:3	O
(	SAPHRIS.xml:S3:11354:1	O
156	SAPHRIS.xml:S3:11355:3	O
)	SAPHRIS.xml:S3:11358:1	O

Proportion	SAPHRIS.xml:S3:11368:10	O
of	SAPHRIS.xml:S3:11379:2	O
Patients	SAPHRIS.xml:S3:11382:8	O
with	SAPHRIS.xml:S3:11391:4	O
Shifts	SAPHRIS.xml:S3:11396:6	O
from	SAPHRIS.xml:S3:11403:4	O
Baseline	SAPHRIS.xml:S3:11408:8	O
to	SAPHRIS.xml:S3:11417:2	O
Endpoint	SAPHRIS.xml:S3:11420:8	O

Normal	SAPHRIS.xml:S3:11433:6	O
to	SAPHRIS.xml:S3:11440:2	O
High	SAPHRIS.xml:S3:11443:4	O
100	SAPHRIS.xml:S3:11448:3	O
to	SAPHRIS.xml:S3:11452:2	O
126	SAPHRIS.xml:S3:11457:3	O
mg	SAPHRIS.xml:S3:11461:2	O
dL	SAPHRIS.xml:S3:11464:2	O
4.1%	SAPHRIS.xml:S3:11468:4	O
4.5%	SAPHRIS.xml:S3:11482:4	O
4.5%	SAPHRIS.xml:S3:11494:4	O
5.0%	SAPHRIS.xml:S3:11509:4	O
3.3%	SAPHRIS.xml:S3:11521:4	O
2.7%	SAPHRIS.xml:S3:11536:4	O

(	SAPHRIS.xml:S3:11554:1	O
n	SAPHRIS.xml:S3:11555:1	O
N	SAPHRIS.xml:S3:11557:1	O
)	SAPHRIS.xml:S3:11560:1	O
(	SAPHRIS.xml:S3:11575:1	O
7	SAPHRIS.xml:S3:11576:1	O
170	SAPHRIS.xml:S3:11578:3	O
)	SAPHRIS.xml:S3:11581:1	O
(	SAPHRIS.xml:S3:11589:1	O
5	SAPHRIS.xml:S3:11590:1	O
111	SAPHRIS.xml:S3:11592:3	O
)	SAPHRIS.xml:S3:11595:1	O
(	SAPHRIS.xml:S3:11601:1	O
5	SAPHRIS.xml:S3:11602:1	O
111	SAPHRIS.xml:S3:11604:3	O
)	SAPHRIS.xml:S3:11607:1	O
(	SAPHRIS.xml:S3:11616:1	O
13	SAPHRIS.xml:S3:11617:2	O
262	SAPHRIS.xml:S3:11620:3	O
)	SAPHRIS.xml:S3:11623:1	O
(	SAPHRIS.xml:S3:11628:1	O
2	SAPHRIS.xml:S3:11629:1	O
61	SAPHRIS.xml:S3:11631:2	O
)	SAPHRIS.xml:S3:11633:1	O
(	SAPHRIS.xml:S3:11643:1	O
3	SAPHRIS.xml:S3:11644:1	O
111	SAPHRIS.xml:S3:11646:3	O
)	SAPHRIS.xml:S3:11649:1	O

Borderline	SAPHRIS.xml:S3:11661:10	O
to	SAPHRIS.xml:S3:11672:2	O
High	SAPHRIS.xml:S3:11675:4	O
100	SAPHRIS.xml:S3:11681:3	O
and	SAPHRIS.xml:S3:11685:3	O
126	SAPHRIS.xml:S3:11690:3	O
to	SAPHRIS.xml:S3:11693:2	O
126	SAPHRIS.xml:S3:11698:3	O
mg	SAPHRIS.xml:S3:11702:2	O
dL	SAPHRIS.xml:S3:11705:2	O
5.9%	SAPHRIS.xml:S3:11709:4	O
6.8%	SAPHRIS.xml:S3:11723:4	O
6.3%	SAPHRIS.xml:S3:11735:4	O
10.5%	SAPHRIS.xml:S3:11750:5	O
0.0%	SAPHRIS.xml:S3:11762:4	O
11.4%	SAPHRIS.xml:S3:11777:5	O

(	SAPHRIS.xml:S3:11795:1	O
n	SAPHRIS.xml:S3:11796:1	O
N	SAPHRIS.xml:S3:11798:1	O
)	SAPHRIS.xml:S3:11801:1	O
(	SAPHRIS.xml:S3:11816:1	O
3	SAPHRIS.xml:S3:11817:1	O
51	SAPHRIS.xml:S3:11819:2	O
)	SAPHRIS.xml:S3:11821:1	O
(	SAPHRIS.xml:S3:11830:1	O
3	SAPHRIS.xml:S3:11831:1	O
44	SAPHRIS.xml:S3:11833:2	O
)	SAPHRIS.xml:S3:11835:1	O
(	SAPHRIS.xml:S3:11842:1	O
2	SAPHRIS.xml:S3:11843:1	O
32	SAPHRIS.xml:S3:11845:2	O
)	SAPHRIS.xml:S3:11847:1	O
(	SAPHRIS.xml:S3:11857:1	O
10	SAPHRIS.xml:S3:11858:2	O
95	SAPHRIS.xml:S3:11861:2	O
)	SAPHRIS.xml:S3:11863:1	O
(	SAPHRIS.xml:S3:11869:1	O
0	SAPHRIS.xml:S3:11870:1	O
23	SAPHRIS.xml:S3:11872:2	O
)	SAPHRIS.xml:S3:11874:1	O
(	SAPHRIS.xml:S3:11884:1	O
4	SAPHRIS.xml:S3:11885:1	O
35	SAPHRIS.xml:S3:11887:2	O
)	SAPHRIS.xml:S3:11889:1	O

In	SAPHRIS.xml:S3:11921:2	O
a	SAPHRIS.xml:S3:11924:1	O
52	SAPHRIS.xml:S3:11926:2	O
-	SAPHRIS.xml:S3:11928:1	O
week	SAPHRIS.xml:S3:11929:4	O
,	SAPHRIS.xml:S3:11933:1	O
double	SAPHRIS.xml:S3:11935:6	O
-	SAPHRIS.xml:S3:11941:1	O
blind	SAPHRIS.xml:S3:11942:5	O
,	SAPHRIS.xml:S3:11947:1	O
comparator	SAPHRIS.xml:S3:11949:10	O
-	SAPHRIS.xml:S3:11959:1	O
controlled	SAPHRIS.xml:S3:11960:10	O
trial	SAPHRIS.xml:S3:11971:5	O
that	SAPHRIS.xml:S3:11977:4	O
included	SAPHRIS.xml:S3:11982:8	O
primarily	SAPHRIS.xml:S3:11991:9	O
patients	SAPHRIS.xml:S3:12001:8	O
with	SAPHRIS.xml:S3:12010:4	O
schizophrenia	SAPHRIS.xml:S3:12015:13	O
,	SAPHRIS.xml:S3:12028:1	O
the	SAPHRIS.xml:S3:12030:3	O
mean	SAPHRIS.xml:S3:12034:4	O
increase	SAPHRIS.xml:S3:12039:8	B-AdverseReaction
from	SAPHRIS.xml:S3:12048:4	O
baseline	SAPHRIS.xml:S3:12053:8	O
of	SAPHRIS.xml:S3:12062:2	I-AdverseReaction
fasting	SAPHRIS.xml:S3:12065:7	I-AdverseReaction
glucose	SAPHRIS.xml:S3:12073:7	I-AdverseReaction
was	SAPHRIS.xml:S3:12081:3	O
2.4	SAPHRIS.xml:S3:12085:3	O
mg	SAPHRIS.xml:S3:12089:2	O
dL	SAPHRIS.xml:S3:12092:2	O
.	SAPHRIS.xml:S3:12094:1	O

Pediatric	SAPHRIS.xml:S3:12106:9	O

Patients	SAPHRIS.xml:S3:12116:8	O
:	SAPHRIS.xml:S3:12124:1	O
Data	SAPHRIS.xml:S3:12127:4	O
from	SAPHRIS.xml:S3:12132:4	O
the	SAPHRIS.xml:S3:12137:3	O
short	SAPHRIS.xml:S3:12141:5	O
-	SAPHRIS.xml:S3:12146:1	O
term	SAPHRIS.xml:S3:12147:4	O
,	SAPHRIS.xml:S3:12151:1	O
placebo	SAPHRIS.xml:S3:12153:7	O
-	SAPHRIS.xml:S3:12160:1	O
controlled	SAPHRIS.xml:S3:12161:10	O
trial	SAPHRIS.xml:S3:12172:5	O
in	SAPHRIS.xml:S3:12178:2	O
pediatric	SAPHRIS.xml:S3:12181:9	O
patients	SAPHRIS.xml:S3:12191:8	O
with	SAPHRIS.xml:S3:12200:4	O
bipolar	SAPHRIS.xml:S3:12205:7	O
I	SAPHRIS.xml:S3:12213:1	O
disorder	SAPHRIS.xml:S3:12215:8	O
are	SAPHRIS.xml:S3:12224:3	O
shown	SAPHRIS.xml:S3:12228:5	O
in	SAPHRIS.xml:S3:12234:2	O
Table	SAPHRIS.xml:S3:12238:5	O
2	SAPHRIS.xml:S3:12244:1	O
.	SAPHRIS.xml:S3:12247:1	O

TABLE	SAPHRIS.xml:S3:12253:5	O
2	SAPHRIS.xml:S3:12259:1	O
:	SAPHRIS.xml:S3:12260:1	O
Changes	SAPHRIS.xml:S3:12262:7	O
in	SAPHRIS.xml:S3:12270:2	O
Fasting	SAPHRIS.xml:S3:12273:7	O
Glucose	SAPHRIS.xml:S3:12281:7	O
in	SAPHRIS.xml:S3:12289:2	O
Pediatric	SAPHRIS.xml:S3:12292:9	O
Subjects	SAPHRIS.xml:S3:12302:8	O

Bipolar	SAPHRIS.xml:S3:12332:7	O
I	SAPHRIS.xml:S3:12340:1	O
Disorder	SAPHRIS.xml:S3:12342:8	O
(	SAPHRIS.xml:S3:12351:1	O
3	SAPHRIS.xml:S3:12352:1	O
-	SAPHRIS.xml:S3:12353:1	O
weeks	SAPHRIS.xml:S3:12354:5	O
)	SAPHRIS.xml:S3:12359:1	O

Placebo	SAPHRIS.xml:S3:12369:7	O
SAPHRIS2	SAPHRIS.xml:S3:12384:8	O
.	SAPHRIS.xml:S3:12392:1	O
5	SAPHRIS.xml:S3:12393:1	O
mgtwice	SAPHRIS.xml:S3:12395:7	O
daily	SAPHRIS.xml:S3:12403:5	O
SAPHRIS5	SAPHRIS.xml:S3:12410:8	O
mgtwice	SAPHRIS.xml:S3:12419:7	O
daily	SAPHRIS.xml:S3:12427:5	O
SAPHRIS10	SAPHRIS.xml:S3:12435:9	O
mgtwice	SAPHRIS.xml:S3:12445:7	O
daily	SAPHRIS.xml:S3:12453:5	O

Mean	SAPHRIS.xml:S3:12482:4	O
Change	SAPHRIS.xml:S3:12487:6	O
from	SAPHRIS.xml:S3:12494:4	O
Baseline	SAPHRIS.xml:S3:12499:8	O
in	SAPHRIS.xml:S3:12508:2	O
Fasting	SAPHRIS.xml:S3:12511:7	O
Glucose	SAPHRIS.xml:S3:12519:7	O
at	SAPHRIS.xml:S3:12527:2	O
Endpoint	SAPHRIS.xml:S3:12530:8	O

Change	SAPHRIS.xml:S3:12547:6	O
from	SAPHRIS.xml:S3:12554:4	O
Baseline	SAPHRIS.xml:S3:12559:8	O
(	SAPHRIS.xml:S3:12568:1	O
mg	SAPHRIS.xml:S3:12569:2	O
dL	SAPHRIS.xml:S3:12572:2	O
)	SAPHRIS.xml:S3:12574:1	O
(	SAPHRIS.xml:S3:12576:1	O
N	SAPHRIS.xml:S3:12577:1	O
)	SAPHRIS.xml:S3:12579:1	O
-	SAPHRIS.xml:S3:12582:1	O
2.24	SAPHRIS.xml:S3:12583:4	O
(	SAPHRIS.xml:S3:12587:1	O
56	SAPHRIS.xml:S3:12588:2	O
)	SAPHRIS.xml:S3:12590:1	O
1.43	SAPHRIS.xml:S3:12604:4	O
(	SAPHRIS.xml:S3:12608:1	O
51	SAPHRIS.xml:S3:12609:2	O
)	SAPHRIS.xml:S3:12611:1	O
-	SAPHRIS.xml:S3:12629:1	O
0.45	SAPHRIS.xml:S3:12630:4	O
(	SAPHRIS.xml:S3:12634:1	O
57	SAPHRIS.xml:S3:12635:2	O
)	SAPHRIS.xml:S3:12637:1	O
0.34	SAPHRIS.xml:S3:12653:4	O
(	SAPHRIS.xml:S3:12657:1	O
52	SAPHRIS.xml:S3:12658:2	O
)	SAPHRIS.xml:S3:12660:1	O

Proportion	SAPHRIS.xml:S3:12691:10	O
of	SAPHRIS.xml:S3:12702:2	O
Subjects	SAPHRIS.xml:S3:12705:8	O
with	SAPHRIS.xml:S3:12714:4	O
Shifts	SAPHRIS.xml:S3:12719:6	O
from	SAPHRIS.xml:S3:12726:4	O
Baseline	SAPHRIS.xml:S3:12731:8	O
to	SAPHRIS.xml:S3:12740:2	O
Endpoint	SAPHRIS.xml:S3:12743:8	O

Normal	SAPHRIS.xml:S3:12760:6	O
to	SAPHRIS.xml:S3:12767:2	O
High	SAPHRIS.xml:S3:12770:4	O
45	SAPHRIS.xml:S3:12775:2	O
100	SAPHRIS.xml:S3:12782:3	O
to	SAPHRIS.xml:S3:12786:2	O
126	SAPHRIS.xml:S3:12791:3	O
mg	SAPHRIS.xml:S3:12795:2	O
dL	SAPHRIS.xml:S3:12798:2	O
0%	SAPHRIS.xml:S3:12802:2	O
0%	SAPHRIS.xml:S3:12824:2	O
1.8%	SAPHRIS.xml:S3:12849:4	O
0%	SAPHRIS.xml:S3:12873:2	O

(	SAPHRIS.xml:S3:12896:1	O
n	SAPHRIS.xml:S3:12897:1	O
N	SAPHRIS.xml:S3:12899:1	O
)	SAPHRIS.xml:S3:12901:1	O
(	SAPHRIS.xml:S3:12911:1	O
0	SAPHRIS.xml:S3:12912:1	O
56	SAPHRIS.xml:S3:12914:2	O
)	SAPHRIS.xml:S3:12916:1	O
(	SAPHRIS.xml:S3:12933:1	O
0	SAPHRIS.xml:S3:12934:1	O
51	SAPHRIS.xml:S3:12936:2	O
)	SAPHRIS.xml:S3:12938:1	O
(	SAPHRIS.xml:S3:12958:1	O
1	SAPHRIS.xml:S3:12959:1	O
57	SAPHRIS.xml:S3:12961:2	O
)	SAPHRIS.xml:S3:12963:1	O
(	SAPHRIS.xml:S3:12982:1	O
0	SAPHRIS.xml:S3:12983:1	O
52	SAPHRIS.xml:S3:12985:2	O
)	SAPHRIS.xml:S3:12987:1	O

Dyslipidemia	SAPHRIS.xml:S3:13019:12	B-AdverseReaction

Undesirable	SAPHRIS.xml:S3:13042:11	B-AdverseReaction

alterations	SAPHRIS.xml:S3:13054:11	I-AdverseReaction
in	SAPHRIS.xml:S3:13066:2	I-AdverseReaction
lipids	SAPHRIS.xml:S3:13069:6	I-AdverseReaction
have	SAPHRIS.xml:S3:13076:4	O
been	SAPHRIS.xml:S3:13081:4	O
observed	SAPHRIS.xml:S3:13086:8	O
in	SAPHRIS.xml:S3:13095:2	O
patients	SAPHRIS.xml:S3:13098:8	O
treated	SAPHRIS.xml:S3:13107:7	O
with	SAPHRIS.xml:S3:13115:4	O
atypical	SAPHRIS.xml:S3:13120:8	B-DrugClass
antipsychotics	SAPHRIS.xml:S3:13129:14	I-DrugClass
.	SAPHRIS.xml:S3:13143:1	O

Adult	SAPHRIS.xml:S3:13155:5	O
Patients	SAPHRIS.xml:S3:13161:8	O
:	SAPHRIS.xml:S3:13169:1	O
Pooled	SAPHRIS.xml:S3:13172:6	O
data	SAPHRIS.xml:S3:13179:4	O
from	SAPHRIS.xml:S3:13184:4	O
the	SAPHRIS.xml:S3:13189:3	O
short	SAPHRIS.xml:S3:13193:5	O
-	SAPHRIS.xml:S3:13198:1	O
term	SAPHRIS.xml:S3:13199:4	O
,	SAPHRIS.xml:S3:13203:1	O
placebo	SAPHRIS.xml:S3:13205:7	O
-	SAPHRIS.xml:S3:13212:1	O
controlled	SAPHRIS.xml:S3:13213:10	O
schizophrenia	SAPHRIS.xml:S3:13224:13	O
and	SAPHRIS.xml:S3:13238:3	O
bipolar	SAPHRIS.xml:S3:13242:7	O
mania	SAPHRIS.xml:S3:13250:5	O
trials	SAPHRIS.xml:S3:13256:6	O
are	SAPHRIS.xml:S3:13263:3	O
presented	SAPHRIS.xml:S3:13267:9	O
in	SAPHRIS.xml:S3:13277:2	O
Table	SAPHRIS.xml:S3:13281:5	O
3	SAPHRIS.xml:S3:13287:1	O
.	SAPHRIS.xml:S3:13288:1	O

TABLE	SAPHRIS.xml:S3:13296:5	O
3	SAPHRIS.xml:S3:13302:1	O
:	SAPHRIS.xml:S3:13303:1	O
Changes	SAPHRIS.xml:S3:13305:7	O
in	SAPHRIS.xml:S3:13313:2	O
Lipids	SAPHRIS.xml:S3:13316:6	O
in	SAPHRIS.xml:S3:13323:2	O
Adult	SAPHRIS.xml:S3:13326:5	O
Patients	SAPHRIS.xml:S3:13332:8	O

N	SAPHRIS.xml:S3:13344:1	O
Number	SAPHRIS.xml:S3:13349:6	O
of	SAPHRIS.xml:S3:13356:2	O
subjects	SAPHRIS.xml:S3:13359:8	O
who	SAPHRIS.xml:S3:13368:3	O
had	SAPHRIS.xml:S3:13372:3	O
assessments	SAPHRIS.xml:S3:13376:11	O
at	SAPHRIS.xml:S3:13388:2	O
both	SAPHRIS.xml:S3:13391:4	O
Baseline	SAPHRIS.xml:S3:13396:8	O
and	SAPHRIS.xml:S3:13405:3	O
Endpoint	SAPHRIS.xml:S3:13409:8	O
.	SAPHRIS.xml:S3:13417:1	O

S	SAPHRIS.xml:S3:13425:1	O
Includes	SAPHRIS.xml:S3:13427:8	O
subjects	SAPHRIS.xml:S3:13436:8	O
treated	SAPHRIS.xml:S3:13445:7	O
with	SAPHRIS.xml:S3:13453:4	O
flexible	SAPHRIS.xml:S3:13458:8	O
dose	SAPHRIS.xml:S3:13467:4	O
of	SAPHRIS.xml:S3:13472:2	O
SAPHRIS	SAPHRIS.xml:S3:13475:7	O
5	SAPHRIS.xml:S3:13483:1	O
or	SAPHRIS.xml:S3:13485:2	O
10	SAPHRIS.xml:S3:13488:2	O
mg	SAPHRIS.xml:S3:13491:2	O
twice	SAPHRIS.xml:S3:13494:5	O
daily	SAPHRIS.xml:S3:13500:5	O
(	SAPHRIS.xml:S3:13506:1	O
N	SAPHRIS.xml:S3:13507:1	O
90	SAPHRIS.xml:S3:13509:2	O
)	SAPHRIS.xml:S3:13511:1	O
.	SAPHRIS.xml:S3:13512:1	O

SAPHRIS	SAPHRIS.xml:S3:13520:7	O
5	SAPHRIS.xml:S3:13528:1	O
mg	SAPHRIS.xml:S3:13530:2	O
or	SAPHRIS.xml:S3:13533:2	O
10	SAPHRIS.xml:S3:13536:2	O
mg	SAPHRIS.xml:S3:13539:2	O
twice	SAPHRIS.xml:S3:13542:5	O
daily	SAPHRIS.xml:S3:13548:5	O
with	SAPHRIS.xml:S3:13554:4	O
flexible	SAPHRIS.xml:S3:13559:8	O
dosing	SAPHRIS.xml:S3:13568:6	O
.	SAPHRIS.xml:S3:13574:1	O

Schizophrenia	SAPHRIS.xml:S3:13603:13	O

(	SAPHRIS.xml:S3:13617:1	O
6	SAPHRIS.xml:S3:13618:1	O
-	SAPHRIS.xml:S3:13619:1	O
weeks	SAPHRIS.xml:S3:13620:5	O
)	SAPHRIS.xml:S3:13625:1	O
Bipolar	SAPHRIS.xml:S3:13628:7	O
(	SAPHRIS.xml:S3:13636:1	O
3	SAPHRIS.xml:S3:13637:1	O
-	SAPHRIS.xml:S3:13638:1	O
weeks	SAPHRIS.xml:S3:13639:5	O
)	SAPHRIS.xml:S3:13644:1	O

Placebo	SAPHRIS.xml:S3:13650:7	O
SAPHRIS	SAPHRIS.xml:S3:13669:7	O
Placebo	SAPHRIS.xml:S3:13684:7	O
SAPHRIS5	SAPHRIS.xml:S3:13700:8	O
or	SAPHRIS.xml:S3:13709:2	O
10	SAPHRIS.xml:S3:13712:2	O
mgtwice	SAPHRIS.xml:S3:13715:7	O
daily	SAPHRIS.xml:S3:13723:5	O

5	SAPHRIS.xml:S3:13737:1	O
mgtwice	SAPHRIS.xml:S3:13739:7	O
daily	SAPHRIS.xml:S3:13747:5	O
10	SAPHRIS.xml:S3:13756:2	O
mgtwice	SAPHRIS.xml:S3:13759:7	O
daily	SAPHRIS.xml:S3:13767:5	O
5	SAPHRIS.xml:S3:13774:1	O
or	SAPHRIS.xml:S3:13776:2	O
10	SAPHRIS.xml:S3:13779:2	O
mgtwice	SAPHRIS.xml:S3:13782:7	O
daily	SAPHRIS.xml:S3:13790:5	O
S	SAPHRIS.xml:S3:13797:1	O

Mean	SAPHRIS.xml:S3:13805:4	O
Change	SAPHRIS.xml:S3:13810:6	O
from	SAPHRIS.xml:S3:13817:4	O
Baseline	SAPHRIS.xml:S3:13822:8	O
(	SAPHRIS.xml:S3:13831:1	O
mg	SAPHRIS.xml:S3:13832:2	O
dL	SAPHRIS.xml:S3:13835:2	O
)	SAPHRIS.xml:S3:13837:1	O

Total	SAPHRIS.xml:S3:13843:5	O
cholesterol	SAPHRIS.xml:S3:13849:11	O
(	SAPHRIS.xml:S3:13860:1	O
N	SAPHRIS.xml:S3:13861:1	O
)	SAPHRIS.xml:S3:13863:1	O
-	SAPHRIS.xml:S3:13866:1	O
2.2	SAPHRIS.xml:S3:13867:3	O
(	SAPHRIS.xml:S3:13870:1	O
351	SAPHRIS.xml:S3:13871:3	O
)	SAPHRIS.xml:S3:13874:1	O
-	SAPHRIS.xml:S3:13881:1	O
2.4	SAPHRIS.xml:S3:13882:3	O
(	SAPHRIS.xml:S3:13885:1	O
258	SAPHRIS.xml:S3:13886:3	O
)	SAPHRIS.xml:S3:13889:1	O
3.3	SAPHRIS.xml:S3:13897:3	O
(	SAPHRIS.xml:S3:13900:1	O
199	SAPHRIS.xml:S3:13901:3	O
)	SAPHRIS.xml:S3:13904:1	O
0.4	SAPHRIS.xml:S3:13913:3	O
(	SAPHRIS.xml:S3:13916:1	O
539	SAPHRIS.xml:S3:13917:3	O
)	SAPHRIS.xml:S3:13920:1	O
-	SAPHRIS.xml:S3:13927:1	O
1.5	SAPHRIS.xml:S3:13928:3	O
(	SAPHRIS.xml:S3:13931:1	O
163	SAPHRIS.xml:S3:13932:3	O
)	SAPHRIS.xml:S3:13935:1	O
1.1	SAPHRIS.xml:S3:13942:3	O
(	SAPHRIS.xml:S3:13945:1	O
322	SAPHRIS.xml:S3:13946:3	O
)	SAPHRIS.xml:S3:13949:1	O

LDL	SAPHRIS.xml:S3:13960:3	O
(	SAPHRIS.xml:S3:13964:1	O
N	SAPHRIS.xml:S3:13965:1	O
)	SAPHRIS.xml:S3:13967:1	O
0.1	SAPHRIS.xml:S3:13979:3	O
(	SAPHRIS.xml:S3:13982:1	O
285	SAPHRIS.xml:S3:13983:3	O
)	SAPHRIS.xml:S3:13986:1	O
-	SAPHRIS.xml:S3:13994:1	O
0.2	SAPHRIS.xml:S3:13995:3	O
(	SAPHRIS.xml:S3:13998:1	O
195	SAPHRIS.xml:S3:13999:3	O
)	SAPHRIS.xml:S3:14002:1	O
2.6	SAPHRIS.xml:S3:14010:3	O
(	SAPHRIS.xml:S3:14013:1	O
195	SAPHRIS.xml:S3:14014:3	O
)	SAPHRIS.xml:S3:14017:1	O
1.3	SAPHRIS.xml:S3:14026:3	O
(	SAPHRIS.xml:S3:14029:1	O
465	SAPHRIS.xml:S3:14030:3	O
)	SAPHRIS.xml:S3:14033:1	O
1.9	SAPHRIS.xml:S3:14040:3	O
(	SAPHRIS.xml:S3:14043:1	O
158	SAPHRIS.xml:S3:14044:3	O
)	SAPHRIS.xml:S3:14047:1	O
1.6	SAPHRIS.xml:S3:14055:3	O
(	SAPHRIS.xml:S3:14058:1	O
304	SAPHRIS.xml:S3:14059:3	O
)	SAPHRIS.xml:S3:14062:1	O

HDL	SAPHRIS.xml:S3:14073:3	O
(	SAPHRIS.xml:S3:14077:1	O
N	SAPHRIS.xml:S3:14078:1	O
)	SAPHRIS.xml:S3:14080:1	O
0.5	SAPHRIS.xml:S3:14092:3	O
(	SAPHRIS.xml:S3:14095:1	O
290	SAPHRIS.xml:S3:14096:3	O
)	SAPHRIS.xml:S3:14099:1	O
0.4	SAPHRIS.xml:S3:14107:3	O
(	SAPHRIS.xml:S3:14110:1	O
199	SAPHRIS.xml:S3:14111:3	O
)	SAPHRIS.xml:S3:14114:1	O
1.0	SAPHRIS.xml:S3:14123:3	O
(	SAPHRIS.xml:S3:14126:1	O
199	SAPHRIS.xml:S3:14127:3	O
)	SAPHRIS.xml:S3:14130:1	O
0.5	SAPHRIS.xml:S3:14139:3	O
(	SAPHRIS.xml:S3:14142:1	O
480	SAPHRIS.xml:S3:14143:3	O
)	SAPHRIS.xml:S3:14146:1	O
0.0	SAPHRIS.xml:S3:14153:3	O
(	SAPHRIS.xml:S3:14156:1	O
163	SAPHRIS.xml:S3:14157:3	O
)	SAPHRIS.xml:S3:14160:1	O
0.9	SAPHRIS.xml:S3:14168:3	O
(	SAPHRIS.xml:S3:14171:1	O
322	SAPHRIS.xml:S3:14172:3	O
)	SAPHRIS.xml:S3:14175:1	O

Fasting	SAPHRIS.xml:S3:14186:7	O
triglycerides	SAPHRIS.xml:S3:14194:13	O
(	SAPHRIS.xml:S3:14208:1	O
N	SAPHRIS.xml:S3:14209:1	O
)	SAPHRIS.xml:S3:14211:1	O
-	SAPHRIS.xml:S3:14214:1	O
7.6	SAPHRIS.xml:S3:14215:3	O
(	SAPHRIS.xml:S3:14218:1	O
233	SAPHRIS.xml:S3:14219:3	O
)	SAPHRIS.xml:S3:14222:1	O
-	SAPHRIS.xml:S3:14229:1	O
1.9	SAPHRIS.xml:S3:14230:3	O
(	SAPHRIS.xml:S3:14233:1	O
159	SAPHRIS.xml:S3:14234:3	O
)	SAPHRIS.xml:S3:14237:1	O
0.1	SAPHRIS.xml:S3:14245:3	O
(	SAPHRIS.xml:S3:14248:1	O
154	SAPHRIS.xml:S3:14249:3	O
)	SAPHRIS.xml:S3:14252:1	O
3.8	SAPHRIS.xml:S3:14261:3	O
(	SAPHRIS.xml:S3:14264:1	O
380	SAPHRIS.xml:S3:14265:3	O
)	SAPHRIS.xml:S3:14268:1	O
-	SAPHRIS.xml:S3:14275:1	O
17.9	SAPHRIS.xml:S3:14276:4	O
(	SAPHRIS.xml:S3:14280:1	O
129	SAPHRIS.xml:S3:14281:3	O
)	SAPHRIS.xml:S3:14284:1	O
-	SAPHRIS.xml:S3:14290:1	O
3.5	SAPHRIS.xml:S3:14291:3	O
(	SAPHRIS.xml:S3:14294:1	O
237	SAPHRIS.xml:S3:14295:3	O
)	SAPHRIS.xml:S3:14298:1	O

Proportion	SAPHRIS.xml:S3:14308:10	O
of	SAPHRIS.xml:S3:14319:2	O
Patients	SAPHRIS.xml:S3:14322:8	O
with	SAPHRIS.xml:S3:14331:4	O
Shifts	SAPHRIS.xml:S3:14336:6	O
from	SAPHRIS.xml:S3:14343:4	O
Baseline	SAPHRIS.xml:S3:14348:8	O
to	SAPHRIS.xml:S3:14357:2	O
Endpoint	SAPHRIS.xml:S3:14360:8	O

Total	SAPHRIS.xml:S3:14373:5	O
cholesterolNormal	SAPHRIS.xml:S3:14379:17	O
to	SAPHRIS.xml:S3:14397:2	O
High	SAPHRIS.xml:S3:14400:4	O
200	SAPHRIS.xml:S3:14405:3	O
to	SAPHRIS.xml:S3:14409:2	O
240	SAPHRIS.xml:S3:14414:3	O
(	SAPHRIS.xml:S3:14417:1	O
mg	SAPHRIS.xml:S3:14418:2	O
dL	SAPHRIS.xml:S3:14421:2	O
)	SAPHRIS.xml:S3:14423:1	O
(	SAPHRIS.xml:S3:14425:1	O
n	SAPHRIS.xml:S3:14426:1	O
N	SAPHRIS.xml:S3:14428:1	O
)	SAPHRIS.xml:S3:14430:1	O
1.3%	SAPHRIS.xml:S3:14433:4	O
(	SAPHRIS.xml:S3:14437:1	O
3	SAPHRIS.xml:S3:14438:1	O
225	SAPHRIS.xml:S3:14440:3	O
)	SAPHRIS.xml:S3:14443:1	O
0.6%	SAPHRIS.xml:S3:14448:4	O
(	SAPHRIS.xml:S3:14452:1	O
1	SAPHRIS.xml:S3:14453:1	O
161	SAPHRIS.xml:S3:14455:3	O
)	SAPHRIS.xml:S3:14458:1	O
2.2%	SAPHRIS.xml:S3:14464:4	O
(	SAPHRIS.xml:S3:14468:1	O
3	SAPHRIS.xml:S3:14469:1	O
134	SAPHRIS.xml:S3:14471:3	O
)	SAPHRIS.xml:S3:14474:1	O
1.7%	SAPHRIS.xml:S3:14480:4	O
(	SAPHRIS.xml:S3:14484:1	O
6	SAPHRIS.xml:S3:14485:1	O
343	SAPHRIS.xml:S3:14487:3	O
)	SAPHRIS.xml:S3:14490:1	O
1.1%	SAPHRIS.xml:S3:14494:4	O
(	SAPHRIS.xml:S3:14498:1	O
1	SAPHRIS.xml:S3:14499:1	O
95	SAPHRIS.xml:S3:14501:2	O
)	SAPHRIS.xml:S3:14503:1	O
2.5%	SAPHRIS.xml:S3:14509:4	O
(	SAPHRIS.xml:S3:14513:1	O
5	SAPHRIS.xml:S3:14514:1	O
204	SAPHRIS.xml:S3:14516:3	O
)	SAPHRIS.xml:S3:14519:1	O

LDLNormal	SAPHRIS.xml:S3:14527:9	O
to	SAPHRIS.xml:S3:14537:2	O
High	SAPHRIS.xml:S3:14540:4	O
100	SAPHRIS.xml:S3:14545:3	O
to	SAPHRIS.xml:S3:14549:2	O
160	SAPHRIS.xml:S3:14554:3	O
(	SAPHRIS.xml:S3:14557:1	O
mg	SAPHRIS.xml:S3:14558:2	O
dL	SAPHRIS.xml:S3:14561:2	O
)	SAPHRIS.xml:S3:14563:1	O
(	SAPHRIS.xml:S3:14565:1	O
n	SAPHRIS.xml:S3:14566:1	O
N	SAPHRIS.xml:S3:14568:1	O
)	SAPHRIS.xml:S3:14570:1	O
1.7%	SAPHRIS.xml:S3:14573:4	O
(	SAPHRIS.xml:S3:14577:1	O
2	SAPHRIS.xml:S3:14578:1	O
117	SAPHRIS.xml:S3:14580:3	O
)	SAPHRIS.xml:S3:14583:1	O
0.0%	SAPHRIS.xml:S3:14588:4	O
(	SAPHRIS.xml:S3:14592:1	O
0	SAPHRIS.xml:S3:14593:1	O
80	SAPHRIS.xml:S3:14595:2	O
)	SAPHRIS.xml:S3:14597:1	O
1.2%	SAPHRIS.xml:S3:14604:4	O
(	SAPHRIS.xml:S3:14608:1	O
1	SAPHRIS.xml:S3:14609:1	O
86	SAPHRIS.xml:S3:14611:2	O
)	SAPHRIS.xml:S3:14613:1	O
1.0%	SAPHRIS.xml:S3:14620:4	O
(	SAPHRIS.xml:S3:14624:1	O
2	SAPHRIS.xml:S3:14625:1	O
196	SAPHRIS.xml:S3:14627:3	O
)	SAPHRIS.xml:S3:14630:1	O
1.9%	SAPHRIS.xml:S3:14634:4	O
(	SAPHRIS.xml:S3:14638:1	O
1	SAPHRIS.xml:S3:14639:1	O
53	SAPHRIS.xml:S3:14641:2	O
)	SAPHRIS.xml:S3:14643:1	O
0.0%	SAPHRIS.xml:S3:14649:4	O
(	SAPHRIS.xml:S3:14653:1	O
0	SAPHRIS.xml:S3:14654:1	O
141	SAPHRIS.xml:S3:14656:3	O
)	SAPHRIS.xml:S3:14659:1	O

HDLNormal	SAPHRIS.xml:S3:14667:9	O
to	SAPHRIS.xml:S3:14677:2	O
Low	SAPHRIS.xml:S3:14680:3	O
40	SAPHRIS.xml:S3:14685:2	O
to	SAPHRIS.xml:S3:14688:2	O
40	SAPHRIS.xml:S3:14692:2	O
(	SAPHRIS.xml:S3:14695:1	O
mg	SAPHRIS.xml:S3:14696:2	O
dL	SAPHRIS.xml:S3:14699:2	O
)	SAPHRIS.xml:S3:14701:1	O
(	SAPHRIS.xml:S3:14703:1	O
n	SAPHRIS.xml:S3:14704:1	O
N	SAPHRIS.xml:S3:14706:1	O
)	SAPHRIS.xml:S3:14708:1	O
10.7%	SAPHRIS.xml:S3:14711:5	O
(	SAPHRIS.xml:S3:14716:1	O
21	SAPHRIS.xml:S3:14717:2	O
196	SAPHRIS.xml:S3:14720:3	O
)	SAPHRIS.xml:S3:14723:1	O
13.3%	SAPHRIS.xml:S3:14726:5	O
(	SAPHRIS.xml:S3:14731:1	O
18	SAPHRIS.xml:S3:14732:2	O
135	SAPHRIS.xml:S3:14735:3	O
)	SAPHRIS.xml:S3:14738:1	O
14.7%	SAPHRIS.xml:S3:14742:5	O
(	SAPHRIS.xml:S3:14747:1	O
20	SAPHRIS.xml:S3:14748:2	O
136	SAPHRIS.xml:S3:14751:3	O
)	SAPHRIS.xml:S3:14754:1	O
14.0%	SAPHRIS.xml:S3:14758:5	O
(	SAPHRIS.xml:S3:14763:1	O
45	SAPHRIS.xml:S3:14764:2	O
322	SAPHRIS.xml:S3:14767:3	O
)	SAPHRIS.xml:S3:14770:1	O
7.4%	SAPHRIS.xml:S3:14773:4	O
(	SAPHRIS.xml:S3:14777:1	O
9	SAPHRIS.xml:S3:14778:1	O
122	SAPHRIS.xml:S3:14780:3	O
)	SAPHRIS.xml:S3:14783:1	O
8.7%	SAPHRIS.xml:S3:14788:4	O
(	SAPHRIS.xml:S3:14792:1	O
21	SAPHRIS.xml:S3:14793:2	O
242	SAPHRIS.xml:S3:14796:3	O
)	SAPHRIS.xml:S3:14799:1	O

Fasting	SAPHRIS.xml:S3:14806:7	O
triglyceridesNormal	SAPHRIS.xml:S3:14814:19	O
to	SAPHRIS.xml:S3:14834:2	O
High	SAPHRIS.xml:S3:14837:4	O
150	SAPHRIS.xml:S3:14842:3	O
to	SAPHRIS.xml:S3:14846:2	O
200	SAPHRIS.xml:S3:14851:3	O
(	SAPHRIS.xml:S3:14855:1	O
mg	SAPHRIS.xml:S3:14856:2	O
dL	SAPHRIS.xml:S3:14859:2	O
)	SAPHRIS.xml:S3:14861:1	O
(	SAPHRIS.xml:S3:14863:1	O
n	SAPHRIS.xml:S3:14864:1	O
N	SAPHRIS.xml:S3:14866:1	O
)	SAPHRIS.xml:S3:14868:1	O
2.4%	SAPHRIS.xml:S3:14871:4	O
(	SAPHRIS.xml:S3:14875:1	O
4	SAPHRIS.xml:S3:14876:1	O
167	SAPHRIS.xml:S3:14878:3	O
)	SAPHRIS.xml:S3:14881:1	O
7.0%	SAPHRIS.xml:S3:14886:4	O
(	SAPHRIS.xml:S3:14890:1	O
8	SAPHRIS.xml:S3:14891:1	O
115	SAPHRIS.xml:S3:14893:3	O
)	SAPHRIS.xml:S3:14896:1	O
8.3%	SAPHRIS.xml:S3:14902:4	O
(	SAPHRIS.xml:S3:14906:1	O
9	SAPHRIS.xml:S3:14907:1	O
108	SAPHRIS.xml:S3:14909:3	O
)	SAPHRIS.xml:S3:14912:1	O
7.7%	SAPHRIS.xml:S3:14918:4	O
(	SAPHRIS.xml:S3:14922:1	O
20	SAPHRIS.xml:S3:14923:2	O
260	SAPHRIS.xml:S3:14926:3	O
)	SAPHRIS.xml:S3:14929:1	O
5.1%	SAPHRIS.xml:S3:14932:4	O
(	SAPHRIS.xml:S3:14936:1	O
4	SAPHRIS.xml:S3:14937:1	O
78	SAPHRIS.xml:S3:14939:2	O
)	SAPHRIS.xml:S3:14941:1	O
7.4%	SAPHRIS.xml:S3:14947:4	O
(	SAPHRIS.xml:S3:14951:1	O
11	SAPHRIS.xml:S3:14952:2	O
148	SAPHRIS.xml:S3:14955:3	O
)	SAPHRIS.xml:S3:14958:1	O

In	SAPHRIS.xml:S3:14981:2	O
short	SAPHRIS.xml:S3:14984:5	O
-	SAPHRIS.xml:S3:14989:1	O
term	SAPHRIS.xml:S3:14990:4	O
schizophrenia	SAPHRIS.xml:S3:14995:13	O
trials	SAPHRIS.xml:S3:15009:6	O
,	SAPHRIS.xml:S3:15015:1	O
the	SAPHRIS.xml:S3:15017:3	O
proportion	SAPHRIS.xml:S3:15021:10	O
of	SAPHRIS.xml:S3:15032:2	O
patients	SAPHRIS.xml:S3:15035:8	O
with	SAPHRIS.xml:S3:15044:4	O
total	SAPHRIS.xml:S3:15049:5	B-AdverseReaction
cholesterol	SAPHRIS.xml:S3:15055:11	I-AdverseReaction
elevations	SAPHRIS.xml:S3:15067:10	I-AdverseReaction
240	SAPHRIS.xml:S3:15080:3	B-Severity
mg	SAPHRIS.xml:S3:15084:2	I-Severity
dL	SAPHRIS.xml:S3:15087:2	I-Severity
(	SAPHRIS.xml:S3:15090:1	O
at	SAPHRIS.xml:S3:15091:2	O
Endpoint	SAPHRIS.xml:S3:15094:8	O
)	SAPHRIS.xml:S3:15102:1	O
was	SAPHRIS.xml:S3:15104:3	O
8.3%	SAPHRIS.xml:S3:15108:4	O
for	SAPHRIS.xml:S3:15113:3	O
SAPHRIS	SAPHRIS.xml:S3:15117:7	O
-	SAPHRIS.xml:S3:15124:1	O
treated	SAPHRIS.xml:S3:15125:7	O
patients	SAPHRIS.xml:S3:15133:8	O
versus	SAPHRIS.xml:S3:15142:6	O
7%	SAPHRIS.xml:S3:15149:2	O
for	SAPHRIS.xml:S3:15152:3	O
placebo	SAPHRIS.xml:S3:15156:7	O
-	SAPHRIS.xml:S3:15163:1	O
treated	SAPHRIS.xml:S3:15164:7	O
patients	SAPHRIS.xml:S3:15172:8	O
.	SAPHRIS.xml:S3:15180:1	O

The	SAPHRIS.xml:S3:15182:3	O
proportion	SAPHRIS.xml:S3:15186:10	O
of	SAPHRIS.xml:S3:15197:2	O
patients	SAPHRIS.xml:S3:15200:8	O
with	SAPHRIS.xml:S3:15209:4	O
elevations	SAPHRIS.xml:S3:15214:10	B-AdverseReaction
in	SAPHRIS.xml:S3:15225:2	I-AdverseReaction
triglycerides	SAPHRIS.xml:S3:15228:13	I-AdverseReaction
200	SAPHRIS.xml:S3:15244:3	B-Severity
mg	SAPHRIS.xml:S3:15248:2	I-Severity
dL	SAPHRIS.xml:S3:15251:2	I-Severity
(	SAPHRIS.xml:S3:15254:1	O
at	SAPHRIS.xml:S3:15255:2	O
Endpoint	SAPHRIS.xml:S3:15258:8	O
)	SAPHRIS.xml:S3:15266:1	O
was	SAPHRIS.xml:S3:15268:3	O
13.2%	SAPHRIS.xml:S3:15272:5	O
for	SAPHRIS.xml:S3:15278:3	O
SAPHRIS	SAPHRIS.xml:S3:15282:7	O
-	SAPHRIS.xml:S3:15289:1	O
treated	SAPHRIS.xml:S3:15290:7	O
patients	SAPHRIS.xml:S3:15298:8	O
versus	SAPHRIS.xml:S3:15307:6	O
10.5%	SAPHRIS.xml:S3:15314:5	O
for	SAPHRIS.xml:S3:15320:3	O
placebo	SAPHRIS.xml:S3:15324:7	O
-	SAPHRIS.xml:S3:15331:1	O
treated	SAPHRIS.xml:S3:15332:7	O
patients	SAPHRIS.xml:S3:15340:8	O
.	SAPHRIS.xml:S3:15348:1	O

In	SAPHRIS.xml:S3:15350:2	O
short	SAPHRIS.xml:S3:15353:5	O
-	SAPHRIS.xml:S3:15358:1	O
term	SAPHRIS.xml:S3:15359:4	O
,	SAPHRIS.xml:S3:15363:1	O
placebo	SAPHRIS.xml:S3:15365:7	O
-	SAPHRIS.xml:S3:15372:1	O
controlled	SAPHRIS.xml:S3:15373:10	O
bipolar	SAPHRIS.xml:S3:15384:7	O
mania	SAPHRIS.xml:S3:15392:5	O
trials	SAPHRIS.xml:S3:15398:6	O
,	SAPHRIS.xml:S3:15404:1	O
the	SAPHRIS.xml:S3:15406:3	O
proportion	SAPHRIS.xml:S3:15410:10	O
of	SAPHRIS.xml:S3:15421:2	O
patients	SAPHRIS.xml:S3:15424:8	O
with	SAPHRIS.xml:S3:15433:4	O
total	SAPHRIS.xml:S3:15438:5	B-AdverseReaction
cholesterol	SAPHRIS.xml:S3:15444:11	I-AdverseReaction
elevations	SAPHRIS.xml:S3:15456:10	I-AdverseReaction
240	SAPHRIS.xml:S3:15469:3	B-Severity
mg	SAPHRIS.xml:S3:15473:2	I-Severity
dL	SAPHRIS.xml:S3:15476:2	I-Severity
(	SAPHRIS.xml:S3:15479:1	O
at	SAPHRIS.xml:S3:15480:2	O
Endpoint	SAPHRIS.xml:S3:15483:8	O
)	SAPHRIS.xml:S3:15491:1	O
was	SAPHRIS.xml:S3:15493:3	O
8.7%	SAPHRIS.xml:S3:15497:4	O
for	SAPHRIS.xml:S3:15502:3	O
SAPHRIS	SAPHRIS.xml:S3:15506:7	O
-	SAPHRIS.xml:S3:15513:1	O
treated	SAPHRIS.xml:S3:15514:7	O
patients	SAPHRIS.xml:S3:15522:8	O
versus	SAPHRIS.xml:S3:15531:6	O
8.6%	SAPHRIS.xml:S3:15538:4	O
for	SAPHRIS.xml:S3:15543:3	O
placebo	SAPHRIS.xml:S3:15547:7	O
-	SAPHRIS.xml:S3:15554:1	O
treated	SAPHRIS.xml:S3:15555:7	O
patients	SAPHRIS.xml:S3:15563:8	O
.	SAPHRIS.xml:S3:15571:1	O

The	SAPHRIS.xml:S3:15573:3	O
proportion	SAPHRIS.xml:S3:15577:10	O
of	SAPHRIS.xml:S3:15588:2	O
patients	SAPHRIS.xml:S3:15591:8	O
with	SAPHRIS.xml:S3:15600:4	O
elevations	SAPHRIS.xml:S3:15605:10	B-AdverseReaction
in	SAPHRIS.xml:S3:15616:2	I-AdverseReaction
triglycerides	SAPHRIS.xml:S3:15619:13	I-AdverseReaction
200	SAPHRIS.xml:S3:15635:3	B-Severity
mg	SAPHRIS.xml:S3:15639:2	I-Severity
dL	SAPHRIS.xml:S3:15642:2	I-Severity
(	SAPHRIS.xml:S3:15645:1	O
at	SAPHRIS.xml:S3:15646:2	O
Endpoint	SAPHRIS.xml:S3:15649:8	O
)	SAPHRIS.xml:S3:15657:1	O
was	SAPHRIS.xml:S3:15659:3	O
15.2%	SAPHRIS.xml:S3:15663:5	O
for	SAPHRIS.xml:S3:15669:3	O
SAPHRIS	SAPHRIS.xml:S3:15673:7	O
-	SAPHRIS.xml:S3:15680:1	O
treated	SAPHRIS.xml:S3:15681:7	O
patients	SAPHRIS.xml:S3:15689:8	O
versus	SAPHRIS.xml:S3:15698:6	O
11.4%	SAPHRIS.xml:S3:15705:5	O
for	SAPHRIS.xml:S3:15711:3	O
placebo	SAPHRIS.xml:S3:15715:7	O
-	SAPHRIS.xml:S3:15722:1	O
treated	SAPHRIS.xml:S3:15723:7	O
patients	SAPHRIS.xml:S3:15731:8	O
.	SAPHRIS.xml:S3:15739:1	O

In	SAPHRIS.xml:S3:15749:2	O

a	SAPHRIS.xml:S3:15752:1	O
52	SAPHRIS.xml:S3:15754:2	O
-	SAPHRIS.xml:S3:15756:1	O
week	SAPHRIS.xml:S3:15757:4	O
,	SAPHRIS.xml:S3:15761:1	O
double	SAPHRIS.xml:S3:15763:6	O
-	SAPHRIS.xml:S3:15769:1	O
blind	SAPHRIS.xml:S3:15770:5	O
,	SAPHRIS.xml:S3:15775:1	O
comparator	SAPHRIS.xml:S3:15777:10	O
-	SAPHRIS.xml:S3:15787:1	O
controlled	SAPHRIS.xml:S3:15788:10	O
trial	SAPHRIS.xml:S3:15799:5	O
that	SAPHRIS.xml:S3:15805:4	O
included	SAPHRIS.xml:S3:15810:8	O
primarily	SAPHRIS.xml:S3:15819:9	O
patients	SAPHRIS.xml:S3:15829:8	O
with	SAPHRIS.xml:S3:15838:4	O
schizophrenia	SAPHRIS.xml:S3:15843:13	O
,	SAPHRIS.xml:S3:15856:1	O
the	SAPHRIS.xml:S3:15858:3	O
mean	SAPHRIS.xml:S3:15862:4	O
decrease	SAPHRIS.xml:S3:15867:8	O
from	SAPHRIS.xml:S3:15876:4	O
baseline	SAPHRIS.xml:S3:15881:8	O
of	SAPHRIS.xml:S3:15890:2	O
total	SAPHRIS.xml:S3:15893:5	O
cholesterol	SAPHRIS.xml:S3:15899:11	O
was	SAPHRIS.xml:S3:15911:3	O
6	SAPHRIS.xml:S3:15915:1	O
mg	SAPHRIS.xml:S3:15917:2	O
dL	SAPHRIS.xml:S3:15920:2	O
and	SAPHRIS.xml:S3:15923:3	O
the	SAPHRIS.xml:S3:15927:3	O
mean	SAPHRIS.xml:S3:15931:4	O
decrease	SAPHRIS.xml:S3:15936:8	O
from	SAPHRIS.xml:S3:15945:4	O
baseline	SAPHRIS.xml:S3:15950:8	O
of	SAPHRIS.xml:S3:15959:2	O
fasting	SAPHRIS.xml:S3:15962:7	O
triglycerides	SAPHRIS.xml:S3:15970:13	O
was	SAPHRIS.xml:S3:15984:3	O
9.8	SAPHRIS.xml:S3:15988:3	O
mg	SAPHRIS.xml:S3:15992:2	O
dL	SAPHRIS.xml:S3:15995:2	O
.	SAPHRIS.xml:S3:15997:1	O

Pediatric	SAPHRIS.xml:S3:16011:9	O
Patients	SAPHRIS.xml:S3:16021:8	O
:	SAPHRIS.xml:S3:16029:1	O
Data	SAPHRIS.xml:S3:16032:4	O
from	SAPHRIS.xml:S3:16037:4	O
the	SAPHRIS.xml:S3:16042:3	O
short	SAPHRIS.xml:S3:16046:5	O
-	SAPHRIS.xml:S3:16051:1	O
term	SAPHRIS.xml:S3:16052:4	O
,	SAPHRIS.xml:S3:16056:1	O
placebo	SAPHRIS.xml:S3:16058:7	O
-	SAPHRIS.xml:S3:16065:1	O
controlled	SAPHRIS.xml:S3:16066:10	O
bipolar	SAPHRIS.xml:S3:16077:7	O
mania	SAPHRIS.xml:S3:16085:5	O
trial	SAPHRIS.xml:S3:16091:5	O
are	SAPHRIS.xml:S3:16097:3	O
presented	SAPHRIS.xml:S3:16101:9	O
in	SAPHRIS.xml:S3:16111:2	O
Table	SAPHRIS.xml:S3:16115:5	O
4	SAPHRIS.xml:S3:16121:1	O
.	SAPHRIS.xml:S3:16124:1	O

TABLE	SAPHRIS.xml:S3:16130:5	O
4	SAPHRIS.xml:S3:16136:1	O
:	SAPHRIS.xml:S3:16137:1	O
Changes	SAPHRIS.xml:S3:16139:7	O
in	SAPHRIS.xml:S3:16147:2	O
Fasting	SAPHRIS.xml:S3:16150:7	O
Lipids	SAPHRIS.xml:S3:16158:6	O
in	SAPHRIS.xml:S3:16165:2	O
Pediatric	SAPHRIS.xml:S3:16168:9	O
Subjects	SAPHRIS.xml:S3:16178:8	O

N	SAPHRIS.xml:S3:16190:1	O
Number	SAPHRIS.xml:S3:16195:6	O
of	SAPHRIS.xml:S3:16202:2	O
patients	SAPHRIS.xml:S3:16205:8	O
who	SAPHRIS.xml:S3:16214:3	O
had	SAPHRIS.xml:S3:16218:3	O
assessments	SAPHRIS.xml:S3:16222:11	O
at	SAPHRIS.xml:S3:16234:2	O
both	SAPHRIS.xml:S3:16237:4	O
Baseline	SAPHRIS.xml:S3:16242:8	O
and	SAPHRIS.xml:S3:16251:3	O
Endpoint	SAPHRIS.xml:S3:16255:8	O

Bipolar	SAPHRIS.xml:S3:16304:7	O

I	SAPHRIS.xml:S3:16312:1	O
Disorder	SAPHRIS.xml:S3:16314:8	O
(	SAPHRIS.xml:S3:16323:1	O
3	SAPHRIS.xml:S3:16324:1	O
-	SAPHRIS.xml:S3:16325:1	O
weeks	SAPHRIS.xml:S3:16326:5	O
)	SAPHRIS.xml:S3:16331:1	O

Placebo	SAPHRIS.xml:S3:16369:7	O
SAPHRIS2	SAPHRIS.xml:S3:16385:8	O
.	SAPHRIS.xml:S3:16393:1	O
5	SAPHRIS.xml:S3:16394:1	O
mgtwice	SAPHRIS.xml:S3:16396:7	O
daily	SAPHRIS.xml:S3:16404:5	O
SAPHRIS5	SAPHRIS.xml:S3:16411:8	O
mgtwice	SAPHRIS.xml:S3:16420:7	O
daily	SAPHRIS.xml:S3:16428:5	O
SAPHRIS10	SAPHRIS.xml:S3:16435:9	O
mgtwice	SAPHRIS.xml:S3:16445:7	O
daily	SAPHRIS.xml:S3:16453:5	O

Mean	SAPHRIS.xml:S3:16463:4	O
Change	SAPHRIS.xml:S3:16468:6	O
from	SAPHRIS.xml:S3:16475:4	O
Baseline	SAPHRIS.xml:S3:16480:8	O
(	SAPHRIS.xml:S3:16489:1	O
mg	SAPHRIS.xml:S3:16490:2	O
dL	SAPHRIS.xml:S3:16493:2	O
)	SAPHRIS.xml:S3:16495:1	O

Total	SAPHRIS.xml:S3:16501:5	O
fasting	SAPHRIS.xml:S3:16507:7	O
cholesterol	SAPHRIS.xml:S3:16515:11	O
(	SAPHRIS.xml:S3:16527:1	O
N	SAPHRIS.xml:S3:16528:1	O
)	SAPHRIS.xml:S3:16530:1	O
-	SAPHRIS.xml:S3:16533:1	O
2.3	SAPHRIS.xml:S3:16534:3	O
(	SAPHRIS.xml:S3:16537:1	O
57	SAPHRIS.xml:S3:16538:2	O
)	SAPHRIS.xml:S3:16540:1	O
3.7	SAPHRIS.xml:S3:16549:3	O
(	SAPHRIS.xml:S3:16552:1	O
50	SAPHRIS.xml:S3:16553:2	O
)	SAPHRIS.xml:S3:16555:1	O
7.2	SAPHRIS.xml:S3:16569:3	O
(	SAPHRIS.xml:S3:16572:1	O
57	SAPHRIS.xml:S3:16573:2	O
)	SAPHRIS.xml:S3:16575:1	O
9.3	SAPHRIS.xml:S3:16589:3	O
(	SAPHRIS.xml:S3:16592:1	O
52	SAPHRIS.xml:S3:16593:2	O
)	SAPHRIS.xml:S3:16595:1	O

Fasting	SAPHRIS.xml:S3:16612:7	O
LDL	SAPHRIS.xml:S3:16620:3	O
(	SAPHRIS.xml:S3:16623:1	O
N	SAPHRIS.xml:S3:16624:1	O
)	SAPHRIS.xml:S3:16626:1	O
-	SAPHRIS.xml:S3:16644:1	O
2.5	SAPHRIS.xml:S3:16645:3	O
(	SAPHRIS.xml:S3:16648:1	O
57	SAPHRIS.xml:S3:16649:2	O
)	SAPHRIS.xml:S3:16651:1	O
-	SAPHRIS.xml:S3:16660:1	O
0.2	SAPHRIS.xml:S3:16661:3	O
(	SAPHRIS.xml:S3:16664:1	O
50	SAPHRIS.xml:S3:16665:2	O
)	SAPHRIS.xml:S3:16667:1	O
3.0	SAPHRIS.xml:S3:16680:3	O
(	SAPHRIS.xml:S3:16683:1	O
57	SAPHRIS.xml:S3:16684:2	O
)	SAPHRIS.xml:S3:16686:1	O
4.9	SAPHRIS.xml:S3:16700:3	O
(	SAPHRIS.xml:S3:16703:1	O
51	SAPHRIS.xml:S3:16704:2	O
)	SAPHRIS.xml:S3:16706:1	O

Fasting	SAPHRIS.xml:S3:16723:7	O
HDL	SAPHRIS.xml:S3:16731:3	O
(	SAPHRIS.xml:S3:16734:1	O
N	SAPHRIS.xml:S3:16735:1	O
)	SAPHRIS.xml:S3:16737:1	O
1.6	SAPHRIS.xml:S3:16755:3	O
(	SAPHRIS.xml:S3:16758:1	O
57	SAPHRIS.xml:S3:16759:2	O
)	SAPHRIS.xml:S3:16761:1	O
2.3	SAPHRIS.xml:S3:16771:3	O
(	SAPHRIS.xml:S3:16774:1	O
50	SAPHRIS.xml:S3:16775:2	O
)	SAPHRIS.xml:S3:16777:1	O
1.5	SAPHRIS.xml:S3:16791:3	O
(	SAPHRIS.xml:S3:16794:1	O
57	SAPHRIS.xml:S3:16795:2	O
)	SAPHRIS.xml:S3:16797:1	O
1.7	SAPHRIS.xml:S3:16811:3	O
(	SAPHRIS.xml:S3:16814:1	O
52	SAPHRIS.xml:S3:16815:2	O
)	SAPHRIS.xml:S3:16817:1	O

Fasting	SAPHRIS.xml:S3:16834:7	O
triglycerides	SAPHRIS.xml:S3:16842:13	O
(	SAPHRIS.xml:S3:16856:1	O
N	SAPHRIS.xml:S3:16857:1	O
)	SAPHRIS.xml:S3:16859:1	O
-	SAPHRIS.xml:S3:16866:1	O
6.6	SAPHRIS.xml:S3:16867:3	O
(	SAPHRIS.xml:S3:16870:1	O
57	SAPHRIS.xml:S3:16871:2	O
)	SAPHRIS.xml:S3:16873:1	O
8.7	SAPHRIS.xml:S3:16882:3	O
(	SAPHRIS.xml:S3:16885:1	O
50	SAPHRIS.xml:S3:16886:2	O
)	SAPHRIS.xml:S3:16888:1	O
13.4	SAPHRIS.xml:S3:16902:4	O
(	SAPHRIS.xml:S3:16906:1	O
57	SAPHRIS.xml:S3:16907:2	O
)	SAPHRIS.xml:S3:16909:1	O
14.7	SAPHRIS.xml:S3:16922:4	O
(	SAPHRIS.xml:S3:16926:1	O
52	SAPHRIS.xml:S3:16927:2	O
)	SAPHRIS.xml:S3:16929:1	O

Proportion	SAPHRIS.xml:S3:16945:10	O
of	SAPHRIS.xml:S3:16956:2	O
Subjects	SAPHRIS.xml:S3:16959:8	O
with	SAPHRIS.xml:S3:16968:4	O
Shifts	SAPHRIS.xml:S3:16973:6	O
from	SAPHRIS.xml:S3:16980:4	O
Baseline	SAPHRIS.xml:S3:16985:8	O
to	SAPHRIS.xml:S3:16994:2	O
Endpoint	SAPHRIS.xml:S3:16997:8	O

Total	SAPHRIS.xml:S3:17010:5	O
fasting	SAPHRIS.xml:S3:17016:7	O
cholesterolNormal	SAPHRIS.xml:S3:17024:17	O
to	SAPHRIS.xml:S3:17042:2	O
High	SAPHRIS.xml:S3:17045:4	O
170	SAPHRIS.xml:S3:17050:3	O
to	SAPHRIS.xml:S3:17054:2	O
200	SAPHRIS.xml:S3:17059:3	O
(	SAPHRIS.xml:S3:17062:1	O
mg	SAPHRIS.xml:S3:17063:2	O
dL	SAPHRIS.xml:S3:17066:2	O
)(	SAPHRIS.xml:S3:17068:2	O
n	SAPHRIS.xml:S3:17070:1	O
N	SAPHRIS.xml:S3:17072:1	O
)	SAPHRIS.xml:S3:17074:1	O
1.8%	SAPHRIS.xml:S3:17077:4	O
(	SAPHRIS.xml:S3:17081:1	O
1	SAPHRIS.xml:S3:17082:1	O
57	SAPHRIS.xml:S3:17084:2	O
)	SAPHRIS.xml:S3:17086:1	O
0%	SAPHRIS.xml:S3:17093:2	O
(	SAPHRIS.xml:S3:17095:1	O
0	SAPHRIS.xml:S3:17096:1	O
50	SAPHRIS.xml:S3:17098:2	O
)	SAPHRIS.xml:S3:17100:1	O
1.8%	SAPHRIS.xml:S3:17113:4	O
(	SAPHRIS.xml:S3:17117:1	O
1	SAPHRIS.xml:S3:17118:1	O
57	SAPHRIS.xml:S3:17120:2	O
)	SAPHRIS.xml:S3:17122:1	O
0%	SAPHRIS.xml:S3:17133:2	O
(	SAPHRIS.xml:S3:17135:1	O
0	SAPHRIS.xml:S3:17136:1	O
52	SAPHRIS.xml:S3:17138:2	O
)	SAPHRIS.xml:S3:17140:1	O

Fasting	SAPHRIS.xml:S3:17156:7	O
LDLNormal	SAPHRIS.xml:S3:17164:9	O
to	SAPHRIS.xml:S3:17174:2	O
High	SAPHRIS.xml:S3:17177:4	O
110	SAPHRIS.xml:S3:17182:3	O
to	SAPHRIS.xml:S3:17186:2	O
130	SAPHRIS.xml:S3:17191:3	O
(	SAPHRIS.xml:S3:17194:1	O
n	SAPHRIS.xml:S3:17195:1	O
N	SAPHRIS.xml:S3:17197:1	O
)	SAPHRIS.xml:S3:17199:1	O
1.8%	SAPHRIS.xml:S3:17202:4	O
(	SAPHRIS.xml:S3:17206:1	O
1	SAPHRIS.xml:S3:17207:1	O
57	SAPHRIS.xml:S3:17209:2	O
)	SAPHRIS.xml:S3:17211:1	O
2.0%	SAPHRIS.xml:S3:17218:4	O
(	SAPHRIS.xml:S3:17222:1	O
1	SAPHRIS.xml:S3:17223:1	O
50	SAPHRIS.xml:S3:17225:2	O
)	SAPHRIS.xml:S3:17227:1	O
1.8%	SAPHRIS.xml:S3:17238:4	O
(	SAPHRIS.xml:S3:17242:1	O
1	SAPHRIS.xml:S3:17243:1	O
57	SAPHRIS.xml:S3:17245:2	O
)	SAPHRIS.xml:S3:17247:1	O
0%	SAPHRIS.xml:S3:17258:2	O
(	SAPHRIS.xml:S3:17260:1	O
0	SAPHRIS.xml:S3:17261:1	O
51	SAPHRIS.xml:S3:17263:2	O
)	SAPHRIS.xml:S3:17265:1	O

Fasting	SAPHRIS.xml:S3:17281:7	O
HDLNormal	SAPHRIS.xml:S3:17289:9	O
to	SAPHRIS.xml:S3:17299:2	O
Low	SAPHRIS.xml:S3:17302:3	O
40	SAPHRIS.xml:S3:17307:2	O
to	SAPHRIS.xml:S3:17310:2	O
40	SAPHRIS.xml:S3:17314:2	O
(	SAPHRIS.xml:S3:17317:1	O
mg	SAPHRIS.xml:S3:17318:2	O
dL	SAPHRIS.xml:S3:17321:2	O
)(	SAPHRIS.xml:S3:17323:2	O
n	SAPHRIS.xml:S3:17325:1	O
N	SAPHRIS.xml:S3:17327:1	O
)	SAPHRIS.xml:S3:17329:1	O
3.5%	SAPHRIS.xml:S3:17332:4	O
(	SAPHRIS.xml:S3:17336:1	O
2	SAPHRIS.xml:S3:17337:1	O
57	SAPHRIS.xml:S3:17339:2	O
)	SAPHRIS.xml:S3:17341:1	O
6.0%	SAPHRIS.xml:S3:17348:4	O
(	SAPHRIS.xml:S3:17352:1	O
3	SAPHRIS.xml:S3:17353:1	O
50	SAPHRIS.xml:S3:17355:2	O
)	SAPHRIS.xml:S3:17357:1	O
3.5%	SAPHRIS.xml:S3:17368:4	O
(	SAPHRIS.xml:S3:17372:1	O
2	SAPHRIS.xml:S3:17373:1	O
57	SAPHRIS.xml:S3:17375:2	O
)	SAPHRIS.xml:S3:17377:1	O
9.6%	SAPHRIS.xml:S3:17388:4	O
(	SAPHRIS.xml:S3:17392:1	O
5	SAPHRIS.xml:S3:17393:1	O
52	SAPHRIS.xml:S3:17395:2	O
)	SAPHRIS.xml:S3:17397:1	O

Fasting	SAPHRIS.xml:S3:17411:7	O
triglyceridesNormal	SAPHRIS.xml:S3:17419:19	O
to	SAPHRIS.xml:S3:17439:2	O
High	SAPHRIS.xml:S3:17442:4	O
150	SAPHRIS.xml:S3:17447:3	O
to	SAPHRIS.xml:S3:17451:2	O
200	SAPHRIS.xml:S3:17456:3	O
(	SAPHRIS.xml:S3:17460:1	O
mg	SAPHRIS.xml:S3:17461:2	O
dL	SAPHRIS.xml:S3:17464:2	O
)(	SAPHRIS.xml:S3:17466:2	O
n	SAPHRIS.xml:S3:17468:1	O
N	SAPHRIS.xml:S3:17470:1	O
)	SAPHRIS.xml:S3:17472:1	O
0%	SAPHRIS.xml:S3:17475:2	O
(	SAPHRIS.xml:S3:17477:1	O
0	SAPHRIS.xml:S3:17478:1	O
57	SAPHRIS.xml:S3:17480:2	O
)	SAPHRIS.xml:S3:17482:1	O
4.0%	SAPHRIS.xml:S3:17491:4	O
(	SAPHRIS.xml:S3:17495:1	O
2	SAPHRIS.xml:S3:17496:1	O
50	SAPHRIS.xml:S3:17498:2	O
)	SAPHRIS.xml:S3:17500:1	O
3.5%	SAPHRIS.xml:S3:17511:4	O
(	SAPHRIS.xml:S3:17515:1	O
2	SAPHRIS.xml:S3:17516:1	O
57	SAPHRIS.xml:S3:17518:2	O
)	SAPHRIS.xml:S3:17520:1	O
1.9%	SAPHRIS.xml:S3:17531:4	O
(	SAPHRIS.xml:S3:17535:1	O
1	SAPHRIS.xml:S3:17536:1	O
52	SAPHRIS.xml:S3:17538:2	O
)	SAPHRIS.xml:S3:17540:1	O

Weight	SAPHRIS.xml:S3:17572:6	O
Gain	SAPHRIS.xml:S3:17579:4	O

Increases	SAPHRIS.xml:S3:17594:9	B-AdverseReaction

in	SAPHRIS.xml:S3:17604:2	I-AdverseReaction
weight	SAPHRIS.xml:S3:17607:6	I-AdverseReaction
have	SAPHRIS.xml:S3:17614:4	O
been	SAPHRIS.xml:S3:17619:4	O
observed	SAPHRIS.xml:S3:17624:8	O
in	SAPHRIS.xml:S3:17633:2	O
pre	SAPHRIS.xml:S3:17636:3	O
-	SAPHRIS.xml:S3:17639:1	O
marketing	SAPHRIS.xml:S3:17640:9	O
clinical	SAPHRIS.xml:S3:17650:8	O
trials	SAPHRIS.xml:S3:17659:6	O
with	SAPHRIS.xml:S3:17666:4	O
SAPHRIS	SAPHRIS.xml:S3:17671:7	O
.	SAPHRIS.xml:S3:17678:1	O

Patients	SAPHRIS.xml:S3:17680:8	O
receiving	SAPHRIS.xml:S3:17689:9	O
SAPHRIS	SAPHRIS.xml:S3:17699:7	O
should	SAPHRIS.xml:S3:17707:6	O
receive	SAPHRIS.xml:S3:17714:7	O
regular	SAPHRIS.xml:S3:17722:7	O
monitoring	SAPHRIS.xml:S3:17730:10	O
of	SAPHRIS.xml:S3:17741:2	O
weight	SAPHRIS.xml:S3:17744:6	O
[	SAPHRIS.xml:S3:17752:1	O
see	SAPHRIS.xml:S3:17753:3	O
Patient	SAPHRIS.xml:S3:17757:7	O
Counseling	SAPHRIS.xml:S3:17765:10	O
Information	SAPHRIS.xml:S3:17776:11	O
(	SAPHRIS.xml:S3:17788:1	O
17	SAPHRIS.xml:S3:17789:2	O
)]	SAPHRIS.xml:S3:17791:2	O
.	SAPHRIS.xml:S3:17795:1	O

Adult	SAPHRIS.xml:S3:17807:5	O
Patients	SAPHRIS.xml:S3:17813:8	O
:	SAPHRIS.xml:S3:17821:1	O
Pooled	SAPHRIS.xml:S3:17824:6	O
data	SAPHRIS.xml:S3:17831:4	O
on	SAPHRIS.xml:S3:17836:2	O
mean	SAPHRIS.xml:S3:17839:4	O
changes	SAPHRIS.xml:S3:17844:7	O
in	SAPHRIS.xml:S3:17852:2	O
body	SAPHRIS.xml:S3:17855:4	O
weight	SAPHRIS.xml:S3:17860:6	O
and	SAPHRIS.xml:S3:17867:3	O
the	SAPHRIS.xml:S3:17871:3	O
proportion	SAPHRIS.xml:S3:17875:10	O
of	SAPHRIS.xml:S3:17886:2	O
subjects	SAPHRIS.xml:S3:17889:8	O
meeting	SAPHRIS.xml:S3:17898:7	O
a	SAPHRIS.xml:S3:17906:1	O
weight	SAPHRIS.xml:S3:17908:6	B-AdverseReaction
gain	SAPHRIS.xml:S3:17915:4	I-AdverseReaction
criterion	SAPHRIS.xml:S3:17920:9	O
of	SAPHRIS.xml:S3:17930:2	O
7%	SAPHRIS.xml:S3:17935:2	B-Severity
of	SAPHRIS.xml:S3:17938:2	O
body	SAPHRIS.xml:S3:17941:4	O
weight	SAPHRIS.xml:S3:17946:6	O
from	SAPHRIS.xml:S3:17953:4	O
the	SAPHRIS.xml:S3:17958:3	O
short	SAPHRIS.xml:S3:17962:5	O
-	SAPHRIS.xml:S3:17967:1	O
term	SAPHRIS.xml:S3:17968:4	O
,	SAPHRIS.xml:S3:17972:1	O
placebo	SAPHRIS.xml:S3:17974:7	O
-	SAPHRIS.xml:S3:17981:1	O
controlled	SAPHRIS.xml:S3:17982:10	O
schizophrenia	SAPHRIS.xml:S3:17993:13	O
and	SAPHRIS.xml:S3:18007:3	O
bipolar	SAPHRIS.xml:S3:18011:7	O
mania	SAPHRIS.xml:S3:18019:5	O
trials	SAPHRIS.xml:S3:18025:6	O
are	SAPHRIS.xml:S3:18032:3	O
presented	SAPHRIS.xml:S3:18036:9	O
in	SAPHRIS.xml:S3:18046:2	O
Table	SAPHRIS.xml:S3:18050:5	O
5	SAPHRIS.xml:S3:18056:1	O
.	SAPHRIS.xml:S3:18057:1	O

Table	SAPHRIS.xml:S3:18065:5	O
5	SAPHRIS.xml:S3:18071:1	O
:	SAPHRIS.xml:S3:18072:1	O
Change	SAPHRIS.xml:S3:18074:6	O
in	SAPHRIS.xml:S3:18081:2	O
Body	SAPHRIS.xml:S3:18084:4	O
Weight	SAPHRIS.xml:S3:18089:6	O
in	SAPHRIS.xml:S3:18096:2	O
Adult	SAPHRIS.xml:S3:18099:5	O
Patients	SAPHRIS.xml:S3:18105:8	O
from	SAPHRIS.xml:S3:18114:4	O
Baseline	SAPHRIS.xml:S3:18119:8	O

N	SAPHRIS.xml:S3:18131:1	O
Number	SAPHRIS.xml:S3:18136:6	O
of	SAPHRIS.xml:S3:18143:2	O
subjects	SAPHRIS.xml:S3:18146:8	O
who	SAPHRIS.xml:S3:18155:3	O
had	SAPHRIS.xml:S3:18159:3	O
assessments	SAPHRIS.xml:S3:18163:11	O
at	SAPHRIS.xml:S3:18175:2	O
both	SAPHRIS.xml:S3:18178:4	O
Baseline	SAPHRIS.xml:S3:18183:8	O
and	SAPHRIS.xml:S3:18192:3	O
Endpoint	SAPHRIS.xml:S3:18196:8	O
.	SAPHRIS.xml:S3:18204:1	O

S	SAPHRIS.xml:S3:18212:1	O
Includes	SAPHRIS.xml:S3:18214:8	O
subjects	SAPHRIS.xml:S3:18223:8	O
treated	SAPHRIS.xml:S3:18232:7	O
with	SAPHRIS.xml:S3:18240:4	O
flexible	SAPHRIS.xml:S3:18245:8	O
dose	SAPHRIS.xml:S3:18254:4	O
of	SAPHRIS.xml:S3:18259:2	O
SAPHRIS	SAPHRIS.xml:S3:18262:7	O
5	SAPHRIS.xml:S3:18270:1	O
or	SAPHRIS.xml:S3:18272:2	O
10	SAPHRIS.xml:S3:18275:2	O
mg	SAPHRIS.xml:S3:18278:2	O
twice	SAPHRIS.xml:S3:18281:5	O
daily	SAPHRIS.xml:S3:18287:5	O
(	SAPHRIS.xml:S3:18293:1	O
N	SAPHRIS.xml:S3:18294:1	O
90	SAPHRIS.xml:S3:18296:2	O
)	SAPHRIS.xml:S3:18298:1	O
.	SAPHRIS.xml:S3:18299:1	O

SAPHRIS	SAPHRIS.xml:S3:18307:7	O
5	SAPHRIS.xml:S3:18315:1	O
mg	SAPHRIS.xml:S3:18317:2	O
or	SAPHRIS.xml:S3:18320:2	O
10	SAPHRIS.xml:S3:18323:2	O
mg	SAPHRIS.xml:S3:18326:2	O
twice	SAPHRIS.xml:S3:18329:5	O
daily	SAPHRIS.xml:S3:18335:5	O
with	SAPHRIS.xml:S3:18341:4	O
flexible	SAPHRIS.xml:S3:18346:8	O
dosing	SAPHRIS.xml:S3:18355:6	O
.	SAPHRIS.xml:S3:18361:1	O

Schizophrenia	SAPHRIS.xml:S3:18391:13	O

(	SAPHRIS.xml:S3:18405:1	O
6	SAPHRIS.xml:S3:18406:1	O
-	SAPHRIS.xml:S3:18407:1	O
weeks	SAPHRIS.xml:S3:18408:5	O
)	SAPHRIS.xml:S3:18413:1	O
Bipolar	SAPHRIS.xml:S3:18416:7	O
(	SAPHRIS.xml:S3:18424:1	O
3	SAPHRIS.xml:S3:18425:1	O
-	SAPHRIS.xml:S3:18426:1	O
weeks	SAPHRIS.xml:S3:18427:5	O
)	SAPHRIS.xml:S3:18432:1	O

Placebo	SAPHRIS.xml:S3:18438:7	O
SAPHRIS	SAPHRIS.xml:S3:18458:7	O
Placebo	SAPHRIS.xml:S3:18473:7	O
SAPHRIS5	SAPHRIS.xml:S3:18487:8	O
or	SAPHRIS.xml:S3:18496:2	O
10	SAPHRIS.xml:S3:18499:2	O
mgtwice	SAPHRIS.xml:S3:18502:7	O
daily	SAPHRIS.xml:S3:18510:5	O

5	SAPHRIS.xml:S3:18524:1	O
mgtwice	SAPHRIS.xml:S3:18526:7	O
daily	SAPHRIS.xml:S3:18534:5	O
10	SAPHRIS.xml:S3:18544:2	O
mgtwice	SAPHRIS.xml:S3:18547:7	O
daily	SAPHRIS.xml:S3:18555:5	O
5	SAPHRIS.xml:S3:18562:1	O
or	SAPHRIS.xml:S3:18564:2	O
10	SAPHRIS.xml:S3:18567:2	O
mgtwice	SAPHRIS.xml:S3:18570:7	O
daily	SAPHRIS.xml:S3:18578:5	O
S	SAPHRIS.xml:S3:18585:1	O

Change	SAPHRIS.xml:S3:18593:6	O
from	SAPHRIS.xml:S3:18600:4	O
Baseline	SAPHRIS.xml:S3:18605:8	O
(	SAPHRIS.xml:S3:18614:1	O
kg	SAPHRIS.xml:S3:18615:2	O
)	SAPHRIS.xml:S3:18617:1	O
(	SAPHRIS.xml:S3:18619:1	O
N	SAPHRIS.xml:S3:18620:1	O
)	SAPHRIS.xml:S3:18622:1	O
0.0	SAPHRIS.xml:S3:18625:3	O
(	SAPHRIS.xml:S3:18628:1	O
348	SAPHRIS.xml:S3:18629:3	O
)	SAPHRIS.xml:S3:18632:1	O
1.0	SAPHRIS.xml:S3:18640:3	O
(	SAPHRIS.xml:S3:18643:1	O
251	SAPHRIS.xml:S3:18644:3	O
)	SAPHRIS.xml:S3:18647:1	O
0.9	SAPHRIS.xml:S3:18654:3	O
(	SAPHRIS.xml:S3:18657:1	O
200	SAPHRIS.xml:S3:18658:3	O
)	SAPHRIS.xml:S3:18661:1	O
1.1	SAPHRIS.xml:S3:18670:3	O
(	SAPHRIS.xml:S3:18673:1	O
532	SAPHRIS.xml:S3:18674:3	O
)	SAPHRIS.xml:S3:18677:1	O
0.2	SAPHRIS.xml:S3:18686:3	O
(	SAPHRIS.xml:S3:18689:1	O
171	SAPHRIS.xml:S3:18690:3	O
)	SAPHRIS.xml:S3:18693:1	O
1.3	SAPHRIS.xml:S3:18700:3	O
(	SAPHRIS.xml:S3:18703:1	O
336	SAPHRIS.xml:S3:18704:3	O
)	SAPHRIS.xml:S3:18707:1	O

Proportion	SAPHRIS.xml:S3:18718:10	O
of	SAPHRIS.xml:S3:18729:2	O
Patients	SAPHRIS.xml:S3:18732:8	O
with	SAPHRIS.xml:S3:18741:4	O
a	SAPHRIS.xml:S3:18746:1	O
7%	SAPHRIS.xml:S3:18750:2	B-Severity
Increase	SAPHRIS.xml:S3:18753:8	B-AdverseReaction
in	SAPHRIS.xml:S3:18762:2	I-AdverseReaction
Body	SAPHRIS.xml:S3:18765:4	I-AdverseReaction
Weight	SAPHRIS.xml:S3:18770:6	I-AdverseReaction

with	SAPHRIS.xml:S3:18783:4	O
7%	SAPHRIS.xml:S3:18790:2	B-Severity
increase	SAPHRIS.xml:S3:18793:8	B-AdverseReaction
in	SAPHRIS.xml:S3:18802:2	I-AdverseReaction
body	SAPHRIS.xml:S3:18805:4	I-AdverseReaction
weight	SAPHRIS.xml:S3:18810:6	I-AdverseReaction
1.6%	SAPHRIS.xml:S3:18818:4	O
4.4%	SAPHRIS.xml:S3:18833:4	O
4.8%	SAPHRIS.xml:S3:18847:4	O
4.9%	SAPHRIS.xml:S3:18863:4	O
0.5%	SAPHRIS.xml:S3:18879:4	O
5.8%	SAPHRIS.xml:S3:18893:4	O

Adult	SAPHRIS.xml:S3:18931:5	O
Patients	SAPHRIS.xml:S3:18937:8	O
:	SAPHRIS.xml:S3:18945:1	O
In	SAPHRIS.xml:S3:18948:2	O
a	SAPHRIS.xml:S3:18951:1	O
52	SAPHRIS.xml:S3:18953:2	O
-	SAPHRIS.xml:S3:18955:1	O
week	SAPHRIS.xml:S3:18956:4	O
,	SAPHRIS.xml:S3:18960:1	O
double	SAPHRIS.xml:S3:18962:6	O
-	SAPHRIS.xml:S3:18968:1	O
blind	SAPHRIS.xml:S3:18969:5	O
,	SAPHRIS.xml:S3:18974:1	O
comparator	SAPHRIS.xml:S3:18976:10	O
-	SAPHRIS.xml:S3:18986:1	O
controlled	SAPHRIS.xml:S3:18987:10	O
adult	SAPHRIS.xml:S3:18998:5	O
trial	SAPHRIS.xml:S3:19004:5	O
that	SAPHRIS.xml:S3:19010:4	O
included	SAPHRIS.xml:S3:19015:8	O
primarily	SAPHRIS.xml:S3:19024:9	O
patients	SAPHRIS.xml:S3:19034:8	O
with	SAPHRIS.xml:S3:19043:4	O
schizophrenia	SAPHRIS.xml:S3:19048:13	O
,	SAPHRIS.xml:S3:19061:1	O
the	SAPHRIS.xml:S3:19063:3	O
mean	SAPHRIS.xml:S3:19067:4	O
weight	SAPHRIS.xml:S3:19072:6	B-AdverseReaction
gain	SAPHRIS.xml:S3:19079:4	I-AdverseReaction
from	SAPHRIS.xml:S3:19084:4	O
baseline	SAPHRIS.xml:S3:19089:8	O
was	SAPHRIS.xml:S3:19098:3	O
0.9	SAPHRIS.xml:S3:19102:3	O
kg	SAPHRIS.xml:S3:19106:2	O
.	SAPHRIS.xml:S3:19108:1	O

The	SAPHRIS.xml:S3:19110:3	O
proportion	SAPHRIS.xml:S3:19114:10	O
of	SAPHRIS.xml:S3:19125:2	O
patients	SAPHRIS.xml:S3:19128:8	O
with	SAPHRIS.xml:S3:19137:4	O
a	SAPHRIS.xml:S3:19142:1	O
7%	SAPHRIS.xml:S3:19146:2	B-Severity
increase	SAPHRIS.xml:S3:19149:8	B-AdverseReaction
in	SAPHRIS.xml:S3:19158:2	I-AdverseReaction
body	SAPHRIS.xml:S3:19161:4	I-AdverseReaction
weight	SAPHRIS.xml:S3:19166:6	I-AdverseReaction
(	SAPHRIS.xml:S3:19173:1	O
at	SAPHRIS.xml:S3:19174:2	O
Endpoint	SAPHRIS.xml:S3:19177:8	O
)	SAPHRIS.xml:S3:19185:1	O
was	SAPHRIS.xml:S3:19187:3	O
14.7%	SAPHRIS.xml:S3:19191:5	O
.	SAPHRIS.xml:S3:19196:1	O
Table	SAPHRIS.xml:S3:19197:5	O
5	SAPHRIS.xml:S3:19203:1	O
provides	SAPHRIS.xml:S3:19204:8	O
the	SAPHRIS.xml:S3:19213:3	O
mean	SAPHRIS.xml:S3:19217:4	O
weight	SAPHRIS.xml:S3:19222:6	B-AdverseReaction
change	SAPHRIS.xml:S3:19229:6	I-AdverseReaction
from	SAPHRIS.xml:S3:19236:4	O
baseline	SAPHRIS.xml:S3:19241:8	O
and	SAPHRIS.xml:S3:19250:3	O
the	SAPHRIS.xml:S3:19254:3	O
proportion	SAPHRIS.xml:S3:19258:10	O
of	SAPHRIS.xml:S3:19269:2	O
patients	SAPHRIS.xml:S3:19272:8	O
with	SAPHRIS.xml:S3:19281:4	O
a	SAPHRIS.xml:S3:19286:1	O
weight	SAPHRIS.xml:S3:19288:6	B-AdverseReaction
gain	SAPHRIS.xml:S3:19295:4	I-AdverseReaction
of	SAPHRIS.xml:S3:19300:2	O
7%	SAPHRIS.xml:S3:19305:2	B-Severity
categorized	SAPHRIS.xml:S3:19308:11	O
by	SAPHRIS.xml:S3:19320:2	O
Body	SAPHRIS.xml:S3:19323:4	O
Mass	SAPHRIS.xml:S3:19328:4	O
Index	SAPHRIS.xml:S3:19333:5	O
(	SAPHRIS.xml:S3:19339:1	O
BMI	SAPHRIS.xml:S3:19340:3	O
)	SAPHRIS.xml:S3:19343:1	O
at	SAPHRIS.xml:S3:19345:2	O
baseline	SAPHRIS.xml:S3:19348:8	O
.	SAPHRIS.xml:S3:19356:1	O

Table	SAPHRIS.xml:S3:19362:5	O

6	SAPHRIS.xml:S3:19368:1	O
:	SAPHRIS.xml:S3:19369:1	O
Weight	SAPHRIS.xml:S3:19371:6	O
Change	SAPHRIS.xml:S3:19378:6	O
Results	SAPHRIS.xml:S3:19385:7	O
Categorized	SAPHRIS.xml:S3:19393:11	O
by	SAPHRIS.xml:S3:19405:2	O
BMI	SAPHRIS.xml:S3:19408:3	O
at	SAPHRIS.xml:S3:19412:2	O
Baseline	SAPHRIS.xml:S3:19415:8	O
:	SAPHRIS.xml:S3:19423:1	O
Comparator	SAPHRIS.xml:S3:19425:10	O
-	SAPHRIS.xml:S3:19435:1	O
Controlled	SAPHRIS.xml:S3:19436:10	O
52	SAPHRIS.xml:S3:19447:2	O
-	SAPHRIS.xml:S3:19449:1	O
Week	SAPHRIS.xml:S3:19450:4	O
Study	SAPHRIS.xml:S3:19455:5	O
in	SAPHRIS.xml:S3:19461:2	O
Adults	SAPHRIS.xml:S3:19464:6	O
with	SAPHRIS.xml:S3:19471:4	O
Schizophrenia	SAPHRIS.xml:S3:19476:13	O

BMI	SAPHRIS.xml:S3:19521:3	O
23	SAPHRIS.xml:S3:19526:2	O
SAPHRIS	SAPHRIS.xml:S3:19532:7	O
N	SAPHRIS.xml:S3:19543:1	O
295	SAPHRIS.xml:S3:19545:3	O
BMI	SAPHRIS.xml:S3:19554:3	O
23	SAPHRIS.xml:S3:19558:2	O
-	SAPHRIS.xml:S3:19561:1	O
27	SAPHRIS.xml:S3:19565:2	O
SAPHRIS	SAPHRIS.xml:S3:19571:7	O
N	SAPHRIS.xml:S3:19582:1	O
290	SAPHRIS.xml:S3:19584:3	O
BMI	SAPHRIS.xml:S3:19593:3	O
27	SAPHRIS.xml:S3:19598:2	O
SAPHRIS	SAPHRIS.xml:S3:19604:7	O
N	SAPHRIS.xml:S3:19615:1	O
302	SAPHRIS.xml:S3:19617:3	O

Mean	SAPHRIS.xml:S3:19627:4	O
change	SAPHRIS.xml:S3:19632:6	O
from	SAPHRIS.xml:S3:19639:4	O
Baseline	SAPHRIS.xml:S3:19644:8	O
(	SAPHRIS.xml:S3:19653:1	O
kg	SAPHRIS.xml:S3:19654:2	O
)	SAPHRIS.xml:S3:19656:1	O
1.7	SAPHRIS.xml:S3:19659:3	O
1	SAPHRIS.xml:S3:19686:1	O
0	SAPHRIS.xml:S3:19713:1	O

with	SAPHRIS.xml:S3:19745:4	O
7%	SAPHRIS.xml:S3:19752:2	B-Severity
increase	SAPHRIS.xml:S3:19755:8	B-AdverseReaction
in	SAPHRIS.xml:S3:19764:2	I-AdverseReaction
body	SAPHRIS.xml:S3:19767:4	I-AdverseReaction
weight	SAPHRIS.xml:S3:19772:6	I-AdverseReaction
22%	SAPHRIS.xml:S3:19780:3	O
13%	SAPHRIS.xml:S3:19807:3	O
9%	SAPHRIS.xml:S3:19834:2	O

Pediatric	SAPHRIS.xml:S3:19881:9	O
Patients	SAPHRIS.xml:S3:19891:8	O
:	SAPHRIS.xml:S3:19899:1	O
Data	SAPHRIS.xml:S3:19902:4	O
on	SAPHRIS.xml:S3:19907:2	O
mean	SAPHRIS.xml:S3:19910:4	O
changes	SAPHRIS.xml:S3:19915:7	B-AdverseReaction
in	SAPHRIS.xml:S3:19923:2	I-AdverseReaction
body	SAPHRIS.xml:S3:19926:4	I-AdverseReaction
weight	SAPHRIS.xml:S3:19931:6	I-AdverseReaction
and	SAPHRIS.xml:S3:19938:3	O
the	SAPHRIS.xml:S3:19942:3	O
proportion	SAPHRIS.xml:S3:19946:10	O
of	SAPHRIS.xml:S3:19957:2	O
pediatric	SAPHRIS.xml:S3:19960:9	O
patients	SAPHRIS.xml:S3:19970:8	O
meeting	SAPHRIS.xml:S3:19979:7	O
a	SAPHRIS.xml:S3:19987:1	O
weight	SAPHRIS.xml:S3:19989:6	B-AdverseReaction
gain	SAPHRIS.xml:S3:19996:4	I-AdverseReaction
criterion	SAPHRIS.xml:S3:20001:9	O
of	SAPHRIS.xml:S3:20011:2	O
7%	SAPHRIS.xml:S3:20016:2	B-Severity
of	SAPHRIS.xml:S3:20019:2	O
body	SAPHRIS.xml:S3:20022:4	O
weight	SAPHRIS.xml:S3:20027:6	O
from	SAPHRIS.xml:S3:20034:4	O
the	SAPHRIS.xml:S3:20039:3	O
short	SAPHRIS.xml:S3:20043:5	O
-	SAPHRIS.xml:S3:20048:1	O
term	SAPHRIS.xml:S3:20049:4	O
,	SAPHRIS.xml:S3:20053:1	O
placebo	SAPHRIS.xml:S3:20055:7	O
-	SAPHRIS.xml:S3:20062:1	O
controlled	SAPHRIS.xml:S3:20063:10	O
bipolar	SAPHRIS.xml:S3:20074:7	O
mania	SAPHRIS.xml:S3:20082:5	O
trial	SAPHRIS.xml:S3:20088:5	O
are	SAPHRIS.xml:S3:20094:3	O
presented	SAPHRIS.xml:S3:20098:9	O
in	SAPHRIS.xml:S3:20108:2	O
Table	SAPHRIS.xml:S3:20112:5	O
7	SAPHRIS.xml:S3:20118:1	O
.	SAPHRIS.xml:S3:20121:1	O

To	SAPHRIS.xml:S3:20123:2	O
adjust	SAPHRIS.xml:S3:20126:6	O
for	SAPHRIS.xml:S3:20133:3	O
normal	SAPHRIS.xml:S3:20137:6	O
growth	SAPHRIS.xml:S3:20144:6	O
,	SAPHRIS.xml:S3:20150:1	O
z	SAPHRIS.xml:S3:20152:1	O
-	SAPHRIS.xml:S3:20153:1	O
scores	SAPHRIS.xml:S3:20154:6	O
were	SAPHRIS.xml:S3:20161:4	O
derived	SAPHRIS.xml:S3:20166:7	O
(	SAPHRIS.xml:S3:20174:1	O
measured	SAPHRIS.xml:S3:20175:8	O
in	SAPHRIS.xml:S3:20184:2	O
standard	SAPHRIS.xml:S3:20187:8	O
deviations	SAPHRIS.xml:S3:20196:10	O
[	SAPHRIS.xml:S3:20207:1	O
SD	SAPHRIS.xml:S3:20208:2	O
])	SAPHRIS.xml:S3:20210:2	O
,	SAPHRIS.xml:S3:20212:1	O
which	SAPHRIS.xml:S3:20214:5	O
normalize	SAPHRIS.xml:S3:20220:9	O
for	SAPHRIS.xml:S3:20230:3	O
the	SAPHRIS.xml:S3:20234:3	O
natural	SAPHRIS.xml:S3:20238:7	O
growth	SAPHRIS.xml:S3:20246:6	O
of	SAPHRIS.xml:S3:20253:2	O
pediatric	SAPHRIS.xml:S3:20256:9	O
patients	SAPHRIS.xml:S3:20266:8	O
by	SAPHRIS.xml:S3:20275:2	O
comparisons	SAPHRIS.xml:S3:20278:11	O
to	SAPHRIS.xml:S3:20290:2	O
age	SAPHRIS.xml:S3:20293:3	O
-	SAPHRIS.xml:S3:20296:1	O
and	SAPHRIS.xml:S3:20298:3	O
sex	SAPHRIS.xml:S3:20302:3	O
-	SAPHRIS.xml:S3:20305:1	O
matched	SAPHRIS.xml:S3:20306:7	O
population	SAPHRIS.xml:S3:20314:10	O
standards	SAPHRIS.xml:S3:20325:9	O
.	SAPHRIS.xml:S3:20334:1	O

The	SAPHRIS.xml:S3:20344:3	O

distance	SAPHRIS.xml:S3:20348:8	O
of	SAPHRIS.xml:S3:20357:2	O
a	SAPHRIS.xml:S3:20360:1	O
z	SAPHRIS.xml:S3:20362:1	O
-	SAPHRIS.xml:S3:20363:1	O
score	SAPHRIS.xml:S3:20364:5	O
from	SAPHRIS.xml:S3:20370:4	O
0	SAPHRIS.xml:S3:20375:1	O
represents	SAPHRIS.xml:S3:20377:10	O
the	SAPHRIS.xml:S3:20388:3	O
distance	SAPHRIS.xml:S3:20392:8	O
of	SAPHRIS.xml:S3:20401:2	O
a	SAPHRIS.xml:S3:20404:1	O
percentile	SAPHRIS.xml:S3:20406:10	O
from	SAPHRIS.xml:S3:20417:4	O
the	SAPHRIS.xml:S3:20422:3	O
median	SAPHRIS.xml:S3:20426:6	O
,	SAPHRIS.xml:S3:20432:1	O
measured	SAPHRIS.xml:S3:20434:8	O
in	SAPHRIS.xml:S3:20443:2	O
standard	SAPHRIS.xml:S3:20446:8	O
deviations	SAPHRIS.xml:S3:20455:10	O
(	SAPHRIS.xml:S3:20466:1	O
SD	SAPHRIS.xml:S3:20467:2	O
)	SAPHRIS.xml:S3:20469:1	O
.	SAPHRIS.xml:S3:20470:1	O

After	SAPHRIS.xml:S3:20472:5	O
adjusting	SAPHRIS.xml:S3:20478:9	O
for	SAPHRIS.xml:S3:20488:3	O
age	SAPHRIS.xml:S3:20492:3	O
and	SAPHRIS.xml:S3:20496:3	O
sex	SAPHRIS.xml:S3:20500:3	O
,	SAPHRIS.xml:S3:20503:1	O
the	SAPHRIS.xml:S3:20505:3	O
mean	SAPHRIS.xml:S3:20509:4	O
change	SAPHRIS.xml:S3:20514:6	O
from	SAPHRIS.xml:S3:20521:4	O
baseline	SAPHRIS.xml:S3:20526:8	O
to	SAPHRIS.xml:S3:20535:2	O
endpoint	SAPHRIS.xml:S3:20538:8	O
in	SAPHRIS.xml:S3:20547:2	O
weight	SAPHRIS.xml:S3:20550:6	O
z	SAPHRIS.xml:S3:20557:1	O
-	SAPHRIS.xml:S3:20558:1	O
score	SAPHRIS.xml:S3:20559:5	O
for	SAPHRIS.xml:S3:20565:3	O
SAPHRS	SAPHRIS.xml:S3:20569:6	O
2.5	SAPHRIS.xml:S3:20576:3	O
mg	SAPHRIS.xml:S3:20580:2	O
,	SAPHRIS.xml:S3:20582:1	O
5	SAPHRIS.xml:S3:20584:1	O
mg	SAPHRIS.xml:S3:20586:2	O
,	SAPHRIS.xml:S3:20588:1	O
and	SAPHRIS.xml:S3:20590:3	O
10	SAPHRIS.xml:S3:20594:2	O
mg	SAPHRIS.xml:S3:20597:2	O
twice	SAPHRIS.xml:S3:20600:5	O
daily	SAPHRIS.xml:S3:20606:5	O
,	SAPHRIS.xml:S3:20611:1	O
was	SAPHRIS.xml:S3:20613:3	O
0.11	SAPHRIS.xml:S3:20617:4	O
,	SAPHRIS.xml:S3:20621:1	O
0.08	SAPHRIS.xml:S3:20623:4	O
and	SAPHRIS.xml:S3:20628:3	O
0.09	SAPHRIS.xml:S3:20632:4	O
SD	SAPHRIS.xml:S3:20637:2	O
versus	SAPHRIS.xml:S3:20640:6	O
0.02	SAPHRIS.xml:S3:20647:4	O
SD	SAPHRIS.xml:S3:20652:2	O
for	SAPHRIS.xml:S3:20655:3	O
placebo	SAPHRIS.xml:S3:20659:7	O
,	SAPHRIS.xml:S3:20666:1	O
respectively	SAPHRIS.xml:S3:20668:12	O
.	SAPHRIS.xml:S3:20680:1	O

When	SAPHRIS.xml:S3:20690:4	O
treating	SAPHRIS.xml:S3:20695:8	O
pediatric	SAPHRIS.xml:S3:20704:9	O
patients	SAPHRIS.xml:S3:20714:8	O
,	SAPHRIS.xml:S3:20722:1	O
weight	SAPHRIS.xml:S3:20724:6	O
gain	SAPHRIS.xml:S3:20731:4	O
should	SAPHRIS.xml:S3:20736:6	O
be	SAPHRIS.xml:S3:20743:2	O
monitored	SAPHRIS.xml:S3:20746:9	O
and	SAPHRIS.xml:S3:20756:3	O
assessed	SAPHRIS.xml:S3:20760:8	O
against	SAPHRIS.xml:S3:20769:7	O
that	SAPHRIS.xml:S3:20777:4	O
expected	SAPHRIS.xml:S3:20782:8	O
for	SAPHRIS.xml:S3:20791:3	O
normal	SAPHRIS.xml:S3:20795:6	O
growth	SAPHRIS.xml:S3:20802:6	O
.	SAPHRIS.xml:S3:20808:1	O

Table	SAPHRIS.xml:S3:20814:5	O
7	SAPHRIS.xml:S3:20820:1	O
:	SAPHRIS.xml:S3:20821:1	O
Change	SAPHRIS.xml:S3:20823:6	O
in	SAPHRIS.xml:S3:20830:2	O
Body	SAPHRIS.xml:S3:20833:4	O
Weight	SAPHRIS.xml:S3:20838:6	O
in	SAPHRIS.xml:S3:20845:2	O
Pediatric	SAPHRIS.xml:S3:20848:9	O
Subjects	SAPHRIS.xml:S3:20858:8	O
from	SAPHRIS.xml:S3:20867:4	O
Baseline	SAPHRIS.xml:S3:20872:8	O

N	SAPHRIS.xml:S3:20884:1	O
Number	SAPHRIS.xml:S3:20889:6	O
of	SAPHRIS.xml:S3:20896:2	O
subjects	SAPHRIS.xml:S3:20899:8	O
who	SAPHRIS.xml:S3:20908:3	O
had	SAPHRIS.xml:S3:20912:3	O
assessments	SAPHRIS.xml:S3:20916:11	O
at	SAPHRIS.xml:S3:20928:2	O
both	SAPHRIS.xml:S3:20931:4	O
Baseline	SAPHRIS.xml:S3:20936:8	O
and	SAPHRIS.xml:S3:20945:3	O
Endpoint	SAPHRIS.xml:S3:20949:8	O
.	SAPHRIS.xml:S3:20957:1	O

Bipolar	SAPHRIS.xml:S3:20985:7	O

I	SAPHRIS.xml:S3:20993:1	O
Disorder	SAPHRIS.xml:S3:20995:8	O
(	SAPHRIS.xml:S3:21004:1	O
3	SAPHRIS.xml:S3:21005:1	O
-	SAPHRIS.xml:S3:21006:1	O
weeks	SAPHRIS.xml:S3:21007:5	O
)	SAPHRIS.xml:S3:21012:1	O

Placebo	SAPHRIS.xml:S3:21018:7	O
SAPHRIS2	SAPHRIS.xml:S3:21036:8	O
.	SAPHRIS.xml:S3:21044:1	O
5	SAPHRIS.xml:S3:21045:1	O
mgtwice	SAPHRIS.xml:S3:21047:7	O
daily	SAPHRIS.xml:S3:21055:5	O
SAPHRIS5	SAPHRIS.xml:S3:21062:8	O
mgtwice	SAPHRIS.xml:S3:21071:7	O
daily	SAPHRIS.xml:S3:21079:5	O
SAPHRIS10	SAPHRIS.xml:S3:21086:9	O
mgtwice	SAPHRIS.xml:S3:21096:7	O
daily	SAPHRIS.xml:S3:21104:5	O

Change	SAPHRIS.xml:S3:21114:6	O
from	SAPHRIS.xml:S3:21121:4	O
Baseline	SAPHRIS.xml:S3:21126:8	O
(	SAPHRIS.xml:S3:21135:1	O
kg	SAPHRIS.xml:S3:21136:2	O
)	SAPHRIS.xml:S3:21138:1	O
(	SAPHRIS.xml:S3:21140:1	O
N	SAPHRIS.xml:S3:21141:1	O
)	SAPHRIS.xml:S3:21143:1	O
0.5	SAPHRIS.xml:S3:21146:3	O
(	SAPHRIS.xml:S3:21149:1	O
89	SAPHRIS.xml:S3:21150:2	O
)	SAPHRIS.xml:S3:21152:1	O
1.7	SAPHRIS.xml:S3:21167:3	O
(	SAPHRIS.xml:S3:21170:1	O
92	SAPHRIS.xml:S3:21171:2	O
)	SAPHRIS.xml:S3:21173:1	O
1.6	SAPHRIS.xml:S3:21190:3	O
(	SAPHRIS.xml:S3:21193:1	O
90	SAPHRIS.xml:S3:21194:2	O
)	SAPHRIS.xml:S3:21196:1	O
1.4	SAPHRIS.xml:S3:21212:3	O
(	SAPHRIS.xml:S3:21215:1	O
87	SAPHRIS.xml:S3:21216:2	O
)	SAPHRIS.xml:S3:21218:1	O

Proportion	SAPHRIS.xml:S3:21256:10	O
of	SAPHRIS.xml:S3:21267:2	O
Subjects	SAPHRIS.xml:S3:21270:8	O
with	SAPHRIS.xml:S3:21279:4	O
a	SAPHRIS.xml:S3:21284:1	O
7%	SAPHRIS.xml:S3:21288:2	B-Severity
Increase	SAPHRIS.xml:S3:21291:8	B-AdverseReaction
in	SAPHRIS.xml:S3:21300:2	I-AdverseReaction
Body	SAPHRIS.xml:S3:21303:4	I-AdverseReaction
Weight	SAPHRIS.xml:S3:21308:6	I-AdverseReaction

with	SAPHRIS.xml:S3:21321:4	O
7%	SAPHRIS.xml:S3:21328:2	B-Severity
increase	SAPHRIS.xml:S3:21331:8	B-AdverseReaction
in	SAPHRIS.xml:S3:21340:2	I-AdverseReaction
body	SAPHRIS.xml:S3:21343:4	I-AdverseReaction
weight	SAPHRIS.xml:S3:21348:6	I-AdverseReaction
1.1%	SAPHRIS.xml:S3:21356:4	O
12.0%	SAPHRIS.xml:S3:21377:5	O
8.9%	SAPHRIS.xml:S3:21400:4	O
8.0%	SAPHRIS.xml:S3:21422:4	O

5.6	SAPHRIS.xml:S3:21464:3	O
Hypersensitivity	SAPHRIS.xml:S3:21468:16	O
Reactions	SAPHRIS.xml:S3:21485:9	O

Hypersensitivity	SAPHRIS.xml:S3:21502:16	B-AdverseReaction
reactions	SAPHRIS.xml:S3:21519:9	I-AdverseReaction
have	SAPHRIS.xml:S3:21529:4	O
been	SAPHRIS.xml:S3:21534:4	O
observed	SAPHRIS.xml:S3:21539:8	O
in	SAPHRIS.xml:S3:21548:2	O
patients	SAPHRIS.xml:S3:21551:8	O
treated	SAPHRIS.xml:S3:21560:7	O
with	SAPHRIS.xml:S3:21568:4	O
SAPHRIS	SAPHRIS.xml:S3:21573:7	O
.	SAPHRIS.xml:S3:21580:1	O

In	SAPHRIS.xml:S3:21582:2	O
several	SAPHRIS.xml:S3:21585:7	O
cases	SAPHRIS.xml:S3:21593:5	O
,	SAPHRIS.xml:S3:21598:1	O
these	SAPHRIS.xml:S3:21600:5	O
reactions	SAPHRIS.xml:S3:21606:9	O
occurred	SAPHRIS.xml:S3:21616:8	O
after	SAPHRIS.xml:S3:21625:5	O
the	SAPHRIS.xml:S3:21631:3	O
first	SAPHRIS.xml:S3:21635:5	O
dose	SAPHRIS.xml:S3:21641:4	O
.	SAPHRIS.xml:S3:21645:1	O

These	SAPHRIS.xml:S3:21647:5	O
hypersensitivity	SAPHRIS.xml:S3:21653:16	B-AdverseReaction
reactions	SAPHRIS.xml:S3:21670:9	I-AdverseReaction
included	SAPHRIS.xml:S3:21680:8	O
:	SAPHRIS.xml:S3:21688:1	O
anaphylaxis	SAPHRIS.xml:S3:21690:11	B-AdverseReaction
,	SAPHRIS.xml:S3:21701:1	O
angioedema	SAPHRIS.xml:S3:21703:10	B-AdverseReaction
,	SAPHRIS.xml:S3:21713:1	O
hypotension	SAPHRIS.xml:S3:21715:11	B-AdverseReaction
,	SAPHRIS.xml:S3:21726:1	O
tachycardia	SAPHRIS.xml:S3:21728:11	B-AdverseReaction
,	SAPHRIS.xml:S3:21739:1	O
swollen	SAPHRIS.xml:S3:21741:7	B-AdverseReaction
tongue	SAPHRIS.xml:S3:21749:6	I-AdverseReaction
,	SAPHRIS.xml:S3:21755:1	O
dyspnea	SAPHRIS.xml:S3:21757:7	B-AdverseReaction
,	SAPHRIS.xml:S3:21764:1	O
wheezing	SAPHRIS.xml:S3:21766:8	B-AdverseReaction
and	SAPHRIS.xml:S3:21775:3	O
rash	SAPHRIS.xml:S3:21779:4	B-AdverseReaction
.	SAPHRIS.xml:S3:21783:1	O

5.7	SAPHRIS.xml:S3:21795:3	O
Orthostatic	SAPHRIS.xml:S3:21799:11	O
Hypotension	SAPHRIS.xml:S3:21811:11	O
,	SAPHRIS.xml:S3:21822:1	O
Syncope	SAPHRIS.xml:S3:21824:7	O
,	SAPHRIS.xml:S3:21831:1	O
and	SAPHRIS.xml:S3:21833:3	O
Other	SAPHRIS.xml:S3:21837:5	O
Hemodynamic	SAPHRIS.xml:S3:21843:11	O
Effects	SAPHRIS.xml:S3:21855:7	O

SAPHRIS	SAPHRIS.xml:S3:21870:7	O
may	SAPHRIS.xml:S3:21878:3	B-Factor
induce	SAPHRIS.xml:S3:21882:6	O
orthostatic	SAPHRIS.xml:S3:21889:11	B-AdverseReaction
hypotension	SAPHRIS.xml:S3:21901:11	I-AdverseReaction
and	SAPHRIS.xml:S3:21913:3	O
syncope	SAPHRIS.xml:S3:21917:7	B-AdverseReaction
in	SAPHRIS.xml:S3:21925:2	O
some	SAPHRIS.xml:S3:21928:4	O
patients	SAPHRIS.xml:S3:21933:8	O
,	SAPHRIS.xml:S3:21941:1	O
especially	SAPHRIS.xml:S3:21943:10	O
early	SAPHRIS.xml:S3:21954:5	O
in	SAPHRIS.xml:S3:21960:2	O
treatment	SAPHRIS.xml:S3:21963:9	O
,	SAPHRIS.xml:S3:21972:1	O
because	SAPHRIS.xml:S3:21974:7	O
of	SAPHRIS.xml:S3:21982:2	O
its	SAPHRIS.xml:S3:21985:3	O
alpha1	SAPHRIS.xml:S3:21989:6	O
-	SAPHRIS.xml:S3:21995:1	O
adrenergic	SAPHRIS.xml:S3:21996:10	O
antagonist	SAPHRIS.xml:S3:22007:10	O
activity	SAPHRIS.xml:S3:22018:8	O
.	SAPHRIS.xml:S3:22026:1	O

In	SAPHRIS.xml:S3:22028:2	O
short	SAPHRIS.xml:S3:22031:5	O
-	SAPHRIS.xml:S3:22036:1	O
term	SAPHRIS.xml:S3:22037:4	O
schizophrenia	SAPHRIS.xml:S3:22042:13	O
adult	SAPHRIS.xml:S3:22056:5	O
trials	SAPHRIS.xml:S3:22062:6	O
,	SAPHRIS.xml:S3:22068:1	O
syncope	SAPHRIS.xml:S3:22070:7	B-AdverseReaction
was	SAPHRIS.xml:S3:22078:3	O
reported	SAPHRIS.xml:S3:22082:8	O
in	SAPHRIS.xml:S3:22091:2	O
0.2%	SAPHRIS.xml:S3:22094:4	O
(	SAPHRIS.xml:S3:22099:1	O
1	SAPHRIS.xml:S3:22100:1	O
572	SAPHRIS.xml:S3:22102:3	O
)	SAPHRIS.xml:S3:22105:1	O
of	SAPHRIS.xml:S3:22107:2	O
patients	SAPHRIS.xml:S3:22110:8	O
treated	SAPHRIS.xml:S3:22119:7	O
with	SAPHRIS.xml:S3:22127:4	O
therapeutic	SAPHRIS.xml:S3:22132:11	O
doses	SAPHRIS.xml:S3:22144:5	O
(	SAPHRIS.xml:S3:22150:1	O
5	SAPHRIS.xml:S3:22151:1	O
mg	SAPHRIS.xml:S3:22153:2	O
or	SAPHRIS.xml:S3:22156:2	O
10	SAPHRIS.xml:S3:22159:2	O
mg	SAPHRIS.xml:S3:22162:2	O
twice	SAPHRIS.xml:S3:22165:5	O
daily	SAPHRIS.xml:S3:22171:5	O
)	SAPHRIS.xml:S3:22176:1	O
of	SAPHRIS.xml:S3:22178:2	O
SAPHRIS	SAPHRIS.xml:S3:22181:7	O
,	SAPHRIS.xml:S3:22188:1	O
compared	SAPHRIS.xml:S3:22190:8	O
to	SAPHRIS.xml:S3:22199:2	O
0.3%	SAPHRIS.xml:S3:22202:4	O
(	SAPHRIS.xml:S3:22207:1	O
1	SAPHRIS.xml:S3:22208:1	O
378	SAPHRIS.xml:S3:22210:3	O
)	SAPHRIS.xml:S3:22213:1	O
of	SAPHRIS.xml:S3:22215:2	O
patients	SAPHRIS.xml:S3:22218:8	O
treated	SAPHRIS.xml:S3:22227:7	O
with	SAPHRIS.xml:S3:22235:4	O
placebo	SAPHRIS.xml:S3:22240:7	O
.	SAPHRIS.xml:S3:22247:1	O

In	SAPHRIS.xml:S3:22249:2	O
short	SAPHRIS.xml:S3:22252:5	O
-	SAPHRIS.xml:S3:22257:1	O
term	SAPHRIS.xml:S3:22258:4	O
bipolar	SAPHRIS.xml:S3:22263:7	O
mania	SAPHRIS.xml:S3:22271:5	O
adult	SAPHRIS.xml:S3:22277:5	O
trials	SAPHRIS.xml:S3:22283:6	O
,	SAPHRIS.xml:S3:22289:1	O
syncope	SAPHRIS.xml:S3:22291:7	B-AdverseReaction
was	SAPHRIS.xml:S3:22299:3	O
reported	SAPHRIS.xml:S3:22303:8	O
in	SAPHRIS.xml:S3:22312:2	O
0.3%	SAPHRIS.xml:S3:22315:4	O
(	SAPHRIS.xml:S3:22320:1	O
1	SAPHRIS.xml:S3:22321:1	O
379	SAPHRIS.xml:S3:22323:3	O
)	SAPHRIS.xml:S3:22326:1	O
of	SAPHRIS.xml:S3:22328:2	O
patients	SAPHRIS.xml:S3:22331:8	O
treated	SAPHRIS.xml:S3:22340:7	O
with	SAPHRIS.xml:S3:22348:4	O
therapeutic	SAPHRIS.xml:S3:22353:11	O
doses	SAPHRIS.xml:S3:22365:5	O
(	SAPHRIS.xml:S3:22371:1	O
5	SAPHRIS.xml:S3:22372:1	O
mg	SAPHRIS.xml:S3:22374:2	O
or	SAPHRIS.xml:S3:22377:2	O
10	SAPHRIS.xml:S3:22380:2	O
mg	SAPHRIS.xml:S3:22383:2	O
twice	SAPHRIS.xml:S3:22386:5	O
daily	SAPHRIS.xml:S3:22392:5	O
)	SAPHRIS.xml:S3:22397:1	O
of	SAPHRIS.xml:S3:22399:2	O
SAPHRIS	SAPHRIS.xml:S3:22402:7	O
,	SAPHRIS.xml:S3:22409:1	O
compared	SAPHRIS.xml:S3:22411:8	O
to	SAPHRIS.xml:S3:22420:2	O
0%	SAPHRIS.xml:S3:22423:2	O
(	SAPHRIS.xml:S3:22426:1	O
0	SAPHRIS.xml:S3:22427:1	O
203	SAPHRIS.xml:S3:22429:3	O
)	SAPHRIS.xml:S3:22432:1	O
of	SAPHRIS.xml:S3:22434:2	O
patients	SAPHRIS.xml:S3:22437:8	O
treated	SAPHRIS.xml:S3:22446:7	O
with	SAPHRIS.xml:S3:22454:4	O
placebo	SAPHRIS.xml:S3:22459:7	O
.	SAPHRIS.xml:S3:22466:1	O

During	SAPHRIS.xml:S3:22468:6	O
adult	SAPHRIS.xml:S3:22475:5	O
pre	SAPHRIS.xml:S3:22481:3	O
-	SAPHRIS.xml:S3:22484:1	O
marketing	SAPHRIS.xml:S3:22485:9	O
clinical	SAPHRIS.xml:S3:22495:8	O
trials	SAPHRIS.xml:S3:22504:6	O
with	SAPHRIS.xml:S3:22511:4	O
SAPHRIS	SAPHRIS.xml:S3:22516:7	O
,	SAPHRIS.xml:S3:22523:1	O
including	SAPHRIS.xml:S3:22525:9	O
long	SAPHRIS.xml:S3:22535:4	O
-	SAPHRIS.xml:S3:22539:1	O
term	SAPHRIS.xml:S3:22540:4	O
trials	SAPHRIS.xml:S3:22545:6	O
without	SAPHRIS.xml:S3:22552:7	O
comparison	SAPHRIS.xml:S3:22560:10	O
to	SAPHRIS.xml:S3:22571:2	O
placebo	SAPHRIS.xml:S3:22574:7	O
,	SAPHRIS.xml:S3:22581:1	O
syncope	SAPHRIS.xml:S3:22583:7	B-AdverseReaction
was	SAPHRIS.xml:S3:22591:3	O
reported	SAPHRIS.xml:S3:22595:8	O
in	SAPHRIS.xml:S3:22604:2	O
0.6%	SAPHRIS.xml:S3:22607:4	O
(	SAPHRIS.xml:S3:22612:1	O
11	SAPHRIS.xml:S3:22613:2	O
1953	SAPHRIS.xml:S3:22616:4	O
)	SAPHRIS.xml:S3:22620:1	O
of	SAPHRIS.xml:S3:22622:2	O
patients	SAPHRIS.xml:S3:22625:8	O
treated	SAPHRIS.xml:S3:22634:7	O
with	SAPHRIS.xml:S3:22642:4	O
SAPHRIS	SAPHRIS.xml:S3:22647:7	O
.	SAPHRIS.xml:S3:22654:1	O

In	SAPHRIS.xml:S3:22656:2	O
a	SAPHRIS.xml:S3:22659:1	O
3	SAPHRIS.xml:S3:22661:1	O
-	SAPHRIS.xml:S3:22662:1	O
week	SAPHRIS.xml:S3:22663:4	O
,	SAPHRIS.xml:S3:22667:1	O
bipolar	SAPHRIS.xml:S3:22669:7	O
mania	SAPHRIS.xml:S3:22677:5	O
pediatric	SAPHRIS.xml:S3:22683:9	O
trial	SAPHRIS.xml:S3:22693:5	O
,	SAPHRIS.xml:S3:22698:1	O
syncope	SAPHRIS.xml:S3:22700:7	B-AdverseReaction
was	SAPHRIS.xml:S3:22708:3	O
reported	SAPHRIS.xml:S3:22712:8	O
in	SAPHRIS.xml:S3:22721:2	O
1%	SAPHRIS.xml:S3:22724:2	O
(	SAPHRIS.xml:S3:22727:1	O
1	SAPHRIS.xml:S3:22728:1	O
104	SAPHRIS.xml:S3:22730:3	O
)	SAPHRIS.xml:S3:22733:1	O
of	SAPHRIS.xml:S3:22735:2	O
patients	SAPHRIS.xml:S3:22738:8	O
treated	SAPHRIS.xml:S3:22747:7	O
with	SAPHRIS.xml:S3:22755:4	O
SAPHRIS	SAPHRIS.xml:S3:22760:7	O
2.5	SAPHRIS.xml:S3:22768:3	O
mg	SAPHRIS.xml:S3:22772:2	O
twice	SAPHRIS.xml:S3:22775:5	O
daily	SAPHRIS.xml:S3:22781:5	O
,	SAPHRIS.xml:S3:22786:1	O
1%	SAPHRIS.xml:S3:22788:2	O
(	SAPHRIS.xml:S3:22791:1	O
1	SAPHRIS.xml:S3:22792:1	O
99	SAPHRIS.xml:S3:22794:2	O
)	SAPHRIS.xml:S3:22796:1	O
of	SAPHRIS.xml:S3:22798:2	O
patients	SAPHRIS.xml:S3:22801:8	O
treated	SAPHRIS.xml:S3:22810:7	O
with	SAPHRIS.xml:S3:22818:4	O
SAPHRIS	SAPHRIS.xml:S3:22823:7	O
5	SAPHRIS.xml:S3:22831:1	O
mg	SAPHRIS.xml:S3:22833:2	O
twice	SAPHRIS.xml:S3:22836:5	O
daily	SAPHRIS.xml:S3:22842:5	O
,	SAPHRIS.xml:S3:22847:1	O
and	SAPHRIS.xml:S3:22849:3	O
0%	SAPHRIS.xml:S3:22853:2	O
(	SAPHRIS.xml:S3:22856:1	O
0	SAPHRIS.xml:S3:22857:1	O
99	SAPHRIS.xml:S3:22859:2	O
)	SAPHRIS.xml:S3:22861:1	O
for	SAPHRIS.xml:S3:22863:3	O
patients	SAPHRIS.xml:S3:22867:8	O
treated	SAPHRIS.xml:S3:22876:7	O
with	SAPHRIS.xml:S3:22884:4	O
SAPHRIS	SAPHRIS.xml:S3:22889:7	O
10	SAPHRIS.xml:S3:22897:2	O
mg	SAPHRIS.xml:S3:22900:2	O
twice	SAPHRIS.xml:S3:22903:5	O
daily	SAPHRIS.xml:S3:22909:5	O
compared	SAPHRIS.xml:S3:22915:8	O
to	SAPHRIS.xml:S3:22924:2	O
0%	SAPHRIS.xml:S3:22927:2	O
(	SAPHRIS.xml:S3:22930:1	O
0	SAPHRIS.xml:S3:22931:1	O
101	SAPHRIS.xml:S3:22933:3	O
)	SAPHRIS.xml:S3:22936:1	O
for	SAPHRIS.xml:S3:22938:3	O
patients	SAPHRIS.xml:S3:22942:8	O
treated	SAPHRIS.xml:S3:22951:7	O
with	SAPHRIS.xml:S3:22959:4	O
placebo	SAPHRIS.xml:S3:22964:7	O
.	SAPHRIS.xml:S3:22971:1	O

Patients	SAPHRIS.xml:S3:22981:8	O
should	SAPHRIS.xml:S3:22990:6	O
be	SAPHRIS.xml:S3:22997:2	O
instructed	SAPHRIS.xml:S3:23000:10	O
about	SAPHRIS.xml:S3:23011:5	O
non	SAPHRIS.xml:S3:23017:3	O
-	SAPHRIS.xml:S3:23020:1	O
pharmacologic	SAPHRIS.xml:S3:23021:13	O
interventions	SAPHRIS.xml:S3:23035:13	O
that	SAPHRIS.xml:S3:23049:4	O
help	SAPHRIS.xml:S3:23054:4	O
to	SAPHRIS.xml:S3:23059:2	O
reduce	SAPHRIS.xml:S3:23062:6	O
the	SAPHRIS.xml:S3:23069:3	O
occurrence	SAPHRIS.xml:S3:23073:10	O
of	SAPHRIS.xml:S3:23084:2	O
orthostatic	SAPHRIS.xml:S3:23087:11	O
hypotension	SAPHRIS.xml:S3:23099:11	O
(	SAPHRIS.xml:S3:23111:1	O
e	SAPHRIS.xml:S3:23112:1	O
.	SAPHRIS.xml:S3:23113:1	O
g	SAPHRIS.xml:S3:23114:1	O
.	SAPHRIS.xml:S3:23115:1	O
,	SAPHRIS.xml:S3:23116:1	O
sitting	SAPHRIS.xml:S3:23118:7	O
on	SAPHRIS.xml:S3:23126:2	O
the	SAPHRIS.xml:S3:23129:3	O
edge	SAPHRIS.xml:S3:23133:4	O
of	SAPHRIS.xml:S3:23138:2	O
the	SAPHRIS.xml:S3:23141:3	O
bed	SAPHRIS.xml:S3:23145:3	O
for	SAPHRIS.xml:S3:23149:3	O
several	SAPHRIS.xml:S3:23153:7	O
minutes	SAPHRIS.xml:S3:23161:7	O
before	SAPHRIS.xml:S3:23169:6	O
attempting	SAPHRIS.xml:S3:23176:10	O
to	SAPHRIS.xml:S3:23187:2	O
stand	SAPHRIS.xml:S3:23190:5	O
in	SAPHRIS.xml:S3:23196:2	O
the	SAPHRIS.xml:S3:23199:3	O
morning	SAPHRIS.xml:S3:23203:7	O
and	SAPHRIS.xml:S3:23211:3	O
slowly	SAPHRIS.xml:S3:23215:6	O
rising	SAPHRIS.xml:S3:23222:6	O
from	SAPHRIS.xml:S3:23229:4	O
a	SAPHRIS.xml:S3:23234:1	O
seated	SAPHRIS.xml:S3:23236:6	O
position	SAPHRIS.xml:S3:23243:8	O
)	SAPHRIS.xml:S3:23251:1	O
.	SAPHRIS.xml:S3:23252:1	O

SAPHRIS	SAPHRIS.xml:S3:23254:7	O
should	SAPHRIS.xml:S3:23262:6	O
be	SAPHRIS.xml:S3:23269:2	O
used	SAPHRIS.xml:S3:23272:4	O
with	SAPHRIS.xml:S3:23277:4	O
caution	SAPHRIS.xml:S3:23282:7	O
in	SAPHRIS.xml:S3:23290:2	O
(	SAPHRIS.xml:S3:23293:1	O
1	SAPHRIS.xml:S3:23294:1	O
)	SAPHRIS.xml:S3:23295:1	O
patients	SAPHRIS.xml:S3:23297:8	O
with	SAPHRIS.xml:S3:23306:4	O
known	SAPHRIS.xml:S3:23311:5	O
cardiovascular	SAPHRIS.xml:S3:23317:14	O
disease	SAPHRIS.xml:S3:23332:7	O
(	SAPHRIS.xml:S3:23340:1	O
history	SAPHRIS.xml:S3:23341:7	O
of	SAPHRIS.xml:S3:23349:2	O
myocardial	SAPHRIS.xml:S3:23352:10	O
infarction	SAPHRIS.xml:S3:23363:10	O
or	SAPHRIS.xml:S3:23374:2	O
ischemic	SAPHRIS.xml:S3:23377:8	O
heart	SAPHRIS.xml:S3:23386:5	O
disease	SAPHRIS.xml:S3:23392:7	O
,	SAPHRIS.xml:S3:23399:1	O
heart	SAPHRIS.xml:S3:23401:5	O
failure	SAPHRIS.xml:S3:23407:7	O
or	SAPHRIS.xml:S3:23415:2	O
conduction	SAPHRIS.xml:S3:23418:10	O
abnormalities	SAPHRIS.xml:S3:23429:13	O
)	SAPHRIS.xml:S3:23442:1	O
,	SAPHRIS.xml:S3:23443:1	O
cerebrovascular	SAPHRIS.xml:S3:23445:15	O
disease	SAPHRIS.xml:S3:23461:7	O
,	SAPHRIS.xml:S3:23468:1	O
or	SAPHRIS.xml:S3:23470:2	O
conditions	SAPHRIS.xml:S3:23473:10	O
which	SAPHRIS.xml:S3:23484:5	O
would	SAPHRIS.xml:S3:23490:5	O
predispose	SAPHRIS.xml:S3:23496:10	O
patients	SAPHRIS.xml:S3:23507:8	O
to	SAPHRIS.xml:S3:23516:2	O
hypotension	SAPHRIS.xml:S3:23519:11	O
(	SAPHRIS.xml:S3:23531:1	O
dehydration	SAPHRIS.xml:S3:23532:11	O
,	SAPHRIS.xml:S3:23543:1	O
hypovolemia	SAPHRIS.xml:S3:23545:11	O
,	SAPHRIS.xml:S3:23556:1	O
and	SAPHRIS.xml:S3:23558:3	O
treatment	SAPHRIS.xml:S3:23562:9	O
with	SAPHRIS.xml:S3:23572:4	O
antihypertensive	SAPHRIS.xml:S3:23577:16	O
medications	SAPHRIS.xml:S3:23594:11	O
)	SAPHRIS.xml:S3:23605:1	O
;	SAPHRIS.xml:S3:23606:1	O
and	SAPHRIS.xml:S3:23608:3	O
(	SAPHRIS.xml:S3:23612:1	O
2	SAPHRIS.xml:S3:23613:1	O
)	SAPHRIS.xml:S3:23614:1	O
in	SAPHRIS.xml:S3:23616:2	O
the	SAPHRIS.xml:S3:23619:3	O
elderly	SAPHRIS.xml:S3:23623:7	O
.	SAPHRIS.xml:S3:23630:1	O

SAPHRIS	SAPHRIS.xml:S3:23632:7	O
should	SAPHRIS.xml:S3:23640:6	O
be	SAPHRIS.xml:S3:23647:2	O
used	SAPHRIS.xml:S3:23650:4	O
cautiously	SAPHRIS.xml:S3:23655:10	O
when	SAPHRIS.xml:S3:23666:4	O
treating	SAPHRIS.xml:S3:23671:8	O
patients	SAPHRIS.xml:S3:23680:8	O
who	SAPHRIS.xml:S3:23689:3	O
receive	SAPHRIS.xml:S3:23693:7	O
treatment	SAPHRIS.xml:S3:23701:9	O
with	SAPHRIS.xml:S3:23711:4	O
other	SAPHRIS.xml:S3:23716:5	O
drugs	SAPHRIS.xml:S3:23722:5	O
that	SAPHRIS.xml:S3:23728:4	O
can	SAPHRIS.xml:S3:23733:3	O
induce	SAPHRIS.xml:S3:23737:6	O
hypotension	SAPHRIS.xml:S3:23744:11	O
,	SAPHRIS.xml:S3:23755:1	O
bradycardia	SAPHRIS.xml:S3:23757:11	O
,	SAPHRIS.xml:S3:23768:1	O
respiratory	SAPHRIS.xml:S3:23770:11	O
or	SAPHRIS.xml:S3:23782:2	O
central	SAPHRIS.xml:S3:23785:7	O
nervous	SAPHRIS.xml:S3:23793:7	O
system	SAPHRIS.xml:S3:23801:6	O
depression	SAPHRIS.xml:S3:23808:10	O
[	SAPHRIS.xml:S3:23820:1	O
see	SAPHRIS.xml:S3:23821:3	O
Drug	SAPHRIS.xml:S3:23825:4	O
Interactions	SAPHRIS.xml:S3:23830:12	O
(	SAPHRIS.xml:S3:23843:1	O
7.1	SAPHRIS.xml:S3:23844:3	O
)]	SAPHRIS.xml:S3:23847:2	O
.	SAPHRIS.xml:S3:23851:1	O

Monitoring	SAPHRIS.xml:S3:23853:10	O
of	SAPHRIS.xml:S3:23864:2	O
orthostatic	SAPHRIS.xml:S3:23867:11	O
vital	SAPHRIS.xml:S3:23879:5	O
signs	SAPHRIS.xml:S3:23885:5	O
should	SAPHRIS.xml:S3:23891:6	O
be	SAPHRIS.xml:S3:23898:2	O
considered	SAPHRIS.xml:S3:23901:10	O
in	SAPHRIS.xml:S3:23912:2	O
all	SAPHRIS.xml:S3:23915:3	O
such	SAPHRIS.xml:S3:23919:4	O
patients	SAPHRIS.xml:S3:23924:8	O
,	SAPHRIS.xml:S3:23932:1	O
and	SAPHRIS.xml:S3:23934:3	O
a	SAPHRIS.xml:S3:23938:1	O
dose	SAPHRIS.xml:S3:23940:4	O
reduction	SAPHRIS.xml:S3:23945:9	O
should	SAPHRIS.xml:S3:23955:6	O
be	SAPHRIS.xml:S3:23962:2	O
considered	SAPHRIS.xml:S3:23965:10	O
if	SAPHRIS.xml:S3:23976:2	O
hypotension	SAPHRIS.xml:S3:23979:11	O
occurs	SAPHRIS.xml:S3:23991:6	O
.	SAPHRIS.xml:S3:23997:1	O

5.8	SAPHRIS.xml:S3:24009:3	O
Leukopenia	SAPHRIS.xml:S3:24013:10	O
,	SAPHRIS.xml:S3:24023:1	O
Neutropenia	SAPHRIS.xml:S3:24025:11	O
,	SAPHRIS.xml:S3:24036:1	O
and	SAPHRIS.xml:S3:24038:3	O
Agranulocytosis	SAPHRIS.xml:S3:24042:15	O

In	SAPHRIS.xml:S3:24065:2	O
clinical	SAPHRIS.xml:S3:24068:8	O
trial	SAPHRIS.xml:S3:24077:5	O
and	SAPHRIS.xml:S3:24083:3	O
postmarketing	SAPHRIS.xml:S3:24087:13	O
experience	SAPHRIS.xml:S3:24101:10	O
,	SAPHRIS.xml:S3:24111:1	O
leukopenia	SAPHRIS.xml:S3:24113:10	B-AdverseReaction
and	SAPHRIS.xml:S3:24124:3	O
neutropenia	SAPHRIS.xml:S3:24128:11	B-AdverseReaction
have	SAPHRIS.xml:S3:24140:4	O
been	SAPHRIS.xml:S3:24145:4	O
reported	SAPHRIS.xml:S3:24150:8	O
temporally	SAPHRIS.xml:S3:24159:10	O
related	SAPHRIS.xml:S3:24170:7	O
to	SAPHRIS.xml:S3:24178:2	O
antipsychotic	SAPHRIS.xml:S3:24181:13	O
agents	SAPHRIS.xml:S3:24195:6	O
,	SAPHRIS.xml:S3:24201:1	O
including	SAPHRIS.xml:S3:24203:9	O
SAPHRIS	SAPHRIS.xml:S3:24213:7	O
.	SAPHRIS.xml:S3:24220:1	O

Agranulocytosis	SAPHRIS.xml:S3:24222:15	B-AdverseReaction
(	SAPHRIS.xml:S3:24238:1	O
including	SAPHRIS.xml:S3:24239:9	O
fatal	SAPHRIS.xml:S3:24249:5	B-AdverseReaction
cases	SAPHRIS.xml:S3:24255:5	O
)	SAPHRIS.xml:S3:24260:1	O
has	SAPHRIS.xml:S3:24262:3	O
been	SAPHRIS.xml:S3:24266:4	O
reported	SAPHRIS.xml:S3:24271:8	O
with	SAPHRIS.xml:S3:24280:4	O
other	SAPHRIS.xml:S3:24285:5	B-DrugClass
agents	SAPHRIS.xml:S3:24291:6	I-DrugClass
in	SAPHRIS.xml:S3:24298:2	I-DrugClass
the	SAPHRIS.xml:S3:24301:3	I-DrugClass
class	SAPHRIS.xml:S3:24305:5	I-DrugClass
.	SAPHRIS.xml:S3:24310:1	O

Possible	SAPHRIS.xml:S3:24320:8	O
risk	SAPHRIS.xml:S3:24329:4	O
factors	SAPHRIS.xml:S3:24334:7	O
for	SAPHRIS.xml:S3:24342:3	O
leukopenia	SAPHRIS.xml:S3:24346:10	O
neutropenia	SAPHRIS.xml:S3:24357:11	O
include	SAPHRIS.xml:S3:24369:7	O
pre	SAPHRIS.xml:S3:24377:3	O
-	SAPHRIS.xml:S3:24380:1	O
existing	SAPHRIS.xml:S3:24381:8	O
low	SAPHRIS.xml:S3:24390:3	O
white	SAPHRIS.xml:S3:24394:5	O
blood	SAPHRIS.xml:S3:24400:5	O
cell	SAPHRIS.xml:S3:24406:4	O
count	SAPHRIS.xml:S3:24411:5	O
(	SAPHRIS.xml:S3:24417:1	O
WBC	SAPHRIS.xml:S3:24418:3	O
)	SAPHRIS.xml:S3:24421:1	O
absolute	SAPHRIS.xml:S3:24423:8	O
neutrophil	SAPHRIS.xml:S3:24432:10	O
count	SAPHRIS.xml:S3:24443:5	O
(	SAPHRIS.xml:S3:24449:1	O
ANC	SAPHRIS.xml:S3:24450:3	O
)	SAPHRIS.xml:S3:24453:1	O
and	SAPHRIS.xml:S3:24455:3	O
history	SAPHRIS.xml:S3:24459:7	O
of	SAPHRIS.xml:S3:24467:2	O
drug	SAPHRIS.xml:S3:24470:4	O
induced	SAPHRIS.xml:S3:24475:7	O
leukopenia	SAPHRIS.xml:S3:24483:10	O
neutropenia	SAPHRIS.xml:S3:24494:11	O
.	SAPHRIS.xml:S3:24505:1	O

In	SAPHRIS.xml:S3:24507:2	O
patients	SAPHRIS.xml:S3:24510:8	O
with	SAPHRIS.xml:S3:24519:4	O
a	SAPHRIS.xml:S3:24524:1	O
pre	SAPHRIS.xml:S3:24526:3	O
-	SAPHRIS.xml:S3:24529:1	O
existing	SAPHRIS.xml:S3:24530:8	O
low	SAPHRIS.xml:S3:24539:3	O
WBC	SAPHRIS.xml:S3:24543:3	O
ANC	SAPHRIS.xml:S3:24547:3	O
or	SAPHRIS.xml:S3:24551:2	O
drug	SAPHRIS.xml:S3:24554:4	O
-	SAPHRIS.xml:S3:24558:1	O
induced	SAPHRIS.xml:S3:24559:7	O
leukopenia	SAPHRIS.xml:S3:24567:10	O
neutropenia	SAPHRIS.xml:S3:24578:11	O
,	SAPHRIS.xml:S3:24589:1	O
perform	SAPHRIS.xml:S3:24591:7	O
a	SAPHRIS.xml:S3:24599:1	O
complete	SAPHRIS.xml:S3:24601:8	O
blood	SAPHRIS.xml:S3:24610:5	O
count	SAPHRIS.xml:S3:24616:5	O
(	SAPHRIS.xml:S3:24622:1	O
CBC	SAPHRIS.xml:S3:24623:3	O
)	SAPHRIS.xml:S3:24626:1	O
frequently	SAPHRIS.xml:S3:24628:10	O
during	SAPHRIS.xml:S3:24639:6	O
the	SAPHRIS.xml:S3:24646:3	O
first	SAPHRIS.xml:S3:24650:5	O
few	SAPHRIS.xml:S3:24656:3	O
months	SAPHRIS.xml:S3:24660:6	O
of	SAPHRIS.xml:S3:24667:2	O
therapy	SAPHRIS.xml:S3:24670:7	O
.	SAPHRIS.xml:S3:24677:1	O

In	SAPHRIS.xml:S3:24679:2	O
such	SAPHRIS.xml:S3:24682:4	O
patients	SAPHRIS.xml:S3:24687:8	O
,	SAPHRIS.xml:S3:24695:1	O
consider	SAPHRIS.xml:S3:24697:8	O
discontinuation	SAPHRIS.xml:S3:24706:15	O
of	SAPHRIS.xml:S3:24722:2	O
SAPHRIS	SAPHRIS.xml:S3:24725:7	O
at	SAPHRIS.xml:S3:24733:2	O
the	SAPHRIS.xml:S3:24736:3	O
first	SAPHRIS.xml:S3:24740:5	O
sign	SAPHRIS.xml:S3:24746:4	O
of	SAPHRIS.xml:S3:24751:2	O
a	SAPHRIS.xml:S3:24754:1	O
clinically	SAPHRIS.xml:S3:24756:10	O
significant	SAPHRIS.xml:S3:24767:11	O
decline	SAPHRIS.xml:S3:24779:7	O
in	SAPHRIS.xml:S3:24787:2	O
WBC	SAPHRIS.xml:S3:24790:3	O
in	SAPHRIS.xml:S3:24794:2	O
the	SAPHRIS.xml:S3:24797:3	O
absence	SAPHRIS.xml:S3:24801:7	O
of	SAPHRIS.xml:S3:24809:2	O
other	SAPHRIS.xml:S3:24812:5	O
causative	SAPHRIS.xml:S3:24818:9	O
factors	SAPHRIS.xml:S3:24828:7	O
.	SAPHRIS.xml:S3:24835:1	O

Monitor	SAPHRIS.xml:S3:24845:7	O
patients	SAPHRIS.xml:S3:24853:8	O
with	SAPHRIS.xml:S3:24862:4	O
clinically	SAPHRIS.xml:S3:24867:10	O
significant	SAPHRIS.xml:S3:24878:11	O
neutropenia	SAPHRIS.xml:S3:24890:11	O
for	SAPHRIS.xml:S3:24902:3	O
fever	SAPHRIS.xml:S3:24906:5	O
or	SAPHRIS.xml:S3:24912:2	O
other	SAPHRIS.xml:S3:24915:5	O
symptoms	SAPHRIS.xml:S3:24921:8	O
or	SAPHRIS.xml:S3:24930:2	O
signs	SAPHRIS.xml:S3:24933:5	O
of	SAPHRIS.xml:S3:24939:2	O
infection	SAPHRIS.xml:S3:24942:9	O
and	SAPHRIS.xml:S3:24952:3	O
treat	SAPHRIS.xml:S3:24956:5	O
promptly	SAPHRIS.xml:S3:24962:8	O
if	SAPHRIS.xml:S3:24971:2	O
such	SAPHRIS.xml:S3:24974:4	O
symptoms	SAPHRIS.xml:S3:24979:8	O
or	SAPHRIS.xml:S3:24988:2	O
signs	SAPHRIS.xml:S3:24991:5	O
occur	SAPHRIS.xml:S3:24997:5	O
.	SAPHRIS.xml:S3:25002:1	O

Discontinue	SAPHRIS.xml:S3:25004:11	O
SAPHRIS	SAPHRIS.xml:S3:25016:7	O
in	SAPHRIS.xml:S3:25024:2	O
patients	SAPHRIS.xml:S3:25027:8	O
with	SAPHRIS.xml:S3:25036:4	O
severe	SAPHRIS.xml:S3:25041:6	O
neutropenia	SAPHRIS.xml:S3:25048:11	O
(	SAPHRIS.xml:S3:25060:1	O
absolute	SAPHRIS.xml:S3:25061:8	O
neutrophil	SAPHRIS.xml:S3:25070:10	O
count	SAPHRIS.xml:S3:25081:5	O
1000	SAPHRIS.xml:S3:25088:4	O
mm	SAPHRIS.xml:S3:25093:2	O
3	SAPHRIS.xml:S3:25097:1	O
)	SAPHRIS.xml:S3:25100:1	O
and	SAPHRIS.xml:S3:25102:3	O
follow	SAPHRIS.xml:S3:25106:6	O
their	SAPHRIS.xml:S3:25113:5	O
WBC	SAPHRIS.xml:S3:25119:3	O
until	SAPHRIS.xml:S3:25123:5	O
recovery	SAPHRIS.xml:S3:25129:8	O
.	SAPHRIS.xml:S3:25137:1	O

5.9	SAPHRIS.xml:S3:25149:3	O
QT	SAPHRIS.xml:S3:25153:2	O
Prolongation	SAPHRIS.xml:S3:25156:12	O

The	SAPHRIS.xml:S3:25176:3	O
effects	SAPHRIS.xml:S3:25180:7	O
of	SAPHRIS.xml:S3:25188:2	O
SAPHRIS	SAPHRIS.xml:S3:25191:7	O
on	SAPHRIS.xml:S3:25199:2	O
the	SAPHRIS.xml:S3:25202:3	O
QT	SAPHRIS.xml:S3:25206:2	O
QTc	SAPHRIS.xml:S3:25209:3	O
interval	SAPHRIS.xml:S3:25213:8	O
were	SAPHRIS.xml:S3:25222:4	O
evaluated	SAPHRIS.xml:S3:25227:9	O
in	SAPHRIS.xml:S3:25237:2	O
a	SAPHRIS.xml:S3:25240:1	O
dedicated	SAPHRIS.xml:S3:25242:9	O
adult	SAPHRIS.xml:S3:25252:5	O
QT	SAPHRIS.xml:S3:25258:2	O
study	SAPHRIS.xml:S3:25261:5	O
.	SAPHRIS.xml:S3:25266:1	O

This	SAPHRIS.xml:S3:25268:4	O
trial	SAPHRIS.xml:S3:25273:5	O
involved	SAPHRIS.xml:S3:25279:8	O
SAPHRIS	SAPHRIS.xml:S3:25288:7	O
doses	SAPHRIS.xml:S3:25296:5	O
of	SAPHRIS.xml:S3:25302:2	O
5	SAPHRIS.xml:S3:25305:1	O
mg	SAPHRIS.xml:S3:25307:2	O
,	SAPHRIS.xml:S3:25309:1	O
10	SAPHRIS.xml:S3:25311:2	O
mg	SAPHRIS.xml:S3:25314:2	O
,	SAPHRIS.xml:S3:25316:1	O
15	SAPHRIS.xml:S3:25318:2	O
mg	SAPHRIS.xml:S3:25321:2	O
,	SAPHRIS.xml:S3:25323:1	O
and	SAPHRIS.xml:S3:25325:3	O
20	SAPHRIS.xml:S3:25329:2	O
mg	SAPHRIS.xml:S3:25332:2	O
twice	SAPHRIS.xml:S3:25335:5	O
daily	SAPHRIS.xml:S3:25341:5	O
,	SAPHRIS.xml:S3:25346:1	O
and	SAPHRIS.xml:S3:25348:3	O
placebo	SAPHRIS.xml:S3:25352:7	O
,	SAPHRIS.xml:S3:25359:1	O
and	SAPHRIS.xml:S3:25361:3	O
was	SAPHRIS.xml:S3:25365:3	O
conducted	SAPHRIS.xml:S3:25369:9	O
in	SAPHRIS.xml:S3:25379:2	O
151	SAPHRIS.xml:S3:25382:3	O
clinically	SAPHRIS.xml:S3:25386:10	O
stable	SAPHRIS.xml:S3:25397:6	O
patients	SAPHRIS.xml:S3:25404:8	O
with	SAPHRIS.xml:S3:25413:4	O
schizophrenia	SAPHRIS.xml:S3:25418:13	O
,	SAPHRIS.xml:S3:25431:1	O
with	SAPHRIS.xml:S3:25433:4	O
electrocardiographic	SAPHRIS.xml:S3:25438:20	O
assessments	SAPHRIS.xml:S3:25459:11	O
throughout	SAPHRIS.xml:S3:25471:10	O
the	SAPHRIS.xml:S3:25482:3	O
dosing	SAPHRIS.xml:S3:25486:6	O
interval	SAPHRIS.xml:S3:25493:8	O
at	SAPHRIS.xml:S3:25502:2	O
baseline	SAPHRIS.xml:S3:25505:8	O
and	SAPHRIS.xml:S3:25514:3	O
steady	SAPHRIS.xml:S3:25518:6	O
state	SAPHRIS.xml:S3:25525:5	O
.	SAPHRIS.xml:S3:25530:1	O

At	SAPHRIS.xml:S3:25532:2	O
these	SAPHRIS.xml:S3:25535:5	O
doses	SAPHRIS.xml:S3:25541:5	O
,	SAPHRIS.xml:S3:25546:1	O
SAPHRIS	SAPHRIS.xml:S3:25548:7	O
was	SAPHRIS.xml:S3:25556:3	O
associated	SAPHRIS.xml:S3:25560:10	O
with	SAPHRIS.xml:S3:25571:4	O
increases	SAPHRIS.xml:S3:25576:9	B-AdverseReaction
in	SAPHRIS.xml:S3:25586:2	I-AdverseReaction
QTc	SAPHRIS.xml:S3:25589:3	I-AdverseReaction
interval	SAPHRIS.xml:S3:25593:8	I-AdverseReaction
ranging	SAPHRIS.xml:S3:25602:7	O
from	SAPHRIS.xml:S3:25610:4	O
2	SAPHRIS.xml:S3:25615:1	B-Severity
to	SAPHRIS.xml:S3:25617:2	I-Severity
5	SAPHRIS.xml:S3:25620:1	I-Severity
msec	SAPHRIS.xml:S3:25622:4	I-Severity
compared	SAPHRIS.xml:S3:25627:8	O
to	SAPHRIS.xml:S3:25636:2	O
placebo	SAPHRIS.xml:S3:25639:7	O
.	SAPHRIS.xml:S3:25646:1	O

No	SAPHRIS.xml:S3:25648:2	B-Negation
patients	SAPHRIS.xml:S3:25651:8	O
treated	SAPHRIS.xml:S3:25660:7	O
with	SAPHRIS.xml:S3:25668:4	O
SAPHRIS	SAPHRIS.xml:S3:25673:7	O
experienced	SAPHRIS.xml:S3:25681:11	O
QTc	SAPHRIS.xml:S3:25693:3	B-AdverseReaction
increases	SAPHRIS.xml:S3:25697:9	I-AdverseReaction
60	SAPHRIS.xml:S3:25709:2	B-Severity
msec	SAPHRIS.xml:S3:25712:4	I-Severity
from	SAPHRIS.xml:S3:25717:4	O
baseline	SAPHRIS.xml:S3:25722:8	O
measurements	SAPHRIS.xml:S3:25731:12	O
,	SAPHRIS.xml:S3:25743:1	O
nor	SAPHRIS.xml:S3:25745:3	B-Negation
did	SAPHRIS.xml:S3:25749:3	O
any	SAPHRIS.xml:S3:25753:3	O
patient	SAPHRIS.xml:S3:25757:7	O
experience	SAPHRIS.xml:S3:25765:10	O
a	SAPHRIS.xml:S3:25776:1	O
QTc	SAPHRIS.xml:S3:25778:3	B-AdverseReaction
of	SAPHRIS.xml:S3:25782:2	I-AdverseReaction
500	SAPHRIS.xml:S3:25787:3	I-AdverseReaction
msec	SAPHRIS.xml:S3:25791:4	I-AdverseReaction
.	SAPHRIS.xml:S3:25795:1	O

Electrocardiogram	SAPHRIS.xml:S3:25805:17	O
(	SAPHRIS.xml:S3:25823:1	O
ECG	SAPHRIS.xml:S3:25824:3	O
)	SAPHRIS.xml:S3:25827:1	O
measurements	SAPHRIS.xml:S3:25829:12	O
were	SAPHRIS.xml:S3:25842:4	O
taken	SAPHRIS.xml:S3:25847:5	O
at	SAPHRIS.xml:S3:25853:2	O
various	SAPHRIS.xml:S3:25856:7	O
time	SAPHRIS.xml:S3:25864:4	O
points	SAPHRIS.xml:S3:25869:6	O
during	SAPHRIS.xml:S3:25876:6	O
the	SAPHRIS.xml:S3:25883:3	O
SAPHRIS	SAPHRIS.xml:S3:25887:7	O
clinical	SAPHRIS.xml:S3:25895:8	O
trial	SAPHRIS.xml:S3:25904:5	O
program	SAPHRIS.xml:S3:25910:7	O
(	SAPHRIS.xml:S3:25918:1	O
5	SAPHRIS.xml:S3:25919:1	O
mg	SAPHRIS.xml:S3:25921:2	O
or	SAPHRIS.xml:S3:25924:2	O
10	SAPHRIS.xml:S3:25927:2	O
mg	SAPHRIS.xml:S3:25930:2	O
twice	SAPHRIS.xml:S3:25933:5	O
daily	SAPHRIS.xml:S3:25939:5	O
doses	SAPHRIS.xml:S3:25945:5	O
)	SAPHRIS.xml:S3:25950:1	O
.	SAPHRIS.xml:S3:25951:1	O

Post	SAPHRIS.xml:S3:25953:4	O
-	SAPHRIS.xml:S3:25957:1	O
baseline	SAPHRIS.xml:S3:25958:8	O
QT	SAPHRIS.xml:S3:25967:2	B-AdverseReaction
prolongations	SAPHRIS.xml:S3:25970:13	I-AdverseReaction
exceeding	SAPHRIS.xml:S3:25984:9	O
500	SAPHRIS.xml:S3:25994:3	B-Severity
msec	SAPHRIS.xml:S3:25998:4	I-Severity
were	SAPHRIS.xml:S3:26003:4	O
reported	SAPHRIS.xml:S3:26008:8	O
at	SAPHRIS.xml:S3:26017:2	O
comparable	SAPHRIS.xml:S3:26020:10	O
rates	SAPHRIS.xml:S3:26031:5	O
for	SAPHRIS.xml:S3:26037:3	O
SAPHRIS	SAPHRIS.xml:S3:26041:7	O
and	SAPHRIS.xml:S3:26049:3	O
placebo	SAPHRIS.xml:S3:26053:7	O
in	SAPHRIS.xml:S3:26061:2	O
these	SAPHRIS.xml:S3:26064:5	O
short	SAPHRIS.xml:S3:26070:5	O
-	SAPHRIS.xml:S3:26075:1	O
term	SAPHRIS.xml:S3:26076:4	O
trials	SAPHRIS.xml:S3:26081:6	O
.	SAPHRIS.xml:S3:26087:1	O

There	SAPHRIS.xml:S3:26089:5	O
were	SAPHRIS.xml:S3:26095:4	O
no	SAPHRIS.xml:S3:26100:2	B-Negation
reports	SAPHRIS.xml:S3:26103:7	O
of	SAPHRIS.xml:S3:26111:2	O
Torsade	SAPHRIS.xml:S3:26114:7	B-AdverseReaction
de	SAPHRIS.xml:S3:26122:2	I-AdverseReaction
Pointes	SAPHRIS.xml:S3:26125:7	I-AdverseReaction
or	SAPHRIS.xml:S3:26133:2	O
any	SAPHRIS.xml:S3:26136:3	O
other	SAPHRIS.xml:S3:26140:5	O
adverse	SAPHRIS.xml:S3:26146:7	O
reactions	SAPHRIS.xml:S3:26154:9	O
associated	SAPHRIS.xml:S3:26164:10	O
with	SAPHRIS.xml:S3:26175:4	O
delayed	SAPHRIS.xml:S3:26180:7	B-AdverseReaction
ventricular	SAPHRIS.xml:S3:26188:11	I-AdverseReaction
repolarization	SAPHRIS.xml:S3:26200:14	I-AdverseReaction
.	SAPHRIS.xml:S3:26214:1	O

The	SAPHRIS.xml:S3:26224:3	O
use	SAPHRIS.xml:S3:26228:3	O
of	SAPHRIS.xml:S3:26232:2	O
SAPHRIS	SAPHRIS.xml:S3:26235:7	O
should	SAPHRIS.xml:S3:26243:6	O
be	SAPHRIS.xml:S3:26250:2	O
avoided	SAPHRIS.xml:S3:26253:7	O
in	SAPHRIS.xml:S3:26261:2	O
combination	SAPHRIS.xml:S3:26264:11	O
with	SAPHRIS.xml:S3:26276:4	O
other	SAPHRIS.xml:S3:26281:5	O
drugs	SAPHRIS.xml:S3:26287:5	O
known	SAPHRIS.xml:S3:26293:5	O
to	SAPHRIS.xml:S3:26299:2	O
prolong	SAPHRIS.xml:S3:26302:7	O
QTc	SAPHRIS.xml:S3:26310:3	O
including	SAPHRIS.xml:S3:26314:9	O
Class	SAPHRIS.xml:S3:26324:5	O
1	SAPHRIS.xml:S3:26330:1	O
A	SAPHRIS.xml:S3:26331:1	O
antiarrhythmics	SAPHRIS.xml:S3:26333:15	O
(	SAPHRIS.xml:S3:26349:1	O
e	SAPHRIS.xml:S3:26350:1	O
.	SAPHRIS.xml:S3:26351:1	O
g	SAPHRIS.xml:S3:26352:1	O
.	SAPHRIS.xml:S3:26353:1	O
,	SAPHRIS.xml:S3:26354:1	O
quinidine	SAPHRIS.xml:S3:26356:9	O
,	SAPHRIS.xml:S3:26365:1	O
procainamide	SAPHRIS.xml:S3:26367:12	O
)	SAPHRIS.xml:S3:26379:1	O
or	SAPHRIS.xml:S3:26381:2	O
Class	SAPHRIS.xml:S3:26384:5	O
3	SAPHRIS.xml:S3:26390:1	O
antiarrhythmics	SAPHRIS.xml:S3:26392:15	O
(	SAPHRIS.xml:S3:26408:1	O
e	SAPHRIS.xml:S3:26409:1	O
.	SAPHRIS.xml:S3:26410:1	O
g	SAPHRIS.xml:S3:26411:1	O
.	SAPHRIS.xml:S3:26412:1	O
,	SAPHRIS.xml:S3:26413:1	O
amiodarone	SAPHRIS.xml:S3:26415:10	O
,	SAPHRIS.xml:S3:26425:1	O
sotalol	SAPHRIS.xml:S3:26427:7	O
)	SAPHRIS.xml:S3:26434:1	O
,	SAPHRIS.xml:S3:26435:1	O
antipsychotic	SAPHRIS.xml:S3:26437:13	O
medications	SAPHRIS.xml:S3:26451:11	O
(	SAPHRIS.xml:S3:26463:1	O
e	SAPHRIS.xml:S3:26464:1	O
.	SAPHRIS.xml:S3:26465:1	O
g	SAPHRIS.xml:S3:26466:1	O
.	SAPHRIS.xml:S3:26467:1	O
,	SAPHRIS.xml:S3:26468:1	O
ziprasidone	SAPHRIS.xml:S3:26470:11	O
,	SAPHRIS.xml:S3:26481:1	O
chlorpromazine	SAPHRIS.xml:S3:26483:14	O
,	SAPHRIS.xml:S3:26497:1	O
thioridazine	SAPHRIS.xml:S3:26499:12	O
)	SAPHRIS.xml:S3:26511:1	O
,	SAPHRIS.xml:S3:26512:1	O
and	SAPHRIS.xml:S3:26514:3	O
antibiotics	SAPHRIS.xml:S3:26518:11	O
(	SAPHRIS.xml:S3:26530:1	O
e	SAPHRIS.xml:S3:26531:1	O
.	SAPHRIS.xml:S3:26532:1	O
g	SAPHRIS.xml:S3:26533:1	O
.	SAPHRIS.xml:S3:26534:1	O
,	SAPHRIS.xml:S3:26535:1	O
gatifloxacin	SAPHRIS.xml:S3:26537:12	O
,	SAPHRIS.xml:S3:26549:1	O
moxifloxacin	SAPHRIS.xml:S3:26551:12	O
)	SAPHRIS.xml:S3:26563:1	O
.	SAPHRIS.xml:S3:26564:1	O

SAPHRIS	SAPHRIS.xml:S3:26566:7	O
should	SAPHRIS.xml:S3:26574:6	O
also	SAPHRIS.xml:S3:26581:4	O
be	SAPHRIS.xml:S3:26586:2	O
avoided	SAPHRIS.xml:S3:26589:7	O
in	SAPHRIS.xml:S3:26597:2	O
patients	SAPHRIS.xml:S3:26600:8	O
with	SAPHRIS.xml:S3:26609:4	O
a	SAPHRIS.xml:S3:26614:1	O
history	SAPHRIS.xml:S3:26616:7	O
of	SAPHRIS.xml:S3:26624:2	O
cardiac	SAPHRIS.xml:S3:26627:7	O
arrhythmias	SAPHRIS.xml:S3:26635:11	O
and	SAPHRIS.xml:S3:26647:3	O
in	SAPHRIS.xml:S3:26651:2	O
other	SAPHRIS.xml:S3:26654:5	O
circumstances	SAPHRIS.xml:S3:26660:13	O
that	SAPHRIS.xml:S3:26674:4	O
may	SAPHRIS.xml:S3:26679:3	O
increase	SAPHRIS.xml:S3:26683:8	O
the	SAPHRIS.xml:S3:26692:3	O
risk	SAPHRIS.xml:S3:26696:4	O
of	SAPHRIS.xml:S3:26701:2	O
the	SAPHRIS.xml:S3:26704:3	O
occurrence	SAPHRIS.xml:S3:26708:10	O
of	SAPHRIS.xml:S3:26719:2	O
torsade	SAPHRIS.xml:S3:26722:7	O
de	SAPHRIS.xml:S3:26730:2	O
pointes	SAPHRIS.xml:S3:26733:7	O
and	SAPHRIS.xml:S3:26741:3	O
or	SAPHRIS.xml:S3:26745:2	O
sudden	SAPHRIS.xml:S3:26748:6	O
death	SAPHRIS.xml:S3:26755:5	O
in	SAPHRIS.xml:S3:26761:2	O
association	SAPHRIS.xml:S3:26764:11	O
with	SAPHRIS.xml:S3:26776:4	O
the	SAPHRIS.xml:S3:26781:3	O
use	SAPHRIS.xml:S3:26785:3	O
of	SAPHRIS.xml:S3:26789:2	O
drugs	SAPHRIS.xml:S3:26792:5	O
that	SAPHRIS.xml:S3:26798:4	O
prolong	SAPHRIS.xml:S3:26803:7	O
the	SAPHRIS.xml:S3:26811:3	O
QTc	SAPHRIS.xml:S3:26815:3	O
interval	SAPHRIS.xml:S3:26819:8	O
,	SAPHRIS.xml:S3:26827:1	O
including	SAPHRIS.xml:S3:26829:9	O
bradycardia	SAPHRIS.xml:S3:26839:11	O
;	SAPHRIS.xml:S3:26850:1	O
hypokalemia	SAPHRIS.xml:S3:26852:11	O
or	SAPHRIS.xml:S3:26864:2	O
hypomagnesemia	SAPHRIS.xml:S3:26867:14	O
;	SAPHRIS.xml:S3:26881:1	O
and	SAPHRIS.xml:S3:26883:3	O
presence	SAPHRIS.xml:S3:26887:8	O
of	SAPHRIS.xml:S3:26896:2	O
congenital	SAPHRIS.xml:S3:26899:10	O
prolongation	SAPHRIS.xml:S3:26910:12	O
of	SAPHRIS.xml:S3:26923:2	O
the	SAPHRIS.xml:S3:26926:3	O
QT	SAPHRIS.xml:S3:26930:2	O
interval	SAPHRIS.xml:S3:26933:8	O
.	SAPHRIS.xml:S3:26941:1	O

5.10	SAPHRIS.xml:S3:26953:4	O
Hyperprolactinemia	SAPHRIS.xml:S3:26958:18	O

Like	SAPHRIS.xml:S3:26984:4	O
other	SAPHRIS.xml:S3:26989:5	O
drugs	SAPHRIS.xml:S3:26995:5	O
that	SAPHRIS.xml:S3:27001:4	O
antagonize	SAPHRIS.xml:S3:27006:10	O
dopamine	SAPHRIS.xml:S3:27017:8	O
D2receptors	SAPHRIS.xml:S3:27026:11	O
,	SAPHRIS.xml:S3:27037:1	O
SAPHRIS	SAPHRIS.xml:S3:27039:7	O
can	SAPHRIS.xml:S3:27047:3	B-Factor
elevate	SAPHRIS.xml:S3:27051:7	B-AdverseReaction
prolactin	SAPHRIS.xml:S3:27059:9	I-AdverseReaction
levels	SAPHRIS.xml:S3:27069:6	I-AdverseReaction
,	SAPHRIS.xml:S3:27075:1	O
and	SAPHRIS.xml:S3:27077:3	O
the	SAPHRIS.xml:S3:27081:3	O
elevation	SAPHRIS.xml:S3:27085:9	O
can	SAPHRIS.xml:S3:27095:3	O
persist	SAPHRIS.xml:S3:27099:7	O
during	SAPHRIS.xml:S3:27107:6	O
chronic	SAPHRIS.xml:S3:27114:7	O
administration	SAPHRIS.xml:S3:27122:14	O
.	SAPHRIS.xml:S3:27136:1	O

Hyperprolactinemia	SAPHRIS.xml:S3:27138:18	B-AdverseReaction
may	SAPHRIS.xml:S3:27157:3	B-Factor
suppress	SAPHRIS.xml:S3:27161:8	B-AdverseReaction
hypothalamic	SAPHRIS.xml:S3:27170:12	I-AdverseReaction
GnRH	SAPHRIS.xml:S3:27183:4	I-AdverseReaction
,	SAPHRIS.xml:S3:27187:1	O
resulting	SAPHRIS.xml:S3:27189:9	O
in	SAPHRIS.xml:S3:27199:2	O
reduced	SAPHRIS.xml:S3:27202:7	B-AdverseReaction
pituitary	SAPHRIS.xml:S3:27210:9	I-AdverseReaction
gonadotropin	SAPHRIS.xml:S3:27220:12	I-AdverseReaction
secretion	SAPHRIS.xml:S3:27233:9	I-AdverseReaction
.	SAPHRIS.xml:S3:27242:1	O

This	SAPHRIS.xml:S3:27244:4	O
,	SAPHRIS.xml:S3:27248:1	O
in	SAPHRIS.xml:S3:27250:2	O
turn	SAPHRIS.xml:S3:27253:4	O
,	SAPHRIS.xml:S3:27257:1	O
may	SAPHRIS.xml:S3:27259:3	B-Factor
inhibit	SAPHRIS.xml:S3:27263:7	B-AdverseReaction
reproductive	SAPHRIS.xml:S3:27271:12	I-AdverseReaction
function	SAPHRIS.xml:S3:27284:8	I-AdverseReaction
by	SAPHRIS.xml:S3:27293:2	O
impairing	SAPHRIS.xml:S3:27296:9	B-AdverseReaction
gonadal	SAPHRIS.xml:S3:27306:7	I-AdverseReaction
steroidogenesis	SAPHRIS.xml:S3:27314:15	I-AdverseReaction
in	SAPHRIS.xml:S3:27330:2	O
both	SAPHRIS.xml:S3:27333:4	O
female	SAPHRIS.xml:S3:27338:6	O
and	SAPHRIS.xml:S3:27345:3	O
male	SAPHRIS.xml:S3:27349:4	O
patients	SAPHRIS.xml:S3:27354:8	O
.	SAPHRIS.xml:S3:27362:1	O

Galactorrhea	SAPHRIS.xml:S3:27364:12	B-AdverseReaction
,	SAPHRIS.xml:S3:27376:1	O
amenorrhea	SAPHRIS.xml:S3:27378:10	B-AdverseReaction
,	SAPHRIS.xml:S3:27388:1	O
gynecomastia	SAPHRIS.xml:S3:27390:12	B-AdverseReaction
,	SAPHRIS.xml:S3:27402:1	O
and	SAPHRIS.xml:S3:27404:3	O
impotence	SAPHRIS.xml:S3:27408:9	B-AdverseReaction
have	SAPHRIS.xml:S3:27418:4	O
been	SAPHRIS.xml:S3:27423:4	O
reported	SAPHRIS.xml:S3:27428:8	O
in	SAPHRIS.xml:S3:27437:2	O
patients	SAPHRIS.xml:S3:27440:8	O
receiving	SAPHRIS.xml:S3:27449:9	O
prolactin	SAPHRIS.xml:S3:27459:9	B-DrugClass
-	SAPHRIS.xml:S3:27468:1	I-DrugClass
elevating	SAPHRIS.xml:S3:27469:9	I-DrugClass
compounds	SAPHRIS.xml:S3:27479:9	I-DrugClass
.	SAPHRIS.xml:S3:27488:1	O

Long	SAPHRIS.xml:S3:27490:4	O
-	SAPHRIS.xml:S3:27494:1	O
standing	SAPHRIS.xml:S3:27495:8	O
hyperprolactinemia	SAPHRIS.xml:S3:27504:18	B-AdverseReaction
when	SAPHRIS.xml:S3:27523:4	O
associated	SAPHRIS.xml:S3:27528:10	O
with	SAPHRIS.xml:S3:27539:4	O
hypogonadism	SAPHRIS.xml:S3:27544:12	B-AdverseReaction
may	SAPHRIS.xml:S3:27557:3	B-Factor
lead	SAPHRIS.xml:S3:27561:4	O
to	SAPHRIS.xml:S3:27566:2	O
decreased	SAPHRIS.xml:S3:27569:9	B-AdverseReaction
bone	SAPHRIS.xml:S3:27579:4	I-AdverseReaction
density	SAPHRIS.xml:S3:27584:7	I-AdverseReaction
in	SAPHRIS.xml:S3:27592:2	O
both	SAPHRIS.xml:S3:27595:4	O
female	SAPHRIS.xml:S3:27600:6	O
and	SAPHRIS.xml:S3:27607:3	O
male	SAPHRIS.xml:S3:27611:4	O
subjects	SAPHRIS.xml:S3:27616:8	O
.	SAPHRIS.xml:S3:27624:1	O

In	SAPHRIS.xml:S3:27626:2	O
SAPHRIS	SAPHRIS.xml:S3:27629:7	O
adult	SAPHRIS.xml:S3:27637:5	O
clinical	SAPHRIS.xml:S3:27643:8	O
trials	SAPHRIS.xml:S3:27652:6	O
,	SAPHRIS.xml:S3:27658:1	O
the	SAPHRIS.xml:S3:27660:3	O
incidences	SAPHRIS.xml:S3:27664:10	O
of	SAPHRIS.xml:S3:27675:2	O
adverse	SAPHRIS.xml:S3:27678:7	O
events	SAPHRIS.xml:S3:27686:6	O
related	SAPHRIS.xml:S3:27693:7	O
to	SAPHRIS.xml:S3:27701:2	O
abnormal	SAPHRIS.xml:S3:27704:8	B-AdverseReaction
prolactin	SAPHRIS.xml:S3:27713:9	I-AdverseReaction
levels	SAPHRIS.xml:S3:27723:6	I-AdverseReaction
were	SAPHRIS.xml:S3:27730:4	O
0.4%	SAPHRIS.xml:S3:27735:4	O
versus	SAPHRIS.xml:S3:27740:6	O
0%	SAPHRIS.xml:S3:27747:2	O
for	SAPHRIS.xml:S3:27750:3	O
placebo	SAPHRIS.xml:S3:27754:7	O
.	SAPHRIS.xml:S3:27761:1	O

In	SAPHRIS.xml:S3:27763:2	O
a	SAPHRIS.xml:S3:27766:1	O
3	SAPHRIS.xml:S3:27768:1	O
-	SAPHRIS.xml:S3:27769:1	O
week	SAPHRIS.xml:S3:27770:4	O
,	SAPHRIS.xml:S3:27774:1	O
bipolar	SAPHRIS.xml:S3:27776:7	O
mania	SAPHRIS.xml:S3:27784:5	O
pediatric	SAPHRIS.xml:S3:27790:9	O
trial	SAPHRIS.xml:S3:27800:5	O
,	SAPHRIS.xml:S3:27805:1	O
the	SAPHRIS.xml:S3:27807:3	O
incidence	SAPHRIS.xml:S3:27811:9	O
of	SAPHRIS.xml:S3:27821:2	O
adverse	SAPHRIS.xml:S3:27824:7	O
events	SAPHRIS.xml:S3:27832:6	O
related	SAPHRIS.xml:S3:27839:7	O
to	SAPHRIS.xml:S3:27847:2	O
abnormal	SAPHRIS.xml:S3:27850:8	B-AdverseReaction
prolactin	SAPHRIS.xml:S3:27859:9	I-AdverseReaction
levels	SAPHRIS.xml:S3:27869:6	I-AdverseReaction
were	SAPHRIS.xml:S3:27876:4	O
0%	SAPHRIS.xml:S3:27881:2	O
in	SAPHRIS.xml:S3:27884:2	O
the	SAPHRIS.xml:S3:27887:3	O
SAPHRIS	SAPHRIS.xml:S3:27891:7	O
2.5	SAPHRIS.xml:S3:27899:3	O
mg	SAPHRIS.xml:S3:27903:2	O
twice	SAPHRIS.xml:S3:27906:5	O
daily	SAPHRIS.xml:S3:27912:5	O
treatment	SAPHRIS.xml:S3:27918:9	O
group	SAPHRIS.xml:S3:27928:5	O
,	SAPHRIS.xml:S3:27933:1	O
2%	SAPHRIS.xml:S3:27935:2	O
in	SAPHRIS.xml:S3:27938:2	O
the	SAPHRIS.xml:S3:27941:3	O
SAPHRIS	SAPHRIS.xml:S3:27945:7	O
5	SAPHRIS.xml:S3:27953:1	O
mg	SAPHRIS.xml:S3:27955:2	O
twice	SAPHRIS.xml:S3:27958:5	O
daily	SAPHRIS.xml:S3:27964:5	O
treatment	SAPHRIS.xml:S3:27970:9	O
group	SAPHRIS.xml:S3:27980:5	O
,	SAPHRIS.xml:S3:27985:1	O
and	SAPHRIS.xml:S3:27987:3	O
1%	SAPHRIS.xml:S3:27991:2	O
in	SAPHRIS.xml:S3:27994:2	O
the	SAPHRIS.xml:S3:27997:3	O
SAPHRIS	SAPHRIS.xml:S3:28001:7	O
10	SAPHRIS.xml:S3:28009:2	O
mg	SAPHRIS.xml:S3:28012:2	O
twice	SAPHRIS.xml:S3:28015:5	O
daily	SAPHRIS.xml:S3:28021:5	O
treatment	SAPHRIS.xml:S3:28027:9	O
group	SAPHRIS.xml:S3:28037:5	O
versus	SAPHRIS.xml:S3:28043:6	O
to	SAPHRIS.xml:S3:28050:2	O
1%	SAPHRIS.xml:S3:28053:2	O
for	SAPHRIS.xml:S3:28056:3	O
patients	SAPHRIS.xml:S3:28060:8	O
treated	SAPHRIS.xml:S3:28069:7	O
with	SAPHRIS.xml:S3:28077:4	O
placebo	SAPHRIS.xml:S3:28082:7	O
[	SAPHRIS.xml:S3:28091:1	O
see	SAPHRIS.xml:S3:28092:3	O
Adverse	SAPHRIS.xml:S3:28096:7	O
Reactions	SAPHRIS.xml:S3:28104:9	O
(	SAPHRIS.xml:S3:28114:1	O
6.1	SAPHRIS.xml:S3:28115:3	O
)]	SAPHRIS.xml:S3:28118:2	O
.	SAPHRIS.xml:S3:28122:1	O

Tissue	SAPHRIS.xml:S3:28132:6	O
culture	SAPHRIS.xml:S3:28139:7	O
experiments	SAPHRIS.xml:S3:28147:11	O
indicate	SAPHRIS.xml:S3:28159:8	O
that	SAPHRIS.xml:S3:28168:4	O
approximately	SAPHRIS.xml:S3:28173:13	O
one	SAPHRIS.xml:S3:28187:3	O
-	SAPHRIS.xml:S3:28190:1	O
third	SAPHRIS.xml:S3:28191:5	O
of	SAPHRIS.xml:S3:28197:2	O
human	SAPHRIS.xml:S3:28200:5	O
breast	SAPHRIS.xml:S3:28206:6	O
cancers	SAPHRIS.xml:S3:28213:7	O
are	SAPHRIS.xml:S3:28221:3	O
prolactin	SAPHRIS.xml:S3:28225:9	O
-	SAPHRIS.xml:S3:28234:1	O
dependent	SAPHRIS.xml:S3:28235:9	O
in	SAPHRIS.xml:S3:28246:2	O
vitro	SAPHRIS.xml:S3:28249:5	O
,	SAPHRIS.xml:S3:28256:1	O
a	SAPHRIS.xml:S3:28258:1	O
factor	SAPHRIS.xml:S3:28260:6	O
of	SAPHRIS.xml:S3:28267:2	O
potential	SAPHRIS.xml:S3:28270:9	O
importance	SAPHRIS.xml:S3:28280:10	O
if	SAPHRIS.xml:S3:28291:2	O
the	SAPHRIS.xml:S3:28294:3	O
prescription	SAPHRIS.xml:S3:28298:12	O
of	SAPHRIS.xml:S3:28311:2	O
these	SAPHRIS.xml:S3:28314:5	O
drugs	SAPHRIS.xml:S3:28320:5	O
is	SAPHRIS.xml:S3:28326:2	O
considered	SAPHRIS.xml:S3:28329:10	O
in	SAPHRIS.xml:S3:28340:2	O
a	SAPHRIS.xml:S3:28343:1	O
patient	SAPHRIS.xml:S3:28345:7	O
with	SAPHRIS.xml:S3:28353:4	O
previously	SAPHRIS.xml:S3:28358:10	O
-	SAPHRIS.xml:S3:28368:1	O
detected	SAPHRIS.xml:S3:28369:8	O
breast	SAPHRIS.xml:S3:28378:6	O
cancer	SAPHRIS.xml:S3:28385:6	O
.	SAPHRIS.xml:S3:28391:1	O

Neither	SAPHRIS.xml:S3:28393:7	B-Negation
clinical	SAPHRIS.xml:S3:28401:8	O
studies	SAPHRIS.xml:S3:28410:7	O
nor	SAPHRIS.xml:S3:28418:3	I-Negation
epidemiologic	SAPHRIS.xml:S3:28422:13	O
studies	SAPHRIS.xml:S3:28436:7	O
conducted	SAPHRIS.xml:S3:28444:9	O
to	SAPHRIS.xml:S3:28454:2	O
date	SAPHRIS.xml:S3:28457:4	O
have	SAPHRIS.xml:S3:28462:4	O
shown	SAPHRIS.xml:S3:28467:5	O
an	SAPHRIS.xml:S3:28473:2	O
association	SAPHRIS.xml:S3:28476:11	O
between	SAPHRIS.xml:S3:28488:7	O
chronic	SAPHRIS.xml:S3:28496:7	O
administration	SAPHRIS.xml:S3:28504:14	O
of	SAPHRIS.xml:S3:28519:2	O
this	SAPHRIS.xml:S3:28522:4	O
class	SAPHRIS.xml:S3:28527:5	O
of	SAPHRIS.xml:S3:28533:2	O
drugs	SAPHRIS.xml:S3:28536:5	O
and	SAPHRIS.xml:S3:28542:3	O
tumorigenesis	SAPHRIS.xml:S3:28546:13	B-AdverseReaction
in	SAPHRIS.xml:S3:28560:2	O
humans	SAPHRIS.xml:S3:28563:6	O
,	SAPHRIS.xml:S3:28569:1	O
but	SAPHRIS.xml:S3:28571:3	O
the	SAPHRIS.xml:S3:28575:3	O
available	SAPHRIS.xml:S3:28579:9	O
evidence	SAPHRIS.xml:S3:28589:8	O
is	SAPHRIS.xml:S3:28598:2	O
too	SAPHRIS.xml:S3:28601:3	O
limited	SAPHRIS.xml:S3:28605:7	O
to	SAPHRIS.xml:S3:28613:2	O
be	SAPHRIS.xml:S3:28616:2	O
conclusive	SAPHRIS.xml:S3:28619:10	O
.	SAPHRIS.xml:S3:28629:1	O

5.11	SAPHRIS.xml:S3:28641:4	O
Seizures	SAPHRIS.xml:S3:28646:8	O

Seizures	SAPHRIS.xml:S3:28662:8	B-AdverseReaction
were	SAPHRIS.xml:S3:28671:4	O
reported	SAPHRIS.xml:S3:28676:8	O
in	SAPHRIS.xml:S3:28685:2	O
0%	SAPHRIS.xml:S3:28688:2	O
and	SAPHRIS.xml:S3:28691:3	O
0.3%	SAPHRIS.xml:S3:28695:4	O
(	SAPHRIS.xml:S3:28700:1	O
0	SAPHRIS.xml:S3:28701:1	O
572	SAPHRIS.xml:S3:28703:3	O
,	SAPHRIS.xml:S3:28706:1	O
1	SAPHRIS.xml:S3:28708:1	O
379	SAPHRIS.xml:S3:28710:3	O
)	SAPHRIS.xml:S3:28713:1	O
of	SAPHRIS.xml:S3:28715:2	O
adult	SAPHRIS.xml:S3:28718:5	O
patients	SAPHRIS.xml:S3:28724:8	O
treated	SAPHRIS.xml:S3:28733:7	O
with	SAPHRIS.xml:S3:28741:4	O
doses	SAPHRIS.xml:S3:28746:5	O
of	SAPHRIS.xml:S3:28752:2	O
5	SAPHRIS.xml:S3:28755:1	O
mg	SAPHRIS.xml:S3:28757:2	O
and	SAPHRIS.xml:S3:28760:3	O
10	SAPHRIS.xml:S3:28764:2	O
mg	SAPHRIS.xml:S3:28767:2	O
twice	SAPHRIS.xml:S3:28770:5	O
daily	SAPHRIS.xml:S3:28776:5	O
of	SAPHRIS.xml:S3:28782:2	O
SAPHRIS	SAPHRIS.xml:S3:28785:7	O
,	SAPHRIS.xml:S3:28792:1	O
respectively	SAPHRIS.xml:S3:28794:12	O
,	SAPHRIS.xml:S3:28806:1	O
compared	SAPHRIS.xml:S3:28808:8	O
to	SAPHRIS.xml:S3:28817:2	O
0%	SAPHRIS.xml:S3:28820:2	O
(	SAPHRIS.xml:S3:28823:1	O
0	SAPHRIS.xml:S3:28824:1	O
503	SAPHRIS.xml:S3:28826:3	O
,	SAPHRIS.xml:S3:28829:1	O
0	SAPHRIS.xml:S3:28831:1	O
203	SAPHRIS.xml:S3:28833:3	O
)	SAPHRIS.xml:S3:28836:1	O
of	SAPHRIS.xml:S3:28838:2	O
patients	SAPHRIS.xml:S3:28841:8	O
treated	SAPHRIS.xml:S3:28850:7	O
with	SAPHRIS.xml:S3:28858:4	O
placebo	SAPHRIS.xml:S3:28863:7	O
in	SAPHRIS.xml:S3:28871:2	O
short	SAPHRIS.xml:S3:28874:5	O
-	SAPHRIS.xml:S3:28879:1	O
term	SAPHRIS.xml:S3:28880:4	O
schizophrenia	SAPHRIS.xml:S3:28885:13	O
and	SAPHRIS.xml:S3:28899:3	O
bipolar	SAPHRIS.xml:S3:28903:7	O
mania	SAPHRIS.xml:S3:28911:5	O
trials	SAPHRIS.xml:S3:28917:6	O
,	SAPHRIS.xml:S3:28923:1	O
respectively	SAPHRIS.xml:S3:28925:12	O
.	SAPHRIS.xml:S3:28937:1	O

During	SAPHRIS.xml:S3:28939:6	O
adult	SAPHRIS.xml:S3:28946:5	O
pre	SAPHRIS.xml:S3:28952:3	O
-	SAPHRIS.xml:S3:28955:1	O
marketing	SAPHRIS.xml:S3:28956:9	O
clinical	SAPHRIS.xml:S3:28966:8	O
trials	SAPHRIS.xml:S3:28975:6	O
with	SAPHRIS.xml:S3:28982:4	O
SAPHRIS	SAPHRIS.xml:S3:28987:7	O
,	SAPHRIS.xml:S3:28994:1	O
including	SAPHRIS.xml:S3:28996:9	O
long	SAPHRIS.xml:S3:29006:4	O
-	SAPHRIS.xml:S3:29010:1	O
term	SAPHRIS.xml:S3:29011:4	O
trials	SAPHRIS.xml:S3:29016:6	O
without	SAPHRIS.xml:S3:29023:7	O
comparison	SAPHRIS.xml:S3:29031:10	O
to	SAPHRIS.xml:S3:29042:2	O
placebo	SAPHRIS.xml:S3:29045:7	O
,	SAPHRIS.xml:S3:29052:1	O
seizures	SAPHRIS.xml:S3:29054:8	B-AdverseReaction
were	SAPHRIS.xml:S3:29063:4	O
reported	SAPHRIS.xml:S3:29068:8	O
in	SAPHRIS.xml:S3:29077:2	O
0.3%	SAPHRIS.xml:S3:29080:4	O
(	SAPHRIS.xml:S3:29085:1	O
5	SAPHRIS.xml:S3:29086:1	O
1953	SAPHRIS.xml:S3:29088:4	O
)	SAPHRIS.xml:S3:29092:1	O
of	SAPHRIS.xml:S3:29094:2	O
patients	SAPHRIS.xml:S3:29097:8	O
treated	SAPHRIS.xml:S3:29106:7	O
with	SAPHRIS.xml:S3:29114:4	O
SAPHRIS	SAPHRIS.xml:S3:29119:7	O
.	SAPHRIS.xml:S3:29126:1	O

There	SAPHRIS.xml:S3:29128:5	O
were	SAPHRIS.xml:S3:29134:4	O
no	SAPHRIS.xml:S3:29139:2	B-Negation
reports	SAPHRIS.xml:S3:29142:7	O
of	SAPHRIS.xml:S3:29150:2	O
seizures	SAPHRIS.xml:S3:29153:8	B-AdverseReaction
in	SAPHRIS.xml:S3:29162:2	O
pediatric	SAPHRIS.xml:S3:29165:9	O
patients	SAPHRIS.xml:S3:29175:8	O
treated	SAPHRIS.xml:S3:29184:7	O
with	SAPHRIS.xml:S3:29192:4	O
SAPHRIS	SAPHRIS.xml:S3:29197:7	O
in	SAPHRIS.xml:S3:29205:2	O
a	SAPHRIS.xml:S3:29208:1	O
3	SAPHRIS.xml:S3:29210:1	O
-	SAPHRIS.xml:S3:29211:1	O
week	SAPHRIS.xml:S3:29212:4	O
-	SAPHRIS.xml:S3:29216:1	O
term	SAPHRIS.xml:S3:29217:4	O
,	SAPHRIS.xml:S3:29221:1	O
bipolar	SAPHRIS.xml:S3:29223:7	O
mania	SAPHRIS.xml:S3:29231:5	O
trial	SAPHRIS.xml:S3:29237:5	O
.	SAPHRIS.xml:S3:29242:1	O

As	SAPHRIS.xml:S3:29252:2	O
with	SAPHRIS.xml:S3:29255:4	O
other	SAPHRIS.xml:S3:29260:5	O
antipsychotic	SAPHRIS.xml:S3:29266:13	O
drugs	SAPHRIS.xml:S3:29280:5	O
,	SAPHRIS.xml:S3:29285:1	O
SAPHRIS	SAPHRIS.xml:S3:29287:7	O
should	SAPHRIS.xml:S3:29295:6	O
be	SAPHRIS.xml:S3:29302:2	O
used	SAPHRIS.xml:S3:29305:4	O
with	SAPHRIS.xml:S3:29310:4	O
caution	SAPHRIS.xml:S3:29315:7	O
in	SAPHRIS.xml:S3:29323:2	O
patients	SAPHRIS.xml:S3:29326:8	O
with	SAPHRIS.xml:S3:29335:4	O
a	SAPHRIS.xml:S3:29340:1	O
history	SAPHRIS.xml:S3:29342:7	O
of	SAPHRIS.xml:S3:29350:2	O
seizures	SAPHRIS.xml:S3:29353:8	O
or	SAPHRIS.xml:S3:29362:2	O
with	SAPHRIS.xml:S3:29365:4	O
conditions	SAPHRIS.xml:S3:29370:10	O
that	SAPHRIS.xml:S3:29381:4	O
potentially	SAPHRIS.xml:S3:29386:11	O
lower	SAPHRIS.xml:S3:29398:5	O
the	SAPHRIS.xml:S3:29404:3	O
seizure	SAPHRIS.xml:S3:29408:7	O
threshold	SAPHRIS.xml:S3:29416:9	O
.	SAPHRIS.xml:S3:29425:1	O

Conditions	SAPHRIS.xml:S3:29427:10	O
that	SAPHRIS.xml:S3:29438:4	O
lower	SAPHRIS.xml:S3:29443:5	O
the	SAPHRIS.xml:S3:29449:3	O
seizure	SAPHRIS.xml:S3:29453:7	O
threshold	SAPHRIS.xml:S3:29461:9	O
may	SAPHRIS.xml:S3:29471:3	O
be	SAPHRIS.xml:S3:29475:2	O
more	SAPHRIS.xml:S3:29478:4	O
prevalent	SAPHRIS.xml:S3:29483:9	O
in	SAPHRIS.xml:S3:29493:2	O
patients	SAPHRIS.xml:S3:29496:8	O
65	SAPHRIS.xml:S3:29505:2	O
years	SAPHRIS.xml:S3:29508:5	O
or	SAPHRIS.xml:S3:29514:2	O
older	SAPHRIS.xml:S3:29517:5	O
.	SAPHRIS.xml:S3:29522:1	O

5.12	SAPHRIS.xml:S3:29534:4	O
Potential	SAPHRIS.xml:S3:29539:9	O
for	SAPHRIS.xml:S3:29549:3	O
Cognitive	SAPHRIS.xml:S3:29553:9	O
and	SAPHRIS.xml:S3:29563:3	O
Motor	SAPHRIS.xml:S3:29567:5	O
Impairment	SAPHRIS.xml:S3:29573:10	O

Somnolence	SAPHRIS.xml:S3:29591:10	B-AdverseReaction
was	SAPHRIS.xml:S3:29602:3	O
reported	SAPHRIS.xml:S3:29606:8	O
in	SAPHRIS.xml:S3:29615:2	O
patients	SAPHRIS.xml:S3:29618:8	O
treated	SAPHRIS.xml:S3:29627:7	O
with	SAPHRIS.xml:S3:29635:4	O
SAPHRIS	SAPHRIS.xml:S3:29640:7	O
.	SAPHRIS.xml:S3:29647:1	O

It	SAPHRIS.xml:S3:29649:2	O
was	SAPHRIS.xml:S3:29652:3	O
usually	SAPHRIS.xml:S3:29656:7	O
transient	SAPHRIS.xml:S3:29664:9	O
with	SAPHRIS.xml:S3:29674:4	O
the	SAPHRIS.xml:S3:29679:3	O
highest	SAPHRIS.xml:S3:29683:7	O
incidence	SAPHRIS.xml:S3:29691:9	O
reported	SAPHRIS.xml:S3:29701:8	O
during	SAPHRIS.xml:S3:29710:6	O
the	SAPHRIS.xml:S3:29717:3	O
first	SAPHRIS.xml:S3:29721:5	O
week	SAPHRIS.xml:S3:29727:4	O
of	SAPHRIS.xml:S3:29732:2	O
treatment	SAPHRIS.xml:S3:29735:9	O
.	SAPHRIS.xml:S3:29744:1	O

In	SAPHRIS.xml:S3:29746:2	O
short	SAPHRIS.xml:S3:29749:5	O
-	SAPHRIS.xml:S3:29754:1	O
term	SAPHRIS.xml:S3:29755:4	O
,	SAPHRIS.xml:S3:29759:1	O
fixed	SAPHRIS.xml:S3:29761:5	O
-	SAPHRIS.xml:S3:29766:1	O
dose	SAPHRIS.xml:S3:29767:4	O
,	SAPHRIS.xml:S3:29771:1	O
placebo	SAPHRIS.xml:S3:29773:7	O
-	SAPHRIS.xml:S3:29780:1	O
controlled	SAPHRIS.xml:S3:29781:10	O
schizophrenia	SAPHRIS.xml:S3:29792:13	O
adult	SAPHRIS.xml:S3:29806:5	O
trials	SAPHRIS.xml:S3:29812:6	O
,	SAPHRIS.xml:S3:29818:1	O
somnolence	SAPHRIS.xml:S3:29820:10	B-AdverseReaction
was	SAPHRIS.xml:S3:29831:3	O
reported	SAPHRIS.xml:S3:29835:8	O
in	SAPHRIS.xml:S3:29844:2	O
15%	SAPHRIS.xml:S3:29847:3	O
(	SAPHRIS.xml:S3:29851:1	O
41	SAPHRIS.xml:S3:29852:2	O
274	SAPHRIS.xml:S3:29855:3	O
)	SAPHRIS.xml:S3:29858:1	O
of	SAPHRIS.xml:S3:29860:2	O
patients	SAPHRIS.xml:S3:29863:8	O
on	SAPHRIS.xml:S3:29872:2	O
SAPHRIS	SAPHRIS.xml:S3:29875:7	O
5	SAPHRIS.xml:S3:29883:1	O
mg	SAPHRIS.xml:S3:29885:2	O
twice	SAPHRIS.xml:S3:29888:5	O
daily	SAPHRIS.xml:S3:29894:5	O
and	SAPHRIS.xml:S3:29900:3	O
in	SAPHRIS.xml:S3:29904:2	O
13%	SAPHRIS.xml:S3:29907:3	O
(	SAPHRIS.xml:S3:29911:1	O
26	SAPHRIS.xml:S3:29912:2	O
208	SAPHRIS.xml:S3:29915:3	O
)	SAPHRIS.xml:S3:29918:1	O
of	SAPHRIS.xml:S3:29920:2	O
patients	SAPHRIS.xml:S3:29923:8	O
on	SAPHRIS.xml:S3:29932:2	O
SAPHRIS	SAPHRIS.xml:S3:29935:7	O
10	SAPHRIS.xml:S3:29943:2	O
mg	SAPHRIS.xml:S3:29946:2	O
twice	SAPHRIS.xml:S3:29949:5	O
daily	SAPHRIS.xml:S3:29955:5	O
compared	SAPHRIS.xml:S3:29961:8	O
to	SAPHRIS.xml:S3:29970:2	O
7%	SAPHRIS.xml:S3:29973:2	O
(	SAPHRIS.xml:S3:29976:1	O
26	SAPHRIS.xml:S3:29977:2	O
378	SAPHRIS.xml:S3:29980:3	O
)	SAPHRIS.xml:S3:29983:1	O
of	SAPHRIS.xml:S3:29985:2	O
placebo	SAPHRIS.xml:S3:29988:7	O
patients	SAPHRIS.xml:S3:29996:8	O
.	SAPHRIS.xml:S3:30004:1	O

In	SAPHRIS.xml:S3:30006:2	O
short	SAPHRIS.xml:S3:30009:5	O
-	SAPHRIS.xml:S3:30014:1	O
term	SAPHRIS.xml:S3:30015:4	O
,	SAPHRIS.xml:S3:30019:1	O
placebo	SAPHRIS.xml:S3:30021:7	O
-	SAPHRIS.xml:S3:30028:1	O
controlled	SAPHRIS.xml:S3:30029:10	O
bipolar	SAPHRIS.xml:S3:30040:7	O
mania	SAPHRIS.xml:S3:30048:5	O
adult	SAPHRIS.xml:S3:30054:5	O
trials	SAPHRIS.xml:S3:30060:6	O
of	SAPHRIS.xml:S3:30067:2	O
therapeutic	SAPHRIS.xml:S3:30070:11	O
doses	SAPHRIS.xml:S3:30082:5	O
(	SAPHRIS.xml:S3:30088:1	O
5	SAPHRIS.xml:S3:30089:1	O
-	SAPHRIS.xml:S3:30090:1	O
10	SAPHRIS.xml:S3:30091:2	O
mg	SAPHRIS.xml:S3:30094:2	O
twice	SAPHRIS.xml:S3:30097:5	O
daily	SAPHRIS.xml:S3:30103:5	O
)	SAPHRIS.xml:S3:30108:1	O
,	SAPHRIS.xml:S3:30109:1	O
somnolence	SAPHRIS.xml:S3:30111:10	B-AdverseReaction
was	SAPHRIS.xml:S3:30122:3	O
reported	SAPHRIS.xml:S3:30126:8	O
in	SAPHRIS.xml:S3:30135:2	O
24%	SAPHRIS.xml:S3:30138:3	O
(	SAPHRIS.xml:S3:30142:1	O
90	SAPHRIS.xml:S3:30143:2	O
379	SAPHRIS.xml:S3:30146:3	O
)	SAPHRIS.xml:S3:30149:1	O
of	SAPHRIS.xml:S3:30151:2	O
patients	SAPHRIS.xml:S3:30154:8	O
on	SAPHRIS.xml:S3:30163:2	O
SAPHRIS	SAPHRIS.xml:S3:30166:7	O
compared	SAPHRIS.xml:S3:30174:8	O
to	SAPHRIS.xml:S3:30183:2	O
6%	SAPHRIS.xml:S3:30186:2	O
(	SAPHRIS.xml:S3:30189:1	O
13	SAPHRIS.xml:S3:30190:2	O
203	SAPHRIS.xml:S3:30193:3	O
)	SAPHRIS.xml:S3:30196:1	O
of	SAPHRIS.xml:S3:30198:2	O
placebo	SAPHRIS.xml:S3:30201:7	O
patients	SAPHRIS.xml:S3:30209:8	O
.	SAPHRIS.xml:S3:30217:1	O

During	SAPHRIS.xml:S3:30219:6	O
adult	SAPHRIS.xml:S3:30226:5	O
pre	SAPHRIS.xml:S3:30232:3	O
-	SAPHRIS.xml:S3:30235:1	O
marketing	SAPHRIS.xml:S3:30236:9	O
clinical	SAPHRIS.xml:S3:30246:8	O
trials	SAPHRIS.xml:S3:30255:6	O
with	SAPHRIS.xml:S3:30262:4	O
SAPHRIS	SAPHRIS.xml:S3:30267:7	O
,	SAPHRIS.xml:S3:30274:1	O
including	SAPHRIS.xml:S3:30276:9	O
long	SAPHRIS.xml:S3:30286:4	O
-	SAPHRIS.xml:S3:30290:1	O
term	SAPHRIS.xml:S3:30291:4	O
trials	SAPHRIS.xml:S3:30296:6	O
without	SAPHRIS.xml:S3:30303:7	O
comparison	SAPHRIS.xml:S3:30311:10	O
to	SAPHRIS.xml:S3:30322:2	O
placebo	SAPHRIS.xml:S3:30325:7	O
,	SAPHRIS.xml:S3:30332:1	O
somnolence	SAPHRIS.xml:S3:30334:10	B-AdverseReaction
was	SAPHRIS.xml:S3:30345:3	O
reported	SAPHRIS.xml:S3:30349:8	O
in	SAPHRIS.xml:S3:30358:2	O
18%	SAPHRIS.xml:S3:30361:3	O
(	SAPHRIS.xml:S3:30365:1	O
358	SAPHRIS.xml:S3:30366:3	O
1953	SAPHRIS.xml:S3:30370:4	O
)	SAPHRIS.xml:S3:30374:1	O
of	SAPHRIS.xml:S3:30376:2	O
patients	SAPHRIS.xml:S3:30379:8	O
treated	SAPHRIS.xml:S3:30388:7	O
with	SAPHRIS.xml:S3:30396:4	O
SAPHRIS	SAPHRIS.xml:S3:30401:7	O
.	SAPHRIS.xml:S3:30408:1	O

Somnolence	SAPHRIS.xml:S3:30410:10	B-AdverseReaction
(	SAPHRIS.xml:S3:30421:1	O
including	SAPHRIS.xml:S3:30422:9	O
sedation	SAPHRIS.xml:S3:30432:8	B-AdverseReaction
)	SAPHRIS.xml:S3:30440:1	O
led	SAPHRIS.xml:S3:30442:3	O
to	SAPHRIS.xml:S3:30446:2	O
discontinuation	SAPHRIS.xml:S3:30449:15	O
in	SAPHRIS.xml:S3:30465:2	O
0.6%	SAPHRIS.xml:S3:30468:4	O
(	SAPHRIS.xml:S3:30473:1	O
12	SAPHRIS.xml:S3:30474:2	O
1953	SAPHRIS.xml:S3:30477:4	O
)	SAPHRIS.xml:S3:30481:1	O
of	SAPHRIS.xml:S3:30483:2	O
patients	SAPHRIS.xml:S3:30486:8	O
in	SAPHRIS.xml:S3:30495:2	O
short	SAPHRIS.xml:S3:30498:5	O
-	SAPHRIS.xml:S3:30503:1	O
term	SAPHRIS.xml:S3:30504:4	O
,	SAPHRIS.xml:S3:30508:1	O
placebo	SAPHRIS.xml:S3:30510:7	O
-	SAPHRIS.xml:S3:30517:1	O
controlled	SAPHRIS.xml:S3:30518:10	O
trials	SAPHRIS.xml:S3:30529:6	O
.	SAPHRIS.xml:S3:30535:1	O

In	SAPHRIS.xml:S3:30545:2	O
a	SAPHRIS.xml:S3:30548:1	O
3	SAPHRIS.xml:S3:30550:1	O
-	SAPHRIS.xml:S3:30551:1	O
week	SAPHRIS.xml:S3:30552:4	O
,	SAPHRIS.xml:S3:30556:1	O
placebo	SAPHRIS.xml:S3:30558:7	O
-	SAPHRIS.xml:S3:30565:1	O
controlled	SAPHRIS.xml:S3:30566:10	O
,	SAPHRIS.xml:S3:30576:1	O
bipolar	SAPHRIS.xml:S3:30578:7	O
I	SAPHRIS.xml:S3:30586:1	O
pediatric	SAPHRIS.xml:S3:30588:9	O
trial	SAPHRIS.xml:S3:30598:5	O
,	SAPHRIS.xml:S3:30603:1	O
the	SAPHRIS.xml:S3:30605:3	O
incidence	SAPHRIS.xml:S3:30609:9	O
of	SAPHRIS.xml:S3:30619:2	O
somnolence	SAPHRIS.xml:S3:30622:10	B-AdverseReaction
(	SAPHRIS.xml:S3:30633:1	O
including	SAPHRIS.xml:S3:30634:9	O
sedation	SAPHRIS.xml:S3:30644:8	B-AdverseReaction
and	SAPHRIS.xml:S3:30653:3	O
hypersomnia	SAPHRIS.xml:S3:30657:11	B-AdverseReaction
)	SAPHRIS.xml:S3:30668:1	O
for	SAPHRIS.xml:S3:30670:3	O
placebo	SAPHRIS.xml:S3:30674:7	O
,	SAPHRIS.xml:S3:30681:1	O
SAPHRIS	SAPHRIS.xml:S3:30683:7	O
2.5	SAPHRIS.xml:S3:30691:3	O
mg	SAPHRIS.xml:S3:30695:2	O
twice	SAPHRIS.xml:S3:30698:5	O
daily	SAPHRIS.xml:S3:30704:5	O
,	SAPHRIS.xml:S3:30709:1	O
5	SAPHRIS.xml:S3:30711:1	O
mg	SAPHRIS.xml:S3:30713:2	O
twice	SAPHRIS.xml:S3:30716:5	O
daily	SAPHRIS.xml:S3:30722:5	O
,	SAPHRIS.xml:S3:30727:1	O
and	SAPHRIS.xml:S3:30729:3	O
10	SAPHRIS.xml:S3:30733:2	O
mg	SAPHRIS.xml:S3:30736:2	O
twice	SAPHRIS.xml:S3:30739:5	O
daily	SAPHRIS.xml:S3:30745:5	O
,	SAPHRIS.xml:S3:30750:1	O
was	SAPHRIS.xml:S3:30752:3	O
12%	SAPHRIS.xml:S3:30756:3	O
(	SAPHRIS.xml:S3:30760:1	O
12	SAPHRIS.xml:S3:30761:2	O
101	SAPHRIS.xml:S3:30764:3	O
)	SAPHRIS.xml:S3:30767:1	O
,	SAPHRIS.xml:S3:30768:1	O
46%	SAPHRIS.xml:S3:30770:3	O
(	SAPHRIS.xml:S3:30774:1	O
48	SAPHRIS.xml:S3:30775:2	O
104	SAPHRIS.xml:S3:30778:3	O
)	SAPHRIS.xml:S3:30781:1	O
,	SAPHRIS.xml:S3:30782:1	O
53%	SAPHRIS.xml:S3:30784:3	O
(	SAPHRIS.xml:S3:30788:1	O
52	SAPHRIS.xml:S3:30789:2	O
99	SAPHRIS.xml:S3:30792:2	O
)	SAPHRIS.xml:S3:30794:1	O
,	SAPHRIS.xml:S3:30795:1	O
and	SAPHRIS.xml:S3:30797:3	O
49%	SAPHRIS.xml:S3:30801:3	O
(	SAPHRIS.xml:S3:30805:1	O
49	SAPHRIS.xml:S3:30806:2	O
99	SAPHRIS.xml:S3:30809:2	O
)	SAPHRIS.xml:S3:30811:1	O
,	SAPHRIS.xml:S3:30812:1	O
respectively	SAPHRIS.xml:S3:30814:12	O
.	SAPHRIS.xml:S3:30826:1	O

Somnolence	SAPHRIS.xml:S3:30828:10	B-AdverseReaction
led	SAPHRIS.xml:S3:30839:3	O
to	SAPHRIS.xml:S3:30843:2	O
discontinuation	SAPHRIS.xml:S3:30846:15	O
in	SAPHRIS.xml:S3:30862:2	O
0%	SAPHRIS.xml:S3:30865:2	O
,	SAPHRIS.xml:S3:30867:1	O
3%	SAPHRIS.xml:S3:30869:2	O
,	SAPHRIS.xml:S3:30871:1	O
1%	SAPHRIS.xml:S3:30873:2	O
,	SAPHRIS.xml:S3:30875:1	O
and	SAPHRIS.xml:S3:30877:3	O
2%	SAPHRIS.xml:S3:30881:2	O
of	SAPHRIS.xml:S3:30884:2	O
patients	SAPHRIS.xml:S3:30887:8	O
treated	SAPHRIS.xml:S3:30896:7	O
with	SAPHRIS.xml:S3:30904:4	O
placebo	SAPHRIS.xml:S3:30909:7	O
,	SAPHRIS.xml:S3:30916:1	O
and	SAPHRIS.xml:S3:30918:3	O
SAPHRIS	SAPHRIS.xml:S3:30922:7	O
2.5	SAPHRIS.xml:S3:30930:3	O
mg	SAPHRIS.xml:S3:30934:2	O
twice	SAPHRIS.xml:S3:30937:5	O
daily	SAPHRIS.xml:S3:30943:5	O
,	SAPHRIS.xml:S3:30948:1	O
5	SAPHRIS.xml:S3:30950:1	O
mg	SAPHRIS.xml:S3:30952:2	O
twice	SAPHRIS.xml:S3:30955:5	O
daily	SAPHRIS.xml:S3:30961:5	O
,	SAPHRIS.xml:S3:30966:1	O
and	SAPHRIS.xml:S3:30968:3	O
10	SAPHRIS.xml:S3:30972:2	O
mg	SAPHRIS.xml:S3:30975:2	O
twice	SAPHRIS.xml:S3:30978:5	O
daily	SAPHRIS.xml:S3:30984:5	O
,	SAPHRIS.xml:S3:30989:1	O
respectively	SAPHRIS.xml:S3:30991:12	O
.	SAPHRIS.xml:S3:31003:1	O

Patients	SAPHRIS.xml:S3:31013:8	O
should	SAPHRIS.xml:S3:31022:6	O
be	SAPHRIS.xml:S3:31029:2	O
cautioned	SAPHRIS.xml:S3:31032:9	O
about	SAPHRIS.xml:S3:31042:5	O
performing	SAPHRIS.xml:S3:31048:10	O
activities	SAPHRIS.xml:S3:31059:10	O
requiring	SAPHRIS.xml:S3:31070:9	O
mental	SAPHRIS.xml:S3:31080:6	O
alertness	SAPHRIS.xml:S3:31087:9	O
,	SAPHRIS.xml:S3:31096:1	O
such	SAPHRIS.xml:S3:31098:4	O
as	SAPHRIS.xml:S3:31103:2	O
operating	SAPHRIS.xml:S3:31106:9	O
hazardous	SAPHRIS.xml:S3:31116:9	O
machinery	SAPHRIS.xml:S3:31126:9	O
or	SAPHRIS.xml:S3:31136:2	O
operating	SAPHRIS.xml:S3:31139:9	O
a	SAPHRIS.xml:S3:31149:1	O
motor	SAPHRIS.xml:S3:31151:5	O
vehicle	SAPHRIS.xml:S3:31157:7	O
,	SAPHRIS.xml:S3:31164:1	O
until	SAPHRIS.xml:S3:31166:5	O
they	SAPHRIS.xml:S3:31172:4	O
are	SAPHRIS.xml:S3:31177:3	O
reasonably	SAPHRIS.xml:S3:31181:10	O
certain	SAPHRIS.xml:S3:31192:7	O
that	SAPHRIS.xml:S3:31200:4	O
SAPHRIS	SAPHRIS.xml:S3:31205:7	O
therapy	SAPHRIS.xml:S3:31213:7	O
does	SAPHRIS.xml:S3:31221:4	O
not	SAPHRIS.xml:S3:31226:3	O
affect	SAPHRIS.xml:S3:31230:6	O
them	SAPHRIS.xml:S3:31237:4	O
adversely	SAPHRIS.xml:S3:31242:9	O
.	SAPHRIS.xml:S3:31251:1	O

5.13	SAPHRIS.xml:S3:31263:4	O
Body	SAPHRIS.xml:S3:31268:4	O
Temperature	SAPHRIS.xml:S3:31273:11	O
Regulation	SAPHRIS.xml:S3:31285:10	O

Disruption	SAPHRIS.xml:S3:31303:10	B-AdverseReaction
of	SAPHRIS.xml:S3:31314:2	I-AdverseReaction
the	SAPHRIS.xml:S3:31317:3	I-AdverseReaction
body	SAPHRIS.xml:S3:31321:4	I-AdverseReaction
's	SAPHRIS.xml:S3:31325:2	I-AdverseReaction
ability	SAPHRIS.xml:S3:31328:7	I-AdverseReaction
to	SAPHRIS.xml:S3:31336:2	I-AdverseReaction
reduce	SAPHRIS.xml:S3:31339:6	I-AdverseReaction
core	SAPHRIS.xml:S3:31346:4	I-AdverseReaction
body	SAPHRIS.xml:S3:31351:4	I-AdverseReaction
temperature	SAPHRIS.xml:S3:31356:11	I-AdverseReaction
has	SAPHRIS.xml:S3:31368:3	O
been	SAPHRIS.xml:S3:31372:4	O
attributed	SAPHRIS.xml:S3:31377:10	O
to	SAPHRIS.xml:S3:31388:2	O
antipsychotic	SAPHRIS.xml:S3:31391:13	B-DrugClass
agents	SAPHRIS.xml:S3:31405:6	I-DrugClass
.	SAPHRIS.xml:S3:31411:1	O

In	SAPHRIS.xml:S3:31413:2	O
the	SAPHRIS.xml:S3:31416:3	O
short	SAPHRIS.xml:S3:31420:5	O
-	SAPHRIS.xml:S3:31425:1	O
term	SAPHRIS.xml:S3:31426:4	O
placebo	SAPHRIS.xml:S3:31431:7	O
-	SAPHRIS.xml:S3:31438:1	O
controlled	SAPHRIS.xml:S3:31439:10	O
trials	SAPHRIS.xml:S3:31450:6	O
for	SAPHRIS.xml:S3:31457:3	O
both	SAPHRIS.xml:S3:31461:4	O
schizophrenia	SAPHRIS.xml:S3:31466:13	O
and	SAPHRIS.xml:S3:31480:3	O
acute	SAPHRIS.xml:S3:31484:5	O
bipolar	SAPHRIS.xml:S3:31490:7	O
disorder	SAPHRIS.xml:S3:31498:8	O
,	SAPHRIS.xml:S3:31506:1	O
the	SAPHRIS.xml:S3:31508:3	O
incidence	SAPHRIS.xml:S3:31512:9	O
of	SAPHRIS.xml:S3:31522:2	O
adverse	SAPHRIS.xml:S3:31525:7	O
reactions	SAPHRIS.xml:S3:31533:9	O
suggestive	SAPHRIS.xml:S3:31543:10	O
of	SAPHRIS.xml:S3:31554:2	O
body	SAPHRIS.xml:S3:31557:4	B-AdverseReaction
temperature	SAPHRIS.xml:S3:31562:11	I-AdverseReaction
increases	SAPHRIS.xml:S3:31574:9	I-AdverseReaction
was	SAPHRIS.xml:S3:31584:3	O
low	SAPHRIS.xml:S3:31588:3	O
(	SAPHRIS.xml:S3:31592:1	O
1%	SAPHRIS.xml:S3:31595:2	O
)	SAPHRIS.xml:S3:31597:1	O
and	SAPHRIS.xml:S3:31599:3	O
comparable	SAPHRIS.xml:S3:31603:10	O
to	SAPHRIS.xml:S3:31614:2	O
placebo	SAPHRIS.xml:S3:31617:7	O
(	SAPHRIS.xml:S3:31625:1	O
0%	SAPHRIS.xml:S3:31626:2	O
)	SAPHRIS.xml:S3:31628:1	O
.	SAPHRIS.xml:S3:31629:1	O

During	SAPHRIS.xml:S3:31631:6	O
clinical	SAPHRIS.xml:S3:31638:8	O
trials	SAPHRIS.xml:S3:31647:6	O
with	SAPHRIS.xml:S3:31654:4	O
SAPHRIS	SAPHRIS.xml:S3:31659:7	O
,	SAPHRIS.xml:S3:31666:1	O
including	SAPHRIS.xml:S3:31668:9	O
long	SAPHRIS.xml:S3:31678:4	O
-	SAPHRIS.xml:S3:31682:1	O
term	SAPHRIS.xml:S3:31683:4	O
trials	SAPHRIS.xml:S3:31688:6	O
without	SAPHRIS.xml:S3:31695:7	O
comparison	SAPHRIS.xml:S3:31703:10	O
to	SAPHRIS.xml:S3:31714:2	O
placebo	SAPHRIS.xml:S3:31717:7	O
,	SAPHRIS.xml:S3:31724:1	O
the	SAPHRIS.xml:S3:31726:3	O
incidence	SAPHRIS.xml:S3:31730:9	O
of	SAPHRIS.xml:S3:31740:2	O
adverse	SAPHRIS.xml:S3:31743:7	O
reactions	SAPHRIS.xml:S3:31751:9	O
suggestive	SAPHRIS.xml:S3:31761:10	O
of	SAPHRIS.xml:S3:31772:2	O
body	SAPHRIS.xml:S3:31775:4	B-AdverseReaction
temperature	SAPHRIS.xml:S3:31780:11	I-AdverseReaction
increases	SAPHRIS.xml:S3:31792:9	I-AdverseReaction
(	SAPHRIS.xml:S3:31802:1	O
pyrexia	SAPHRIS.xml:S3:31803:7	B-AdverseReaction
and	SAPHRIS.xml:S3:31811:3	O
feeling	SAPHRIS.xml:S3:31815:7	B-AdverseReaction
hot	SAPHRIS.xml:S3:31823:3	I-AdverseReaction
)	SAPHRIS.xml:S3:31826:1	O
was	SAPHRIS.xml:S3:31828:3	O
1%	SAPHRIS.xml:S3:31834:2	O
.	SAPHRIS.xml:S3:31836:1	O

Appropriate	SAPHRIS.xml:S3:31846:11	O
care	SAPHRIS.xml:S3:31858:4	O
is	SAPHRIS.xml:S3:31863:2	O
advised	SAPHRIS.xml:S3:31866:7	O
when	SAPHRIS.xml:S3:31874:4	O
prescribing	SAPHRIS.xml:S3:31879:11	O
SAPHRIS	SAPHRIS.xml:S3:31891:7	O
for	SAPHRIS.xml:S3:31899:3	O
patients	SAPHRIS.xml:S3:31903:8	O
who	SAPHRIS.xml:S3:31912:3	O
will	SAPHRIS.xml:S3:31916:4	O
be	SAPHRIS.xml:S3:31921:2	O
experiencing	SAPHRIS.xml:S3:31924:12	O
conditions	SAPHRIS.xml:S3:31937:10	O
that	SAPHRIS.xml:S3:31948:4	O
may	SAPHRIS.xml:S3:31953:3	O
contribute	SAPHRIS.xml:S3:31957:10	O
to	SAPHRIS.xml:S3:31968:2	O
an	SAPHRIS.xml:S3:31971:2	O
elevation	SAPHRIS.xml:S3:31974:9	O
in	SAPHRIS.xml:S3:31984:2	O
core	SAPHRIS.xml:S3:31987:4	O
body	SAPHRIS.xml:S3:31992:4	O
temperature	SAPHRIS.xml:S3:31997:11	O
,	SAPHRIS.xml:S3:32008:1	O
e	SAPHRIS.xml:S3:32010:1	O
.	SAPHRIS.xml:S3:32011:1	O
g	SAPHRIS.xml:S3:32012:1	O
.	SAPHRIS.xml:S3:32013:1	O
,	SAPHRIS.xml:S3:32014:1	O
exercising	SAPHRIS.xml:S3:32016:10	O
strenuously	SAPHRIS.xml:S3:32027:11	O
,	SAPHRIS.xml:S3:32038:1	O
exposure	SAPHRIS.xml:S3:32040:8	O
to	SAPHRIS.xml:S3:32049:2	O
extreme	SAPHRIS.xml:S3:32052:7	O
heat	SAPHRIS.xml:S3:32060:4	O
,	SAPHRIS.xml:S3:32064:1	O
receiving	SAPHRIS.xml:S3:32066:9	O
concomitant	SAPHRIS.xml:S3:32076:11	O
medication	SAPHRIS.xml:S3:32088:10	O
with	SAPHRIS.xml:S3:32099:4	O
anticholinergic	SAPHRIS.xml:S3:32104:15	O
activity	SAPHRIS.xml:S3:32120:8	O
,	SAPHRIS.xml:S3:32128:1	O
or	SAPHRIS.xml:S3:32130:2	O
being	SAPHRIS.xml:S3:32133:5	O
subject	SAPHRIS.xml:S3:32139:7	O
to	SAPHRIS.xml:S3:32147:2	O
dehydration	SAPHRIS.xml:S3:32150:11	O
.	SAPHRIS.xml:S3:32161:1	O

5.14	SAPHRIS.xml:S3:32173:4	O
Suicide	SAPHRIS.xml:S3:32178:7	O

The	SAPHRIS.xml:S3:32193:3	O
possibility	SAPHRIS.xml:S3:32197:11	O
of	SAPHRIS.xml:S3:32209:2	O
a	SAPHRIS.xml:S3:32212:1	O
suicide	SAPHRIS.xml:S3:32214:7	O
attempt	SAPHRIS.xml:S3:32222:7	O
is	SAPHRIS.xml:S3:32230:2	O
inherent	SAPHRIS.xml:S3:32233:8	O
in	SAPHRIS.xml:S3:32242:2	O
psychotic	SAPHRIS.xml:S3:32245:9	O
illnesses	SAPHRIS.xml:S3:32255:9	O
and	SAPHRIS.xml:S3:32265:3	O
bipolar	SAPHRIS.xml:S3:32269:7	O
disorder	SAPHRIS.xml:S3:32277:8	O
,	SAPHRIS.xml:S3:32285:1	O
and	SAPHRIS.xml:S3:32287:3	O
close	SAPHRIS.xml:S3:32291:5	O
supervision	SAPHRIS.xml:S3:32297:11	O
of	SAPHRIS.xml:S3:32309:2	O
high	SAPHRIS.xml:S3:32312:4	O
-	SAPHRIS.xml:S3:32316:1	O
risk	SAPHRIS.xml:S3:32317:4	O
patients	SAPHRIS.xml:S3:32322:8	O
should	SAPHRIS.xml:S3:32331:6	O
accompany	SAPHRIS.xml:S3:32338:9	O
drug	SAPHRIS.xml:S3:32348:4	O
therapy	SAPHRIS.xml:S3:32353:7	O
.	SAPHRIS.xml:S3:32360:1	O

Prescriptions	SAPHRIS.xml:S3:32362:13	O
for	SAPHRIS.xml:S3:32376:3	O
SAPHRIS	SAPHRIS.xml:S3:32380:7	O
should	SAPHRIS.xml:S3:32388:6	O
be	SAPHRIS.xml:S3:32395:2	O
written	SAPHRIS.xml:S3:32398:7	O
for	SAPHRIS.xml:S3:32406:3	O
the	SAPHRIS.xml:S3:32410:3	O
smallest	SAPHRIS.xml:S3:32414:8	O
quantity	SAPHRIS.xml:S3:32423:8	O
of	SAPHRIS.xml:S3:32432:2	O
tablets	SAPHRIS.xml:S3:32435:7	O
consistent	SAPHRIS.xml:S3:32443:10	O
with	SAPHRIS.xml:S3:32454:4	O
good	SAPHRIS.xml:S3:32459:4	O
patient	SAPHRIS.xml:S3:32464:7	O
management	SAPHRIS.xml:S3:32472:10	O
in	SAPHRIS.xml:S3:32483:2	O
order	SAPHRIS.xml:S3:32486:5	O
to	SAPHRIS.xml:S3:32492:2	O
reduce	SAPHRIS.xml:S3:32495:6	O
the	SAPHRIS.xml:S3:32502:3	O
risk	SAPHRIS.xml:S3:32506:4	O
of	SAPHRIS.xml:S3:32511:2	O
overdose	SAPHRIS.xml:S3:32514:8	O
.	SAPHRIS.xml:S3:32522:1	O

5.15	SAPHRIS.xml:S3:32534:4	O
Dysphagia	SAPHRIS.xml:S3:32539:9	O

Esophageal	SAPHRIS.xml:S3:32552:10	B-AdverseReaction
dysmotility	SAPHRIS.xml:S3:32563:11	I-AdverseReaction
and	SAPHRIS.xml:S3:32575:3	O
aspiration	SAPHRIS.xml:S3:32579:10	B-AdverseReaction
have	SAPHRIS.xml:S3:32590:4	O
been	SAPHRIS.xml:S3:32595:4	O
associated	SAPHRIS.xml:S3:32600:10	O
with	SAPHRIS.xml:S3:32611:4	O
antipsychotic	SAPHRIS.xml:S3:32616:13	B-DrugClass
drug	SAPHRIS.xml:S3:32630:4	I-DrugClass
use	SAPHRIS.xml:S3:32635:3	O
.	SAPHRIS.xml:S3:32638:1	O

Dysphagia	SAPHRIS.xml:S3:32640:9	B-AdverseReaction
was	SAPHRIS.xml:S3:32650:3	O
reported	SAPHRIS.xml:S3:32654:8	O
in	SAPHRIS.xml:S3:32663:2	O
0.2%	SAPHRIS.xml:S3:32666:4	O
and	SAPHRIS.xml:S3:32671:3	O
0%	SAPHRIS.xml:S3:32675:2	O
(	SAPHRIS.xml:S3:32678:1	O
1	SAPHRIS.xml:S3:32679:1	O
572	SAPHRIS.xml:S3:32681:3	O
,	SAPHRIS.xml:S3:32684:1	O
0	SAPHRIS.xml:S3:32686:1	O
379	SAPHRIS.xml:S3:32688:3	O
)	SAPHRIS.xml:S3:32691:1	O
of	SAPHRIS.xml:S3:32693:2	O
patients	SAPHRIS.xml:S3:32696:8	O
treated	SAPHRIS.xml:S3:32705:7	O
with	SAPHRIS.xml:S3:32713:4	O
therapeutic	SAPHRIS.xml:S3:32718:11	O
doses	SAPHRIS.xml:S3:32730:5	O
(	SAPHRIS.xml:S3:32736:1	O
5	SAPHRIS.xml:S3:32737:1	O
-	SAPHRIS.xml:S3:32738:1	O
10	SAPHRIS.xml:S3:32739:2	O
mg	SAPHRIS.xml:S3:32742:2	O
twice	SAPHRIS.xml:S3:32745:5	O
daily	SAPHRIS.xml:S3:32751:5	O
)	SAPHRIS.xml:S3:32756:1	O
of	SAPHRIS.xml:S3:32758:2	O
SAPHRIS	SAPHRIS.xml:S3:32761:7	O
as	SAPHRIS.xml:S3:32769:2	O
compared	SAPHRIS.xml:S3:32772:8	O
to	SAPHRIS.xml:S3:32781:2	O
0%	SAPHRIS.xml:S3:32784:2	O
(	SAPHRIS.xml:S3:32787:1	O
0	SAPHRIS.xml:S3:32788:1	O
378	SAPHRIS.xml:S3:32790:3	O
,	SAPHRIS.xml:S3:32793:1	O
0	SAPHRIS.xml:S3:32795:1	O
203	SAPHRIS.xml:S3:32797:3	O
)	SAPHRIS.xml:S3:32800:1	O
of	SAPHRIS.xml:S3:32802:2	O
patients	SAPHRIS.xml:S3:32805:8	O
treated	SAPHRIS.xml:S3:32814:7	O
with	SAPHRIS.xml:S3:32822:4	O
placebo	SAPHRIS.xml:S3:32827:7	O
in	SAPHRIS.xml:S3:32835:2	O
short	SAPHRIS.xml:S3:32838:5	O
-	SAPHRIS.xml:S3:32843:1	O
term	SAPHRIS.xml:S3:32844:4	O
schizophrenia	SAPHRIS.xml:S3:32849:13	O
and	SAPHRIS.xml:S3:32863:3	O
bipolar	SAPHRIS.xml:S3:32867:7	O
mania	SAPHRIS.xml:S3:32875:5	O
adult	SAPHRIS.xml:S3:32881:5	O
trials	SAPHRIS.xml:S3:32887:6	O
,	SAPHRIS.xml:S3:32893:1	O
respectively	SAPHRIS.xml:S3:32895:12	O
.	SAPHRIS.xml:S3:32907:1	O

During	SAPHRIS.xml:S3:32909:6	O
adult	SAPHRIS.xml:S3:32916:5	O
pre	SAPHRIS.xml:S3:32922:3	O
-	SAPHRIS.xml:S3:32925:1	O
marketing	SAPHRIS.xml:S3:32926:9	O
clinical	SAPHRIS.xml:S3:32936:8	O
trials	SAPHRIS.xml:S3:32945:6	O
with	SAPHRIS.xml:S3:32952:4	O
SAPHRIS	SAPHRIS.xml:S3:32957:7	O
,	SAPHRIS.xml:S3:32964:1	O
including	SAPHRIS.xml:S3:32966:9	O
long	SAPHRIS.xml:S3:32976:4	O
-	SAPHRIS.xml:S3:32980:1	O
term	SAPHRIS.xml:S3:32981:4	O
trials	SAPHRIS.xml:S3:32986:6	O
without	SAPHRIS.xml:S3:32993:7	O
comparison	SAPHRIS.xml:S3:33001:10	O
to	SAPHRIS.xml:S3:33012:2	O
placebo	SAPHRIS.xml:S3:33015:7	O
,	SAPHRIS.xml:S3:33022:1	O
dysphagia	SAPHRIS.xml:S3:33024:9	B-AdverseReaction
was	SAPHRIS.xml:S3:33034:3	O
reported	SAPHRIS.xml:S3:33038:8	O
in	SAPHRIS.xml:S3:33047:2	O
0.1%	SAPHRIS.xml:S3:33050:4	O
(	SAPHRIS.xml:S3:33055:1	O
2	SAPHRIS.xml:S3:33056:1	O
1953	SAPHRIS.xml:S3:33058:4	O
)	SAPHRIS.xml:S3:33062:1	O
of	SAPHRIS.xml:S3:33064:2	O
patients	SAPHRIS.xml:S3:33067:8	O
treated	SAPHRIS.xml:S3:33076:7	O
with	SAPHRIS.xml:S3:33084:4	O
SAPHRIS	SAPHRIS.xml:S3:33089:7	O
.	SAPHRIS.xml:S3:33096:1	O

Aspiration	SAPHRIS.xml:S3:33106:10	O
pneumonia	SAPHRIS.xml:S3:33117:9	O
is	SAPHRIS.xml:S3:33127:2	O
a	SAPHRIS.xml:S3:33130:1	O
common	SAPHRIS.xml:S3:33132:6	O
cause	SAPHRIS.xml:S3:33139:5	O
of	SAPHRIS.xml:S3:33145:2	O
morbidity	SAPHRIS.xml:S3:33148:9	O
and	SAPHRIS.xml:S3:33158:3	O
mortality	SAPHRIS.xml:S3:33162:9	O
in	SAPHRIS.xml:S3:33172:2	O
elderly	SAPHRIS.xml:S3:33175:7	O
patients	SAPHRIS.xml:S3:33183:8	O
,	SAPHRIS.xml:S3:33191:1	O
in	SAPHRIS.xml:S3:33193:2	O
particular	SAPHRIS.xml:S3:33196:10	O
those	SAPHRIS.xml:S3:33207:5	O
with	SAPHRIS.xml:S3:33213:4	O
advanced	SAPHRIS.xml:S3:33218:8	O
Alzheimer	SAPHRIS.xml:S3:33227:9	O
's	SAPHRIS.xml:S3:33236:2	O
dementia	SAPHRIS.xml:S3:33239:8	O
.	SAPHRIS.xml:S3:33247:1	O

SAPHRIS	SAPHRIS.xml:S3:33249:7	O
is	SAPHRIS.xml:S3:33257:2	O
not	SAPHRIS.xml:S3:33260:3	O
indicated	SAPHRIS.xml:S3:33264:9	O
for	SAPHRIS.xml:S3:33274:3	O
the	SAPHRIS.xml:S3:33278:3	O
treatment	SAPHRIS.xml:S3:33282:9	O
of	SAPHRIS.xml:S3:33292:2	O
dementia	SAPHRIS.xml:S3:33295:8	O
-	SAPHRIS.xml:S3:33303:1	O
related	SAPHRIS.xml:S3:33304:7	O
psychosis	SAPHRIS.xml:S3:33312:9	O
,	SAPHRIS.xml:S3:33321:1	O
and	SAPHRIS.xml:S3:33323:3	O
should	SAPHRIS.xml:S3:33327:6	O
not	SAPHRIS.xml:S3:33334:3	O
be	SAPHRIS.xml:S3:33338:2	O
used	SAPHRIS.xml:S3:33341:4	O
in	SAPHRIS.xml:S3:33346:2	O
patients	SAPHRIS.xml:S3:33349:8	O
at	SAPHRIS.xml:S3:33358:2	O
risk	SAPHRIS.xml:S3:33361:4	O
for	SAPHRIS.xml:S3:33366:3	O
aspiration	SAPHRIS.xml:S3:33370:10	O
pneumonia	SAPHRIS.xml:S3:33381:9	O
[	SAPHRIS.xml:S3:33392:1	O
see	SAPHRIS.xml:S3:33393:3	O
also	SAPHRIS.xml:S3:33397:4	O
Warnings	SAPHRIS.xml:S3:33402:8	O
and	SAPHRIS.xml:S3:33411:3	O
Precautions	SAPHRIS.xml:S3:33415:11	O
(	SAPHRIS.xml:S3:33427:1	O
5.1	SAPHRIS.xml:S3:33428:3	O
)]	SAPHRIS.xml:S3:33431:2	O
.	SAPHRIS.xml:S3:33435:1	O

5.16	SAPHRIS.xml:S3:33447:4	O
Use	SAPHRIS.xml:S3:33452:3	O
in	SAPHRIS.xml:S3:33456:2	O
Patients	SAPHRIS.xml:S3:33459:8	O
with	SAPHRIS.xml:S3:33468:4	O
Concomitant	SAPHRIS.xml:S3:33473:11	O
Illness	SAPHRIS.xml:S3:33485:7	O

Clinical	SAPHRIS.xml:S3:33500:8	O
experience	SAPHRIS.xml:S3:33509:10	O
with	SAPHRIS.xml:S3:33520:4	O
SAPHRIS	SAPHRIS.xml:S3:33525:7	O
in	SAPHRIS.xml:S3:33533:2	O
patients	SAPHRIS.xml:S3:33536:8	O
with	SAPHRIS.xml:S3:33545:4	O
certain	SAPHRIS.xml:S3:33550:7	O
concomitant	SAPHRIS.xml:S3:33558:11	O
systemic	SAPHRIS.xml:S3:33570:8	O
illnesses	SAPHRIS.xml:S3:33579:9	O
is	SAPHRIS.xml:S3:33589:2	O
limited	SAPHRIS.xml:S3:33592:7	O
[	SAPHRIS.xml:S3:33601:1	O
see	SAPHRIS.xml:S3:33602:3	O
Clinical	SAPHRIS.xml:S3:33606:8	O
Pharmacology	SAPHRIS.xml:S3:33615:12	O
(	SAPHRIS.xml:S3:33628:1	O
12.3	SAPHRIS.xml:S3:33629:4	O
)]	SAPHRIS.xml:S3:33633:2	O
.	SAPHRIS.xml:S3:33637:1	O

SAPHRIS	SAPHRIS.xml:S3:33647:7	O
has	SAPHRIS.xml:S3:33655:3	O
not	SAPHRIS.xml:S3:33659:3	O
been	SAPHRIS.xml:S3:33663:4	O
evaluated	SAPHRIS.xml:S3:33668:9	O
in	SAPHRIS.xml:S3:33678:2	O
patients	SAPHRIS.xml:S3:33681:8	O
with	SAPHRIS.xml:S3:33690:4	O
a	SAPHRIS.xml:S3:33695:1	O
recent	SAPHRIS.xml:S3:33697:6	O
history	SAPHRIS.xml:S3:33704:7	O
of	SAPHRIS.xml:S3:33712:2	O
myocardial	SAPHRIS.xml:S3:33715:10	O
infarction	SAPHRIS.xml:S3:33726:10	O
or	SAPHRIS.xml:S3:33737:2	O
unstable	SAPHRIS.xml:S3:33740:8	O
heart	SAPHRIS.xml:S3:33749:5	O
disease	SAPHRIS.xml:S3:33755:7	O
.	SAPHRIS.xml:S3:33762:1	O

Patients	SAPHRIS.xml:S3:33764:8	O
with	SAPHRIS.xml:S3:33773:4	O
these	SAPHRIS.xml:S3:33778:5	O
diagnoses	SAPHRIS.xml:S3:33784:9	O
were	SAPHRIS.xml:S3:33794:4	O
excluded	SAPHRIS.xml:S3:33799:8	O
from	SAPHRIS.xml:S3:33808:4	O
pre	SAPHRIS.xml:S3:33813:3	O
-	SAPHRIS.xml:S3:33816:1	O
marketing	SAPHRIS.xml:S3:33817:9	O
clinical	SAPHRIS.xml:S3:33827:8	O
trials	SAPHRIS.xml:S3:33836:6	O
.	SAPHRIS.xml:S3:33842:1	O

Because	SAPHRIS.xml:S3:33844:7	O
of	SAPHRIS.xml:S3:33852:2	O
the	SAPHRIS.xml:S3:33855:3	O
risk	SAPHRIS.xml:S3:33859:4	O
of	SAPHRIS.xml:S3:33864:2	O
orthostatic	SAPHRIS.xml:S3:33867:11	O
hypotension	SAPHRIS.xml:S3:33879:11	O
with	SAPHRIS.xml:S3:33891:4	O
SAPHRIS	SAPHRIS.xml:S3:33896:7	O
,	SAPHRIS.xml:S3:33903:1	O
caution	SAPHRIS.xml:S3:33905:7	O
should	SAPHRIS.xml:S3:33913:6	O
be	SAPHRIS.xml:S3:33920:2	O
observed	SAPHRIS.xml:S3:33923:8	O
in	SAPHRIS.xml:S3:33932:2	O
cardiac	SAPHRIS.xml:S3:33935:7	O
patients	SAPHRIS.xml:S3:33943:8	O
[	SAPHRIS.xml:S3:33953:1	O
see	SAPHRIS.xml:S3:33954:3	O
Warnings	SAPHRIS.xml:S3:33958:8	O
and	SAPHRIS.xml:S3:33967:3	O
Precautions	SAPHRIS.xml:S3:33971:11	O
(	SAPHRIS.xml:S3:33983:1	O
5.7	SAPHRIS.xml:S3:33984:3	O
)]	SAPHRIS.xml:S3:33987:2	O
.	SAPHRIS.xml:S3:33991:1	O
